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Abstract
Clostridium botulinum and some strains of C. baratii and C. butyricum produce one 
of the most potent toxins known to man, botulinum neurotoxin, and are responsible 
for the disease botulism. This severe neuroparalytic disease is the result of 
botulinum neurotoxin negotiating a complex path to the cholinergic nerve endings. 
There, it interferes with the release of excitatory neurotransmitters resulting in 
flaccid paralysis and if untreated, death. The neurotoxin, itself a multi-faceted 
protein, does not act alone but is produced as part of a large, hetero-multimeric 
complex with the associated non-toxic proteins. This complex, known to protect 
the toxin from acids and proteases in the gut, has recently been suggested to play 
a more active role in toxicity. Here, the proteins from the lesser-studied toxin 
complex type (the OrfX type) are shown for the first time to share sequence 
similarity and synteny with clusters of proteins that are co-localised with various 
putative toxin genes in diverse other species. The extracellular supernatant 
proteome of C. botulinum is characterised and mined for potential novel virulence 
factors, with metabolic cost of extracellular protein being highlighted as a potential 
marker of virulence associated extracellular proteins. The supernatant of 22 
clinical strains of C. botulinum were investigated for the presence of the toxin 
complex; all toxin complex components were identified in the majority of strains 
indicating the importance of these proteins in the causation of botulism. A 
relationship between OrfX-encoding strains and infant botulism was also 
uncovered in clinical strains from the UK. Hypotheses to explain this association 
are explored. Finally, the transcriptome of C. botulinum was investigated using 
RNA-sequencing. This uncovered a complex and diverse picture of transcription in 
C. botulinum and raised questions as to the role of the alternative sigma factor 
BotR in the regulation of bont.
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1. Introduction
1.1. C lostridium -The Genus
The genus Clostridium has traditionally been classified as anaerobic or 
aerotolerant, endospore-forming rods that are gram positive (at least in the early 
stages of growth) (Collins et al, 1994). As a result of these broad defining criteria, 
Clostridium is a large and diverse group with a wide range of G+C contents (22- 
55%) although the toxigenic species have a much narrower GC range (24-29%) 
(Hatheway, 1990). Designation of a bacterial isolate as a Clostridium is 
dependent on it fulfilling 4 criteria (1) the ability to produce endospores (2) having 
an anaerobic energy metabolism not involving oxygen as an electron acceptor (3) 
the inability to reduce sulphate to sulphide -  this characteristic separates them 
from Desulfotomaculum (4) Gram positive cell wall, at least in the early stages of 
growth.
Bergey’s Manual of Systematic Bacteriology; The Firmicutes (Vos et al, 2009), lists 
200 species in the genus Clostridium. When the phylogeny of the genus is 
analysed using gene or protein sequences the 200 constituent species do not form 
a monophyletic group (Collins et al., 1994; Gupta and Gao, 2009). In a seminal 
paper on the phylogeny of Clostridium by Collins et al (1994) the genus was 
divided into 19 clusters based on 16S rDNA sequences. Three of these 
Clostridium clusters account for 70% of the Clostridia present in the normal faecal 
flora of humans (Finegold et al, 2002). Included in cluster I were Clostridium 
butyricum (the genus type species) and the medically important species C. 
botulinum, C. tetani, C. perfringens and C. baratii. Collins et al. suggested that the 
definition of the genus Clostridium be restricted to species in cluster I only, this 
would reduce the number of species in the Clostridium genus by over 50%. In
addition to the 16S rDNA based study of Collins et al., the phylogeny of 
Clostridium was investigated by concatenating 37 conserved proteins and 
analysing them for the presence of indels (Gupta and Gao, 2009). In the 
phylogenies generated by this methodology, the cluster I Clostridium species were 
clearly distinguishable from other clusters, replicating the results obtained in 16S 
rDNA phylogeny.
In addition to the many pathogens in the genus Clostridium there are also some 
industrially important species such as C. acetobutylicum (belongs to cluster I) that 
is capable of fermenting starch to acetone, butanol and ethanol.
1.2. Clostridium -  The Pathogens
Clostridia are among the most widely distributed pathogens in the environment. 
There are at least 35 pathogenic Clostridium that are found in a range of habitats 
including soil and the gut microflora of humans and other animals (Peck, 2009). 
Clostridium produce more types of protein toxins than any other genus of 
microorganisms with at least 20 identified toxins produced by 15 different species. 
These toxins include neurotoxins, proteases, cytotoxins, lipases, collagenases, 
necrotizing toxins, ADP-ribosyltransferases and neuraminidases (Hatheway, 1990).
Clostridium perfringens is the most frequently identified Clostridium pathogen, 
accounting for 20% of Clostridium encountered in clinical specimens (Allen et al, 
2003). It is implicated in a wide variety of clinical conditions including but not 
limited to myonecrosis, cellulitis; intra-abdominal sepsis, septicaemia, intra- 
vascular hemolysis and is one of the most common bacterial causes of food
12
poisoning gastroenteritis in the USA and elsewhere in the developed world 
(Thomas et al., 2013; Gormley et al., 2011; Olsen, 2000). C. perfringens food 
poisoning is associated with food products that have been time and temperature 
abused. Clostridial myonecrosis, otherwise known as gas gangrene, is a life- 
threatening, rapidly developing condition caused by, primarily, C. perfringens 
although other Clostridium species can be responsible.
Although tetanus is a relatively minor problem in the developed world it is still a 
major problem in the developing world. The World Health Organisation estimate 
that 59000 newborn children died from neonatal tetanus in 2008 
(http://www.who.int/immunization_monitoring/diseases/MNTE_initiative/en/index.ht 
ml). Clostridium tetani spores are widespread in the environment and can infect 
anaerobic wounds (Popoff, 1995).
Clostridium difficile is the major cause of antibiotic associated diarrhoea and 
pseudo-membranous colitis as well as being the most frequent nosocomial 
diarrhoeal pathogen (Lessa et al., 2012). This rise has been attributed to the 
emergence of a previously rare, hypervirulent strain, C. difficile 027 that shows 
increased resistance to fluoroquinolones and increased toxin production (Lessa et 
al., 2012).
Botulism is caused by Clostridium botulinum and rare strains of C. baratii and C. 
butyricum which produce the most lethal protein toxin known to man, botulinum 
neurotoxin (BoNT).
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1.3. Botulism and Clostridium botulinum
The disease botulism was first described in 1821 (Erbguth, 2004) but it wasn't until 
Emile van Ermengem investigated a cluster of food-borne botulism at a funeral in 
Belgium in the 1890s that Clostridium botulinum (then known as Bacillus botulinus) 
was established as the causative agent of botulism (1979 translation of van 
Ermengem, 1897). It was not until the latter half of the 20th Century that the ability 
of C. botulinum to cause wound (Davis et al., 1951) and infant botulism (Pickett et 
al, 1976) was established. ■ ,
Analysis of 16S rDNA sequences has shown that C. botulinum actually consists of 
four distinct lineages, separated by a large number of other clostridial species 
(Collins et al., 1994). This finding is additionally supported by DNA hybridisation 
data and Amplified Fragment Length Polymorphism (AFLP) analysis (Collins and 
East, 1998; Hill et al, 2007). Each of the four lineages has other, non-C. botulinum 
species that are much more closely related to it than the other C. botulinum 
lineages (Table 1). However, historical precedent combined with the clinical 
relevance of the botulinum toxin producing phenotype have resulted in a single 
species name being applied to what, in phylogenetic terms, are four separate 
species. Additionally, the botulinum toxin has also been identified in the genomic 
background of other clostridial species e.g. C. butyricum and C. baratii thereby 
rendering the definition of C. botulinum as all strains that produce BoNT not 
factually accurate.
Eight serologically distinct botulinum neurotoxin serotypes (types A-H) have been 
described with six of eight serotypes having subtypes (Montal, 2010; Barash & 
Arnon, 2013). These strains of C. botulinum may produce one or two different
14
serotypes -  strains tend to produce predominantly one type and less of the other, 
this is expressed as e.g. Ab. Strains that encode the genes for two toxin types but 
only produce one are expressed as e.g. A(B). Four of the BoNT serotypes are 
associated with human disease; types A, B, E and F, while C and D are 
associated with animal disease and type G has not been definitively associated 
with any human or animal disease (Arnon et al., 2001). Type H was very recently 
identified (Barash & Arnon, 2013). The workers who identified it have not yet 
released the amino acid or nucleotide sequence of the toxin as they fear that a 
terrorist group could synthesise the toxin before appropriate anti-toxin was 
developed (Dover et al., 2013).
The four lineages (l-IV) of C. botulinum, in addition to forming distinct genetic 
clusters also form four physiologically distinct groups (Table 1) (Allen, 2003). The 
physiology of these lineages differs in toxin type production, growth temperature 
range, proteolytic activity, the host range in which they cause disease and the ' 
sensitivity of their spores to heat treatment (McLauchlin & Grant, 2007). Thus, in 
addition to the genetic differences highlighted, the phenotypic differences between 
these groups justify their reclassification as separate species. Only group I and II 
C. botulinum are commonly associated with human disease. One characteristic 
distinguishing group II organisms is the ability to grow and produce toxin at 
refrigeration temperatures. This heightens the risk of food contamination in the 
modern food supply chain where refrigeration is frequently relied upon to prevent 
bacterial growth (Chen et al, 2008). Group III strains cause disease in animals and 
birds and can grow at temperatures of 15-40°C. There has only been one reported 
case of human botulism caused by a group III organism, an infant botulism case in 
Japan (Oguma et al, 1990). Group IV C. botulinum is also known as Clostridium
argentinense (Suen et al, 1988). Group IV organisms have not been extensively 
studied as they are rare and have caused no confirmed cases of human botulism. 
However, they have been inconclusively linked with Sudden Infant Death 
Syndrome (SIDS) (Sonnabend et al, 1985).
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Table 1: Characteristics of C. botulinum groups l-IV
Group
I II III IV
Neurotoxin types A, B, F B, E, F C, D G
Human disease Yes Yes No No
Growth temperatures
Minimum °C 10 3.3 15 ND
Optimum °C 35-40 18-25 40 37
Minimum pH for growth 4.6 5 5 ND
Proteolytic activity Yes No No Yes (weak)
Related non-neurotoxigenic 
Clostridia C. sporogenes C. beijerinkii C. novyi
C.
histolyticum
Location of neurotoxin 
genes
Chromosome or 
plasmid Chromosomal Phage Plasmid
Overall G+C content 
(mol %) 26-29 27-29 26-28 28-30
Diocrc* of spores (min) 25 <0.1 ' .
Di2i°c* of spores (min) 0.1-0.2 <0.001
ND = not determined
*D (decimal reduction) values are the time taken to kill 90% of organisms at a specific temperature.
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1.4. Botulism Epidemiology
Botulism is a rare but serious disease that can lead to death. There are three main 
forms of human botulism; food borne botulism, wound botulism and infant botulism. 
In addition to these main forms there are other, exceedingly rare forms including 
inhalational botulism, adult intestinal botulism and iatrogenic botulism.
1.4.1. Food borne botulism
Food-borne botulism occurs when food containing preformed botulinum neurotoxin 
is consumed. Botulinum neurotoxin is typically generated when C. botulinum 
spores contaminate the food and are able to germinate and grow due to a suitable 
anaerobic environment and produce toxin. Even small outbreaks of botulism 
constitute public health emergencies due to the extreme toxicity of botulinum 
neurotoxin and the potential for wide distribution of contaminated food possibly 
resulting in large numbers of victims. Cases of botulism can result in significant 
strain on public health and acute care provision as well as having significant 
medical and financial impact. It has been estimated that the average financial 
impact of a case of botulism is $30 million (Peck, 2009). There were 6 reported 
episodes of food-borne botulism in the UK between 1989-2005 resulting in 33 
reported cases and 3 deaths (McLauchlin et al., 2006) with a total of 62 cases 
being recognised between 1922 and 2005. Since 2005 there have been three 
incidents of food-borne botulism, resulting in 5 cases. The largest of these 
incidents was a familial cluster of botulism cases associated with a commercially 
prepared Korma sauce (Browning et al., 2011), while artisanally produced olives 
were implicated in another case (K. Grant, Personal Communication).
(
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The largest recorded outbreak of botulism in the UK was in 1989 when 27 cases 
were associated with commercially prepared hazelnut yoghurt. Yoghurt would not 
normally be considered a botulism risk food due to it's high acidity, however, it is 
thought that BoNT was produced by C. botulinum in the hazelnut conserve used to 
flavour the yoghurt. Other foods associated with botulism in the UK have included 
home preserved mushrooms in oil from Italy, commercially prepared hummus 
stored at room temperature for several weeks before consumption, various 
traditionally prepared foods from Georgia and home preserved pork from Poland 
(McLauchlin et al., 2006). The deadliest outbreak of food-borne botulism in the UK 
was also the first reported outbreak. Consumption of contaminated duck paste at 
Loch Maree in Scotland caused 8 cases of botulism that all resulted in death 
(Leighton, 1923).
One reason for the low incidence of food-borne botulism is the adoption of a 
'botulinum cook' as a standard part of the production of low-acid canned goods. 
This involves heating the canned food to 121°C for 3 minutes. However, changes 
in eating habits such as higher consumption of minimally processed foods stored 
at refrigeration temperatures has changed the risk profile of foods that could be 
potentially associated with botulism (Peck, 2009).
Certain European countries have much higher numbers of food-borne botulism 
cases than the UK. Poland has one of the highest rates of food-borne botulism in 
the world with nearly 1301 incidents between 1984-87 resulting in 1791 cases 
(Table 2). This extremely high number is due to a culture of home food 
preservation, social and economic turmoil resulting in food shortages in the 1980s
and meticulous recording in 1984-87 (Hauschild, 1993). Between 1988 and 1998 
Italy had 412 cases of foodborne botulism, Germany 177, Spain 92 (Galazka & 
Przybylska 1999) while the USA had 597 cases between 1971-89 (Hauschild, 
1993).
More recent data (1990-2000) provides a detailed breakdown of the foods 
implicated in food-borne botulism in the USA (McLauchlin and Grant, 2007). The 
most frequently implicated source was non-commercial preserved fish or marine 
mammals which resulted in 92 cases, these are typically associated with 
indigenous populations in Alaska. Home canned vegetables caused 70 cases with 
asparagus and olives among the produce implicated (McLauchlin and Grant,
2007). An outbreak in 2006 involved temperature abused, commercial carrot juice 
that affected 6 people, all of whom required mechanical ventilation (Sheth et al.,
2008). Only nine cases of botulism were associated with home preserved meat 
(McLauchlin and Grant, 2007). There is a close association between the 
frequency/toxin type of a botulism outbreak (incidents involving one or more 
botulinum cases) and the occurrence and toxin type of C. botulinum spores in that 
particular environment (Hauschild, 1989).
Different botulinum toxin types are associated with different mortality rates in all 
forms of botulism, botulinum toxin type A has a significantly higher mortality in than 
type B (Hauschild, 1993). This is reflected in food borne botulism mortality rates 
associated with different toxin types. In Poland 94% of botulism cases are caused 
by toxin type B and the mortality rate is 3%. By contrast, in Argentina 77% of 
cases are caused by toxin type A and there is a mortality rate of 36%. This pattern
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is repeated in other countries, France has 97% type B cases and a mortality rate 
of 2% while China has 93% type A cases and a 13% mortality rate (Table 2A, 2B), 
although it is difficicult to control for the effect of different standards of healthcare 
in the two countries (Hauschild, 1993). The difference in mortality rate between 
Argentina and China may be due to the relatively small number of cases in 
Argentina (36) compared with China (4377). There also appears to be a 
relationship between food type and toxin type (Table 2C), In countries that have a 
majority of botulism caused by type B strains, the majority of cases are associated 
with meat products while countries with a higher incidence of type A botulism have 
more cases associated with fruit and vegetables. Type E cases are strongly 
associated with the consumption offish and type E producing strains are typically 
found in aquatic and marine environments (Hauschild, 1993).
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Table 2: Foodborne botulism epidemiology. Table adapted from Hauschild et al., 1993. Dates 
in (B) and (C) same as (A).
(A) Summary of the number of outbreaks, cases and fatalities associated with botulism.
Period Outbreaks Cases Fatalities
(%)
Outbreaks/yr Cases/yr
United States 1971-89 272 597 63(11) 14 31
Canada 1971-89 79 202 28(14) 4 11
Argentina 1980-89 16 36 13(36) 2 4
Poland 1984-87 1301 1791 46 (3) 325 448
Czechoslovakia 1979-84 17 30 0 3 3
Hungary 1985-89 31 57 1 (2) 6 11
Yugoslavia 1984-89 12 51 2 8
Belgium 1982-89 11 25 1(4) 1 3
France 1978-89 175 304 7(2) 15 25
Spain 1969-88 63 198 11 (6) 3 10
Portugal 197-89 24 80 0 1 4
Norway 1961-90 19 42 3(7) <1 1
U.S.S.R 1958-64 95 328 95 (29) 14 47
China 1958-83 986 4377 548 (13) 38 168
Japan 1951-87 97 479 110(23) 3 13
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(B) The percentage of cases associated with different toxin types
Outbreaks 
with type 
identified
A (%) B (%) E (%) Other (%)
United States 252 61 21 17 0.4(F)
Canada 76 4 8 88 0
Argentina 13 77 8 0 15 (Af)
Poland 830 3 94 3 0
Czechoslovakia 6 17 83 0 0
Hungary 31 0 100 0 0
Belgium 11 0 55 9 36 (Be)
France 171 0 97 2 0.6 (Ab)
Spain 36 0 92 3 6 (Ab)
Portugal 18 0 100 0 0
Norway 19 0 47 47 5(F)
U.S.S.R 45 33 38 29 0
' China 733 93 5 1 0.4 (Ab)
Japan 97 2 2 96 0
(C) Type of food associated with outbreaks.
Food type or source 
(%)
Outbreaks Meat Fish
Fruit
and
veg
Mixed Homepreserved Commercial
United States 222 16 17 59 9 92 8
Canada 75 72 20 8 0 96 4
Argentina 14 29 21 36 14 79 21
Poland 1500 83 12 5 0 75 24
Czechoslovakia 14 72 7 14 7 100 0
Hungary 28 89 0 4 7 100 0
Yugoslavia 8 100 0 0 0 100 0
France 123 89 3 6 2 88 12
Spain 48 38 8 60 0 90 10
Portugal 23 91 9 0 0 100 0
Norway 19 16 84 0 . 0 100 0
U.S.S.R 83 17 67 16 0 97 3
China 958 10 0 86 4 N/A N/A
Japan 95 - 0 99 1 0 98 2
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1.4.2. Wound botulism
Wound botulism occurs when a wound, typically caused by either traumatic injury 
or puncture associated with injected drug use (IDUs), becomes contaminated with 
spores of Clostridium botulinum. If the spores are present within ah anaerobic 
wound, they can germinate, grow and release botulinum toxin in vivo. The first 
case of wound infection caused by C. botulinum was reported in 1951 in a trauma 
wound patient from California (Davis et al, 1951). Infection of trauma wounds or 
post-operative infection was the only recognised cause of wound botulism until 
1982 when an injecting drug user who was subcutaneously injecting cocaine (‘skin 
popping’) was diagnosed with wound botulism in New York (Weber et al, 1993). 
This led to the recognition of a new type of wound botulism associated with drug 
use -  the majority of which were due to injecting drug users although there have 
been rare cases that are thought to be associated with sinusitis/intranasal cocaine 
abuse. The recognition of this new cause of wound botulism was due to a dramatic 
increase in the number of cases of wound botulism being diagnosed in California 
(Figure 1). The first reported case of wound botulism in an injecting drug user in the 
UK was in 2000, nearly 20 years after the phenomenon was recognised, although 
more cases quickly accrued afterwards. There were 33 reported cases in the UK 
between 2000-2002 (Brett et al, 2004). Wound botulism was the most commonly 
reported form of botulism in the UK between 2000-2009 with 162 cases (Figure 2). 
However, since then the number of wound botulism cases has declined and now 
there are approximately 5 cases of wound botulism per year. Whether there was 
unreported wound botulism prior to 2000 is unclear. Increased recognition by 
clinicians is likely to have played a role in the increase of detection rate with 
outbreaks also be due to contamination of specific batches of heroin (Akbulut et al, 
2005). : ■
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C. argentinense was isolated from a trauma patient with a compound fracture who 
had developed wound botulism in North Carolina, however the patient responded 
well to a mix of type A/type B antitoxin which makes it unlikely that the causative 
agent of the wound botulism was C. argentinense. This highlights the complexity 
of diagnosing disease caused by a spore forming organism like C. botulinum 
(Taylor et al, 2010).
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Figure 1: Incidence of wound botulism in California by wound type (IDU = Injecting Drug 
User), adapted from Werner et al, 2000
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Figure 2: Incidence of wound botulism in the UK and Eire 2000-13, personal communication 
K. Grant and K. Cullen.
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1.4.3. Infant botulism
Infant botulism is a toxicoinfection caused by the colonisation and toxin production 
in the gut of infants less than 12 months old by C. botulinum. It was first 
recognised as a distinct clinical entity by Midura and Arnon in 1976. To date, infant 
botulism has been reported in 26 countries with the USA, Argentina, Australia,
Italy, Canada and Japan reporting the most cases in descending order (see Table 
3).
The majority of infant botulism cases are caused by C. botulinum groups I and II 
. producing toxin types A, B, E, Ab, Ba, Bf (the designation Ab means the strain 
predominately produces type A but also produces small amounts of type B) and in 
one case in Japan a group III organism producing type C (Koepke et al, 2008). 
Toxigenic, non-C. botulinum species including C. baratii producing BoNT/F and C. 
butyricum producing BoNT/E have also been associated with infant botulism in the 
USA, Japan, Italy and the UK (Fenicla and Anniballi, 2009; Personal 
Communication, Grant). C. argentinense producing type G toxin has been 
associated, inconclusively, with a sudden and unexplained infant death in 
Switzerland (Sonnabend et al, 1981). Most infant botulism is caused by group I 
organisms, the fact that their optimal growth temperature is 35-40 °C while group II 
strains optimal growth temperature is 18-25 °C would place the group II organisms 
at a fitness disadvantage to colonise the infant gut.
More than 82% of the reported worldwide cases of infant botulism have occurred 
in the United States (Koepke et al., 2008). The USA had 2419 cases reported 
between 1976 and 2006 (2.1 cases per 100 000 live births), with roughly equal
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numbers of males and females affected (Koepke et al., 2008). In the USA the 
mean age of onset was 13.8 weeks with 90% of cases falling between 2 weeks 
and 6 months although there was a range from less than a week old to 2 years of 
age (Koepke et al., 2008).
The fact that most cases of infant botulism occur in infants less than one year of 
age reflects the ability of the organism to colonise the gut at this stage in the 
infant’s life. The susceptibility of the infant gut to colonisation is a result of an 
immature gut flora combined with an event that perturbs the gut flora, e.g. weaning, 
change of milk formula or antibiotic treatment (Grant et al, 2009; Dodds, 1992b). 
Infant botulism must be the result of a complex host-pathogen interaction as older 
infants, children and adults are frequently exposed to C. botulinum spores in the 
environment and foods without developing disease. Additionally, infant botulism 
remains a rare disease despite the ubiquitous presence of C. botulinum in the 
environment, therefore risk of disease development is likely a factor of exposure 
and host susceptibility caused by perturbation of immature infant gut. An additional 
environmental factor influencing the exposure of infants to C. botulinum is a dry, 
dusty environment. The presence of building works, farms or other activities that 
may create large amounts of dust can constitute risk factors (Long et al, 1985). 
There was double the number of usual cases in the month following the Northridge 
earthquake in California in January 1994, possibly due to more spores being 
released into the air (Underwood et al, 2007). Another piece of evidence in favour 
of the environment being the source of spores that lead to infant botulism is the 
association between the dominant spore type in an area and the major causative 
type of infant botulism cases in that area. Type A cases predominate west of the 
Rocky Mountains in the US while type B cases predominate in the east, matching
the environmental distribution of C. botulinum spores in these areas (Fenicia and 
Anniballi, 2009; Dodds, 1992b).
Honey is the only food proven, both epidemiologically and microbiologically, to be 
associated with infant botulism. Warning labels on pots of honey stating that honey 
should not be given to children less than 1 year old were introduced in the USA in 
the 1970s. The number of infant botulism cases associated with honey there has 
fallen from 39.7% in the 1970s to 4.7% in the 2000s (Koepke et al, 2008). Similar 
warning labels on honey pots are now in place in many other countries including 
the UK, Japan, Canada and Australia.
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Table 3: Reported cases of infant botulism according to country, 1976-2006, adapted from 
Koepke et al., 2008
Location Timeperiod
Total
No.
Type
A
Type
B
Other
types
Toxin type 
not 
reported
Global total, excluding 
United States 1976-2006 542 437 56 12 19
Asia
China 1986-1989 2 0 1 0 1
Japan 1986-2006 22 14 3 2 3
Taiwan 1987 1 0 1 0 . 0
Australia 1978-2006 32 12 15 1 4
Europe
Czech Republic 1979 1 0 1 0 0
Denmark 1995-2000 2 0 0 1 1
France 1983-2006 4 1 3 0 0
Germany 1993-200 4 2 0 0 2
Greece 2006 1 1 0 0 0
Hungary 1995-2002 2 0 0 1 1
Italy 1984-2006 24 4 17 5 0
Netherlands 2000-2005 3 1 2 0 0
Norway 1997-1999 4 4 0 0 0
Spain 1985-2002 9 2 2 0 5
Sweden 1985-2006 3 2 0 1 0
United Kingdom 1978-2001 5 2 2 1 0
Middle East
Israel 1994-2006 2 0 2 0 0
Kuwait 2005 1 0 0 0 1
Yemen 1989 1 0 1 0 0
Canada 1979-2006 27 22' 5 0 0
Mexico 2001 1 1 0 0 0
United States (exc Rhode 
Island) 1976-2006 2419 1079 1310 28 2
South America
Argentina 1982-2005 366 . 366 0 0 0
Chile 1984-1995 3 2 0 0 1
•Venezuela 2000 1 0 1 0 0
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Infant botulism is rare in the UK with only 16 cases reported since 1978, 10 of 
these have occurred since 2006 with two unrelated cases in a single month in 
2007. In terms of risk factors, 5 infants were being weaned, 7 had received honey 
and one had received antibiotic treatment (Grant et al., 2009; K. Grant, Personal 
Communication).
A link between infant botulism and Sudden Infant Death Syndrome (SIDS) was 
first suggested in 1976 by Midura and Arnon. Studies of necropsy specimens from 
SIDS cases have found varying results depending on the location of the study. 
SIDS cases were screen for C. botulinum toxin or organism in a study in Australia 
that included 248 infants. None of the infants were positive for toxin or organsim 
(Byard et al, 1992). Other studies have found more significant results - 4.3% of 
280 patients in a study in California (Arnon et al, 1978) and 15% of 70 cases in a 
study in Switzerland (Sonnabend et al, 1985) were positive for either botulinum 
toxin or organism. The Swiss study that detected toxin in 15% of cases was 
unusual in that the toxin types C and G were also screened for, this study was also 
the first report of type G being associated with human disease (Sonnabend et al, 
1985; Sonnabend et al, 1981). This association is however, supported by limited 
evidence and remains controversial. There are likely many different causes of 
SIDS, of which infant botulism appears to be one in some areas of the globe.
1.4.4. Other forms of botulism
There are four naturally occurring forms of botulism, three of which (food, wound 
and infant) are covered above. The fourth, adult intestinal colonisation is very rare 
(Fenicia & Anniballi, 2008), and has been associated with host factors such as 
Crohn's disease or having undergone bowel surgery which disrupt the intestinal
flora, allowing C. botulinum spores the chance to germinate and produce toxin 
within the host (Sheppard et al., 2012).
Two documented man-made forms of botulism are inhalational botulism and 
iatrogenic botulism (Sobel, 2005). There has been one known incident of 
inhalational botulism, in German laboratory workers in 1962 (Sobel, 2005). 
Inhalational botulism is also a possible route of transmission for deliberate release 
of botulinum toxin (Arnon et al., 2001). Iatrogenic botulism is caused by injection of 
toxin for cosmetic or therapeutic purposes. Recommended doses for cosmetic 
treatment are too low to cause systemic disease but injection of unlicensed, highly 
concentration botulinum toxin has caused severe botulism (Sobel, 2005). There 
have been anecdotal reports of botulism after injection of botulinum toxin to control 
muscle movement disorders as the doses used for this are much higher than the 
recommended cosmetic dosage (Sobel, 2005).
,  ■ ■ . r  '
Botulism also affects many animal species. Group III strains of C. botulinum 
producing toxins C and D cause botulism in livestock animals and birds. Type C 
toxin affects most animal species, notably wild ducks, pheasant, chickens, mink, 
horses and cattle (Degernes, 2008; Wylie & Proudman, 2009). Type D is best 
known for outbreaks in cattle with the usual source of intoxication is spoiled silage 
or fodder (Lindstom et al., 2010). Prevalence in animals is not well known but 
estimates of 10 000 to 50 000 birds a year die from botulism. Dogs, cats and pigs 
are comparatively resistant to botulism for reasons that remain unclear (Critchley, 
1991).
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1.4.5. Symptoms, diagnosis and treatment of botulism
Food-borne botulism has a period between toxin consumption and symptom 
development that ranges from 6 hours to 10 days, with symptoms generally 
apparent 18-36 h after consumption of toxin (McLaughlin & Grant, 2007). Typically, 
the first symptoms will be gastrointestinal (e.g. vomiting and diarrhea) followed by 
other symptoms such as blurred/double vision, drooping eyelids, difficulty 
swallowing and slurred speech while maintaining an alert mental state (Table 4). 
There may not always be gastrointestinal symptoms. Symptoms progress via a 
characteristic descending bilateral flaccid paralysis to ventilatory paralysis and 
potentially, death (McLauchlin et al., 2006).
The incubation time of wound botulism is hard to determine as most patients will 
inject drugs multiple times per day, so it is difficult to know at what time exposure 
occurred. The neurological symptoms are indistinguishable from food-botulism, but 
there are no gastrointestinal symptoms. The abscess is often a minor lesion, 
resembling mild cellulitis (Sobel, 2005).
The initial symptoms of infant botulism are less apparent than food-borne botulism 
with the most common and earliest being constipation. There is usually a weak cry 
and general weakness, feeding difficulty, poor sucking, lethargy, lack of facial 
expression, irritability and progressive ‘floppiness’. Ocular dysfunctions including 
ptosis and dilated and sluggish pupils usually become evident during the course of 
the disease. Respiratory arrests frequently occur but are rarely fatal due to access 
to infant intensive care medicine including artificial ventilation. Diagnosis is difficult 
due to lack of specific symptoms and variety of disease severity as well as the
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rarity of disease. Identification of BoNT or C. botulinum in the stool is important for 
diagnosis (Dodds, 1992b; Lindstrom & Korkeala, 2006). Most infant botulism 
patients require hospitalisation and then return to full health, although there are a 
small number of extremes case where out patient care is sufficient or death occurs. 
Of the 2419 cases'in the USA between 1976 and 2006, 9 patients (0.4%) did not 
require hospitalisation and 20 infections resulted in the death of the infant (0.8%) 
(Koepke et al., 2008). Mild cases are likely under-diagnosed.
Botulinum neurotoxin (BoNT) A is associated with more severe disease than 
BoNT/B or E (Woodruff et al., 1992). People intoxicated with BoNT/A consult 
clinicians earlier, are more likely to need artificial ventilation and require longer 
hospitalisation (Hughes et al, 1981). Recovery requires the growth of new 
neuromuscular connections and it is not uncommon for patients to require 2-8 
weeks of ventilator support; whilst some patients may require several months of 
support before the return of muscular function (Shapiro et al., 1998). One factor 
behind the longer effects of BoNT/A compared with BoNT/E is that BoNT/E is 
ubiquitylated and rapidly degraded in cells while BoNT/A appears much more 
stable (Tsai et al., 2010).
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Table 4: Symptoms of foodborne botulism caused by toxin types A and B*
Symptoms Cases, % Signs Cases, %
Fatigue 77 Alert mental status 90
Dizziness 51
Ptosis 73
Double vision 91 Gaze paralysis 65
Blurred vision 65 Pupil dilation 44
Nystagmus 22
Dysphagia 96
Dry mouth 93 Facial Palsy 63
Dysarthria 84
Sore throat 54 Diminished gag reflex 65
Tongue weakness 58
Dyspnea 60
Arm weaknesss 75
Constipation 73 Leg weakness 69
Nausea 64 Hyporeflexia 40
Vomiting 59 Ataxia 17.
Abdominal cramps 42
Diarrhea 19
Arm weakness 73
Legweakness 69
Paresthesia 14 N -
*Data is from the 1981 Hughes et al study on outbreaks of botulism reported in the United 
States in 1973-74, number of patients varied from 35 to 55.
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Botulism is a clinical diagnosis with laboratory confirmation by detection of BoNT 
and isolation of C. botulinum. Diagnosis of botulism is based on a combination of 
the presence of compatible clinical symptoms and laboratory confirmation through 
detection of BoNT in serum, faeces or suspect foods. Diagnosis and subsequent 
treatment should not depend on the results of laboratory testing due to the life- 
threatening nature of the disease and need for urgent treatment (Lindstrom and 
Korkeala, 2006).
The gold standard diagnostic test for botulism is the detection of BoNT by mouse 
.bioassay (MBA) (Lindstrom and Korkeala, 2006). Faecal material or a suspected 
source of intoxication is homogenised, filtered (to prevent infection) and injected 
intra-peritoneally into mice. If the sample is positive for BoNT then the animals will 
show signs of intoxication within 1-4 days. If infection by a non-proteolytic strain is 
suspected the homogenised sample is treated with trypsin to activate the toxin. 
This is done as standard as it is not usually known whether an implicated 
organism is proteolytic or not. Neutralisation of classic symptoms in the MBA using 
specific anti-sera confirms the presence of BoNT and also determines toxin type. 
There are numerous issues with the MBA including the fact that it takes 4 days to 
return a negative result and the cost and ethically sensitive nature of animal 
testing. Also, the sensitivity of the MBA at identifying wound botulism infections is 
not ideal for all scenarios; one study found that only 50/73 (68%) wound botulism 
tissue samples were positive by MBA (Wheeler et al., 2009). Therefore molecular 
techniques have been widely adopted as a rapid, sensitive and specific test to 
supplement the MBA. Multiplex conventional polymerase chain reaction 
(Lindstrom et al., 2001) and real time polymerase chain reaction (Akbulut et al., 
2004; Grant et al., 2009) assays have been developed for the detection of the
different subtypes of BoNT encoding gene. These assays can be used to screen 
suspect material/patient samples to confirm or reject a clinical diagnosis (K. Grant, 
personal communication).
In addition to direct toxin or molecular testing, the isolation and identification of the 
causative organism is important for reference microbiology and outbreak 
investigation. C. botulinum isolation medium uses a base of egg yolk agar 
supplemented with cycloserine, sulfamethoxazole and trimethorpim to select group 
I C. botulinum. The presence of the egg yolk agar enables the lipase reaction 
typical of C. botulinum (Lindstrom & Korkeala, 2006).
Symptomatic treatment, in particular the use of artificial respiration to alleviate 
respiratory failure, has been vital in reducing botulism mortality (Sobel, 2005). In 
addition to intensive care treatment, BoNT antitoxin is a widely used therapeutic. It 
binds and inactivates BoNT, thus preventing the toxin binding at the 
neuromuscular junction, to be effective antitoxin needs to be administered early on 
in the onset of disease, preferably < 24 h after onset of symptoms so it can 
deactivate circulating toxin before the BoNT enters the neuron (Sobel, 2005). 
Antibiotic treatment is not advised in treating food or infant botulism as lysis of any 
C. botulinum may lead to an increase in the amount of circulating toxin. However, 
metronidazole is often used to treat the wound botulism, after antitoxin treatment.
Until recently the only treatment for infant botulism was supportive therapy such as 
artificial ventilation. Equine antitoxin used for treatment in adult botulism is not 
advised due to the high risk of infants suffering a serious adverse reaction.
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However, in 2003 an immune globulin treatment was licensed by the Food and 
Drug Administration in the USA and is now available from the Infant Botulism 
Treatment and Prevention Program at cost (£64000). The treatment is known as 
Botulism Immune Globulin Intravenous (BIG-IV or BabyBIG) and is produced from 
high-titre immune plasma donated by volunteers who have been immunized with 
pentavalent (A-E) botulinum toxoid. Treatment with BIG-IV has resulted in a total 
of 30 years of avoided hospital stay and saved more than $50 million in hospital 
costs. It cost approximately $10 million and took nearly 15 years to develop, 
license and produce BIG-IV (Arnon, 2007). Even after antitoxin administration, it is 
still vital that supportive therapy is applied to ensure a full recovery.
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1.5. Botulinum Toxin
The botulinum neurotoxin (BoNT) is a bacterial exotoxin produced by C. botulinum 
and, less frequently, by other Clostridium species. It is widely regarded as the 
most toxic protein (Lamanna, 1959; Simpson, 2004). The potency of BoNT is such 
that no one has yet quantified the minimum concentration, or minimum number of 
molecules required to disrupt a vulnerable cell (Simpson, 2004) although it has 
been estimated that 1 gram of crystalline toxin would be sufficient to kill more than 
1 million people (Arnon, 2001). This potency is all the more remarkable 
considering the long and complex route between the toxin point of origin (i.e. the 
gut in food-borne and infant botulism) and the final site of toxin activity (i.e. the 
pre-synaptic neuron cytosol) (Simpson, 2004).
A neurotoxin is a toxin that acts specifically on nerve cells, neurotoxins are among 
the most potent of natural and man-made toxins (Simpson, 2004; Munro et al, 
1994). Botulinum and tetanus neurotoxins are orders of magnitude more toxic than 
any other naturally produced neurotoxins (Table 5).
Seven botulinum neurotoxin serotypes (types A-G) have been described with six 
of seven serotypes having subtypes (Montal, 2010). The different BoNT serotypes 
vary by 35-70% of their amino acid sequence while BoNT subtypes vary by 
between 2-32% of their amino acid residues (Peck et al, 2011).
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Table 5: Potency of various natural neurotoxins (adapted from Gil, 1982).
Source Test LD50 pg/kg
Bungarus multicinctus, Taiwanese 
banded krait Mouse, intraperitoneal LD 50 14
Oxyuranus microlepidotus, Australian 
taipan Mouse, intravenous LD 50 2
Clostridium botulinum Mouse, intraperitoneal LD 50 0.0012
Clostridium tetani Mouse, unknown LD 50 0.001
Crotalus durissus cascavella, 
Brazillian rattlesnake Mouse, intravenous LD 50 82
Naja haje, Egyptian cobra Mouse, sub-cutaneous LD 50 50
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1.5.1. Bacterial toxin complexes
Botulinum toxin is produced as part of a non-covalently associated, 300-900 kDa 
protein complex together with associated non-toxic proteins (ANTPs) (Sugii & 
Sakaguchi, 1975). The full contribution of the ANTPs to BoNT toxicity remains 
controversial (Simpson, 2004; Fujinaga, 2010).
Botulinum neurotoxin is not the only bacterial protein toxin produced as part of a 
hetero-multimeric toxin complex; the insect pathogens Xenorhabdus nematophilus 
and Photorhabdus luminscens also produce such complexes. These pathogens 
reside in the gut of entomophagous nematodes and are released into the insect’s
hemocoel (circulatory system) by the nematode where they grow, produce toxin
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and typically kill the insect with 24-48 h (Bowen et al., 1998). The toxins produced 
by these two species are heteromultimeric toxin complexes, known collectively as 
Tc family proteins (Waterfield et al., 2001). The toxicity and breadth of insect host 
susceptibility made the P. luminescens toxin complex a potential candidate for use 
in transgenic plants as a form of insect control (Bowen et al, 1998). The three part 
toxin complex is encoded by co-located genes (Waterfield et al., 2001) and was 
first identified in P. luminescens but has been more thoroughly characterised in X. 
nematophilus. In this species the three parts of the toxin complex are known as as 
XptA2 (280 kDa); XptB1 (170 kDa); and XptC1 (77 kDa) and bind together with a 
stoichiometry of 4:1:1 resulting in a toxin complex with an overall molecular weight 
of around 1 megadalton. The XptA2 tetramer binds to insect gut membranes and 
forms a pore in a model lipid bilayer system clearly implying a role in transport 
across the gut epithelium. XptB1 and C1 form a strongly associated complex 
which then binds to the tetrameric XptA2 forming the complete and fully active
toxin complex (Sheets et al, 2011). The class C protein component is an ADP- 
ribosyltransferase which modifies actin causing it to cluster resulting in disruption 
to the insect gut epithelium. The role of class B proteins is thought to be a 
chaperone or link between the A and C components (Lang et al, 2010). 
Orthologues of the toxin complex genes have been found in a range of bacterial 
pathogens associated with insects (e.g. Yersiniae). The P. lumienscens toxin 
complex shows that a large toxin complex can be essential in toxin activity 
(Sergeant et al., 2003).
Another bacterial toxin produced as part of a large protein complex is the pertussis 
toxin, produced by Bordetella pertussis, causative agent of whooping cough. 
Pertussis toxin (PTX) is one of the most complex soluble bacterial proteins and is 
composed of 5 subunits arranged in an AB structure (Tamura et al., 1982). The 
activity subunit consists of a single protein, an enzyme with an ADP-ribosylating 
activity. The binding subunit consists of the other 4 proteins that make up PTX, in 
a 1:1:2:1 stoichiometry (Stein et al., 1994). The heterologous binding subunit 
allows the PTX to bind to a variety of target cells, including almost all mammalian 
cells, with binding mediated by a variety of glycoproteins, glycolipids and receptor 
proteins. This promiscuity of binding may account for the wide spectrum of 
biological activities of the PTX (Locht et al., 2011).
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1.5.2. Botulinum toxin and the associated non-toxin proteins
Botulinum neurotoxin is encoded alongside and co-expressed with an associated 
non-toxic protein encoding gene cluster that is 12000 base pairs (bp) to 14000 bp 
in length, depending on toxin gene cluster subtype. There are two known subtypes
of toxin gene cluster-the haemagglutinin (HA) type (Henderson et al., 1996) and 
the OrfX type (Dineen et al., 2004). The HA type gene cluster consists of bont, 
ntnH and botR which are encoded on the forward strand and ha33, ha17 and ha70 
which are encoded on the reverse strand (Figure 3A). The naming of these genes 
varies in the literature, this is the nomenclature that will be used here. In C. 
botulinum A l ATCC 19397 bont/A is 3886 bp long encoding a 149.4 kDa protein, 
ntnH is 3581 bp long encoding a 138.2 kDa protein and botR is 536 bp long 
encoding a 21.7 kDa protein. In ATCC 19397 ha33 is 881 bp long encoding a 33.8 
kDa protein, ha17 is 440 bp long encoding a 17 kDa protein and ha70 is 1881 bp 
long encoding a 71.1 kDa protein.
The genomic arrangement of the OrfX type cluster (Figure 3B) differs from that of 
the HA cluster. The OrfX cluster consists, with some variants, of bont, ntnH and 
p47 encoded on the forward strand and botR, orfX/1, orfX/2 and orfX/3 encoded 
on the reverse strand. In C. botulinum A3 Loch Maree bont/A is a 3879 bp gene 
encoding a 148.6 kDa protein, ntnH is 3480 bp long encoding a 134.6 kDa protein, 
p47 is 1248 bp long and encodes a 47.4 kDa protein. On the reverse strand botR 
is 552 bp long and encodes a 22.2 kDa protein, orfX/1 is 429 bp long and encodes 
a 16.5 kDa protein, orfX/2 is 2253 bp long and encodes a 84.3 kDa protein and 
orfX/3 is 1473 bp long and encodes a 55.2 kDa protein. BoNT/A1, A5, B, C, D and 
G have been identified encoded in HA gene clusters while BoNT/A 1 (rarely), A2, 
A3, A4, E and F have been identified encoded in OrfX gene clusters. A schematic 
of the various arrangements of the HA and OrfX encoding gene clusters can be 
seen in Figure 4. BoNT/H, which has only recently been identified, in a bivalent Bh 
strain, is encoded as part of an OrfX cluster.
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Figure 3: Genomic arrangement of (A) bont/A1 in a HA gene cluster from C. botulinum A1 
ATCC 19397 and (B) bont/A3 from C. botulinum A3 NCTC 2012 in an OrfX gene cluster.
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Figure 4: The different neurotoxin cluster arrangement in HA+ve/OrfX-ve strains, HA- 
ve/OrfX+ve strains and the bivalent A5b strain.
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The BoNT-HA complex ranges from 300-900 kDa depending on which ANTPs 
form the toxin complex. These different complexes are known as 12S, 16S and 
19S and the ANTPs present in each one can be seen in Figure 5. Multiple different 
complex sizes can be identified within the same culture and their relative 
abundance depends on strain, serotype and growth conditions (Sugii & Suguyama, 
1975).
The toxin complexes of strains encoding BoNT/A2-OrfX have been examined (Lin 
et al., 2010). They only purified one 300 kDa BoNT complex, composed of 
BoNT/A2 and NTNH, with no OrfX cluster proteins. Previous work by the same 
group had found that bont, ntnH and p47 were transcribed on the same tri-cistronic 
mRNA(Dineen et al., 2004). Other workers examining the complexes formed by a 
BoNT/E producing strain found a spontaneous association between BoNT/E and 
the OrfX proteins (Kukreja & Singh, 2007).
A recent paper has shed more light on the role of the HA toxin complex in the 
toxicity via the oral route of the botulinum toxin (Lee et al., 2013). They reported 
that the BoNT 16S protein complex consisted of 14-subunits with a combined 
molecular weight of -760 kDa (Figure 6). They proposed a model whereby the 16S 
protein complex is divided into two structurally and functionally independent sub­
complexes. One that consists of BoNT-NTNH while the other consists of 
HA70:HA17:HA33 in a 3:3:6 stoichiometry (Lee et al., 2013).
46
9S 12S 16S 19S
BoNT
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HA33
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HA70
Figure 5: The different compositions of the complexes known as 9S, 12S, 16S and 19S. 
BoNT is Botulinum Neurotoxin, NTNH is Non-Toxic Non-Haemagglutinin, HA33,17 and 70 
have haemagglutinin properties. NTNH and HA33, 17 and 70 are Associated Non-Toxic 
Proteins (ANTPs).
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Figure 6: The molecular architecture of the large BoNT/A toxin complex (A) 3D-EM 
reconstruction of large BoNT/A toxin complex. The red arrow indicates the viewing direction 
of (C). (B) Surface representation large BoNT/A toxin complex in the same orientation as (A). 
(C) A different view of large BoNT/A toxin complex. (D) An open-book view of the interface 
that is highlighted in the box in (B)
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1.5.3. The role of the ANTPs in BoNT intoxication
The toxicity of BoNT via the oral route is increased 100-1000 fold by the presence 
of associated non-toxic proteins (ANTPs) but the full role of the ANTPs in the 
intoxication of a botulinum poisoning victim has not been elucidated (Ohishi et al., 
1977; Sakaguchi, 1982; Kukreja & Singh, 2007). The ANTPs bind non-covalently 
to the toxin forming a heterogenous complex of 290-900 kDa. The oral toxicity of 
BoNT increases with incremental association with ANTPs. Type B toxin shows this 
effect most dramatically with 12S toxin 20 times more toxic than BoNT alone and 
16S 1000 times more toxic than 12S (Sakaguchi, 1982). This increase is, at least, 
partially explained by the close interlocking interaction of BoNT and NTNH 
resulting in protection against acids and proteases in the gut (Gu et al., 2012).
Botulinum toxin proteins are too large to be efficiently taken up in the gut up by 
paracellular diffusion. Toxin uptake through the gut epithelium occurs by a process 
of receptor binding to epithelial cells with the upper small intestine being the most 
important site of toxin uptake in both infant and food botulism (Fujinaga, 2010). At 
present there are two schools of thought as to how the toxin crosses the gut 
epithelium. The main difference between them is whether the moiety responsible 
for toxin binding to the gut epithelium is on the toxin or toxin complex. Simpson 
and colleagues, have argued that the binding capability is mediated primarily by 
the toxin itself. The counterview, held by Oguma and associates, is that the 
binding domain is present on the toxin complex.
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In vitro experiments have shown that in the absence of ANTPs BoNT/A and 
BoNT/B bind to polarized human intestinal epithelial cells and undergo 
transcytosis from the apical to basolateral side (Maksymowych & Simpson, 1998). 
The binding site on the toxin is proposed to be on the carboxy-terminal portion of 
the heavy chain, which is also the location of the neuronal cell-binding site 
(Maksymowych & Simpson, 2004). Another parallel with binding to neuronal cells 
is that gangliosides, including GD1b and GTib, and the SV2 protein have been 
implicated in the transcytosis of BoNT/A through polarised human epithelial cell 
lines (Gaco-2 orT84 cells) (Couesnon et al, 2009). Once bound, BoNT/A is 
transported through polarized human intestinal epithelial cells in 30-60 minutes.
No significant difference in transcytosis was found between BoNT/A in pure and 
complexed states after 120 minutes when assayed by mouse bioassay. BoNT/A 
passage rate was 10-fold more efficient through an intestinal crypt cell line (m-ICCi2) 
which has a higher level of SV2 proteins than Caco-2 cells (Couesnon et al, 2008). 
These studies found no significant increase in toxin transcytosis if the ANTPs were 
present.
A different mechanism was proposed following experiments using ligated intestinal 
loops of guinea pigs and type C toxins which showed that only when toxin was 
complexed with the NTNH and HA proteins did it bind the microvilli of the upper 
small intestine via sialic acid residues in cell surface glycoconjugates (Fujinaga et 
al, 1997). Type C toxin in complex with NTNH and HA proteins was shown to bind 
and enter the human intestinal epithelial cell line (HT-29) via cell surface sialic acid 
containing glycoproteins. This binding activity was much less significant in the 
absence of the HA proteins (Nishikawa et al, 2004) leading to speculation that the 
HA proteins may play a pivotal role in the absorption of BoNT from the lumen of
the gut. Studies on type D toxin also implicated the HA proteins in having a key 
role in transcytosis of this serotype (Niwa et al, 2007).
These sets of experiments propose directly opposite ideas. However, most of the 
work was done using in vitro cell lines that are not always physiologically relevant. 
In terms of the initial binding site of the BoNT complex to the gut epithelium neither 
BoNT nor the ANTPs can be ruled out and the true situation is likely to be a 
combination of both. There may also be subtype specific modes of toxin binding to 
the gut epithelium, as there are for binding of the toxin to neuronal cells.
Evidence has recently emerged which suggests that the role of the ANTPs may be 
involved in more than just binding; HA from BoNT/B has been found to disrupt the 
epithelial barrier by opening intercellular tight junctions (Matsumara et al, 2008). 
When 16S toxin complex was added to the apical side of Caco-2 cells there was a 
time-dependent decrease in transepithelial resistance (TER, a measurement of the 
‘intactness’ of a membrane) with almost complete abolishment by 48 h 
(Matsumara et al, 2008). This epithelial disruption resulted in 10-fold more BoNT/B 
crossing Caco-2 monolayers after 24 h when toxin complex was used rather than 
just BoNT or BoNT/NTNH. The epthelial disruption may have been dismissed as 
non-specific deterioration of the in vitro membrane in previous experiments. The 
TER disruption was not observed when buffer, pure toxin or toxin complexed with 
NTNH was applied. TER was maintained if the toxin complex was treated with 
anti^HA antibodies before application to cells while disruption still occurred if the 
toxin complex was treated with anti-BoNT antibodies prior to application 
(Matsumara et al., 2008).
The disruption of the epithelium occurs from the basolateral side of the gut 
epithelium. When the toxin was added basolaterally both the 16S toxin complex 
and the HA proteins alone caused abolishment of TER within a few hours rather 
than 48 h when applied apically. No cell death was detected indicating a specific 
mode of action in the abolishment of TER (Matsumara et al., 2008). The in vivo 
effect was measured by assaying the intestinal absorption of an inert fluorescein 
dextran for which no active take up mechanism exists in the gut (Matsumara et al., 
2008). When mouse intestinal loops were treated with ANTPs uptake of 
fluorescein dextrans of 4 kDa and 10 kDa were strongly enhanced, uptake of a 
150 kDa fluorescein dextran was weakly enhanced. The ANTPs were 
intraintestinafly co-injected with BoNT/NTNH into mice reducing the time until 
death two-fold. As the ANTPs were not complexed with the BoNT/NTNH this effect 
was not due to protection from digestion. Thus the ANTPs seem to compromise 
the intestinal barrier function facilitating the absorption of BoNT and other proteins 
by passive diffusion (Matsumara et al, 2008).
Further work by the same group revealed that BoNT/B HA disrupts epithelial 
cadherin (E-cadherin), a calcium dependent cell adhesion protein involved in tight 
end junction binding (Suguwara et al., 2010) (Figure 7). There is variation between 
animal species in their susceptibility to different BoNT types. This variation could 
be due to the specificty of interaction between the products of HA genes encoded 
alongside those toxin types and the epithelium protein E-cadherin (Suguwara et al., 
2010). BoNT/B HA interacts with human, mouse and bovine E-cadherin but not rat 
or chicken. Avian botulism caused by type B strains is rare and birds have been 
shown to be resistant to BoNT/B, especially when administered orally (Gross &
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Smith, 1971). HA from BoNT/C encoding strains, which don't cause human 
botulism, is unable to interact with human E-cadherin (Suguwara et al., 2010).
Several pathogens (Bacteroides fragilis, Porphyromonas gingivalis and Candida 
albicans) produce proteases that cleave E-cadherin, leading to epithelial barrier 
disruption and tissue invasion. BoNT/B HA also disrupts the epithelial barrier in an 
E-cadherin mediated way but without proteolytic cleavage -  the precise 
mechanism remains unknown (Sugawara et al, 2010).
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Figure 7: BoNT/B disrupts epithelial tight junctions via an E-cadherin dependent mechanism. 
A diagram of the location of tight junctions within the epithelial barriers (top) and a 
schematic of the tight junction itself (bottom). The protein complexes responsible for tight 
junction integrity are shown in green and include E-cadherin which is key to the integrity of 
the tight junction (adapted from Gruenheid et al, 2003).
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These discoveries led to a 3-step model for BoNT crossing the gut epithelium 
being proposed. Step 1 is transcytosis mediated by either HA or BoNT heavy 
chain, step 2 involves basolateral HA disrupting E-cadherin, damaging the gut 
epithelium and facilitating step 3, the non-specific paracellular movement of 
macromolecules, including BoNT to the basolateral side of the gut epithelium
i
(Fujinaga, 2010). This model portrays the BoNT complex as a multifunctional , 
protein assembly equipped with the machinery to efficiently breach the intestinal 
barrier enabling the toxin to act on peripheral Cholinergic cells.
As stated previously the toxin can be produced as part of two different toxin
complexes, the HA type and the OrfX type. The previous paragraphs describe the
\ '
HA complex as most research has been done on this type due to the fact that 
most isolates from clinical cases, particularly of food botulism, have been found to 
be caused by HA encoding strains. The toxin complex type is rarely determined for 
clinical cases of botulism, as it is not deemed clinically relevant. However, 
investigating the distribution of HA and OrfX toxin complex types among clinical 
strains from different forms of botulism may provide insight into the differences
between the two toxin complex types and any associations with food, wound or
(
infant botulism.
Insight into the possible role of the ANTPs can be gained by comparing the 
situation with the botulinum neurotoxin with that of the related tetanus neurotoxin 
(TeNT). Two striking dissimilarities between BoNT and TeNT are that TeNT lacks 
a toxin complex and is incapable of poisoning via oral ingestion. The fact that 
TeNT causes intoxication through infected wounds indicates that ANTPs are not
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necessary for this to occur (Singh et al, 1995). BoNT and tetanus neurotoxin are 
closely related proteins with approximately 30% amino acid identity and similar 
modes of action (Montecucco & Schiavo, 1994).
Recent work has been done on the structure and function of the BoNT complex 
(Lee et al., 2013). It was found that the hetero-dodecameric, 470 kDa complex 
(HA70:HA17:HA33 in a 3:3:6 stoichiometry) facilitates the absorption through the 
gut epithelium. The absorption is mediated by nine glycan-binding sites on the HA 
sub-complex that form multivalent interactions with carbohydrate receptors on 
intestinal epithelial cells. Competitive antagonists of these carbohydrate receptors 
blocked intoxication via the oral route in mice (Lee et al., 2013). It was also found 
that the disruption of the gut epithelium by the HA sub-complex was more effective 
when applied from the basolateral side than the apical side, mirroring the findings 
of Sugawara et al. (2010).
1.5.4. Major steps in botulinum neurotoxin action
Botulinum neurotoxin is synthesised as a single-chain, 150 kDa polypeptide. The 
precise mechanism by which the toxin is released from the bacterial cell remains 
unelucidated. Botulinum neurotoxin does not have a signal peptide indicating that 
it is secreted by a non-signal peptide secretion system such as the flagella export 
apparatus (Rao et al, 2007).
In order for BoNT to inhibit cholingeric transmission it must first be activated. This 
activation takes the form of host or endogenous proteases nicking the single chain 
polypeptide produced by the bacteria to create a dichain consisting of a heavy
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chain (around 100 kDa) and a light chain (around 50 kDa) which are linked by a 
disulphide bond (Simpson, 2004; Barth et al., 2004).
The toxin complex spontaneously disassociates at the physiological pH of 7,4 and , 
ionic strength it is exposed to after it has crossed the gut epithelium (Simpson, 
2004). Once BoNT has crossed the gut epithelium it enters the circulation and 
then has to exit the vasculature and enter the extracellular space in the vicinity of 
the peripheral cholinergic nerve ending. However, the mechanism for this egress 
is unknown with no studies performed on this aspect of BoNT action (Simpson, 
2004). It is known that large molecules can diffuse between vascular endothelial 
cells which raises the possibility that some of the toxin egress is due to passive 
diffusion. The fact that BoNT cannot pass across the much less permeable blood 
brain barrier lends a certain amount of strength to this hypothesis. However, much 
work needs to be done before any certainty can be accorded to this idea and such 
a non-specific mechanism seems unlikely for account for the transfer a potent 
toxin (Simpson, 2004).
Once in the vicinity of the pre-synaptic cholinergic nerve cell, BoNT is taken up by 
a four-step process before exerting its effect, namely:
1. Binding to the plasma membrane
2. Receptor mediated endocytosis
3. pH-induced translocation across the endosome membrane
4. Intracellular cleavage of target protein
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The first step, the binding of BoNT to nerve cells, occurs according to a dual 
receptor model involving two types of receptor; membrane gangliosides and 
synaptic vesicle proteins.
BoNT first binds to gangliosides that are enriched in neuronal plasma membranes, 
specifically disialo- and trisialo- gangliosides (GD1b, GT1bs), with affinities in the 
nM range (Montal, 2010). BoNT/D is the only sub-type that hasn't been shown to 
bind gangliosides but it binds phospholipid phosphatidylethanolamine instead 
(Montal, 2010). One proposed model involves a two step process; the initial 
binding of the toxin is mediated by gangliosides that increases the toxin 
concentration in the vicinity of the plasma membrane, the toxin can then diffuse in 
the plane of the membrane, bind it’s protein receptor and be endocytosed 
(Stenmark et al, 2008). BoNT crosses the neuronal cell membrane by essentially, 
hitchhiking with a vesicle that is being recycled (Figure 8). The neuronal membrane 
protein receptor for BoNT/A, E and F is the human synaptic vesicle protein SV2 
(Synaptic Vesicle protein 2) (Dong et al., 2006; Montal, 2010). BoNT binds to the 
SV2 on the luminal surface of the synaptic vesicle and is then endocytosed when 
the vesicle is recycled. This relationship between synaptic vesicle release and 
BoNT/A entry also means that the most active nerve cells are intoxicated first 
(Dong et al, 2006). BoNT/B and G employ a similar mechanism but binding to 
different luminal secretory vesicle proteins, synaptotagmin I and II (Dong et al, 
2003). It is thought that BoNT/C only binds to gangliosides and BoNT/D only binds 
to phosphatidylethanolamine and that neither have a protein receptor (Tsukamoto 
et al, 2005).
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Figure 8: the binding of BoNT to the luminal surface of a recycling synaptic vesicle. The 
illustration depicts the combined role of polysialogangliosides (purple) and a synaptic 
vesicle (SV) protein (SV2 or synaptotagmin; orange) in mediating botulinum neurotoxin 
(BoNT)-neurospecific binding and entry into neurons after the retrieval of the vesicle. It 
suggests additional low-affinity interactions with other molecules (lipids and/or proteins) of 
the SV membrane (green; modified from Montecucco et al. 2004). Multiple interactions with 
molecules of the SV membrane would allow almost irreversible neuron binding, which 
would then become completely irreversible on vesicle fission from the presynaptic 
membrane. The yellow and grey areas denote the different compositions of the SV and 
presynaptic membranes, respectively. H, heavy chain of BoNT; L, light chain of BoNT; 
VAMP, vesicle-associated membrane protein. Adapted from Verderio et al., 2006.
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In order to disrupt it's cytosolic target, botulinum neurotoxin must escape the 
endosome (i.e. the recycled vesicle). This occurs in a pH dependent, manner 
similarly to diphtheria and other bacterial toxins (Simpson, 2004). The normal 
acidification of the endosome has two noteable effects on BoNT, the first of which 
is that it causes a major conformational change in the heavy chain. This, 
conformational change results in the heavy chain being inserted into the 
endosomal membrane where it acts as a transmembrane channel/chaperone, a 
dynamic structural device that achieves translocation of the light chain through the 
endosomal membrane (Koriazova and Montal, 2003). The heavy chain also 
prevents aggregation of the light chain that would otherwise occur under acidic 
conditions. The second effect is a partial unfolding of the light chain allowing it to 
pass through the channel formed by the heavy chain (Fischer and Montal, 2007). If 
the toxin is not nicked (i.e. is a single polypeptide rather than two polypeptides 
linked by a disulphide bond) then the channel can form but is occluded by the light 
chain that remains in the vesicle. The light chain and membrane inserted heavy 
chain dissociate when the disulphide bond linking the two is reduced by the 
naturally reducing conditions in the cytosol. Once in the neutral pH of the cytosol 
the light chain refolds, regaining its active state, allowing the light chain to cleave 
its target substrate. In summary BoNT egress from the endosome requires acidic 
pH, non-reducing conditions inside the endosome and a neutral pH, reducing 
conditions in the cytosol (see Figure 9) (Koriazova and Montal, 2003; Fischer and 
Montal, 2007).
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Figure 9: BoNT translocation through the endosomal membrane. Structure of BoNT/A (light 
chain = purple; translocation domain = orange; membrane binding domain = red) before 
insertion into the membrane (grey bar with magenta boundaries) and then a schematic of 
the membrane inserted BoNT/A during translocation of the light chain (purple) through the 
transmembrane domain of the heavy chain (orange) and the reduction of the disulphide 
bond (green). Acidic pH in the endosome and reducing conditions in the cytosol are shown 
on the left. Adapted from Fischer and Montal, 2007.
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The light chain of botulinum neurotoxin is a zinc dependent endopeptidase that 
cleaves SNARE (Soluble NSF (N-ethylmaleimide sensitive fustion protein) 
Attachment Protein Receptor) proteins. The primary role of SNARE proteins is to 
mediate vesicle-plasma membrane fusion; in this case synaptic vesicles with the 
neuronal membrane (Schiavo et al, 1992; Blasi et al, 1993). Different subtypes of 
BoNT cleave different SNARE proteins. BoNT/A and E cleave SNAP-25, BoNT/C 
cleaves SNAP-25 and syntaxin while BoNT/B, D, F and G cleave vesicle 
associated membrane protein (VAMP), also known as synaptobrevin (Simpson, 
2004). Furthermore each BoNT will only cleave a single peptide bond in it’s 
substrate protein even if that peptide bond is repeated elsewhere in the substrate. 
It has been shown that the light chain requires quite large fragments of the target 
protein for efficient cleavage and single amino acid changes that are not in the 
immediate vicinity of the cleavage site can dramatically reduce proteolysis 
efficiency (Brunger and Rummel, 2009). This specificity is thought to be due to the 
presence of a common motif in the substrate SNARE proteins that acts as binding 
sites for the toxin (Rossetto et al, 1994). This common substrate motif present in 
all the BoNT target proteins explains the targeting of these varied proteins by 
similar enzyme. It also results in only one of the multiple identical peptide bonds 
being exposed to the toxin’s active site, which explains why the SNARE protein is 
only cleaved at a single peptide bond (Simpson, 2004).
The duration of intoxication i.e. presence of clinical symptoms, of BoNT varies with 
serotype, BoNT/A has the most sustained toxicity which can last months while 
BoNT/E's toxicity is shorter, typically only several weeks (Elopra et al, 1998; Tsai 
et al., 2010). One explanation for this discrepancy is that different BoNT serotypes 
are degraded at different rates by ubiquitin mediated proteasomal degradation
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within the neuron. BoNT/E light chain is preferentially targeted by the 
ubiquitinlyation machinery of the neuron when compared to BoNT/A light chain 
(Tsai et al, 2010). This leads to two interesting potential applications; the 
development of a recombinant BoNT for clinical use which is even more resistant 
to ubiquitination than BoNT/A and the development of a ubiquitin ligase targeted to 
BoNT/A light chain for use in cases of botulism (Tsai et al, 2010).
An informative perspective can be gained on the BoNT complex if it is compared 
with the tetanus neurotoxin (TeNT). TeNT has 30% amino acid identity with 
BoNT/A1, is a zinc dependent metallopeptidase which enters nerve cells and 
blocks neurotransmitter release by cleaving part of the cellular machinery involved 
in neuroexocytosis (Montecucco et al, 1994). There are differences in the precise 
mechanism of action at the nerve ending; TeNT undergoes retrograde axonal 
transport, being discharged into the synaptic cleft and then taken up by the post- 
synaptic cell where it cleaves VAMP (a SNARE protein, cleaved by B, D, F and G). 
It shares the three domain architecture of BoNT with the C-terminus of the heavy 
chain involved in neurone binding, N-terminus of the heavy chain involved in pH 
dependent release from the endosome and the light chain having enzymatic 
activity which results in the cleavage of VAMP.
Many bacterial toxins such as Shiga toxin, diphtheria toxin and anthrax toxin are 
AB toxin complexes. These consist of two proteins, the A protein which is 
responsible for the activity of the toxin and the B protein which is responsible for 
the binding and internalisation of the toxin to its specific target (Barth et al., 2004).
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Botulinum neurotoxin is not thought of as an AB toxin as it is encoded by a single 
gene, however, it shares many characteristics with the AB toxins (see Figure 10).
Botulinum toxin, with it's light and heavy chains shares some characteristics with 
AB toxins. However, the presence of the ANTPs in addition to the AB 
characteristics of BoNT highlight the additional complexity of BoNT compared with 
AB toxin complexes. This could be due to the longer route of required for BoNT 
toxicity.
Although the P. luminescens toxin requires it’s associated proteins for toxicity it is 
essentially a more complex variant of the binary AB toxin model. The XptA 
tetramer is the binding domain, XptC is the activity domain while XptB is likely a 
chaperone to facilitate interaction between the XptA and the XptC domains. The 
essential difference between the BoNT complex and any other toxin complex in 
the literature is that BoNT, in addition to having the A/B subunit architecture within 
the BoNT protein has large, highly conserved, associated non-toxic proteins the 
functional and epidemiological consequences of which have not yet been fully 
understood.
i
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The A subunit is translocated from the 
endosomal vesicle to the cytosol, 
during which process It is cleaved by 
host proteases releasing the active 27 
kDa A1 moiety which cleaves 28s 
rRNA inhibiting protein synthesis.
The A subunit ADP-ribosylates 
elongation factor 2, preventing 
protein synthesis.
Also known as the Light Chain, the A  
subunit is a Zn2+ dependent 
endopeptidase which cleaves one of 
a variety of SNARE proteins 
inhibiting neurotransmitter release.
A B
toxins
Shiga ABS toxin
Diptheria AB toxin
Botulihum AB toxin
The S subunit pentamer binds 
to specific glycolipids on the cell 
surface initiating receptor 
mediated endocytosis (RME)
The B subunit has two domains, 
the C terminus binds to the cell 
surface triggering RME and the 
other domain undergoes 
conformational change transferring 
the A subunit through the cell 
membrane
Also known as the heavy chain, the C 
terminus of the B subunit is 
responsible for RME at the peripheral 
cholinergic site. The N terminus 
mediates translocation across the 
membrane of the endosome into the 
cell cytosol.
Figure 10: A comparison of Shiga and Diptheria AB toxins with botulinum toxin which is not 
classed as an AB toxin but which shares certain characteristics with AB toxins.
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1.5.5. Evolution of BoNT and the associated non-toxic proteins
The presence of the botulinum toxin-encoding gene in distinct genetic . 
backgrounds (i.e. group l-IV C. botulinum, C. butyricum, C. beijerincki) indicates 
that BoNT has likely undergone horizontal gene transfer multiple times in 
evolutionary history (Skarin & Segerman, 2011). The presence of the neurotoxin 
gene clusters on plasmids, bacteriophage and partial and incomplete insertion 
sequences flanking bont also lends weight to this hypothesis (Hill et al, 2009; Peck 
etal, 2011).
Clostridial neurotoxins (BoNT and TeNT) are only found in the genus Clostridium 
and possess a unique sequence and structural architecture compared to other 
protein families. Looking for distant homologues of BoNT in the C. botulinum 
genome found evidence that suggests that the neurotoxin evolved from an 
ancestral collagenase-like gene (Doxey et al, 2008). However, certain BoNT 
features such as autocatalysis, polyprotein architecture (meaning one gene 
encodes multiple proteins with separate functions), encoding on bacteriophage 
and similarities of the light chain to viral metallopeptidases indicate a possible viral 
evolutionary history (DasGupta, 2006).
It is likely that BoNT/A1 was originially associated with an OrfX type cluster while 
BoNT/B was associated with the HA type cluster. Then, a recombination event 
occurred approximately in the centre of the ntnH gene resulting in BoNT/A1 being 
combined with an HA type cluster. The resulting BoNT/A1-HA gene cluster 
contains an ntnH gene, the 3' end of which is similar to an OrfX ntnH and the 5' 
end of which is similar to an HA ntnH (Hill et al., 2009). This BoNT/A1 HA
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encoding lineage is frequently associated with foodborne botulism (Peck et al, 
2011).
1.5.6. Regulation of bont and the Clostridium botulinum 
transcriptome
One of the characteristic features of the pathogenic Clostridia is their production of 
toxins. The structure, mode of action and encoding genes of the main clostridial 
toxins are well understood, however, the regulation of synthesis of these toxins 
has not been fully elucidated. The first clostridial toxin regulation system to be 
investigated and understood was that of the C. perfringens toxins which was found 
to be regulated by a two-component signal transduction system, VirR/VirS (Ba- 
Thein et al, 1996). VirS is a membrane-associated sensor that responds to an 
unknown signal by initiating a phosphorylation cascade resulting in phosphorylated 
VirR which then modulates transcription of its target genes. This modulation can 
be either by direct binding to promoters or by promoting transcription of a 
regulatory RNA molecule which in turn controls gene expression. In C. perfringens, 
the VirRIVirS system was found to be a global regulator responsible for the up- 
regulation and down-regulation of various genes including toxin genes, toxin gene 
regulators and amino acid synthesis genes (Banu et al, 2000). Homologues of 
VirR have been found in C. difficile, C. botulinum and C. tetani. Recent work has 
found that there are three two-component systems that, when knocked down, 
directly (i.e. with no effects on growth rate) induced a low level of BoNT/ANTP 
expression (Connan et al., 2012). This reduction in expression was found to be 
independent of botR and indicates that BoNT synthesis is under the control of a 
complex network of regulation. Interestingly, the two Two-Component Systems in
C. botulinum that show similarity to VirR were not directly involved in BoNT 
regulation (Connan et al., 2012).
Regulation of transcription of the gene cluster encoding BoNT and the ANTPs is 
thought to involve BotR (Raffestin et al., 2005), an alternative sigma factor that is a 
positive transcriptional regulator. The gene encoding BotR is in the same 
orientation as the ntnH/bont cluster in the HA encoding strains and in the same 
orientation as the orfX genes in the OrfX encoding strains. (Dupuy & Matamouros, 
2006; Marvaud et al, 1998; Peck et al, 2011). No botR homologue has been 
identified in C. botulinum type E toxin gene clusters. Additionally, C. botulinum 
producing toxin type A5 does not have -35 and -10 binding sites upstream of the 
botR gene, this deletion has no noticeable adverse effect on BoNT production by 
this strain (Peck et al, 2011; Carter et al; 2010). This indicates that an alternative 
mechanism is involved in toxin gene regulation. There is a homologue of botR in C. 
tetani (tetR) that is thought to play a similar role, the signal which leads to 
activation of BotR/TetR is unknown. However, a homologue of the Staphylococcus 
aureus quorum sensing system (agr) has been found in all group I strains. When 
agr\yas knocked out, sporulation and toxin production were significantly reduced 
indicating that quorum sensing could be involved in toxin production (Cooksley et 
al, 2010). In another study, when these genes were knocked out there was no 
impact on toxin production leaving the role of quorum sensing in toxin production 
remaining to be elucidated (Connan et al., 2012).
Previous work on the C. botulinum transcriptome has focussed on the expression 
of the toxin gene. Work by Bradshaw et al in 2004 investigated the kinetics of
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botulinum neurotoxin production in three strains of C. botulinum in two different 
media types from 0-96 hours. This interesting and thorough work used northern 
blotting to analyse mRNA levels and ELISA, Western blots and mouse bioassay to 
assay neurotoxin concentrations. In all three strains studied, mRNA transcripts for 
the toxin complex genes were initially detected in early log phase, reached peak 
levels in early stationary phase and rapidly decreased in mid to late stationary 
phase and during lysis. Toxin expression varied depending on strain and growth 
medium, highlighting the complexity of toxin regulation in C. botulinum. This 
difference between the time of peak toxin mRNA and peak toxin protein levels 
raises interesting questions about the dynamics of neurotoxin mRNA handling and 
toxin protein synthesis.
More recently, Artin et al. (2008) studied the effects of CO2 on neurotoxin gene 
expression in non-proteolytic C. botulinum type E. they used reverse transcription 
quantitative PCR (RT-qPCR) and enzyme linked immunosorbent assays to 
quantify expression of the type E botulinum neurotoxin gene and formation of type 
E neurotoxin. Relative expression of the neurotoxin peaked in the transition 
between exponential phase and stationary phase then rapidly declined in 
stationary phase. The neurotoxin gene mRNA half-life was calculated to be 
approximately 9 minutes. Toxin protein formation occurred in late exponential and 
stationary phase. High CO2 concentrations increased lag time and decreased the 
maximum growth rate. As a follow up to this work, Artin et al (2010) described the 
effects of carbon dioxide on the growth of proteolytic C. botulinum and the 
regulation of neurotoxin and the wider transcriptome. They used a combination of 
reverse transcription quantitative PCR (RT-qPCR) and a whole genome 
microarray. They found that CO2 concentration (10%, 35% and 70%) had no
significant effect on gene expression or neurotoxin formation. There was also no
/ ■
significant effect on the growth curve. At all C02 concentrations the relative 
expression of neurotoxin cluster genes peaked in the transition between 
exponential and stationary phases with some evidence of a second rise in 
expression in late stationary phase. At 10% CO2 their gene expression microarray 
found that neurotoxin gene expression was higher than the neurotoxin regulator 
(botR) as well as toxin complex components ntnH, ha33 and ha70 throughout the 
whole growth curve. They did however confirm previous findings that expression of 
neurotoxin cluster genes is growth phase dependent. They also showed that the 
neurotoxin cluster genes showed a similar response in all growth conditions 
indicating their co-transcription. Their microarray work showed 13 CDSs that had 
similar expression profiles at two or three C02 concentrations. These included 
genes involved in amino acid metabolism, production of antioxidant thioredoxins 
and a CDS potentially implicated in biofilm formation. When the authors examined 
the transcriptional profile of clostripain, the putative toxin activator, they found that 
it appeared to be constitutively expressed. It is therefore likely that clostripain 
contributes to general proteolytic activity in addition to its assumed role as toxin 
activator. One area where there were significant effects with increasing C02 
concentration was in spore germinant receptors and spore coat protein expression. 
If C02 concentrations influenced the resistance of spores then this would be of 
great interest to the food industry where C02 is used as an antimicrobial gas.
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1.6. Research aims
C. botulinum produces one of the deadliest toxins known to man, the botulinum 
neurotoxin, which is encoded alongside the associated, non-toxic proteins 
(ANTPs). The overall objective of this project is to investigate the importance of 
the ANTPs to C. botulinum.
This objective will be addressed via a series of aims:
1. In silico analysis of the toxin complex protein sequences with a focus on the 
identification of related proteins. ■ , ■
2. Investigation of the whole supernatant proteome of C. botulinum with a 
focus on characterisation of potential novel virulence factors.
3. Characterise the toxin complex components produced by a range of clinical 
isolates.
4. Explore the association between toxin complex type, genomic similarity and 
disease type.
5. Investigate the transcriptome of C. botuiinum across a time course to give 
insight into the transcription of bont and the wider botulinum transcriptome.
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2. Methods
All chemicals were supplied by Sigma Aldrich (Gillingham, UK) unless otherwise 
stated. All molecular biology reagents were supplied by Invitrogen (Paisley, UK) 
unless otherwise stated.
2.1. In silico investigation of the botulinum toxin complex and C. 
botulinum proteome
2.1.1. In silico investigation of botulinum neurotoxin and the 
neurotoxin associated proteins
The amino acid sequences of BoNT, the ANTPs and BotR were analysed using 
BLASTp via the NCBI web server (http://blast.ncbi.nlm.nih.gov/Blast.cqi). To aid 
communication of the results of the BLASTp analysis a simple similarity score was 
used. This was the coverage multiplied by the identity, for example, if the matched 
protein showed 30% identity across 96% of the query protein, a similarity score of 
0.29 was calculated. In some scenarios, an alternative protein similarity detection 
tool, HMMer (http://hmmer.ianelia.org/) was used. Typically, this was to confirm or 
repudiate a low similarity match. Interproscan (Quevillon et al., 2005) is a tool that 
combines different protein signature recognition methods in one web server 
(http://www.ebi.ac.uk/Tools/pfa/iprscan/). it was used to identify conserved protein 
domains in amino acid sequences of interest.
To obtain dendrograms for the protein sequences a distance matrix of the amino 
acid sequences was determined using MEGA (Tamura et al., 2011) and a
dendrogram derived from the distance matrix using a Fitch-Margoliash least-
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squares method for clustering based on genetic distance implement in PHYLIP
v
v3.69 (Felsenstein, 1989) and was visualised in Dendroscope (http://ab.inf.uni- 
tuebinqen.de/sdftware/dendroscope/). The 16S phylogeny of the species encoding 
P-47 family gene clusters was determined using a Maximum Likelihood tree 
implemented in MEGA.
The genomic environment of the P-47 family proteins was investigated using 
Artemis (http://www.sanqer.ac.uk/resources/software/artemis/) to load and 
visualise annotated genomes (Genbank format) of the relevant species 
(Rutherford et al., 2000).
2.1.2. Protein sub cellular location
The publically available genome of C. botulinum A1 ATCC 19397 was analysed 
using tools which predict the sub cellular localisation of proteins. The coding 
sequences (CDSs) were analysed using the web interface for PsortB (Yu et al., 
2010), CELLO (Yu et al., 2006), LocateP (Zhou et al., 2008), , SecretomeP 
(Bendtsen et al., 2005) and SignalP (Bendtsen et al., 2004). The results of this 
analysis were then compared using pivot tables in Excel and a consensus formed.
• PsortB is specifically designed for bacteria, discriminating between 4 
possible subcellular localisations for Gram-positive bacteria (cytoplasm, 
membrane, cell wall and extracellular). It uses a combination of BLAST 
homology to proteins of known subcellular localisation, PROSITE motifs 
and profiles, signal peptides and trans-membrane helix predictors based on 
HMMs and one Support Vector Machine (SVM, a supervised learning 
technique involving training on a known dataset) based prediction module 
for each localisation using the occurrence of frequent sub-sequences. It has
been designed with precision in mind and emphasises specificity over
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accuracy. PsortB v 3.0 improves the coverage of the proteome, assigning 
more proteins a subcellular location while maintaining precision. The high 
precision means many proteins (~20%) aren’t assigned a subcellular 
location.
• CELLO 2.5 is designed to work with eukaryotic and Gram negative or 
positive bacteria. It uses a multi-layered SVM approach with the first layer 
making predictions and the second layer combing those predictions and 
providing a final assignment. Four types of sequence coding schemes are 
taken into account: the amino acid composition, the di-peptide composition, 
the partitioned amino acid composition and the sequence composition 
based on the physico-chemical properties of amino acids. The outputs from 
these classifiers are then combined and a final assignment made. CELLO 
has a higher accuracy compared to PsortB but a lower precision.
• LocateP combines many of the existing high-precision subcellular location 
identifiers. It provides a higher degree of specificity than the other tools 
tested distinguishing 7 different subcellular locations in Gram positive 
bacteria - intracellular, multi-transmembrane, N-terminally membrane 
anchored, C-terminally membrane anchored and secreted/released proteins. 
It also distinguishes between Sec- and Tat- It has a high degree of 
accuracy, especially for Gram positive bacteria, and a high level of detail 
with the ability to select either the LocateP prediction or the prediction by 
SwissProt classification.
• SecreteomeP uses a neural network trained on a set of proteins that are 
known to be secreted by non-classical (i.e. non-signal peptide) secretion 
pathways.
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• SignalP consists of two predictors based on neural networks and hidden 
Markov model algorithms. It analyses a protein sequence for the presence 
of a signal peptide.
For PSORTb v3 the data were downloaded from a database of pre-computed 
genomes, any protein for which the primary assignment was extracellular was 
counted as such. For analysis in CELLO each genome the coding sequences was 
downloaded from NCBI (ftp://ftp.ncbi.nih.gov/qenomes/Bacteria/) and used as the 
input for a CELLO search. Any protein for which the only assignment was 
extracellular was counted as such. CELLO classifies many proteins into more than 
one subcellular localisation but since it is known that CELLO already favours 
accuracy over specificity (i.e. it returns more false positives) it was decided to 
narrow down the categorisation to proteins that were assigned a single localisation. 
LocateP can output pre-computed results for a range of bacterial genomes. As 
mentioned above the output can be either the LocateP prediction or a prediction 
bassed on the SwissProt classification. The LocateP algorithm predicts a subset of 
the SwissProt predictions with higher certainty. The proteins which the SwissProt 
based algorithm predicted as extracellular were used as the LocateP algorithm 
gives a small number of results. However, it will be interesting to see whether the 
higher certainty associated with the LocateP predictions gives better agreement 
with the other tools.
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2.2. Microbiology
2.2.1. Strain list
vJ -
Table 6: Strains used in this study, WB = wound botulism, FB = food botulism, IB = infant 
botulism, FPRU -  Foodborne Pathogen Reference Unit at HPA
Species Strain Toxin type Isolated from Source of strain
C. botulinum ATCC 19397 A1 Type strain Type strain - FPRU collection
C. botulinum NCTC 2012 A3 Type strain - food botulism ' NCTC
C.
sporogenes NCTC 275 N/A Gas gangrene NCTC
C. botulinum NCTC 2916 A1(B) Type strain NCTC
C. butyricum NCTC 7423 Non-toxigenic Type strain NCTC
C. botulinum H040660361 A WB Clinical - isolated by FPRU
C. botulinum H040680341 A5(B) • WB Clinical - isolated by FPRU
C. botulinum H042440055 A5(B) WB Clinical - isolated by FPRU
C. botulinum H044020065 A5(B) WB Clinical - isolated by FPRU
C. botulinum H044640107 A5(B) WB Clinical - isolated by FPRU
C. botulinum H052880114 A WB Clinical - isolated by FPRU
C. botulinum H062260493 B WB Clinical - isolated by FPRU
C. botulinum H063740588 AB FB Clinical - isolated by FPRU
C. botulinum H063960325 A WB Clinical - isolated by FPRU
C. botulinum H064620409 A WB Clinical - isolated by FPRU
C. botulinum H065060505 A WB Clinical - isolated by FPRU
C. botulinum H065260139 A WB Clinical - isolated by FPRU
C. botulinum H071040476 A WB Clinical - isolated by FPRU
C. botulinum H071400014 A WB Clinical - isolated by FPRU
C. botulinum H074240407 A IB Clinical - isolated by FPRU
C. botulinum H074400585 B IB Clinical - isolated by FPRU
C. botulinum H074400586 B >B Clinical - isolated by FPRU
C. botulinum H075000578 A WB Clinical - isolated by FPRU
C. botulinum H090840606 B IB Clinical - isolated by FPRU
C. botulinum H091140481 B WB Clinical - isolated by FPRU
C. botulinum H091280045 B WB Clinical - isolated by FPRU
C. botulinum H091640054 AB WB Clinical - isolated by FPRU
C. botulinum H092080005 B WB Clinical - isolated by FPRU
C. botulinum H093320637 A IB Clinical - isolated by FPRU
C. botulinum H093620104 B WB Clinical - isolated by FPRU
C. botulinum H094460264 A IB Clinical - isolated by FPRU
C. butyricum H102020560 E IB Clinical - isolated by FPRU
C. butyricum H102020561 ■ E IB Clinical - isolated by FPRU
C. botulinum H102120680 B WB Clinical - isolated by FPRU
C. botulinum H10212680 B WB Clinical - isolated by FPRU
C. butyricum H110141052 E IB Clinical - isolated by FPRU
C. butyricum H110220838 E IB (adult) Clinical - isolated by FPRU
C. butyricum H110340631 E IB (environment) Clinical - isolated by FPRU
C. butyricum H110480771 E IB Clinical - isolated by FPRU
C. butyricum H110660554 E IB Clinical - isolated by FPRU
C. botulinum H111860974 A IB » Clinical - isolated by FPRU
C. botulinum H112480657 A IB Clinical - isolated by FPRU
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C. botulinum H113660204 A WB Clinical - isolated by FPRU
C. botulinum H114400598 B IB Clinical - isolated by FPRU
C. botulinum H114580650 A FB Clinical - isolated by FPRU
C. botulinum H114580654 A FB Clinical - isolated by FPRU
C. botulinum H114590007 A FB - environmental Clinical - isolated by FPRU
C. botulinum H114680633 A FB Clinical - isolated by FPRU
2.2.2. Growth conditions
Cells were maintained either on beads at -80°C or in Cooked Meat Broth (CMB) 
and then revived by anaerobic incubation (10% CO2, 5% H2, 85% N2) on 
Clostridium botulinum isolation agar (CBI) (Oxoid, UK) at 35°C for 48 h to obtain 
luxuriant growth and ensure pure culture. Starter cultures in either 20 or 100 ml of 
Tryptone Peptone Glucose Yeast extract (TPGY) (Oxoid, UK) broth were 
inoculated with single colonies from CBI plates and incubated for 24 h at 35°C. 
The starter cultures were then used to inoculate either 20 ml of TPGY to an optical 
density (OD) measured at 600 nm of 0.15-0.2. All media were pre-reduced for 24 h 
under anaerobic conditions before use. These growth conditions were used as 
they are the accredited best practice employed by the Food borne Pathogens 
Reference Laboratory at PHE Colindale. TPGY was used for culture as it is widely 
used in other similar studies (Cheng et al., 2008; Bradshaw et al., 2004).
2.2.3. Growth curves
In order to determine growth curves for C. botulinum and C. sporogenes 100 ml of 
pre-reduced TPGY was inoculated to an OD600 of 0.15-0.2 from an overnight 
broth culture of C. botulinum. Samples (1 ml) were then taken at appropriate 
intervals for the period of time being studied. This was typically 12-16 h when RNA
work was being carried out or 24 or 96 h if protein work was being performed.
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Samples were then analysed at 600 nm using the Eppendorf BioPhotometer 
spectrophotometer and the optical density recorded. If the total cell count was 
being carried out then the sample was fixed with 0.1 volume 10% formalin, stained 
with 1-2 pi crystal violet and then diluted to an appropriate factor to allow for 
manual counting using a disposable haemocytometer (C-Chip, Lab Tech 
International, East Sussex) and a microscope. The resulting count was then 
multiplied by the dilution factor to give number of cells per ml of broth.
2.3. Investigation of the proteome of C. botulinum
2.3.1. Protein precipitation
Two protein precipitation methods were used for this work; tricholoroacetic acid 
(TCA) precipitation and acetone precipitation. The protocol for TCA precipitation 
was as follows. A volume of culture supernatant was taken, centrifuged at 12000 g, 
4°C for 10 minutes to pellet the cells, filtered through 0.22 pm filter (Millipore, 
Watford, UK) to ensure it was cell free. For acid precipitation 3 N TCA was added 
to 5%, 10% or 20% (v/v) and the supernatant left on ice for 30 mins, pelleted by 
centrifugation at 12000 g, 4°C for 10 minutes, washed with one volume of 96% 
ethanol followed by one volume of acetone and resuspended in 50mM Tris-HCI, 
1% SDS (Gibco, Invitrogen, Paisley, UK) (v/v). For acetone precipitation, 3 
volumes of acetone was added to 1 volume of cell free culture supernatant and left 
on ice for 30 mins, washed with one volume of 96% ethanol followed by one 
volume of acetone and resuspended in 50mM Tris-HCI, 1% SDS (v/v) (Gibco, 
Invitrogen, Paisley, UK).
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2.3.2. Determination of protein concentration
Total supernatant protein concentration was determined using the Bradford 
colourimetric protein assay (Bradford, 1976). Bovine Serum Albumin protein 
standards of 0, 0.05, 0.125, 0.2, 0.5, 0.75, 1, 1.5 and 2 mg/ml were made up in 
TPGY broth. To obtain the standard curve 5 pi of each Standard was added to a 
flat bottomed 96 well microtitre plate (Sterilin, ThermoFisher, Newport, UK) in 
triplicate. Then 5 pi of each sample being quantified was added to the microtitre 
plate in two different dilutions (typically undiluted and 1 in 5 dilution). Following this 
250 pi of Bradford reagent was added, the plate sealed and shaken and incubated 
at RT for 10 mins and then read using a microplate reader (ELx808, Biotek, 
Bedfordshire, UK) at 595 nm.
The concentration of precipitated proteins which had been resuspended in 50 mM i 
Tris-HCI, 1% SDS (v/v) was determined using the detergent compatible 
bicinchoninic acid (BCA) assay (Pierce, Thermo Scientific, Northumberland, UK). 
Protein standards of 0, 0.05, 0.125, 0.2, 0.5, 0.75, 1, 1.5 and 2 mg/ml were made 
up in 50 mM Tris-HCI, 1% SDS. Then 25 pi of each standard and each sample 
being quantified was added to a microtitre plate in triplicate. Two dilutions, typically 
1 in 5 and 1 in 10 dilution of the unknown sample, were typically assayed. 
Subsequently, 250 pi of BCA reagent working solution was added, the plate 
sealed, briefly vortexed and incubated at 37°C for 30 mins. After cooling to RT the 
plate was briefly centrifuged and read at 565 nm. The gradient of the standard 
curve was calculated and used to convert the absorbance value of the samples 
into protein concentrations.
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2.3.3. Endopeptidase immunoassay for measuring botulinum toxin 
activity
BoNT activity in the culture supernatant was assayed using an in vitro 
endopeptidase activity immunoassay according to the method of Jones et al, 2008. 
A polystyrene 96-well plate (Nunc Maxisorp) were coated with 2 pg/ml SNAP25i37- 
206 peptide substrate in 50 mM carbonate buffer (pH 9,6) at 4°C and then washed 3 
time with PBST (phosphate buffered saline with 0.5%mv/v Tween 20) and blocked 
with 300 pl/well of 5% skimmed milk powder in PBST for 90 min at RT. To test the 
concentration of toxin present in the sample, 100 pi of 1 in 100 diluted culture 
supernatant was added to the plate in duplicate. Each duplicate was serially two­
fold diluted 8 times and incubated overnight at RT. A positive control of a two fold 
dilution series of a BoNT standard of known concentration was included on each 
plate. After incubation, the sample was'removed and the plate was washed 3 
times with PBST. After washing, 100 pi of primary detecting antibody, specific to 
the cleaved substrate epitope (anti-SNAP25(igo-i97) was added and incubated for 
90 mins at RT. The plate was then washed again and 100 pl/well of goat anti- 
rabbit-HRP conjugate (Sigma A0545, 1 in 2000 dilution in antibody buffer) was 
added and incubated for 90 mins at RT. After washing, 100 pl/well of HRP- 
substrate solution (50mMcitric acid pH 4.0, 0.05% w/v ABTS (2,2'-Azino-bis(3-
V
ethylben- zothiazoline-6-sulfonic acid) diammonium salt, and 0.05% v/v of a 30% 
w/v Hydrogen peroxide solution) was added and colour allowed to develop at RT 
for 30 min. The absorbance was then read at 405 nm using a Multiscan plate 
reader. The relative activity of botulinum toxin in the culture supernatant was 
calculated in reference to the known standard.
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2.3.4.1D Sodium Dodecyl Sulphate Polyacrylamide Gel 
electrophoresis (1D SDS-PAGE)
Briefly, 5 pg of protein sample was combined with 1x NuPAGE LDS Sample Buffer, 
1x NuPAGE Reducing Agent made up to 10pl with deionised water and heated at 
70°C for 10 minutes. The sample was loaded onto the gel alongside 5 pi Mark12 
Unstained Standard (Invitrogen). Typically both 12% acrylamide bis-tris gels and 
7% Tris-Acetate gels were run in order to obtain high quality separation across the 
majority of molecular weights relevant to this project. Gels, were run using the 
NuPAGE system (Invitrogen, Paisley UK) and either MOPS buffer (for the bis-tris 
gels) or TA buffer (for the Tris-Acetate gels). After running, the gels were stained 
using Instant Blue (Expedeon, Cambridgeshire, UK) and imaged using the ProPic 
II spot picker (Digilab, Cambridgeshire, UK).
For analysis the gel image was loaded into the ImageQuant TL software (v. 2005, 
Amersham Biosciences, GE Healthcare, Buckinghamshire, UK) which 
automatically assigned lanes and performed background subtraction. Bands were 
then manually picked in each lane, the size calculated by assigning the ladder 
bands their known weights and the band volumes normalised according to the 200 
kDa ladder band allowing for comparison between gels.
2.3.5. In-gel digestion
When samples were to be analysed by LC-MS/MS the appropriate 1D gel lane 
was divided into 12 sections. The sections were destained by washing with 50% 
50mM ammonium bicarbonate/50% methanol. Following dehydration with 
acetonitrile the plugs were incubated with 50 pi 10 pM dithiothreitol (DTT) followed 
by 10 pi 55 mM iodoacetamide (IAA) to ensure reduction and alkylation of the
proteins. After washing with 50 mM ammonium bicarbonate and dehydration with 
acetonitrile the gel plugs were then incubated for 17 h with 50 pi of 10 ng/pl mass 
spectrometry grade trypsin (Promega, Southampton, UK). Following trypsinisation 
50 pi of 0.1 % trifluoroacetic acid was added to the gel plug and incubated at RT for 
1 h and the supernatant transferred to a clean microtitre plate and stored at -80 °C 
untilanalysed.
2.3.6. LC-MS analysis of peptide fragment mixtures
The peptides resulting from in gel digestion were separated by liquid 
chromatography (LC) and analysed by mass spectrometry. Running on the liquid 
chromatography column separates the peptides by hydrophobicity. Subsequently, 
an MS/MS approach1 was used whereby the peptides are ionised in MS mode and 
specific ions are fragmented further in MS/MS mode. The resulting spectra can be 
analysed • using appropriate software which compare the experimental results 
against an in silico database of peptide fragments. The peptide fragments which 
the algorithm identifies as being present in the sample can then be matched to 
their ‘parent’ proteins and, if the analysis criteria are satisfied then the protein is 
‘identified’ as being present in the sample.
The system used for this was an Ultimate 3000 Dionex nano/capillary HPLC 
system (Dionex) coupled to a LTQ Orbitrap mass spectrometer (Thermo Electron). 
The data produced was in the Thermo Finnigan .RAW file format. Mascot (Matrix 
Science, UK) was used to analyse the .RAW files, the parameters were Enzyme = 
Trypsin; fixed modifications = carbamidomethylation of cystine; Variable 
Modifications = oxidation of methionine; Missed Cleavage Sites: 2; peptide mass 
tolerance ±10 ppm. The data from this analysis was visualised using Scaffold 
(Proteome Software, USA).
82
The mobile phase was, buffer A; 2% acetonitrile in water plus 0.1% formic acid, 
buffer B; 10% water in acetonitrile plus 0.1% formic acid. Injection volume was 10 
pi, flow rate loading pump 25 pl/min, micro pump: 300 nl/min. The gradient used 
was:
• Start 0 min: 10% B
• 0 -  40 min: 10% B -  45% B
. 4 0  -  40.2 min: 90% B
• 40.2 -  52 min: 90% B
• 52-52.2 min: 10% B
• 52.2-60 min: 10% B
The mass spectrometer was operated in positive mode with spray voltage at 1.6 
kV, capillary voltage at 38 V, capillary temperature at 200°C and tube lens at 125
V. Helium was used as collision gas but no sheath and auxiliary gas were applied.
Tandem MS (MS/MS) data was acquired in data-dependent mode with automatic 
switching between MS and MS/MS modes. A normalised collision energy of 35%, 
an activation of q = 0.25 and activation time of 30 msec were applied in MS/MS
acquisition. The precursor ion scan (m/z 440-2000) were acquired in the Orbitrap
with a resolution R = 60000 at m/z 400. The six most abundant peptide precursor 
ions detected in the preceding survey scan were dynamically selected and 
subjected for collision-induced dissociation (CID) in the linear ion trap to generate 
MS/MS spectra. The lock mass option, using the polydimethylcyclosiloxane ion 
generated in the electrospray process from ambient air, the protonated 
(Si(CH3)20)6 at m/z 445.120025, was used for internal recalibration in real time 
to enable accurate mass measurement. Samples were analysed in a format of 
technical triplicates. Software used was Xcalibur 2.1.0 sp1.1160.
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The Thermo RAW files were loaded directly into Mascot Daemon v2.2.2 using the 
input filter ‘ThermoFinnigan LCQ /  DECA RAW file’. The databases searched 
depended on the analysis being performed but were either a non-redundant 
version of the NCBI protein database or an orgamism specific database using 
the .faa files from Genbank. Mascot parameters were; fragment tolerance 0.1 Da, 
parent tolerance 10.0 parts per million (ppm), digestion enzyme trypsin and max 
missed cleavages 2. Scaffold (version Scaffold_3.6.5, Proteome Software Inc., 
Portland, OR) was used to validate MS/MS based peptide and protein 
identifications. Peptide identifications were accepted if they could be established at 
greater than 50.0% probability as specified by the Peptide Prophet algorithm 
(Keller et al., 2002 Anal. Chem. 2002;74(20):5383-92). Peptide identifications 
were also required to exceed specific database search engine thresholds. Mascot 
identifications required at least ion scores must be greater than both the 
associated identity scores and, 20, 30 for, doubly, triply charged peptides. Protein 
identifications were accepted if they could be established at greater than 99.0% 
probability and contained at least 2 identified peptides. Protein probabilities were 
assigned by the Protein Prophet algorithm (Nesvizhskii, 2003). Proteins that 
contained similar peptides and could not be differentiated based on MS/MS 
analysis alone were grouped to satisfy the principles of parsimony.
2.3.7. Comparison with MvirDB
The proteins which were detected and identified in the C. botulinum supernatant 
were compared with the virulence database MvirDB using local BLAST (Zhou et 
al., 2007). The homologous protein pairs were parsed for potential virulence 
factors which could play a role in food, wound or infant botulism. Proteins which
had a putative role were then analysed in greater depth to ensure that the areas of
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homology were not generic regions with no pathogenic connotations e.g. 
transmembrane regions. This was done using Interproscan (SwissProt) to 
determine the location of different functional groups. If the C. botulinum 
extracellular protein showed homology, relevant to virulence functional groups with 
the virulence associated protein from the database then it was considered a 
putative virulence protein.
2.3.8. Calculation of extracellular protein cost
The number of high energy phosphate bonds required to synthesise each amino 
acid in chemoheterotrophs was obtained from the literature (Heizer et al., 2006). 
The amino acid content of each identified extracellular protein was obtained from 
NCBI and the cost of synthesis of each protein calculated using a custom Perl 
script.
2.4. Investigation of toxin complex gene type and genomic 
background of botulinum toxin producing strains
2.4.1. DNA extraction
DNA was extracted using either MicroLYSIS (Microzone, UK) reagent or DNeasy 
columns (Qiagen). For MicroLYSIS a 1 pi loop was touched to a single bacterial 
colony and then resuspended in 19 pi of MicroLYSIS reagent in a PCR tube. This 
tube was then placed in a PCR machine with the following programme:
Step 1: 65°C for 5 mins 
Step 2: 96°C for 2 mins
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Step 3: 65°C for 4 mins 
Step 4: 96°C for 1 mins 
Step 5: 65°C for 1 mins 
Step 6: 96°C for 30 secs 
Step 7: 20 °C hold
Once the programme was finished the sample was either placed at 4°C if being 
processed the same day or at -20°C if being processed at a later date.
For extraction using DNeasy columns a 10 pi loop of bacterial growth was 
resuspended in 200 pi Phosphate Buffered Saline and 20 pi proteinase K (18 
mg/ml) (Roche, Burgess Hill, UK). Then 200 pi DNeasy Buffer AL was added, the 
sample vortexed and incubated at 56°C for 10 minutes. The mixture was then 
pipetted into a spin column and centrifuged for 1 min at 12000 rpm. The column 
was then washed with 500 pi wash buffer AW1 and centrifuged for 1 min at 12000 
rpm followed by 500 pi wash buffer AW2 and the column centrifuged for 3 min at 
12000 rpm. The column was then transferred to a new tube and 200 pi elution 
Buffer AE added, incubated for 1 min and then centrifuged for 1 min at 12000 rpm. 
Extracted DNA was stored at 4° C if used with two weeks or at -80°C for long term 
storage.
2.4.2. PCR to determine toxin type and toxin complex type
Two. types of PCR were used in this investigation, block -based PCR and qPCR. 
qPCR assays designed for use in the reference lab (Akbulut et al,. 2004) were 
used to detect bont/A and bont/B. Standard PCR was used to determine the toxin 
complex type using an assay designed for this study comprising two pairs of 
primers specific to ha70 and ha33 and two pairs of primers specific to orfX/2 and 
orfX/3. The primers used in this investigation can be seen in Table 7.
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2.4.3. Fluorescent amplified fragment length polymorphism (fAFLP) 
analysis of clinical strains
Genomic DNA was digested using restriction enzymes Hind III and Hha I and the 
resulting fragments ligated to the appropriate oligonucleotide adaptors (Table 7) in 
a one step reaction. Adapters were annealed prior to this by heating 
complimentary strands to 94°C for 10 minutes and allowing to cool to room 
temperature. Digestion and ligation conditions consisted of 5 pi of DNA, 3 pi of 10x 
NEB buffer 2, 0.3 pi of 100x BSA (NEB), 5 pi of 10x T4 Ligase buffer (NEB), 0.2 pi 
of 400 U/pl T4 ligase (NEB), 0.3 pi of Hindlll 20 U/pl restriction endonuclease 
(NEB), 0.3 pi of 20 U/pl Hhal restriction endonuclease (NEB), 0.3 pi of 2 pM 
annealed Hindlll adaptors (table 2) (Eurogentec), 0.3 pi of 20 pM annealed Hhal 
adaptors (table 2) (Eurogentec), 0.5 pi of 30 mg/ml RNAse (Sigma) and 44 pi of 
molecular grade water. The reaction mixture was incubated at 37°C for 4 hours, 
16°C for 3 hours then 65°C for 10 minutes. The resulting fragments were then 
amplified using a touch down PCR reaction comprised of 5 pi of ligated fragments, 
12.5 pi 2x MegaMix Gold PCR mastermix (Microzone), 2.5 pi 10 pM Hind-0 primer 
(table 2) and 2.5 pi 10 pM Hha-A primer (table 2). The reaction mixture was then 
incubated at 95°C for 5 mins, 10 cycles of 94 °C for 20s, 66 C for 30s (reduced by 
1°C per cycle) and 72°C for 2 mins followed by 20 cycles with the annealing 
temperature at 56°C. The Hha I primer included the selective 3’ A base while the 
Hind III primer had a 6’-carboxyfluorescein label incorporated and no selective 
bases. From the resulting product, 1 ul was added to 10 pi Hi-Di formamide and 
0.5 pi LIZ 600 labelled standard, denatured at 95°C for 5 minutes and cooled to 
4°C. Samples were loaded on to a 3730 ABI sequencer in accordance with the 
manufacturer’s guidelines by a local sequencing service. Reproducibility was
assessed by carrying out the entire fAFLP procedure (digestion-ligation-PCR- 
fragment analysis) procedure in triplicate for 9 samples; this allowed us to 
distinguish between biological and technical variation in the procedure. When 
these samples were clustered the average similarity between each group of three 
replicates was 94.9% with a range of 91.4-96.9%. No differentiation was inferred 
when the similarity between two strains was greater than 90% as it cannot be 
determined if the difference is the result of technical or biological variation.
Electropherograms were analysed using Bionumerics v6.1 (Applied Maths, 
Belgium). Fragments sized between 60 and 600bp were used for further 
investigation. Profiles were manually inspected using Bionumerics and 
Peakscanner (Applied Biosystems, USA). Pearsons correlation coefficient for the 
samples was calculated and the samples clustered using UPGMA, both performed 
within Bionumerics.
2.5. Analysis of transcription in C. botulinum
All work involving RNA was carried out in an area cleaned by RNase ZAP (Ambion, 
Life Technologies, Paisley, UK) using machinery cleaned with RNase ZAP in order 
to reduce RNase contamination. All tubes and tips were RNase free (Ambion, 
Paisley, UK) and all water used was DEPC treated (Severn Biotech, Worcester, 
UK).
2.5.1. Extraction of RNA from C. botulinum culture
88
To prevent RNA degradation one volume (typically 500 pi) of culture was removed 
and added to 2 volumes of RNAprotect Bacteria (Qiagen), vortexed for 5 s and 
incubated at RT for 5 min. Samples were then centrifuged for 10 minutes at 5000 
g, the supernatant discarded and the sample either lysed immediately or stored at 
-80°C.
Two different lysis methods were investigated in order to determine the 
methodology that gave optimal RNA yield and quality; enzyme lysis and bead 
beating lysis.
For enzyme lysis 200 pi of TE buffer (10 mM Tris-CI, 1 mM EDTA, pH 8.0) 
containing 1 mg/ml lysozyme was added to the cell pellet, the sample was 
vortexed for 10 s and incubated at room temperature for 10 min with mixing every 
2 min. Then 700 pi RLT buffer from the RNeasy kit with (B-meracaptoethanol was 
added, the sample was vortexed, centrifuged and the supernatant added to a new 
tube. A 500 pi volume of 100% ethanol was added to the sample before 
purification of the RNA using the RNeasy mini kit (Qiagen) with on column DNase I 
(Invitrogen) treatment according to the manufacturer’s instructions.
For bead beating lysis the bacterial sample was resuspended in 700 pi buffer RLT 
from the RNeasy Mini kit (Qiagen, West Sussex, UK) with added (3- 
meracaptoethanol and approximately 50 mg glass beads were added. The cells 
were disrupted in a bead beater for 30 s, 3 times with a brief rest in between and 
then left on ice for 1 min. The tubes were centrifuged at 21000 g for 1 min and the 
supernatant transferred to a new tube. The volume of the supernatant was 
determined and if column extraction was being performed then an equal volume of
70% ethanol was added before RNA purification using the RNeasy mini kit
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(Qiagen) with on column DNase I (Invitrogen) treatment according to the 
manufacturer’s instructions. If 25:24:1 extraction was being performed then the 
methodology outlined in 2.5.9 was carried out.
The RNeasy mini kit does not capture small RNA (sRNA, <200 bp). In order to 
purify these sRNAs the flow through of the RNeasy columns was captured and the 
RNA purified from it using 25:24:1 purification detailed in 2.5.9.
2.5.2. DNase treatment
Genomic DNA has to be removed before reverse transcription qPCR in order to 
allow accurate assessment of transcript abundance. The amount of gDNA was 
reduced below levels detectable by qPCR for bont/A and gdhA using TURBO 
DMA-free (Ambion, Life Technologies, Paisley, UK). Briefly 0.1 volume 10x Turbo 
DNase buffer and 1-5 pi Turbo DNase were added to the RNA extract, mixed 
gently and then incubated at 37°C for 30 mins. After centrifugation to collect 
condensation, 0.1-0.2 volumes of TURBO DNA-free DNase inactivation reagent 
were added, the sample mixed and incubated at room temperature for 5 mins with 
occasional mixing before centrifugation at 10 000 x g for 90 s. The supernatant 
was then transferred to a new tube and the presence of contaminating gDNA 
assayed using qPCR assays for bont/A and the house keeping gene gluD. If 
gDNA could still be detected the sample was purified using 
phenol:chloroform:isoamyl alcohol purification and DNase treatment repeated until 
gDNA could no longer be detected by qPCR targeting bont and gdhA
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2.5.3. RNA quantity and purity analysis
The RNA content of the DNA-free RNA extract was estimated by UV 
spectrophotometry using the NanoDrop 8000. This gives RNA concentrations and 
260/280 and 260/230 absorption values. A 260/280 ratio of greater than 2.0 was 
taken as ‘pure’ RNA while low 260/230 absorption values (<1.5) indicated 
contamination with carbohydrates or phenol.
When more precise RNA quantification was required the Quant-iT Ribogreen kit 
(Invitrogen, Paisley, UK) was used according to the manufacturer’s instructions.
2.5.4. Analysis of RNA quality by agarose gel electrophoresis
Agarose gels were made up using 1% (w/v) agarose in 1x TAE buffer, GelRed 
safe stain was added to the agarose at 1x concentration. Gels were run at 80-120 
V in 1x TAE buffer. Prior to loading 10 pi of sample was combined with 1.7 pi 6x 
loading buffer. A 100 bp DNA ladder was used for determining size. Gels were 
visualised using the BioRad imager.
2.5.5. Analysis of RNA quality using Agilent Bioanalyser
RNA was analysed using the Bioanalyser RNA 6000 Nano kit. A gel matrix-dye 
solution was made up using 1 pi of dye added to 65 pi filtered gel matrix which 
was mixed and centrifuged. Then 9 pi of gel-dye mix was placed in the primary 
gel-dye mix well on an RNA 6000 Nano chip which was placed in a chip priming 
station. The syringe plunger on the chip priming station was positioned at 1 ml and 
the chip priming station closed. The plunger was depressed until held by the clip
and after exactly 30 seconds the clip was released. After 5 s the plunger was
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pulled back to 1 ml and the chip priming station opened, 9 pi of gel-dye mix was 
added to the secondary gel-dye mix wells and 5 pi of marker was added to every 
sample well and the ladder well. A 1 pi aliquot of RNA Nano 6000 ladder was 
added to the ladder well and 1 pi of sample was added to each sample well with 
any unused wells having 1 pi of marker added. The chip was vortexed in an IKA 
vortexer at 2400 rpm for 1 min and then run on the Agilent 2100 bioanalyser within 
5 minutes.
2.5.6. Reverse Transcription
Reverse transcription was carried out using Superscript III Reverse Transcriptase 
(Invitrogen, Paisley, UK) in a 20 pi reaction with 0.5 pg total RNA, 2 pmol of gene 
specific, reverse primer for bont and gluD, 1 pi of 10 mM dNTP mix (invitrogen, 
Paisley, UK). First the primers, RNA and dNTPs were combined and made up to 
13 pi with water before being heated to 65°C for 5 mins, cooled on ice and briefly 
centrifuged. Then 4 pi 5x First-Strand Buffer, 0.1 pi 0.1 M DTT, 1 pi RNaseOUT 
(Invitrogen, Paisley, UK) and 1 pi Superscript III reverse transcriptase added to 
each reaction. This reaction was then placed in a thermal cycler heated to 25°C for 
5 minutes, 55°C for 45 minutes and 70°C for 15 minutes. The reverse transcription 
for bont/A and gluD were carried out separately. Resultant cDNA was quantified 
using the Nanodrop and 1 pg cDNA used for subsequent qPCR
2.5.7. Quantitative PCR (qPCR)
The Taqman 7500 Fast Real Time PCR system was used for quantitative PCR 
analysis. The standard PCR mix used was a 25 pi reaction consisting of 0.5 pg 
RNA, 12.5 pi TaqMan Fast Universal PCR Master Mix (2x), 0.75 pi 10 pM primers
(Eurogentec, Hampshire, UK), 0.5 pi 5 mM probe (Eurogentec, Hampshire, UK) 
and target sample and SDW to 9.5 pi. To ensure reproducible determination of the 
crossing threshold (Ct) values, it was the point at which the sample in the positive 
control well entered logarithmic amplification.
The efficiency of each qPCR reaction (bont/A and gluD) was determined by 
preparing a standard curve using a serially diluted RNA sample of known 
concentration (from 1 pg/pl to 100 pg/pl). The slope of the standard curve was 
then used to calculate the RT-qPCR efficiency according to Equation 1.
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Equation 1: Calculation of efficiency of the RT-qPCR when the slope of the line of RNA 
concentration compared with reaction Ct value has been derived.
Efficiency =-1+10('1/slope)
Equation 2: Efficiency dependent model for calculating relative gene expression of target 
and housekeeping (reference) genes, the control was the earliest time point sampled
(ERef)Cpsample (E Ref) Cp calibrator
ratio = —— —7 :-------- •+ — — — 7--------- -
(E ta rg e t)  am p ( E target )  P caIibrator
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2.5.8. Relative gene expression analysis
The relative gene expression of bont/A compared to the house keeping gene gluD 
was calculated using the efficiency corrected method (Pfaffl, 2006) detailed in 
Equation 2.
ERef is the efficiency of the PCR for the reference gene (gluD), Etarget is the 
efficiency of the PCR for the target gene (e.g. bont), CpSampie is the crossing point 
(aka the threshold value or Ct) of the sample, Cp calibrator is the crossing point of the 
calibrator sample (in this case the RNA sample from the earliest time point being 
analysed).
2.5.9. Purification of RNA using phenol:chloroform:isoamyl alcohol
Phenol:chloroform:isoamyl alcohol extraction (phenol pH 4.3, saturated with 0.1 M 
citrate buffer; chloroform:isoamyl alcohol 24:1) was employed to purify RNA 
samples containing undesired protein. Two volumes of Phenol:chloroform:isoamyl 
alcohol in the ratio 25:24:1 was added to one volume of RNA in aqueous solution, 
thoroughly mixed and centrifuged at 21000 x g for 30 mins at 4 °C. The upper 
layer was removed, transferred to a new tube and the RNA precipitated by the 
addition of 3 volumes of 100% EtOH:Sodium acetate (30:1) and incubating at - 
80 °C for at least 30 mins. The sample was then centrifuged at 21000 x g for 30 
mins at 4 °C to pellet the RNA, washed with 70% EtOH, dried using a vacuum 
drier and resuspended in DEPC-treated water. RNA was stored at -80 °C in 
aliquots to reduce degradation from freeze-thawing.
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2.5.10. Taking of samples for RNA-seq
Once all the methods were optimised the final samples (i.e. two technical 
replicates of two biological replicates taken at three timepoints; mid-log, late-log 
and early stationary phase) for RNA-seq were taken. The experimental design 
allowed two biological replicates to be analysed. The cultures were sampled (3.5 
ml) once an hour between mid-log to late stationary phase (approximately 6-13 h 
after inoculation). Each sample had a 0.5 ml subsample taken from it, both this 
sample and the 3 ml sample were pelleted and treated with RNAprotect. The 0.5 
ml sample from each time point between 6-13 h was analysed to determine the 
relative gene expression of bont compared with gluD. The relative gene 
expression result was used to determine the time point at which toxin expression 
peaked. Then two time points were chosen, one which was pre-toxin peak and 
another which was post-toxin peak. The 3 ml sample of the pre-peak, peak and 
post-peak toxin expression was then processed, the RT-qPCR result confirmed 
the relative gene expression pattern and the sample was processed for RNA-seq.
2.5.11. Reduction of rRNA before preparation of RNA-seq libraries
rRNA makes up a large proportion (over 90%) of the RNA purified from bacterial 
cultures. In order to minimise the number of sequencing reads which map to the 
rRNA genes the rRNA is reduced prior to sequencing.
Each of the 6 samples (6 h A and B, 9 h A, 10 h B, 1 3 h A  and B) were treated 
with the Ribo-Zero rRNA removal, gram positive bacteria kit (Epicentre, distributed 
in the UK by Cambio, Cambridge, UK). The Ribo-Zero kit uses rRNA-
complementary oligonucleotide probes linked to magnetic beads. The rRNA
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probes bind to 5S, 16S and 23S rRNA in the sample, a magnet was then used to 
pellet the rRNA probes and the rRNA reduced supernatant is removed. The kit 
were used according to manufacturers instructions.
2.5.12. SOLiD sequencing of samples
The SOLiD RNA-seq protocol was carried out according to manufacturer’s 
instructions by the Eastern Sequencing and Informatics Hub (EASIH), based at 
Addenbrokes Hospital.
2.5.13. Analysis of RNA-seq data
Gene expression data resulting from RNA-seq is often presented in terms of the 
reads mapped per kilobase of gene per million mapped reads (RPKM). RPKM is 
calculated on a gene-by-gene basis according to Equation 3. The advantage of 
RPKM is that it takes into account both the length of the gene and the total number 
of reads in a sample. This allows for the comparison of expression level between 
different genes and between different samples.
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Equation 3: Equation to calculate normalised expression level (RPKM)
Number of reads which map to gene
RPKM =
Total number of reads (Millions) x Length of gene (kbp)
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Another way of analysing RNA-seq data is to perform, a differential gene 
expression analysis. This type of analysis typically uses unnormalised expression 
values (i.e. reads mapped rather than RPKM) to take advantage of the expected 
negative binomial distribution of gene expression values. The approach used in 
this work was implemented in edgeR (Robinson et al., 2010), an R package. 
EdgeR uses an over-dispersed Poisson model to model the count data and an 
empirical Bayes procedure is used to shrink the dispersions toward a consensus, 
effectively using gene expression data from all the genes to assess how likely it is 
that the expression of each particular gene is differentially expressed.
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2.6. Primers
Table 7: Primers used in this study
Primer name Sequence 5'->3'
BoNT/A Fw GGAAATGGTTATGGCTCTACTCAA
BoNT/A Rev TTGCCTGCACCTAAAAGAGGAT
BoNT/A Probe FAM-ACTT CAAGTT G ACT CCT CAAAACCAAAT GTAAA-TAMRA
GluD Fw AGTAAAG GTTTT CAAAG GTTATAG
GluD Rev T CTAAAG AAACATTT G GAT G G AA
GluD Probe N E D-CT CAACATAAT GAT G CAGT AG GT CCAACA-MG B-NFQ
HA70Fw TAGTG ATACTATT G ATTT AG CTG ATG GT
HA70Rev CATTT GTT CTTATATAT CCAT GACCCTT
orfX/2 Fw CT AATT CCACACTAAAT G GT ACTT G G AA
orfX/2 Rev T G ATACT G AATT CT CAGTATT CCAT CC
ha33 Fw CAGGATTTATAAGCCAATATTGGGC
ha33 Rev GCT CGT AATTT GAAGCTT AGCAC
-
orfX/3 Fw CCAAGTT AT GTAG ATTAT G CTTATT CAG
orfX/3 Rev CTATTAAAG C AACT G CTAAAAAT G ATCC
Hind III 0- 
primer 5’ FAM -  GACTGCGTACCAGCTTA -  3’
Hha 1 A- primer 5’ GAT G AGT CCT GAT CGCA -  3’
Hind III-ST1 5’ -  CT CGTAG ACTGCGTACC -  3’
Hind III-  ST2 5’ -  AGCTGGTACGCAGTC -  3’
Hha I-ST1 5’ -  GACGATGAGTCCTGATCG -  3’
Hha 1 -  ST2 5’ -  ATCAGGACTCATCG -  3’
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3. Results
3.1. In silico investigation of the botulinum toxin complex and C. 
botulinum proteome
Botulinum neurotoxin is encoded and co-expressed within a gene cluster that is 
12000 bp to 14000 bp in length, depending on the type of toxin gene cluster 
subtype. This gene cluster encodes the associated non-toxic proteins (ANTPs). 
There are two subtypes of toxin gene cluster -  the haemagglutinin (HA) and the 
OrfX.
The HA type gene cluster consists of bont, ntnH and botR which are encoded on 
the forward strand and ha33, ha17 and ha70 which are encoded on the reverse 
strand (Figure 11 A). In C. botulinum A1 ATCC 19397 bont/A is 3886 bp long 
encoding a 149.4 kDa protein, ntnH is 3581 bp long encoding a 138.2 kDa protein 
and botR is 536 bp long encoding a 21.7 kDa protein. In ATCC 19397 ha33 is 881 
bp long encoding a 33.8 kDa protein, ha17 is 440 bp long encoding a 17 kDa 
protein and ha70 is 1881 bp long encoding a 71.1 kDa protein.
The genomic arrangement of the OrfX type cluster (Figure 11B) differs from that of 
the HA cluster. The OrfX cluster consists, with some variants, of bont, ntnH and 
p47 encoded on the forward strand and botR, orfX/1, orfX/2 and orfX/3 encoded 
on the reverse strand. In C. botulinum A3 Loch Maree bont/A is 3879 bp encoding 
a 148.6 kDa protein, ntnH is 3480 bp long encoding a 134.6 kDa protein, p47 is 
1248 bp long and encodes a 47.4 kDa protein. On the reverse strand botR is 552 
bp long and encodes a 22.2 kDa protein, orfX/1 is 429 bp long and encodes a 16.5
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kDa protein, orfX/2 is 2253 bp long and encodes a 84.3 kDa protein and orfX/3 is 
1473 bp long and encodes a 55.2 kDa protein.
BoNT/A1, A5, B, C, D and G are encoded in the HA-type gene cluster while 
BoNT/A1 (rarely), A2, A3, A4, E and F have been identified encoded in OrfX gene 
clusters.
The bont and ntnH genes are 75-80% similar between the HA and OrfX toxin 
clusters (Figure 12), the botR gene sequences are similar but the gene is in the 
opposite orientation between the two toxin cluster subtypes, whilst there is no 
significant similarity between the ha genes and the orfX genes.
Group I C. botulinum cause the majority of botulism in the UK and are the focus of 
this investigation. Therefore, BoNT, NTNH, BotR and the HA cluster protein 
sequences from C. botulinum A1 ATCC 19397 and the OrfX cluster protein 
sequences from C. botulinum A3 Loch Maree were examined in greater detail.
In this section, BLASTp (http://blast.ncbi.nlm.nih.gov/Blast.cqi) was used to 
determine proteins exhibiting significant sequence similarity to the botulinum 
neurotoxin and the neurotoxin-associated proteins. An E-value cut off of 0.01 was 
used to determine significance (i.e. only matches with an e-value less than 0.01 
were considered significant). For the sake of clarity, identity (percentage of 
residues which are the same) and coverage (percentage of protein length which 
exhibits similarity) are multiplied to make a single ‘similarity’ value. For example, if 
a protein was 80% similar over 65% of the protein length, 0.8 x 0.65 = 0.52. 
Identity and coverage values used to derive the similarity values, along with 
BLASTp E-values are presented in the accompanying tables.
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This chapter places the botulinum neurotoxin and associated non-toxin protein 
sequences into a wider context. It describes the similarity between these proteins 
in different types and subtypes of BoNT, conserved functional domains within 
these proteins and their similarity to proteins from other species.
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Figure 11: Genomic arrangement of (A) bont/A1 in a HA gene cluster from C. botulinum A1 
ATCC 19397 and (B) bont/A3 from C. botulinum A3 NCTC 2012 in an OrfX gene cluster.
C. botulinum A1 ATCC 19397
botR
ntnHha70 ha 17 ha33 bot/A3
C. botulinum A3 Loch Maree
bot/A1ntnHorfX3 orfX2 orfX1
Figure 12: Comparison of ha and orfX gene clusters. The C. botulinum A1 ATCC 19397 
bont/A1 gene encoded within a ha gene cluster (above red line) was compared with the C. 
botulinum A3 Loch Maree orfX gene cluster (below red line) using Mauve. Areas of similarity 
are represented with coloured areas, the higher the peaks within the area, the higher the 
similarity between two areas. The similarity of the bont, ntnH and p47 genes between the 
two strains can be seen while no similarity between the ha genes and the orfX  genes was 
detected. The sequence of botR is in the opposite orientation between the strains. Created 
using Mauve v2.3.1.
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3.1.1. In silico investigation of botulinum neurotoxin and the 
neurotoxin associated proteins
3.1.1.1. In silico investigation of botulinum neurotoxin A1
The amino acid sequence of BoNT/A from C. botulinum A1 ATCC 19397 (Uniprot 
id = A7FS63) was compared against the NCBI non-redundant protein database 
using BLASTp. The proteins with the highest similarity to BoNT/A 1 were_ other 
botulinum neurotoxin proteins. BoNT/A5 has the highest similarity to BoNT/A1 with 
a similarity score of 0.96 (in this case there was 99% identity over 97% of the 
protein sequence). BoNT/A2, A4 and A3 have similarity scores of 0.86, 0.84 and 
0.79 respectively. BoNT/F, E, G and B have similarity scores of 0.27, 0.27, 0.24 
and 0.25 while BoNT/D and C are the least similar with scores of 0.21 and 0.20 
respectively. Tetanus neurotoxin (TeNT) is 35.4% similar to BoNT/A1 over 58.9% 
of the protein length. This gives TeNT a sequence similarity score of 0.21, a 
comparable level of similarity to the most distant BoNT protein sequences, 
BoNT/C and D. After TeNT the most similar protein to BoNT/A1 was C. botulinum 
NTNH, which had a similarity score of 0.17.
The protein motifs present in the different BoNT types, TeNT and NTNH were 
analysed using Interproscan, a program to identify functional domains in protein 
sequences. All seven BoNT subtypes and TeNT had identical functional domains 
in an identical arrangement along the length of the protein sequence (Figure 14 A 
& B). There were four protein domains present in the clostridial neurotoxins; 
enzymatic domain, translocation domain, receptor binding N terminal and receptor 
binding C terminal.
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The enzymatically active light chain of the toxin (IPR000395) was identified 
beginning at the N-terminus and finishing, approximately, at amino acid residue 
409 (in BoNT/A, and at a very similar position in the other proteins). Clostridium 
neurotoxin domains responsible for translocation and receptor binding, 
(IPR012500, IPR012928, IPR013104) were identified in the BoNT/A heavy chain 
from approximately amino acid residue 526 to the C terminus of the protein (amino 
acid residue 1296 in BoNT/A). The region responsible for toxin binding to target 
cells, spans amino acids 760 to 1111 (IPR012928), was also identified as a lectin 
domain (IPR008985) that may enhance binding to complex carbohydrates such as 
gangliosides.
A dendrogram (Figure 13) derived from a protein distance matrix concurs with the 
results of the BLASTp analysis (Table 8) (see methods section X). All the BoNT/A 
sequences cluster on the same branch, with BoNT/A1 and A5 most closely related. 
BoNT/C and BoNT/D form a related pair while BoNT/E and BoNT/F form a distinct, 
related pair although the distance between them is greater than the distance 
between BoNT/C and BoNT/D. BoNT/B and BoNT/G are on the same branch of 
the dendrogram but are more distant from each other than BoNT/E and F. TeNT is 
an outlier, clustering with BoNT/B and BoNT/G but it is very distantly related from 
either of these or any other BoNT protein sequence. NTNH is the most distant 
protein included in the dendrogram and roots the tree.
3.1.1.2. In silico investigation of NTNH
The amino acid sequence of NTNH (A7FS63) from C. botulinum A1 ATGC 19397 
was compared against the NCBI non-redundant protein database using BLASTp
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(Table 9). The proteins with the highest similarity to NTNH/A1 were other NTNH 
proteins. NTNH proteins from different subtypes showed higher similarity to 
NTNH/A1 than the different BoNT subtypes did to BoNT/A1 NTNH/A5 was the 
most similar, with a similarity score of 0.98. NTNH/E and NTNH/B had similarity 
scores of 0.90 and 0.83 respectively. NTNH/A2, A3, A4 and F had similarity scores 
of 0.76, 0.76, 0.76 and 0.75 respectively. NTNH C and D had similarity scores of 
0.66 and 0.65 respectively. BoNT/E was the most similar BoNT sequence 
compared with NTHT, with a score of 0.21. TeNT showed minimal similarity with 
NTNH/A1, with a similarity score of only 0.06.
A dendrogram representing the relationship between the protein sequences that 
showed significant similarity to NTNH/A1 was derived (Figure 16). NTNH/C and 
NTNH/D show strong similarity, NTNH B is most similar to C and D while 
NTNH/A1 and NTNH/A5 are halfway between NTNH/B and the cluster of 
NTNH/A2, A3, A4 and F. NTNH/E is most closely related to the NTNH sequences 
from the other OrfX encoding strains (A2, A3, A4 and F). BoNT/E and TeNT are 
both very distant from the NTNH sequences.
The NTNH sequence from each type/subtype in Table 9 was analysed using
Interproscan to identify any conserved protein domains present (Figure 15). All
NTNH types and subtypes had the same three functional domains in an identical
arrangement along the length of the protein sequence. The three domains were -
a clostridial neurotoxin zinc protease (bontoxylisin) domain (IPR000395), a
Clostridium neurotoxin receptor binding N-terminal domain (IPR012928) and a
non-toxic non-haemagglutinin C-terminal domain (IPR013677). The bontoxylisin
domain extends from the first amino acid of the N-terminus to approximately
residue 446 of the 1191 amino acid NTNH/A1 protein sequence. Following the
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bontoxylisin domain there is then a region with no protein domains annotated and 
this spans 399 amino acid residues from amino acid 446 to 845. This region is 
followed by the 208 amino acid neurotoxin receptor binding N-terminal that spans 
amino acid residues 845-1053. This region is also annotated as a lectin domain 
(IPR008985), involved in binding to complex carbohydrates such as gangliosides. 
The final domain is the Non-toxic non-haemagglutinin C-terminal domain that 
spans amino acid residues 1053^1196.
3.1.1.3. In silico investigation of HA70
The amino acid sequence of HA70 from C. botulinum A1 ATCC 19397 (A7FS58) 
was compared with the entire NCBI non-redundant protein database using 
BLASTp. The proteins with the highest similarity to HA70/A1 were other HA70 
proteins. The most similar protein to HA70/A1 was HA70/A5 with a similarity score 
of 0.98, HA70/B also showed strong similarity to HA70/A1 with a score of 0.97. 
The two other subtypes associated with HA type toxin gene clusters are C and D. 
HA70/C had a similarity score of 0.70 while HA70/D had a score of 0.67. In 
addition to highly significant matches against other HA70 proteins (all E-values = 0, 
Table 10) BLASTp returned a match against C. perfringens enterotoxin with an E- 
value of 0.016, which is above the 0.01 cut off for significant matches. However, 
when the alternative sequence similarity detection tool HMMer 
(http://hmmer.ianelia.org/) was used to analyse HA70/A1, there was a significant 
match (E-value = 2x10-6) between HA70/A1 and the C. perfringens enterotoxin. 
There is a low similarity score of 0.13, derived from an amino acid identity of 58% 
over 23% of the protein length indicating that perhaps the proteins share a 
functional domain.
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A dendrogram representing similarity between proteins that were similar to the 
HA70/A1 amino acid sequence was derived (Figure 18). The HA70/A1, A5 and B 
proteins were all very closely related with HA70/C and HA70/D being relatively 
distant. The C. perfringens enterotoxin is very distant from the HA70 proteins.
Interproscan analysis of the HA70 types/subtypes showed that all the 
types/subtypes had only one domain identified — the C. perfringens enterotoxin 
domain (IPR003897). Two separate sections of the HA70 sequence were 
annotated with the C. perfringens enterotoxin domain (Figure 17), the first section 
spans 50-170 amino acid residues. The second domain spans from 245-455 
amino acids of the 626 amino acid protein. This is in contrast to the annotation of 
the C. perfringens enterotoxin itself, which is annotated with the same domain, but 
in a single span covering amino acid residues 60-197 of the 316 amino acid 
protein (Figure 17).
3.1.1.4. In silico investigation of HA17
The amino acid sequence of HA17 from C. botulinum A1 ATCC 19397 (A7FS59) 
was compared against the entire NCBI non-redundant protein database using 
BLASTp (Table 11). The only proteins with significant similarity to HA17/A1 were 
other HA17 proteins. The protein with the highest similarity score compared with 
HA17/A1 was HA17/B with a score of 0.98, HA17/A5 was also highly similar with a 
score of 0.97. HA17 proteins from C. botulinum C and D both had similarity scores 
of 0.63 compared with HA17/A1.
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A dendrogram representing the similarity of proteins that showed similarity to 
HA17/A1 was derived (Figure 20). Two clusters, one consisting of HA17/A1, A5 
and B and the other consisting of HA17/C and D are evident.
The entire length of HA17/A1 shows homology with the Ricin B lectin domain 
(IPR000772), this domain is found in a variety of molecules including plant and 
bacterial AB-toxins, glycosidases and proteases (Figure 19). They are implicated 
in binding to sugars such as galactose and lactose.
3.1.1.5. In silico investigation of HA33
The amino acid sequence of HA33 (A7FS60) from C. botulinum A1 ATCC 19397 
was compared against the entire NCBI non-redundant protein database using
i
BLASTp. The proteins with the highest similarity to HA33/A1 were other HA33 
proteins. HA33/B had a similarity score of 0.97, HA33/A5 had a similarity score of 
0.91 while HA33/C and HA33/D both had similarity scores of 0.38. Two non-C. 
botulinum proteins that were similar to HA33/A1 were a mosquitocidal protein 
(Q03988) from Lysinibacillus sphaericus and Piersin-4 (C6L2F6), an apoptosis 
inducing protein from Aporia crataegi (Black-veined White butterfly).
A dendrogram was derived from the amino acid sequences of the proteins similar 
to HA33/A1 (Figure 22). The HA33 proteins fell into two clusters, one of HA33/B, 
A1 and A5 and the other of HA33/C and D. The two non-C. botulinum proteins that 
were similar to HA33, the mosquitocidal protein from L. sphaericus and the piersin
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protein from A. crataegi showed very little similarity with either the HA33 proteins 
or each other, indicating a separate evolutionary history.
Interproscan analysis of HA33/A1 shows that it contains a Ricin B lectin domain 
(IPR000772). This domain is common in many plant and bacterial AB toxins, 
including the mosquitocidal protein and Piersin-4 identified as similar to HA33/A1 
by BLASTp. It is likely that the presence of this domain explains the BLASTp hit 
between HA33 and the non-C. botulinum proteins detailed above. This domain is 
also present in HA17 (Figure 21 & Figure 19).
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Table 8: Proteins with significant sequence similarity to BoNT/A1. E-value, identity and
coverage all calculated by BLASTp. The similarity score was calculated as the product of
the identity and coverage.
Protein
match Uniprot ID E-value Identity Coverage
Similarity
score
BoNT/A5 C7BEA8 0 • 98.9% 97.1% 0.96
BoNT/A2 E5F1I1 0 95.5% 90.0% 0.86
BoNT/A4 C3KS13 0 94.2% 89.4% 0.84
BoNT/A3 Q3LRX9 0 92.9% • 84.9% 0.79
BoNT/F D2KHS9 6.4x10-277 63.5% 42.9% 0.27
BoNT/E Q54A79 7.6x10-260 65.6% 41.6% 0.27
BoNT/G Q60393 1.1x10-256 60.6% 39.8% 0.24
BoNT/B Q1WA38 3.1x10-254 61.7% 40.5% 0.25
TeNT P04958 1.3x10-201 58.9% 35.4% 0.21
BoNT/D P19321 7.9x10-201 59.9% 35.4% 0.21
BoNT/C Q5DW55 2.2x10-185 58.7% 34.6% 0.20
NTNH A8Y860 5.9x10-15 55.1% 31.7% 0.17
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Figure 13: Dendrogram representing amino acid sequence similarity between BoNT/A-G, 
TeNT and NTNH. NTNH roots the dendrogram as it’s sequence shows the least similarity 
with BoNT/A.
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IPR000395 | Peptidase M27, bontoxilysin
PR00760* 0-0—00- 
C3DSA:3.90. 1240.iop mmmmm 
- rrouAi* wmmamn
•.....>1 Description 
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□ SONTOXILYSIN
■ no description
■ Peptidase_M27
IPR008985 1 Concanavalin A-like lectin/glucanases superfamily
SSF49899x------------------ :--------- — — — ;----— ------;---- :— —— I Concanoraiin A-lika lectins/glucanases
IPR011065 | Kunitz inhibitor STl-like
■ SSF50386*- ——----i— ' /  - ' n -
IPR012500 I Clostridium neurotbxin, translocation 
. PF079S2P— — — — — — — — ——  ------
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I PRO13104 j Clostridium neurotoxin, receptor-binding C-terminal
PF07DS1»  ------—----- — ------- — --------— - ------ :------ —— - |Toxin_R_bind_C
j IPRO133Z0 j Concanavalin A-like lectin/glucanase, subgroup : 
: C3 DSA:2,60.120.200» ' ; v r \ J| no description
nolPR j unintegrated
C3DSA:1.20.1120.10x- 
C3DSA:2.80.10.S0s - 
SSF554S6M
I no description 
I no description
I Metaltoprateases fzincins’l, catalytic dnmain
(B)
InterPro Match *• 1
'1PR000395 1  Peptidase M27, bontoxilysin
PR00760» •©-©-0-0- 
C3DSA:3.90. 1240.10s- 4 
FFD1742M
Query Sequence Description
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□  tONTOXRYSM
■  no description 
Q Peptidase_M27 '
f IPR0089S5 j Concanavalin A-like lectin/glucanases supcrfamity 
SSF49899P.'—— — ..................------------ -------:— — —-------:— — I Concanaralin A-I&e lectins/glucanases
Kunitz inhibitor STl-like
f  IPROlZSbO ~ j Clostridium neurotoxin, translocation 
fF073S2>---------— — —-----— --------- ;-----:---- —
[ ~iPR0Y2^2iBr J  Clostridium neurotoxin, receptor binding N-tcrminal 
• iPF070S3 1 * -    ...........................................................— f i  T o x in J L b ifd .N  •
‘ Clostridium neurotoxin, receptor-binding C-terminal
BTox«iJ?_fcjnd.C
Concanavalin A-like lectin/glucanase, subgroup
C3DSA:2.60.120.200>- : ■  no description
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C3DSA:1.20.1120.10e- 
C3DSA:2.80.10.50» -
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■  no description
■  no description
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Figure 14: Protein domains identified in (A) BoNT/A1 and (B) TeNT by Interproscan. In both 
panels the dotted line at the top is the protein, the location and length of domains identified 
by Interproscan can be seen beneath the query sequence. BoNT and TeNT have identical 
Pfam domains in an identical arrangement.
114
Table 9: Proteins with significant sequence similarity to NTNH/A1. E-value, identity and
coverage all calculated by BLASTp. The similarity score was calculated as the product of
the identity and coverage.
Protein
match Uniprot ID E-value Identity Coverage Similarity
NTNH/A5 E8ZMV9 0 98% 100% 0.98
NTNH/E C4IHM0 0 90% 100% 0.90
NTNH/B C3KSE1 0 83% 100% 0.83
NTNH/A3 B1L2G4 0 76% 100% 0.76
NTNH/A2 C1FUH8 0 76% 100% 0.76
NTNH/A4 C3KS14 0 76% 100% 0.76
NTNH/F A7GBG3 0 75% 100% 0.75
NTNH/D C5VU80 0 66% 100% 0.66
NTNH/C B1BE43 0 66% 99% 0.65
’ BoNT/E Q9K395 4x10-29 23% 92% 0.21
TeNT TETX_CLOTE 2x10-20 28% 22% 0.06
InterPro Match »•..<•         Query Sequence
( IPR00Q395 1 Peptidase M27, bontoxilysin
V PR007^6V'<>Ct-O-O  0—0------— — ------ —— —— — —------------------------------ :---------------- — ------- — —--------  ' □  BONTOXILYSINr.tnc*-I on O a m A . . ------------ :— :---------------------------------------------------;-:—  -------   ■  nadescription ;
PF n  1741►----------------------------------------------------------- — --------------------------------- :------------------:---------—----------------------   B  Peptidase_M27
IPR008985 | Concanavalin A-like lectin/glucanases superfamily
SSF49S99*-—--------:——----------—--------;----———-------—— ------ -----——---------——--------------------------------------------- :-------------- B Concanavalin A-like lectins/glucanases
| I PRO12928 j Clostridium neurotoxin, receptor binding N-terminal
PP0795 3e — — ———-----1----- ——---- — — — —   1 T'.'—  . ■ ----------;- BToxinJt.bind.N
| I PRO 13320 | Concanavalin A-like lectin/glucanase, subgroup
C3DSA:2 .CO. 120.200 >• ' ■ ' .—  -----------  -— -rmiinjsiiiiiM.Mssi^- 1. ---- — -  b no description
l~PR6i3677 [ Nontoxic nonhaemagglutinin C-terminal
, PP0S470>- ;;v ' : v — _ .
j nolPR 1 unintegrated v ....
G3DSA:1.20.1120.10»— ----------  ’---— ------------  -e e M M ^ M iiM i i i i i ie M w i---;      —  B no description
SSFS$4SGxbbbmb^ ------------------------------------------------------------------------------:---------------:  . B Metalloproteases fzincins"), catalytfc domain
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Figure 15: Protein domains identified in NTNH/A1 by Interproscan. These same protein 
domains were idenitified in every NTNH type/subtype analysed.
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Figure 16: Dendrogram representing the relationship between proteins that showed 
significant similarity to NTNH/A1
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Table 10: Proteins with significant sequence similarity to HA70. E-value, identity and
coverage all calculated by BLASTp. The similarity score was calculated as the product of
the identity and coverage.
Protein match UniprotID E-value Identity Coverage Similarity
HA70/A5 E8ZMV5 0 0.98 1 0.98
HA70/B Q33CP8 0 0.97 1 0.97
HA70/C B1BE46 0 0.7 1 0.7
HA70/D C5VU77 0 0.68 0.98 0.67
C. perfringens enterotoxin F7J0F5 BLASTp - 0.016 0.58 0.23 0,13
C. perfringens enterotoxin F7J0F5 HMMer-2x10-6 0.58 0.23 0.13
(A)
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i European Bioinformatics Institute 2006-2012, ESI Is an Outstatlon o f the European Molecular Biology Laboratory.
Figure 17: Protein domains identified by Interproscan in (A) HA70 (B) C. perfringens 
enterotoxin.
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Figure 18: Dendrogram representing the relationship between proteins that showed 
significant similarity to HA70/A1
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Ricin B lectin domain
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Figure 19: Protein domains identified in HA17 by Interproscan
Table 11: Signficiant matches to HA17 identified from BLASTp and HMMer analysis
Protein match Uniprot ID E-value Identity Coverage Similarity
HA17/B Q45841 3x10-97 r 98%
r 10Q%
0.98
HA17/A5 E8ZMV6 6x10-96 97% " 100% 0.97
HA17/C B1BE45 3x10-52 63% " 100% 0.63
HA17/D Q9ZX78 3x10-52 63% '  100% 0.63
r—  HA17/B 
-  HA17/A1 
L- HA17/A5 
-  HA17/C
L HA17/D
Q05
Figure 20: Dendrogram representing the relationship between proteins that showed 
significant similarity to HA17/A1
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Table 12: Significant matches to HA33 identified by BLASTp analysis
Protein match Uniprot ID E-value Identity Coverage Similarity
HA33/B C3KSE3 0 97% r 100% 0.97
HA33/A5 E8ZMV7 0 p 91% r 100% 0.91
HA33/C B1BE44 2E-46 40% ' 94% 0.38
HA33/D C5VU79 2E-46
K»
40% F 94% 0.38
Mosquitocidal toxin Q03988 8E-16 33% r 96% 0.32
Piersin-4 C6L2F6 0.0000002 r 30% r .76% 0.23
Inter Pro Match »• 1 Query Sequence #....| Description 293
tFRSOQ772 1  Ricin B iectin domain
■ W l4 '............—
smdo4$8> :— c r r = =  
FS50233* ..........--------- ;—
nofPR~* " 1  un in teg ra ted
D  PROOOM □ prints OUR □  Pf AM 13 SMART OTlCRfAMs
■ □  HAMAS’ □ prositc ■ s u m F A it iv □SCNAiP QTMHMM □  PANTHER
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Figure 21: Protein domains identified in HA33 by Interproscan
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Figure 22: Dendrogram representing the relationship between proteins that showed 
significant similarity to HA33/A1
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3.1.1.6. In silico investigation of 0RFX1
The amino acid sequence of OrfX1 (B1L2G1) from C. botulinum A3 NCTC 2012 
was compared against the entire NCBI non-redundant protein database using 
BLASTp. The proteins with the highest similarity to OrfX1/A3 were other OrfX1 
proteins. The most similar protein was OrfX1/A2 with a similarity score of 0.97, 
OrfX1/F and OrfX1/A4 were also very similar with scores of 0.94 and 0.88 
respectively. OrfX1/E showed less similarity to OrfX1/A3, with a similarity score of 
0.72. There was also a Paenibacillus dendritiformis protein that showed a low but 
significant level of similarity to OrfX1/A3. This protein was annotated as an OrfX1 
protein and had a similarity score of 0.25 compared with OrfX1/A3. Interproscan 
identified no conserved domains in OrfX1/A3. Due to the presence of a large 
number of non-C. botulinum proteins that show similarity to the OrfX proteins, 
dendrograms representing the similarity of these proteins will be presented and 
discussed in further detail in section 3.1.2.
3.1.1.7. In silico investigation of ORFX2
The amino acid sequence of OrfX2 from C. botulinum A3 NCTC 2012 (B1L2G0) 
was compared against the entire NCBI non-redundant protein database using 
BLASTp. The proteins with the highest similarity to OrfX2/A3 were other OrfX2 
proteins. The most similar OrfX2 protein to OrfX3/A3 was OrfX2/A1 followed by 
OrfX2/A2 and OrfX2/F with similarity scores of 0.96, 0.95 and 0.95 respectively. 
OrfX2/A4 and OrfX2/E had similarity scores of 0.78 and 0.51 compared to 
OrfX2/A3.
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There are multiple proteins similar to OrfX2/A3 from organisms not known to 
encode the botulinum neurotoxin. In many cases these proteins are annotated as 
OrfX2, likely because annotation of coding sequences is often based on similarity 
to previously identified genes. The most similar protein from a non-BoNT encoding 
organism is a coding sequence annotated as OrfX2 from Paenibacillus 
dendritiformis, which has a similarity score of 0.34 compared with OrfX2/A3. The 
same organism also encodes a protein that is similar to OrfX1. Other organisms 
that have coding sequences annotated as OrfX2 are Ricketsiella grylli (similarity 
score of 0.15), Erwinia amylovora (0.14), Erwinia tasmaniensis (0.12), Erwinia 
pyrifoliae (0.11) and Arsenophonus nasoniae (0.16). There are also significant 
matches with coding sequences annotated as hypothetical proteins in 
Pseudomonas putida (0.1) and Nitrobacter winogradskyi (0.12). OrfX2/A3 also 
shows similarity to another BoNT complex protein, with distant but significant 
similarity to OrfX3/F (similarity score of 0.12) and OrfX3/A3 (0.08).
The larger number of proteins that showed similarity to the OrfX proteins 
compared to the HA proteins, combined with the novelty of these observations 
means that an analysis of their relatedness to each other (i.e. dendrograms) will 
be dealt with in a separate section (3.1.2.3).
When OrfX2/A3 was analysed by Interproscan a Clostridium P-47 family domain 
(IPR010567) was identified. This family consists of several proteins from Clostridia 
and other species; its function is unknown. All the other proteins identified as 
similar to OrfX2/A3 in Table X also have a P-47 family domain.
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3.1.1.8. In silico investigation of 0RFX3
The amino acid sequence of OrfX3/A3 from C. botulinum A3 NCTC 2012 was 
compared against the entire NCBI non-redundant protein database using BLASTp. 
The proteins with the highest similarity to OrfX3/A3 were other OrfX3 proteins from 
C. botulinum. The most similar proteins were OrfX3/A2 and OrfX3/F which both 
had a similarity score of 0.97 when compared with OrfX2/A3. OrfX3/A4 and 
OrfX3/A1 were also very similar to OrfX3/A3 with similarity scores of 0.95 and 0.93 
respectively. The most distant OrfX3 protein encoded by a BoNT encoding species 
was OrfX3/E with a similarity score of 0.69.
Similarly to OrfX2 there were a large number of proteins similar to OrfX3 encoded 
by a variety of species. Again, the species with the highest similarity protein to 
OrfX3/A3 was P. dendritiformis that encoded a protein annotated as OrfX3 with a 
similarity score of 0.45 compared with OrfX3/A3. Other species with coding 
sequences similar to OrfX3/A3 that were annotated as hypothetical proteins 
include Halomonas sp. TD01 (similarity score 0.30), N. winogradskyi (0.25), P. 
putida (0.24) and E. tasmaniensis (0.19). Achromobacter xylosoxidans encoded 
two proteins similar to OrfX3/A3, one annotated as OrfX3 that had a similarity 
score of 0.24 and another, annotated as a hypothetical protein with a score of 0.15.
OrfX3/A3 shows similarity to OrfX2/A4, with a score of 0.2 and similarity to P-47 
with a score of 0.15. Some of the proteins identified as similar to OrfX3 were also 
identified as similar to OrfX2. Hypothetical proteins from N. winogradskyi 
(Q3SU91), P. putida (Q88LC9) and E. tasmaniensis (B2VCQ8) were all identified 
as being similar to both OrfX2 and OrfX3. In all three cases, the non-C. botulinum
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proteins were more similar to OrfX3 than OrfX2 as assessed by both BLASTp E- 
value and similarity score.
Interproscan identified the entire length of OrfX3 as containing a Clostridium P-47 
domain. All the other proteins identified as similar to OrfX3/A3 were also identified 
as having P-47 domains.
3.1.1.9. In silico investigation of P-47
The amino acid sequence of P-47 from C. botulinum A3 NCTC 2012 (B1L2G3) 
was compared against the NCBI non-redundant protein database using BLASTp. 
The proteins with the highest similarity to P-47/A3 were other C. botulinum P-47 
proteins. P-47/A1 and P-47/A2 showed the highest similarity with P-47/A3 with 
similarity scores of 0.99 and 0.95 respectively. P-47/F, P-47/A4 and P-47/E had 
similarity scores of 0.8, 0.75 and 0.73 respectively.
There were multiple proteins from non-BoNT encoding species annotated as P-47 
proteins or hypothetical proteins that showed significant similarity to P-47. P. 
dendritiformis encoded the most similar protein to P-47/A3 with a similarity score 
of 0.36, other species encoding proteins similar to P-47/A3 included N. 
winogradskyi (0.24), E. pyrifoliae (0.17), P. putida (0.17) and R. grylii (0.22). P- 
47/A3 also showed to OrfX3/F (0.16) and OrfX2 (0.15).
Interproscan identified a P-47 domain in the P-47 protein. This protein domain 
family is named after this protein.
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3.1.1.10. In silico investigation of BotR
The amino acid sequence of BotR/A1 from C. botulinum A1 ATCC 19397 was 
compared against the entire NCBI non-redundant protein database using BLASTp. 
The most similar proteins were BotR/B and BotR/A5 that had similarity scores of 
0.98 and 0.97 compared with BotR/A1. Following these proteins, TetR, the 
regulator of tetanus neurotoxin showed the closest similarity with BotR/A1 with a 
similarity score of 0.67. BotR/F, BotR/A3 and BotR/A2 all had similarity scores of 
0.61 while both BotR/C and BotR/D had similarity scores of 0.5. UviA, an RNA- 
polymerase sigma factor protein that regulates produciton of a bacteriocin (Dupuy 
et al., 2005) had a similarity score of 0.25 compared with BotR/A1.
A dendrogram representing similarity between sequences that were identified as 
similar to BotR/A1 was derived (Figure 26). BotR/A2, A3, A4 and F form one 
cluster while BotR/A1, B and A5 form a distinct cluster. TetR, the regulatory 
protein from C. tetani fell in between these two groups. BotR/C and D clustered 
together, distantly from these other groups.
BotR contains domains representative of various protein functions and families 
including transcription repressing DNA binding (IPR011991), sigma factor 70 
(IPR014284) and the BotR transcription regulator (IPR017622)
125
Table 13: Significant matches to 0rfX1/A3 identified by BLASTp analysis
Protein match Uniprot ID E-value Identity Coverage Similarity
0rfX1/A2 B0FNQ6 8E-79 ' 97% ' 100% 0.97
OrfX1/F D5VUS3 3E-75 ' 94% O O NO 0s 0.94
OrfX1/A4 C3KS17 5E-70 ' 88% —X O O so 0s 0.88
0rfX1/E C4IHL7 1E-58 72% " 100% 0.72
OrfX1/P.
dendritiformis H3SNG9 0.00000008 26% - 97% 0.25
Table 14: Significant matches to OrfX2/A3 identified by BLASTp analysis
Protein match UniprotID E-value Identity Coverage Similarity
0rfX2/Al C9WWY2 0 96% 100% 0.96
OrfX2/A2 Q6RI02 0 95% 100% 0.95
0rfX2/F D5VUS2 0 95% 100% 0.95
OrfX2/A4 C3KS18 0 78% 100% 0.78
0rfX2/E C4IHL6 0 52% 99% 0.51
0rfX2/R dendritiformis H3SNG8 1.00E-141 35% 97% 0.34
0rfX2/ /?. grylli A8PMG2 1.00E-23 27% 56% 0.15
0rfX2/E. amylovora E5B9Q4 5.00E-22 25% 54% 0.14
0rfX2/E. tosmaniensis B2VCQ8 1.00E-21 26% 48% 0.12
0rfX2/E. pyrifoliae D2T7Z3 2.00E-20 24% 46% 0.11
0rfX2/A nasoniae D2TXI8 4.00E-18 22% 74% 0.16
Hypothetical protein/P. 
putida Q88LC9 1.00E-16 25% 39%
0.10
Hypothetical protein/ N. 
winogradskyi Q3SU91 5.00E-16 22% 53%
0.12
0rfX3/F A7GBF7 2.00E-08 23% 54% 0.12
OrfX3/A3 B1L2F9 9.00E-08 26% 29% 0.08
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Table 15: Significant matches to OrfX3/A3 identified by BLASTp analysis
Protein match UniprotID E-value Identity Coverage Similarity
OrfX3/A2 Q6RI03 0 97% 100% 0.97
0rfX3/F B1QQF2 0 97% 100% 0.97
OrfX3/A4 C3KS19 0 95% 100%, 0.95
0rfX3/Al C9WWY1 0 93% 100% 0.93
0rfX3/E C4IHL5 0 75% 92% 0.69
0rfX3/R dendritiformis H3SNG7 2.00E-131 46% 98%
0.45
Hypothetical 
protein/Halomonas sp TD01 F7SP91 2.00E-57 31% 97%
0.30
Hypothetical protein/A/. 
winogradskyi Q3SU91 2.00E-39 26% 98%
0.25
Hypothetical protein/R 
putida
Q88LC9 7.00E-29 24% 98% 0.24
OrfX3/A xylosoxidans F7SWZ7 2.00E-23 25% 97% 0.24
Hypothetical protein/A. 
xylosoxidans
F7SWZ6 1.00E-16 28% 55% 0.15
Hypothetical protein/E. 
tasmaniensis B2VCQ8 7.00E-14 22% 86%
0.19
OrfX2/A. nasoniae D2TXI8 2.00E-12 24% 57% 0.14
OrfX2/A4 C3KS18 4.00E-10 24% 84% 0.20
p47/C. botulinum A3 C3KS15 4.00E-09 26% 58% 0.15
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Table 16: Significant matches to P-47/A3 identified by BLASTp analysis
Protein match
Uniprot
ID
E-value Identity Coverage Similarity
P-47/A1 C9WWY5 0 99% 100% 0.99
P-47/A2 Q6RI05 0 95% 100% 0.95
P-47/F A7GBG1 0 80% 100% 0.80
P-47/A4 C3KS15 0 75% 100% 0.75
P-47/E C4IHL8 0 73% 100% 0.73
P-47/P. dendritiformis H3SNG6 3.00E-88 36% 99% 0.36
Hypothetical protein/A/. 
winogradskyi Q3SU90 6.00E-21 24% 99%
0.24
P-47/f. pyrifoliae D2T7Z2 3.00E-20 25% 69% 0.17
P-47/P. putida Q88LC8 6.00E-17 26% 67% 0.17
Hypothetical protein//?, grylli A8PMG3 1.00E-16 25% 89% 0.22
Hypothetical protein/f. 
amylovora E5B9Q3 2.00E-16 24% 56%
0.13
Hypothetical protein/f. 
tasmaniensis
B2VCQ7 2.00E-15 26% 56% o;i5
0rfX3/F B1QQF2 3.00E-10 26% 61% 0.16
P-47/A nasoniae D2TXI9 5.00E-10 24% 59% 0.14
P-47/Halomonas sp. TD01 F7SP89 1.00E-09 23% 93% 0.21
OrfX2/A3 B1L2G3 1.00E-04 27% 54% 0.15
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Figure 23: Protein domains identified by Interproscan in OrfX2
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Figure 24: Domains identified in OrfX/3 by Interproscan analysis
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Figure 25: Domains in P-47 identified by Interproscan
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Table 17: Significant matches to BotR/A1 identified by BLASTp analysis
Protein match Uniprot ID E-value Identity Coverage Similarity
BotR/B B1INP7 5.00E-117 98% 100% 0.98
BotR/A5 E8ZMV8 3.00E-115 97% 100% 0.97
TetR/C. tetani Q899V5 9.00E-79 67% 100% 0.67
BotR/F D5VUS4 1.00E-64 61% 100% 0.61
BotR/A3 B1L2G2 3.00E-64 62% 98% 0.61
BotR/A2 C1FUH6 6.00E-64 61% 100% 0.61
BotR/C Q38195 1.00E-37 50% 100% 0.5
BotR/D Q9ZWV5 2.00E-37 50% 100% 0.5
-  BotR/A1
__________________  L BotR/B
BotR/A5
—-----------—  TetR - 0. tetani
------------- _  BotR/A2
"L- BotR/A3
_______ _________________  r- BotR/A4
L  BotR/F 
, BotR/C 
—j BotR/D
---------------------------------------------------------- ------------------------------------ UviA - C. perfringens
I---------- !
0.1
Figure 26: Dendrogram representing the relationship between proteins that showed 
significant similarity to BotR/A1
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3.1.2. Identification of P-47 family gene clusters in non-C. botulinum 
species and their association with genes encoding putative toxin 
proteins
Four proteins typify the OrfX toxin complex type -  OrfXi, OrfX2, OrfX3 and P-47. 
Interproscah identified three of these four proteins (OrfX2, OrfX3 and P-47) as 
containing ‘P-47’ domains, they also show significant homology to one another as 
determined by BLASTp analysis; these proteins are therefore referred to as P-47 
family proteins.
Multiple P-47 family homologues were identified in nine non-C. botulinum species. 
The genomic organisation of these homologues was investigated to determine 
whether they are encoded in clusters, similarly to the C. botulinum P-47 family 
proteins. The nine non-C. botulinum species were Ricketsiella grylli, Paenibacillus 
larvae, Erwinia tasmaniensis, Arsenophonus nasoniae, Halomonas sp TD01, 
Paenibacillus dendritiformis, Nitrobacter winogradskyi, Achromobacter 
xylosoxidans and Pseudomonas putida. In all nine species, the P-47 family 
proteins were clustered together in a broadly similar fashion to the C. botulinum P- 
47 family proteins, although there was variation in how many homologues were 
present and their precise organisation. Furthermore, in 6 of the 10 strains 
examined (including C. botulinum), genes encoding known or putative toxins were 
co-localised with P-47 family proteins.
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3.1.2.1. Analysis of non-C. botulinum species in which P-47
family clusters are associated with putative toxin proteins
Paenibacillus larvae
P. larvae is an anaerobic, endospore forming bacteria found in a range of 
environments such as soil, water and insect larvae, it causes American foulbrood 
in honeybees. P. larvae encodes a cluster of three P-47 family encoding genes. 
Two of these are degraded by frame shift and stop codon insertions (Figure 27 & 
Table 18). As these proteins are degraded they are not present in the NCBI or 
Uniprot databases, this explains why there were no matches to these proteins 
when these databases were searched for proteins similar to the OrfX proteins. 
Two of the P. larvae CDSs are annotated as OrfX2 and OrfX3 due to a strong 
similarity with the C. botulinum OrfX2 and OrfX3. The P. larvae OrfX2 and OrfX3 
encoding genes also show synteny with the C. botulinum genes.
The P-47 cluster also encodes a degraded protein (annotated as two open reading 
frames - PlarlB_020100022873/degraded feature 3) that shows similarity to the 
clostridial C2 toxin and Bacillus anthracis Protective Antigen (PA) as well as close 
similarity with a protein annotated as Protective Antigen in P. dendritiformis. These 
four proteins (P. larvae, P. dendritiformis and B. anthracis PA and the clostridial 
C2 toxin) all have PA'\4 (IPR011658) and bacterial exotoxin B (IPR003896) 
domains. The PA14 domain is thought to play have a role in binding of the 
Protective Antigen and is present in many bacterial enzymes and toxins. The 
bacterial exotoxin B domain is characteristic of the binding subunit of an AB toxin.
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Ricketsiella grylli
Ricketsiella grylli is an intracellular pathogen of insects, including crickets. R. grylli 
encodes two P-47 family genes (Figure 28 & Table 19). One gene encodes a 
protein similar to OrfX2 (similarity score 0.24) and the other a protein similar to P- 
47 (0.23). Two other proteins of interest encoded in the R. grylli P-47 family gene 
cluster are a 17-kDa protein also identified in P-47 family gene clusters in A. 
nasoniae and E. tasmaniensis which has been named P-17. This protein doesn’t 
show similarity to any well characterised proteins and no known domains were 
identified in it’s sequence on Interproscan analysis. The R. grylli P-47 family 
cluster also encodes a Shiga-toxin A-chain homologue immediately upstream of 
the cluster, on the opposite strand, an arrangement similar to the organisation of 
the P-47 family gene cluster and the BoNT gene in C. botulinum.
Erwinia tasmaniensis
E. tasmaniensis is a non-pathogenic species associated with plants. It encodes 
two P-47 family genes (Figure 29 & Table 20), one protein that is most similar by 
BLASTp E-value to OrfX2 and another that is most similar to P-47. However, both 
these proteins also show approximately equivalent similarity to other C. botulinum 
P-47 family proteins. A CDS similar to the P-17 protein identified in R. grylli and A. 
nasoniae was also identified. E. tasmaniensis encodes a toxin within the P-47 
family gene cluster; a nematicidal protein homologue identified in bacteriophage 
and fungi. There was also a hypothetical protein in the P-47 family cluster that was 
identified in the same bacteriophage as the nematicidal protein.
Arsenophonus nasoniae
A. nasoniae encodes a cluster of three P-47 family CDSs (Figure 30 & Table 21).
Two of these CDSs show highest similarity with OrfX2 (similarity scores of 0.31
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and 0.17) and one has closest similarity to P-47 (0.15). However, these proteins 
also show a comparable level of similarity to other P-47 family protein sequences. 
The A. nasoniae P-47 cluster also encodes a protein similar to the P-17 
hypothetical protein in R. grylli and E. tasmaniensis. Also encoded within the A. 
nasoniae P-47 cluster are two putative nematicidal proteins which show similarity 
to the nematicidal protein identified in a P-47 cluster in E. tasmaniensis. These two 
proteins show similarity to putative toxin proteins in Yersinia enterocolitica among 
others.
Halomonas sp. TD01
Halomonas sp. TD01 encodes a cluster containing three P-47 family CDSs (Figure 
31 & Table 22). Two of the genes encode proteins that show the highest similarity 
with OrfX3 with similarity scores of 0.31 and 0.11 respectively, the third CDS 
encodes a protein that is most similar to P-47 (0.2). However, these proteins also 
show a comparable level of similarity to other P-47 family protein sequences. 
Halomonas sp. TD01 also encodes two nematicidal proteins alongside the P-47 
family cluster. When these proteins are compared to each other they have 
similarity score of 0.49/0.48. Both of these proteins also show similarity to AidA 
nematicidal proteins from Ralstonia salanaceaerum and Burkholderia cepacia 
(plant pathogens) as well a hypothetical protein from Xenorhabdus nematophila 
(insect pathogen).
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feature 1 020100022898
Figure 27: The P. larvae P-47 family gene cluster. There are three P-47 family CDSs, two of 
which are degraded by stop codon insertion and frame shift mutations. There is also a 
partially degraded C2 toxin/Protective Antigen homologue.
Table 18: BLASTp matches to proteins from the P. larvae P-47 family cluster
C2 toxin/Protective Antigen
Degraded PlarIB Degraded
feature 3 020100022873 feature 2
Query locus Match protein Matchscore Identity Coverage Similarity Match id
PlarIB 0201000 
22898 OrfX2 1.00E-145 36% 99% 0.36
YP_00171569
8.1
OrfX3 3.00E-15 25% 37% 0.09
YP_00171569
7.1
Degraded 
feature 1 OrfX3 6.00E-143 46% 97% 0.45
YP_00171569
7.1
OrfX2 4.00E-14 22% 86% 0.19
YP_00171569
8.1
Degraded 
feature 2 P-47 5.00E-92 36% 91% 0.33
YP_00171570
1.1
OrfX2 1.00E-08 24% 52% 0.12
YP_00171569
8.1
OrfX3 9.00E-08 22% 83% 0.18
YP_00171569
7.1
PlarlB_0201000 
22873/degraded 
feature 3
Protective antigen 
{P. dendritiformis)
0.00E+0
0 74% 98% 0.73 ZP_09677307
lota toxin 
component lb (C. 
perfringens)
1.7x10-
79 30% 82% 0.25
YP_00467032
3
C2 toxin, 
component II (C. 
botulinum D)
2.1x10-
71 31% 62% 0.19
YP_00303426
6
lota toxin 
component lb (B. 
thurigenesis)
2.7x10-
62 28% 80%
iu
0.22 EEM56627
Protective antigen 
{B. anthracis)
7.9x10-
49 29% 67% 0.19
YP_00281159
6
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Figure 28: The R. grylli P-47 family gene cluster. There are two P-47 family CDSs, one 
encoding a novel protein conserved in other species (P-17), and a Shiga-toxin A-chain 
homologue.
Table 19: BLASTp matches to proteins from the R. grylli P-47 family cluster
Query locus Match
protein
Match
score
Identity Coverage Similarity Match id
RICGR_0717 OrfX2 1.00E-29 25% 97% 0.24 YP_001715698.1
OrfX3 9.00E-09 23% 51% 0.12 YP_001715697.1
RICGR_0718 P-47 2.00E-20 25% 90% 0.23 YP_001715701.1
OrfX3 2.00E-08 24% 62% 0.15 YP_001715697.1
OrfX2 0.024 23% 44% 0.1 YP_001715698.1
Hypothetical
RICGR_0719 protein [A. 
nasoniae)
Hypothetical
1.30E-30 48% 93% 0.45 CBA72108.1
protein (£. 8.00E-12 36% 68% 0.24 CAO98071.1
tasmaniensis)
Shiga toxin 2f
RICGR_0720 A subunit (£. 
coli)
4.50E-60 41% 98% 0.4 BAE79483.1
<
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Nematicidal protein Hypothetical P-17 P-47 OrfX2
rhsA ETA_30240 ETA_30250 ETA_30260 ETA_30270
Figure 29: The E. tasmaniensis P-47 family cluster. There are two P-47 family CDSs, a P-17 
sequence, a hypothetical CDS and a nematicidal protein homologue.
Table 20: BLASTp matches to proteins from the E. tasmaniensis P-47 family cluster
Query
locus Match protein
Match
score Identity Coverage Similarity Match id
ETA_30270 OrfX2 2.00E-25 26% 65% 0.17 YP_001715698.1
OrfX3 5.00E-18 22% 83% 0.18 YP_001715697.1
P-47 3.00E-05 23% 42% 0.1 YP_001715701.1
ETA_30260 P-47 3.00E-19 26% 57% 0.15 YP_001715701.1
OrfX3 6.00E-10 23% 68% 0.16 YP_001715697.1
ETA_30250 Hypothetical proteins (R grylli) 1.10E-11 36% 67% 0.24 ACJ10120.1
Hypothetical protein (A. 
nasonaie) 9.60E-06 30% 74% 0.22 XP_002378664.1
ETAJ30240 Hypothetical protein (Bacteriophage APSE-3) 5x10-67 38% 95% 0.36 ACJ10121.1
Hypothetical protein 
(Aspergillus flavus) 6.70E-10 22% 94% 0.21 EEQ17818.1
rhsA Putative YD-repeat toxin (Bacteriophage APSE-3) 0.00E+00 51% 87% 0.44 ZP_12869720.1
Rhs family protein (Yersinia 
intermdeia) 0.00E+00 40% 87% 0.35 CAC19493.1
Rhs family protein (Yersinia 
enterocolitica) 0.00E+00 40% 87% 0.35 GAA91443.1
Nematicidal protein 
(Xenoharbdus bovienii) 1:9x10-252 36% 88% 0.32 YP_003712026.1
RHS repeat protein 
(Aspergillus kawachii) 4.6x10-188 33% 84% 0.28 EDP45744.1
Putative nematicidal protein 
(Xenorhabdus nematophila) 9.8x10-180 33% 82% 0.27 CBA72108.1
Closest p-47 OrfX2 P-47 OrfX2 P-17 Nematicidal proteins 
family protein   k  k  k i h
Locus ARN_8100 ARN_81020 ARN_8140 ARN_8150
ARN 81010 ARN 8130
Figure 30: The A. nasoniae P-47 family cluster. There are three P-47 family CDSs, a P-17 
homologue and two CDSs encoding nematicidal protein homologues.
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Table 21: BLASTp matches to proteins from the A. nasoniae P-47 family cluster
Query locus Match protein Matchscore Identity Coverage Similarity Match id
ARN_08100 OrfX2
OrfX3
1.00E-
25
8.00E-
19
32%
25%
96%
51%
0.31
0.13
YP_0Q1715698.1 
YP_001715697.1
ARN_081010 P-47
OrfX3
8.00E-
14
3.00E-
10
24% ' 
22%
63%
73%
0.15
0.16
YP_001715701.1 
YP_001715697.1
OrfX2 0.05 45% 6% 0.03 YP_001715698.1
ARN_081020 OrfX2 4.70E-23 23% 74% 0.17 YP_001715698.1
OrfX3 6.70E-05 23% 51% 0.12 YP_001715697.1
P-47 0.0057 23% 46% 0.11 YP_001715701.1
ARN_08130 Hypothetical protein (R. grylli) 
Hypothetical 
protein (E. 
tasmaniensis)
4.50E-
31
2.70E-
06
48%
30%
93%
76%
0.45
0.23
EDP45744.1 
CAO98071.1
ARN_08140
Hypothetical 
protein 
(Photorhabdus 
luminsescens) 
Nematicidal protein 
2 (E. tasmaniensis) 
Rhs family protein 
(Yersinia 
enterocolitica) 
Nematicidal protein 
(Xenorhabdus 
bovieni) 
Nematicidal protein 
(Xenorhabdus 
nematophilia) 
Putative YD-repeat 
toxin 
(Bacteriophage 
APSE-3)
RHS repeat protein 
(Aspergillus 
kawachii)
5.40E-
173
4.80E-
121
1.80E-
113
1.20E-
104
3.40E-
99
1.10E-
95
2.70E-
90
37%
30%
29%
30%
29%
29%
29%
99%
98%
99%
99%
96%
99%
99% .
0.37
0.29
0.29
0.3
0.28
0.29
0.29
NP_929681.1
CA095593.1 
ZP_12869720.1
CAC19493.1
YP_003712026.1
ACJ10121.1
GAA91443.1
ARN_08150
Hypothetical 
protein 
(Photorhabdus 
luminsescens) 
Putative YD-repeat 
toxin 
(Bacteriophage 
APSE-3)
Rhs family protein 
(Yersinia 
enterocolitica) 
Nematicidal protein 
2 (E. tasmaniensis)
4.10E-
98
3.00E-
89
6.60E-
81
4.00E-
76
37%
29%
29%
27%
96%
99%
99%
98%
0.36
0.29
0.29
0.26
NP_929681.1
ACJ10121.1
ZP_12869720.1 
CA095593.1
T39
Nematicidal
P-47 P-47 family OrfX3 proteins Hypothetical
Locus GMEJ1567 GMEJ1572 GMEJ1577 GMEJ1582 GMEJ1592
GME_11587
Figure 31: The Halomonas P-47 family cluster. There are three P-47 family CDSs and two 
nematicidal protein homologue.
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Table 22: BLASTp matches to proteins from the Halomonas sp. TD01 P-47 family gene 
cluster
Query
locus Match protein
Match
score Identity Coverage Similarity Match id
GME_11567 P-47 2.00E-13 23% 88% 0.2 YP_001715701.1
OrfX3 0.003 22% 54% 0.12 YP_001715697.1
OrfX2 0.076 23% 40% ■ 0.09 YP_001715698.1
GME_11572 OrfX3 3.00E-15 30% - 35% 0.11 YP_001715697.1
OrfX2 2.00E-07 28% 13% 0.04 YP_001715698.1
P-47 6.00E-06 22% 25% 0.06 YP_001715701.1
GME_11577 OrfX3 3.00E-67 32% 96% 0.31 YP_001715697.1
P-47 2.00E-10 21% 78% 0.16 YP_001715701.1
OrfX2 5.00E-09 20% 52% 0.1 YP_001715698.1
GME_11582
Hypothetical
protein
(Halomonas
GME_11587)
Nematicidial
3.20E-
50
\
50% 97% 0.49 ZP_08637335.1
protein AidA . 
(Ralstonia 
solanacearum) 
Nematicidial
8.00E-
47 50% 97% 0.49 YP_003744150.1
•
protein AidA 
(Burkholderia 
cepacia) 
Hypothetical 
protein 
(Xenorhabdus 
nematophila)
3.50E-
35
.
2.60E-
19
38%
31%
97%.
96%
0.37
0.3
YP_002153683.1 
YP_003712766.1
GME_11587
Hypothetical 
protein 
(Halomonas 
GME_11582) 
Nematicidial
3.10E-
50 .50% 96% 0.48 EGP19391.1
protein AidA 
(Ralstonia 
solanacearum) 
Nematicidial
8.00E-
47 50% 97% 0.49 YP_003744150.1
-
protein AidA 
(Burkholderia 
cepacia) 
Hypothetical 
protein 
(Xenorhabdus 
nematophila)
3.50E-
35
2.60E-
19
38%
31%
97%
96%
0.37
0,3
YP_002153683.1 
YP_003712766.1
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3.1.2.2. Analysis of species with P-47 family proteins not
associated with toxin proteins
There were four species in which the P-47 family encoding sequences were not 
associated with a putative toxin encoding gene - Paenibacillus dendritiformis, 
Nitrobacter winogradskyi, Achromobacter xylosoxidans and Pseudomonas putida.
The P-47 family gene cluster of P. dendritiformis encodes four P-47 family genes (
Figure 32 & Table 23). It also shows the greatest synteny to the C. botulinum P-47
family gene cluster -  it is the only non-BoNT producing species that encodes a
protein similar to OrfX1. These coding sequences were the only sequences on a
contig that resulted from next-generation sequencing data of this organism,
therefore, the exact genomic surroundings of this cluster are not known.
N. winogradskyi encodes four P-47 family proteins, three proteins similar to OrfX3 
and one protein similar to P-47 (Figure 33 & Table 24). A. xylosoxidans encodes 
three P-47 family proteins, one P-47 family protein which shows equal similarity to 
both OrfX2 and OrfX3, one OrfX3 homologue and one protein similar to P-47 
(Figure 34 & Table 25). P. putida encodes two P-47 family proteins, one protein 
similar to P-47 and one protein similar to OrfX3 (Figure 35 & Table 26).
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Closest P-47 
family protein P-47
■ m b m i
Locus 25581
0rfX2
25591 25596
Figure 32: The P. dendritiformis P-47 family cluster encodes four P-47 family coding 
sequences.
Table 23: BLASTp matches to proteins from the P. dendritiformis P-47 family cluster
Query locus Matchprotein
Match
score Identity Coverage Similarity Match id
PDENDC454_25596 OrfX1 2.30E-09 25% 97% 0.24 ACA57457.1
PDENDC454_25591 0rfX2 2.00E-138 36% 99% 0.36 ACA57564.1
0rfX3 9.50E-12 25% 37% 0.09 ACA57304.1
PDENDC454_25586 OrfX3 2.60E-130 46% 97% 0.45 ACA57304.1
OrfX2 1.70E-16 23% 82% 0..19 ACA57564.1
PDENDC454_25581 P-47 3.20E-81 36% ■91% 0.33 YP_001715701.1
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Closest P-47
family protein
Locus' Nwi_0884 Nwi__0885 Nwi_0886 Nwi_0887
Figure 33: The N. winogradskyi P-47 family cluster encodes four CDSs.
Table 24: BLASTp matches to proteins from the N. winogradskyi P-47 family cluster.
Query
locus
Match
protein
Match
score Identity Coverage Similarity Match id
Nwi_0887 P-47 1.00E-26 24% 98% 0.24 YP_001715701.1
OrfX3 7.00E-18 22% 73% 0.16 YP_001715697.1
Nwi_0886 OrfX3 7.00E-48 27% 87% 0.23 YP_001715697.1
0rfX2 5.00E-20 36% 87% 0.31 YP_001715698.1
P-47 4.00E-14 21% 56% 0.12 YP_001715701.1
Nwi_0885 0rfX3 1.00E-34 23% 88% 0.2 YP_001715697.1
0rfX2 1.00E-12 27% . 37% 0.1 YP_001715698.1
P-47 7.00E-07 22% 58% 0.13 YP_001715701.1
Nwi_0884 OrfX3 7.00E-09 20% 87% 0.17 YP_001715697.1
P-47 0.041 20% 24% 0.05 YP_001715701.1
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Closest P- 4 7  Hypothetical ^ OrfX3
family protein ^  protein
    k ................ k, ! \
   "Y  1 V  I
Locus AXXA_06253 AXXA_06258 AXXA_06263
Figure 34: The A. xylosoxidans P-47 family cluster encodes three P-47 family coding
sequences.
Table 25: BLASTp matches to proteins from the A. xylosoxidans P-47 family cluster
Query locus Matchprotein
Match
score Identity Coverage Similarity Match id
AXXA_06258 OrfX3 2.00E-20 28% 49% 0.14 YP_001715697.1
OrfX2 5.00E-17 23% 99% 0.23 YP_001715698.1
P-47 6.00E-12 21% 47% 0.1 YP_001715701.1
AXXA_06263 OrfX3 2.00E-27 25% 98% 0.25 YP_001715697.1
OrfX2 4.00E-12 23% 51%' 0.12 YP_001715698.1
P-47 3.00E-10 20% 51% 0.1 YP_001715701.1
AXXA_06268 OrfX3 1.00E-04 24% 22% 0.05 YP_001715697.1
P-47
AXXA 06268
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Closest p-47, Transcriptional
family protein regulator , ? OrfX3 P-47
yl .......... .
\  ! \  K
. \ f    \ | .......................   \ j  '
Locus PP_2004 PP_2005 PP_2006 PP_2007
Figure 35: The P. putida P-47 family cluster encodes three P-47 family CDSs.
Table 26: BLASTp matches to proteins from the P. putida P-47 family cluster
Query
locus Match protein
Match
score Identity Coverage Similarity Match id
PP_2007 P-47 2.00E-25 25% 68% 0.17 YP_001715701.1
OrfXB 3.00E-10 21% 74% 0.16 YP_001715697.1
0rfX2 3.00E-05 22% 49% 0.11 YP_001715698.1
PP_2006 OrfX3 5.00E-37 26% 78% 0.2 YP_001715697.1
OrfX2 8.00E-21 22% 69% 0.15 YP_001715698.1
P-47 1.00E-09 22% 50% 0.11 YP_001715701.1
PP_2005
Hypothetical
protein
{Pseudomonas
syringe)
1.20E-137 58% 100% 0.58 YP_234760.1
PP_2004
AraC family 
transcriptional 
regulator 
(Pseudomonas 
syringe)
8.90E-166 74% 97% 0.72 EG H03104.1
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3.1.2.3. Phylogenetic analysis of P-47 family proteins and the 
species encoding them
P-47 family coding sequences have been identified in nine non-G. botulinum 
species. In five of these species the P-47 family cluster is encoded alongside a 
putative toxin gene. Comparison of the P-47-family protein sequences from the 
different species will provide information on the similarity of the coding sequences 
that make up the clusters. Contrasting this data with phylogenetic analysis based 
on ,16S rDNA will provide insight into the evolutionary history of the P-47-family 
genes.
The P-47 proteins from different species were grouped by the C. botulinum P-47 
family protein they were most similar to (i.e. OrfX2, OrfX3 or P-47). In some cases 
there was not a significant difference between the highest similarity match and the 
second highest e.g. the A. nasoniae CDS Arn_08100 was grouped with the OrfX2 
proteins despite having a BLASTp E-value of 1x1 O'25 compared with OrfX2 and an 
E-value of 8x10"19 compared with OrfX3. However, including many highly divergent 
protein sequences disrupts the process of sequence alignment so the sequences 
were compartmentalised. The amino acid sequences of each protein group (i.e. 
the OrfX2 proteins etc) were aligned using ClustalW and a pain/vise similarity 
matrix was calculated (see appendix for full matrices). Trees were derived from the 
resulting matrices using Fitch-Margoliash clustering implemented by PHYLIP 
(http://evolution.genetics.washington.edu/phylip.html) and visualised using 
Dendroscope. (http://ab.inf.uni-tuebinqen.de/software/dendroscope/). All trees 
were rooted on Halomonas TD01 locus 11572 as this sequence was highly 
divergent from the other sequences.
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There were 6 non-C. botulinum proteins that were closest in similarity to OrfX2 and 
a tree representing protein distance was derived for these proteins (Figure 38). 
The C. botulinum sequences cluster together, with the BoNT/A3 and A4 
associated sequences clustering more closely compared with the BoNT/E 
associated sequence. P. dendritiformis and P. larvae don’t cluster together but 
both fall near to the C. botulinum sequences. The sequences from E. tasmaniensis, 
A. nasoniae and R. grylli all cluster together.
On the OrfX3 tree (Figure 37) a similar pattern emerges. The C. botulinum 
sequences cluster together, with the P. Iarvaej and P. dendritiformis sequences 
clustering together, close to the C. botulinum sequences. The P. putida, N. 
winogradskyi and A. xylsoxidans sequences show significant difference from any 
other species. The three A/, winogradskyi OrfX3 sequences which cluster together 
show significant sequence divergence from each other.
On the P-47 tree (Figure 38) the C. botulinum sequences also cluster together, 
with BoNT/A3 and A4 sequences showing more homology to each other than to 
BoNT/E. P. larvae,and P. dendritiformis cluster together, close to the C. botulinum 
sequences. The sequences from E. tasmaniensis, A. nasoniae and R. grylli all 
cluster together, similarly to the OrfX2 tree. P. putida and N. winogradskyi cluster 
loosely together, showing significant sequence difference from any other P-47 
protein.
A phylogenetic tree was derived using 16S rDNA sequences from the species
which encode P-47 family proteins (Figure 39). The similarity between this tree
and the P-47 family protein trees, in particular the P-47 protein tree, is notable.
There are two broad clusters that correspond to the two main phyla with P-47
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family genes -  the Firmicutes and the Gammaproteobacteria. The group I (A3 and 
Ba4) and group II (E) C. botulinum strains cluster together while the Paenibacillus 
species are on a neighbouring branch - these species are all Firmicutes. The other 
broad cluster consists of R. grylli, P. putida, Halomonas TD01, E. tasmaniensis 
and A. nasoniae - these species are all Gammaproteobacteria. N. winogradskyi, 
an Alphaproteobacteria, and A. xylosoxidans, a Bacteroidetes, cluster separately 
from each other and the other species.
One major difference between the 16S tree and the OrfX2/P-47 protein trees is 
that, in the 16S tree Halomonas TD01 and P. putida cluster more closely to E. 
tasmaniensis and A. nasoniae than R. grylli. In the P-47 and OrfX2 protein trees E. 
tasmaniensis, A. nasoniae and R. grylli cluster together and P. putida and 
Halomonas TD01 show lower similarity. This suggests that the R. grylli P-47 family 
protein sequence was acquired more recently than the P. putida/Halomonas TD01 
sequence, likely by horizontal gene transfer. There is also a large degree of 
synteny between the P-47 family clusters of E. tasmaniensis, R. grylli and A. 
nasoniae.
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OrfX2
A. nasoniae ARN 81020
E. tasmaniensis
A. nasoniae ARN 8100
R. grylli
P. dendritiformis
C. botulinum E1
C. botulinum A3
C. botulinum Ba4
P. lan/ae
— .................   — .... ..................................................  Halomonas TD01 11572
0.05
Figure 36: Neighbour joining protein distance tree of OrfX2 sequences from P-47 family 
encoding species. There are two main clusters -  the C. botulinum and Paenibacillus species 
sequences cluster together, and the A. nasoniae, E. tasmaniensis and R. grylli sequences 
cluster together separately. Halomonas TD01 GME_11572 is a P-47 family protein which 
shows equal similarity to OrfX2 and OrfX3 and was used to root the tree.
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OrfX3
 ----------------------------- — ----- P. putida
- ---------------------------------- ----------- - a/. W in o g rad sky i  0884
-------------------    N. winogradskyi 0885
>-------------  — N. winogradskyi 0886
---------------------------------------- Halomonas TD01 11577
------------  P. larvae
 — P. dendritiformis
i- :-----  C. botulinum E1
— C. botulinum A3 
C. botulinum Ba4
— --------------------------------     A  xylosoxidans
-----------------------------------------   Halomonas TD01 11572
Figure 37: Neighbour joining protein distance tree of OrfX3 sequences from P-47 family 
encoding species. The C. botulinum and Paenibacillus sequences cluster together while the 
other sequences are broadly distributed with no distinct clustering.
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P-47
— ---------------------------  —  Halomonas TD01 11567
-----   P. putlda 2007
---------------—— — --------- —  N. winogradskyi 887
—~ ----- P. larvae
L—  ------ P. dendritiformis 25581
   C. botulinum E1
 :------- C. botulinum Ba4
— - —   C. botulinum A3
-------------------------- *— -i E. tasmaniensis 30260
 — — " —  A. nasoniae
------   R. grylli
-------------------------------------------------- — Halomonas TD01 11572
Figure 38: Neighbour joining protein distance tree of P-47 sequences from P-47 family 
encoding species. The P-47 sequences from C. botulinum cluster together with the 
Paenibacillus sequences on an adjoining branch. The sequences from A. nasoniae, E. 
tasmaniensis and R. grylli cluster together, similarly to the OrfX2 tree. The P. putida, 
Halomonas TD01 gene GME_11567 and A. xylosoxidans sequences cluster individually, 
distinctly from the other sequences.
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I C. botulinum A3 
I- C. botulinum Ba4
   C. botulinum E1
  P. larvae
  P. dendritiformis
N. winogradskyi 
A. xylosoxidans
R. grylli
P. putida
  Halomonas TD01
  E. tasmaniensis
------------------  A. nasoniae
0.05
Figure 39: Phylogeny of the P-47 family encoding species constructed from 16S rDNA 
sequences. The C. botulinum group I and group II strains cluster together in independent 
clusters. The Paenibacillus species cluster together on a branch neighbouring the C. 
botulinum strains. N. winogradskyi and A. xylosoxidans cluster independently of any other 
species. R. grylli, Halomonas, E. tasmaniensis and A. nasoniae form a cluster of 
gammaproteobacteria.
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3.1.3. Prediction of supernatant proteins of C. botulinum
The sub-cellular location of the 3550 predicted proteins in the C. botulinum A1 
ATCC 19397 genome were predicted by five in silico tools (CELLO, LocateP, 
PsortB, SecretomeP and SignalP). The number of proteins predicated as 
extracellular by each tool and the number of proteins predicated as extracellular by 
a consensus of 1 to 5 tools was determined (summary Table 27).
There was a range of estimates of the scale of the C. botulinum extracellular 
proteome from 115 proteins estimated by LocateP to 460 by CELLO. There were 
11 proteins predicted to be extracellular by all 5 tools. Of these 11 proteins 6 were 
ther/nolysin metallopeptidases, involved in protein degradation. Two of the 11 
proteins were NlpC/P60 family proteins -  this diverse group of proteins includes 
cell wall peptidases. Another 2 of the 11 proteins are involved in polysaccharide 
metabolism and the last protein is involved in lipid degradation.
The 113 proteins predicted to be extracellular by four tools included clostripain, the 
putative toxin activator, eight cell envelope proteins, three protein fate proteins and 
73 hypothetical proteins.
There were 235 proteins predicted by three tools to be extracellular including 
BoNT and NTNH. The tools which did not predict BoNT and NTNH as extracellular 
was LocateP and SignalP. There were 124 proteins predicted as extracellular by 
two tools, included in this group were the neurotoxin associated haemagglutinin 
proteins -  the tools which didn’t predict these as extracellular were SignalP, 
LocateP and PsortB. There were 72 proteins predicted as extracellular by one tool.
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Table 27: The number of C. botulinum A1 19397 proteins predicted to be extracellular by 5 
different tools (Cello, locatep, psortb, secretomep and signalp) and the number of C. 
botulinum proteins which were predicted to be extracellular by multiple tools.
Tool
Number of proteins 
predicted as 
extracellular
cello 460
locatep 115
psortb 156
secretomep 426
signalp 379
Number of tools
Number of proteins 
predicted as 
extracellular
5 11
4 113
3 235
2 124
1 72
Total 556
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3.1.4. Summary of findings of in silico investigation
There are multiple coding sequences with similarity to P-47 family proteins 
in nine non-C. botulinum species
In four of those nine species, the P-47 family clusters are co-localised with 
putative toxin genes.
This evidence supports the hypothesis that the P-47 family cluster plays a 
role in the toxicity of BoNT.
Sub-cellular location prediction tools gave varied results, with significant 
overlap. Comparison of the predictions of the different tools against 
experimentally identified supernatant proteins will allow informed discussion 
of their relative merits.
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3.2. Proteomic investigation of C. botulinum to establish protein 
profiles associated with toxin producing strains
The mechanism of action of botulinum neurotoxin (BoNT) at the human 
.neuromuscular junction is well understood. However, the variety of botulism 
disease types and severities suggests that there may be a complex interaction of 
BoNT with other C. botulinum proteins, influencing disease outcome. Previous 
reports (Fujinaga, 2010) have implicated proteins encoded by genes co-located 
and co-expressed with the bont gene in the toxicity of BoNT via the oral route. This 
suggests that variation in these proteins may explain variation in disease severity. 
The proteins produced by such genes (the neurotoxin associated proteins) form 
large complexes with BoNT that range in size between 290-900 kDa. The role of 
these neurotoxin-associated proteins in the botulism disease process is not fully 
understood. It has been reported that some of the proteins contribute to toxicity via 
the oral route by protecting the toxin from degradation in the gut and also that they 
have a role in translocation of the toxin across the gut epithelium (Simpson, 2004; 
Sugawara et al., 2010).
In this study, the toxin and associated proteins present in culture supernatants of 
G. botulinum reference strains and isolates from clinical cases of food, wound and 
infant botulism were investigated. Initial experiments to establish the relationship 
between the growth phase of C. botulinum and the amount of extracellular protein 
were performed. The concentration of BoNT at different growth stages was 
assessed using an endopeptidase assay. Based on the results of these 
experiments, a broader characterisation of the supernatant proteome was 
undertaken at two time-points using LC-MS/MS.
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In this chapter the investigation of the presence of the toxin complex, and other 
uncharacterised pathogenicity factors in the extracellular proteome of C. botulinum 
is reported.
3.2.1. C. botulinum and C. sporogenes growth curves
Growth curves were prepared using three reference strains. Two of these were C. 
botulinum strains: C. botulinum A1 ATCC 19397 and C. botulinum B NCTC 7273; 
the other was C. sporogenes NCTC 275 which was used as a known non- 
toxigenic control to optimise procedures before the investigation of toxigenic 
strains. Growth curves for each strain were determined over a 96 h period.
Growth curves produced for all three strains showed similar properties (Figure 40). 
C. sporogenes NCTC 275 O D 6oo increased 6.9 fold between 6 and 12 h but then 
decreased to O D 6oo 1.14 at 48 h and plateaued until 96 h when the experiment 
was terminated. C. botulinum A1 ATCC 19397 showed a 9.8 fold increase in 
ODeoo between 4 h and 12 h, peaking at an ODeooof 3.0, after which it decreased 
gradually to 0.98 at 48 h, holding at this O D 6oo until 96 h. Similarly, C. botulinum 
NCTC 7273 underwent a 10.6 fold increase in ODeoo between 4-11 h, peaking at 
2.7 before gradually decreasing to 0.79 at 48 h. O D 6oo plateaued between 48 and 
96 h.
Cell count was determined using a hemocytometer for one of the strains, ATCC 
19397, at the same time-points used to measure the O D 6oo growth curve (Figure 
41). The concentration of cells increased approximately 200 fold between 4 h and 
14 h, reaching a peak of 1.78x109 cells per ml at 14 h, representing the end of 
logarithmic growth.
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Figure 40: Growth curve of C. botulinum ATCC 19397, NCTC 7273 and C. sporogenes NCTC 
275 under anaerobic incubation in TPGY at 35°C, as measured by OD60o-
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Figure 41: Total cell count of an ATCC 19397 culture grown anaerobically in TPGY at 35°C. 
Note logarithmic scale.
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3.2.2. Optimisation of protein precipitation from C. botulinum culture 
supernatant
3.2.2.1. Comparison of acetone and trichloroacetic acid 
precipitation
Protein precipitation was optimised using culture supernatant from the non- 
toxigenic strain C. sporogenes NCTC 275. Two different precipitants were used: 
acetone and trichloroacetic acid (TCA) (Schwarz et al., 2007) and the total amount 
of protein precipitated and the range of proteins precipitated was compared. The 
range of proteins precipitated was assessed using SDS-PAGE. Having determined 
which precipitant was more suitable, the concentration of precipitant was 
optimised.
After precipitation, proteins were re-suspended in a buffer containing 1% SDS. 
This is above the level of SDS that is compatible with the widely used Bradford 
assay (0.125%), therefore the SDS compatible bicinchoninic acid (BCA) assay 
was used for quantification of precipitated proteins.
Acetone precipitated proteins could not be accurately quantified by the BCA assay, 
due to an unknown interfering substance. Densitometric comparison of the TCA 
precipitant with the acetone precipitant indicated that acetone precipitation yielded 
a lower concentration of protein (Figure 42). There was substantially less protein in 
6.5 pi of acetone precipitant than there was in 2.2 pi of TCA precipitant. In addition 
to lower total yield, there was also a total of 40 protein bands from TCA 
precipitation compared with 16 protein bands from acetone precipitation-detected 
by densitometric comparison (Figure 42). As TCA precipitated a better yield- of a
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wider range of protein bands, and no accurate quantification of acetone 
precipitated samples could be achieved, TCA was used for subsequent protein 
precipitation.
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Figure 42: C. sporogenes NCTC 275 supernatant protein precipitated with TCA and acetone. 
Lane 1: 5 pg TCA (2.2 pi) precipitated protein. Lanes 2-7: 0.1, 0.5, 1, 2, 3 and 6.5 pi of acetone 
precipitated protein.
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3.2.2.2. Optimisation of TCA concentration
Protein precipitation was further optimised by investigating the amount and range 
of protein precipitated from culture supernatant by three concentrations of TCA. 
Culture supernatant from 16 h and 96 h of growth was examined to ensure that 
culture age had no impact on protein precipitation. TCA was used at 5%, 10% and 
20% (v/v), to precipitate proteins from 16h and 96 h cultures of C. sporogenes 
NCTC 275. A TCA concentration of 5% gave a 25±7% higher yield of protein at 24 
h and a 17±6% higher yield of protein at 96 h than either 10% or 20% TCA (Figure 
43). All TCA concentrations gave a similar protein profile when compared using 
1DGE (Figure 44) and therefore 5% TCA was used in future experiments to 
precipitate C. botulinum supernatant proteins.
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Figure 43: Average amount (n = 3) of protein precipitated from C. sporogenes NCTC 275 
supernatant from 16h and 96 h cultures using 5, 10 and 20% TCA. Protein concentration 
measured by BCA assay. Asterisks denote t-test p-value of < 0.05.
A
200
116
97.4
66.3
55.4
36.5
31
21.5
14.4
6
f —  1 2 3 4 . 5  6 7 8 9
ww rnmm •—«* tmmm »—«*
B
200
116
97.4
66.3
55.4
36.5
31
21.5
14.4
6
1 2  3 4 5 6 7 8 9
mm**** &&&& 
*>****■»* ammm
Figure 44: SDS-PAGE of protein precipitated from C. sporogenes culture supernatants from 
cultures grown at (A) 16 h amd (B) 96 h obtained using TCA at 5% (lanes 1-3), 10% (lanes 4-6) 
and 20% TCA (lanes 7-9).
164
3.2.2.3. Comparison of protein concentration of total
supernatant with protein concentration of precipitated 
protein
The amount of protein that was precipitated from the supernatant of a C. 
sporogenes culture was compared to the concentration of total protein in the 
supernatant. Two methods of protein quantification, the Bradford and BCA assays, 
were assessed for their ability to accurately quantify the protein in the total 
supernatant. The BCA assay was unsuitable for measuring the protein 
concentration of the total supernatant due to the presence of an unknown 
interfering agent in the sample. This interference was not removed by dilution or 
by filtering the sample though a 3 kDa molecular weight cut off filter. Therefore the 
Bradford assay was used to measure the concentration of the total supernatant 
protein and the BCA assay was used to measure the concentration of protein in 
the precipitant (as the Bradford assay is not compatible with the detergents 
present in the re-suspended protein precipitant).
Initial results showed that the amount of TCA precipitated protein was 
approximately 10% of the protein content of the total supernatant (data not shown). 
However, when 5 pg of each was analysed by SDS-PAGE (Figure 45), lower 
concentrations of protein were observed for the total supernatant, indicating that 
the Bradford procedure had overestimated the concentration of protein in the 
supernatant. This overestimation was determined to be 3.15x by densitometric 
analysis of the SDS-PAGE gel (Figure 45). When the values obtained by the 
Bradford assay for total supernatant protein content were, therefore, divided by 
3.15, TCA precipitation was estimated to have extracted >75% of the total protein 
in the supernatant (Figure 46). Although the supernatant proteins are under-
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loaded the SDS-PAGE separation shows that the precipitated protein and the 
supernatant protein profiles are very similar (Figure 45).
A comparison of the total supernatant protein concentration and the precipitated 
protein concentration along a time course was carried out. The amount of protein 
in the total supernatant increased 6.1 fold between 0 and 12 h whilst that in the 
precipitant increased 4.7 fold. There was a slower, gradual increase in supernatant 
protein and precipitated protein between 12 and 96 h, which peaked at 5.1 and 3.9 
mg/ml respectively.
Following optimisation of the protein precipitation method using C. sporogenes 
NCTC 275, a C. botulinum ATCC 19397 culture time course was carried out in 
triplicate and supernatant protein was precipitated with 5% TCA at 8 time points 
(Figure 47). There was a gradual 4-fold increase in the concentration of 
precipitated protein between 0 and 72 h. Between 72-96 h there was a 25% 
decrease in the protein precipitant.
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Figure 45: SDS-PAGE gel of precipitated supernatant protein and original supernatant 
protein from 24 h culture of C. sporogenes NCTC 275. Lanes 1-3 contain biological 
replicates of protein precipitated from the supernatant using 5% TCA and lanes 4-6 contain 
total supernatant protein from the same cultures (no precipitation). Lanes 4-6 are under­
loaded compared with lanes 1-3 as accurate quantification of total supernatant protein was 
not possible.
□  Total protein
□ Precipitated 
protein
0 12 16 24 48 96
Time (h)
Figure 46: Average (n = 3) protein concentration of C. sporogenes NCTC 275 total 
supernatant (adjusted by densitometric analysis) and TCA precipitant between 0-96 h.
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Figure 47: Average (n = 3) concentration of protein precipitated from the supernatant of C. 
botulinum A1 ATCC 19397 between 0-96 h.
3.2.3. Determination of toxin concentration in the culture supernatant 
using endopeptidase assay
168
The concentration of active BoNT/A in the culture supernatant was determined 
using an endopeptidase activity assay (Figure 48) (as described in materials and 
methods 1.3.1). This assay involves incubating the culture supernatant with 
synthetic SNAP-25i37-206, the fragment of the BoNT/A substrate that contains the 
target site. An HRP-conjugated antibody, specific to the SNAP25igo-i97 0 Ctapeptide 
epitope of the BoNT/A cleaved substrate, allowed quantification of the BoNT/A 
activity. The results are expressed as MLD50 values (lethal dose for 50% of 
inoculated mice per ml) - MLD50 equivalents could be calculated as the culture 
supernatant was compared against a dilution series of toxin standards of known 
concentration which had been previously established (Sesardic et al., 2003; Jones 
et al., 2008). There were 31464 MLD5o/ml at O h (Figure 48), this is likely to be the 
result of residual toxin present in the 1 ml suspension of ATCC 19397 overnight 
culture used to inoculate the culture. The supernatant toxin concentration rapidly 
increased 15.8-fold, reaching 497337 MLD50/ml by 24 h. The concentration of toxin 
then gradually declined between 24 h and 96 h, decreasing to 32830 MLDso/ml.
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Figure 48: BoNT/A activity of C. botulinum A1 NCTC 19397 culture supernatant incubated 
anaerobically at 35°C. Eight samples were taken between 0-96 h (average of three biological 
replicates) and BoNT/A activity measured by endopeptidase assay.
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3.2.4. Detection and identification of botulinum neurotoxin and other 
proteins in C. botulinum culture supernatant by LC-MS/MS
The whole culture supernatant proteome, including botulinum toxin and the 
associated non-toxic proteins were analysed using an approach involving initial 
separation by SDS-PAGE followed by LC-MS/MS. As the toxin and its associated 
proteins are co-transcribed the culture supernatant was investigated at 24 h, the 
time at which the endopeptidase assay indicated peak toxin concentration (Figure
48). The supernatant proteome was also investigated at 96 h.
In terms of data analysis, all samples were first analysed against a database 
including all NCBI non-redundant protein sequences to ensure that the majority of 
identifications were against C. botulinum strains. If this was the case then the 
proteomic data was compared against a single appropriate reference genome.
3.2.4.1. Analysis of C. botulinum A1 ATCC 19397 culture 
supernatant after 24 and 96 h culture
Supernatant proteins from 24 and 96 hours of broth culture growth (n = 3) were 
separated and analysed by LC-MS/MS. There were a total of 198 proteins 
detected and identified at 24 h and 144 proteins identified at 96 h. These proteins 
were compared using local BLAST which identified 63 proteins unique to culture 
supernatant at 24 h, a large stable proteome of 135 proteins identified at both time 
points and only nine proteins unique to culture supernatants grown for 96 h (a 
complete listing is given in Appendix tables 2-4).
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LC-MS/MS analysis revealed that BoNT, NTNH, HA70, HA33, HA17 and 
clostripain (a protease implicated in C. botulinum pathogenesis) were all 
expressed at both 24 h and 96 h. The regulator, botR was not identified LC- 
MS/MS detection of toxin in the supernatant at both time points confirmed the 
results determined by the endopeptidase assay.
Identified proteins were assigned to one of 21 functional groups (e.g. energy 
metabolism, cell membrane, etc) using protein annotations from the online 
resource, Pathema (http://pathema.icvi.org/cqi-
bin/Clostridium/PathemaHomePaqe.cqi). The number of proteins belonging to 
each functional group that were unique to 24 h, unique to 96 h or present at both 
time points were compared (Table 28).
Only four functional groups had all their proteins identified at both time-points -  
pathogenesis, signal transduction, DNA-metabolism and regulatory function 
associated proteins. Pathogenesis-associated proteins were the largest of these 
four groups, with 6 proteins (BoNT, NTNH, HA70, HA33, HA17 and Clostripain). 
There were two signal transduction proteins (both involved with 
phosphotransferase systems, Uniprot IDs = A7FVX2, A7FVJ3), one regulatory 
function protein (DNA binding protein, A7FSQ9) and one DNA metabolism protein 
(single stranded DNA binding protein, A7FZH0) identified at both time-points.
There was a general trend that more proteins were detected in each functional 
group at 24 h than 96 h. In keeping with this trend there were 20 more proteins of 
unknown or hypothetical function, nine more energy metabolism proteins 
(including thioredoxin family protein, A7FTD9 & arginine deiminase, A7FQ94) and
six more protein synthesis associated proteins (including 30S and 50S ribosomal
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proteins, A7FQ40 & A7FZ57) present in the culture supernatant at 24 h than at 96 
h. There were also three more transport and binding proteins (three ATP binding 
cassette transporters including a molybdate transporter, A7FU00) and three more 
cell envelope construction and maintenance proteins (including a lipoprotein, 
A7FU16) present at 24 h than 96 h. There were additional proteins involved in the 
biosynthesis of amino acids and the biosynthesis of cofactors, prosthetic groups 
and carriers (including thiamine biosynthesis protein, A7FXG9) at 24 h than 96 h. 
The only two functional groups represented at 24 h that were not identified at 96 h 
were adaptations to atypical conditions (major cold shock protein CspA, A7FTR1) 
and mobile and extrachromosomal element functions (phage capsid protein, 
A7FWD9) that have one protein each at 24 h (Table 28).
Detoxification was the only functional group with more proteins at 96 h than at 24 
h; 3 proteins at 96 h versus 2 at 24 h. There were the same number of 
pathogenesis-associated proteins present at both 24 and 96 h (Table 28).
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Table 28: C. botulinum A1 ATCC 19397 supernatant proteins present at 24 h and/or 96 h 
incubation according to functional group.
Functional role
24 h 
only
24 and 
96 h
96 h 
only
Adaptations to atypical conditions 1
Amino acid biosynthesis 4 2
Biosynthesis of cofactors, prosthetic groups, and 
carriers 3 2 • 1
Cell envelope 3 6
Central intermediary metabolism 3 2
Chemotaxis and motility 1 4
Detoxification 2 1
DNA metabolism 1
Energy metabolism 10 43 1
Fatty acid and phospholipid metabolism 1 5
Hypothetical and unknown proteins 20 22 4
Mobile and extrachromosomal element functions 1
Pathogenesis 6
Protein fate 4 19
Protein synthesis 6 9 1
Purines, pyrimidines, nucleosides, and nucleotides 1 4
Regulatory functions 1
Signal transduction 2
Sporulation and germination 1 1
Transcription 1 4
Transport and binding proteins 3 1
Total 63 135 9
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3.2.4.2. Comparison of C. botulinum A1 ATCC 19397
supernatant proteins with the proteins in the MvirDB 
virulence database
The MvirDB (http://predictioncenter.llnl.gov/) is a database of toxins, virulence 
factors and antibiotic resistance associated proteins. BLAST was used to search 
for sequence similarity between the 207 proteins identified in the supernatant 
proteome of C. botulinum A1 ATCC 19397 and the 64000 proteins in the MvirDB 
in order to identify potential novel virulence factors. There were two ATCC 19397 
proteins (not previously annotated as involved in pathogenesis) that showed 
significant homology with virulence proteins in the MvirDB (for more details see 
methods section).
The first C. botulinum A1 ATCC 19397 protein to show homology to a protein in 
MvirDB was a thermolysin metallopeptidase (A7FTX0) that has identical functional 
moieties in a very similar architecture to the C. perfringens lambda toxin (Figure
49). The two proteins have 30.5% amino acid identity. Both proteins have M4 
metallopeptidase domains (IPR001570) spanning amino acid residues 264-580 of 
the 580 amino acid C. botulinum protein and residues 249-553 of the 553 amino 
acid C. perfringens protein. M4 metallopeptidase domains are typical of 
thermolysins which are thermo-stable, secreted proteases. Both proteins also 
have a pro-peptide domain, PepSY (IPR025711), at residues 166-217 of the C. 
botulinum protein and residues 151-201 of the C. perfringens protein. This pro­
peptide prevents premature inactivation of the metalloprotease. The C. perfringens 
lambda toxin is involved in the proteolytic cleavage and activation of the C.
' perfringens epsilon proto-toxin (Jin et al., 1996).
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The second ATCC 19397 protein to show significant sequence similarity to a 
protein in the MvirDB was an ATP-dependent Clp protease (Gl 153933152). The 
ATCC 19397 Clp protease showed 66% amino acid identity across 87% of the 
protein length to a Listeria monocytogenes ATP-dependent Clp protease (Gl 
16804506) (Figure 50). This is an extracellular protease implicated in L. 
monocytogenes interaction with the host including macrophage escape and 
activation of listeriolysin (Gaillot et al.,,2000). The C. botulinum and L  
monocytogenes proteins share the ATP-dependent protease CIpP region 
(IPR001907) which spans the entire length of both proteins. The CIpP active site is 
in the same location in both proteins, consisting of two domains between residues 
95-135 of the 194 amino acid C. botulinum protein and residues 96-136 of the 198 
amino acid L. monocytogenes protein.
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3.2.4.3. Analysis of the supernatant proteome of C. botulinum 
B NCTC 7273 using LC-MS/MS
C. botulinum B NCTC 7273 supernatant proteins were extracted 24 h after 
inoculation (n = 3) and analysed using the 1DGE LC-MS/MS workflow. There were 
118 proteins which were detected and identified in all three biological replicates (a 
complete list is given in Appendix Table 5). Identified proteins were assigned to 
one of 21 functional groups (e.g. energy metabolism, cell membrane, etc) using 
protein annotations from Pathema.
The toxin complex proteins - BoNT/B (Uniprot ID = B1INP5), NTNH (B1INP6), 
HA33 (B1INP8), HA17 (B1INP9) and HA70 (B1INQ0), were all detected in the 
supernatant of NCTC 7273 at 24 h. Clostripain (B1IMT3), an enzyme potentially 
involved in the proteolytic activation of the toxin was also identified. Other proteins 
identified in the supernatant of NCTC 7273 included three amino acid biosynthesis 
proteins, including ornithine carbamoyltransferase (B1IJJ6). There were three cell 
envelope proteins identified, including a myosin-cross-reactive antigen family 
protein (B1IFN3). There were four proteins identified which have a role in 
chemotaxis or motility including a flagellin protein (B1IK59) and a CheA 
chemotaxis protein (B1IKG0). Two sporulation and germination proteins were 
identified -  both stage V, one G protein (B1IH03) and one S protein (B1II33). The 
protein functional group that contained the largest number of proteins identified in 
the supernatant of NCTC 7273 was energy metabolism, with 35 proteins. Of these, 
eight were involved in amino acid energy metabolism, including two arginine 
deiminases (B1ID40), eight were involved with fermentation, including alcohol 
dehydrogenase (B1IKP6) and six were involved in glycolysis/gluconeogenesis 
including a glucose-6-phosphate isomerise (B1ING9). There were two proteins 
involved in fatty acid and phospholipid metabolism, including an acyl-CoA
dehydrogenase which is involved in fatty acid degradation. There were 16 proteins 
which were hypothetical or of unknown function. The second most represented 
group of proteins identified in the NCTC 7273 supernatant were involved in protein 
fate, 20 of these proteins were identified. Of these 20, 14 were involved with the 
degradation of proteins including a collagenase (B1ILP0) and numerous 
peptidases including peptidase T (B1IEF5). Other proteins identified that have a 
role in protein fate included four protein folding and stabilisation proteins including 
chaperonin GroEL (B1IFD5). There were nine protein synthesis proteins, four of 
which were tRNA aminoacylation proteins including methionyl-tRNA synthetase 
(B1ID49), three translation factors including translation elongation factor Tu 
(B1IGF6). There were two signal transduction proteins, both involved in 
phosphotransferase systems including a phosphocarrier protein HPr (B1II28). 
There were four transport and binding proteins identified including an amino acid 
transport protein (B1IKD4).
3.2.4.4. Comparison of the supernatant proteome of C.
botulinum B NCTC 7273 with the virulence database MVirDB
The proteins identified in all replicates of the C. botulinum B NCTC 7273
supernatant were compared against the MvirDB virulence database. One C.
botulinum B NCTC 7273 protein that had a high quality match (see materials and
methods) for a protein present in MvirDB was a thermolysin metallopeptidase
(B1IKQ2). This protein had a similar architecture to both the C. perfringens lambda
toxin and the C. botulinum A1 ATCC 19397 thermolysin metallopeptidase that
showed homology to the lambda toxin (Figure 51). Both proteins have M4
metallopeptidase domains (IPR001570) spanning amino acid residues 264-579 of
the 579 amino acid C. botulinum B NCTC 7273 protein and residues 249-553 of
180
the 553 amino acid C. perfringens lambda toxin. Both proteins have a pro-peptide 
domain, PepSY (IPR025711), at residues 164-216 of the C. botulinum protein and 
residues 151-201 of the C. perfringens protein. This pro-peptide prevents 
premature inactivation of the metalloprotease. The C. perfringens lambda toxin is 
involved in the proteolytic cleavage and activation of the C. perfringens epsilon 
proto-toxin (Jin et al., 1996). The C. botulinum B NCTC 7273 thermolysin and the 
C. botulinum A1 ATCC 19397 protein shared 86.9% amino acid identity while the 
C. botulinum B NCTC 7273 thermolysin metallopeptidase has 30.4% identity with 
the C. perfringens lambda toxin.
Another C. botulinum B NCTC 7273 protein highlighted as a potential virulence 
factor by comparison with MvirDB is a collagenase protein (B1ILP0) that shows 
38.9% amino acid identity and very similar protein architecture with a C. 
perfringens collagenase. Both proteins have a domain indicative of extracellular 
proteins (IPR022409) and multiple domains typical of a collagenase (IPR013661, 
IPR007280 and IPR002169), in the same order along the length of the protein.
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Figure 51: Comparison of the functional moieties of (A) C. botulinum B NCTC 7273 
thermolysin metallopeptidase (B1IKQ2) and (B) C. perfringens lambda toxin as determined 
by Interproscan
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Figure 52: Comparison of the functional moieties of (A) C. botulinum  B NCTC 7273 
collagenase (B1ILP0) and (B) C. perfringens collagenase as determined by Interproscan
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3.2.4.5. Comparison of supernatant proteome of C. botulinum
A1 ATCC 19397 and C. botulinum B NCTC 7273
The extracellular proteomes of C. botulinum A1 ATCC 19397 and C. botulinum B 
NCTC 7273 were compared using local BLAST. This comparison revealed a core 
proteome of 100 homologous (BLAST E-value of <1x10‘3°) proteins that were 
shared between the two strains, 18 proteins unique to NCTC 7273 and 98 proteins 
unique to ATCC 19397 (Figure 53).
The number of proteins belonging to 21 different functional groups that were 
detected in ATCC 19397 only, NCTC 7273 only and in both strains (core proteins) 
was determined (Table 29).
The size of the pan-proteome (i.e. the core and accessory proteome of ATCC 
19397 and NCTC 7273) was established for each functional group of proteins. The 
similarity of the core proteome compared with the pan proteome was calculated for 
each functional group. For example, if every protein in a functional group was 
present in both ATCC 19397 and NCTC 7273 then there was 100% overlap 
between the pan and core proteome. The expression of proteins that are present 
in the core proteome is more highly conserved between the different strains, 
therefore these proteins are likely to be important in the ecological niche of the 
organism.
There were three functional groups where all identified proteins were present in 
both ATCC 19397 and NCTC 7273 i.e. a 100% overlap between the core and pan- 
proteome. These three groups were pathogenesis, adaptation to atypical 
conditions and signal transduction proteins. Pathogenesis had 6 proteins (BoNT,
A7FS63; NTNH, A7FS62; HA33, A7FS60; HA17, A7FS59; HA70, A7FS58 and
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clostripain, A7FUX5) while signal transduction contained two proteins 
(phosphotransferase systems) and adaptation to atypical conditions consisted of 
one protein (a cold shock protein).
Functional groups of proteins which had a core/pan-proteome overlap of more 
than 50% were protein fate (including thermolysin metalloprotease, A7FTX0 and 
chaperone protein DnaK, A7FXL5), energy metabolism (including butyrate kinase, 
A7FZ18) nucleotide metabolism and transcription (RNA polymerase, A7FZ44).
Protein functional groups which had a core/pan-proteome overlap of 25-50% were 
amino acid biosynthesis, chemotaxis and motility (including flagellin, A7FWY1), 
detoxification (including desulfoferrodoxin, A7FYS9), sporulation and germination 
(Stage V sporulation protein S, A7FVX7), protein synthesis (including 30S 
ribosomal protein, AFZ55 and translation elongation factors, A7FPZ7), fatty acid 
and phospholipid metabolism and transport and binding proteins (ferritin family 
protein, A7FUJ4).
Protein functional groups with a low overlap between the core and pan-proteomes 
of 0-25% included proteins involved in biosynthesis of cofactors, cell envelope, 
central intermediary metabolism, DNA metabolism, mobile and extrachromosomal 
element functions, regulatory functions and hypothetical and unknown proteins 
(Table 29).
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Figure 53: Core and unique proteins identified in 24 h culture supernatant of C. botulinum 
A1 ATCC 19397 and C. botulinum B NCTC 7273. The core and pan-proteomes are indicated.
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Table 29: Comparison of the proteins identified in the supernatant of C. botulinum A1 ATCC 
19397 and C. botulinum B NCTC 7273 by functional group. A protein is classified as 
belonging to the core proteome if it is present in the supernatant of both strains.
Protein functional group Core
ATCC 19397 
unique 
proteins
NCTC 7273 
unique 
proteins
Pan
proteome
Percentage 
core proteins
Adaptations to atypical 
conditions 1 0 0 1 100%
Amino acid biosynthesis 3 3 0 6 50%
Biosynthesis of cofactors, 
prosthetic groups, and carriers 1 4 0 5 20%
Cell envelope 2 7 1 10 20%
Central intermediary metabolism 1 4 1 6 17%
Chemotaxis and motility 3 2 1 6 50%
Detoxification1 1 1 0 2 50%
DNA metabolism 0 1 0 1 0%
Energy metabolism 33 20 2 55 60%
Fatty acid and phospholipid 
metabolism 2 4 0 6 33%
Hypothetical and unknown 
proteins 10 • 32 6 48 21%
Mobile and extrachromosomal 0 ' 1 0 1 0%element functions
Pathogenesis 6 0 0 6 100%
Protein fate 19 4 '•1 24 79%
Protein synthesis 7 8 2 17 41%
Purines, pyrimidines, 
nucleosides, and nucleotides 3 2 0 5 60%
Regulatory functions 0 1 1 2 0%
Signal transduction 2 0 0 2 100%
Sporulation and germination 1 0 1 2 50%
Transcription 3 2 0 5 60%
Transport and binding proteins 2 2 2 . 6 33%
Total 100 98 18 216
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3.2.5. Comparison of predicted and experimentally identified
supernatant proteins of C. botulinum A1 ATCC 19397
Sub-cellular location of the protein products of the 3550 open reading frames in 
the C. botulinum A1 ATCC 19397 genome were predicted using five different tools 
(see section 3.1.3) (CELLO, LocateP, PsortB, SecretomeP and SignalP, for details 
see methods section 2.1.2). A consensus of the number of tools that predicted 
each protein to be extracellular was determined (summary in Table 30). This 
consensus was compared with the ATCC 19397 proteins that had been 
experimentally identified as extracellular at either 24 h or 96 h.
There were 11 proteins predicted by all five tools to be extracellular and four of 
these proteins (36.4%) were experimentally detected in the supernatant (see 
Table 30). Of the proteins predicted as extracellular by four tools 7.9% were 
experimentally identified as extracellular, of the proteins predicted by three tools 
3.8% were extracellular, of the proteins predicted by two tools 4% were 
extracellular and of the proteins predicted by a single tool 9.7% were 
experimentally identified as extracellular. Of the 2994 proteins which were not 
predicted as extracellular by any tools, 5.5% were extracellular, a higher 
percentage than predicted by a consensus of two or three tools (Table 30).
Extracellular proteins predicted by each of the five tools were compared with the 
experimentally identified extracellular proteins; the percentage of predicted 
proteins that were detected in the supernatant was calculated. Prediction accuracy 
ranged between 4.9-15.7%, with the tool LocateP predicting extracellular proteins 
with the highest accuracy and SecretomeP predicting with the lowest accuracy 
(Table 31). The accuracy measurement was determined as the percentage of
188
experimentally observed proteins that were predicted to be extracellular by each 
tool.
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Table 30: The number of C. botulinum A1 ATCC 19397 proteins predicted as extracellular by 
a consensus of 5, 4, 3, 2, 1 and 0 tools and the percentage of those proteins experimentally 
identified as supernatant proteins.
A consensus of 
this many tools 
predicted a protein 
to be extracellular
Number of proteins 
predicted to be 
extracellular
Number of 
experimentally 
identified extracellular 
proteins which were 
predicted to be 
extracellular
Percentage of 
predicted proteins that 
were experimentally 
identified as 
extracellular
5 11 4 36.4
4 113 9 7.9
3 235 9 3.8
2 124 5 4
1 72 7 9.7
0 2994 173 5.7
Table 31: The total number of predicted proteins, accurately predicted proteins and 
percentage of correct predictions by the 5 tools used to predict subcellular location when 
compared against the experimentally identified extracellular proteins.
Tool
Total number 
of predicted 
proteins
Total number 
of accurately 
predicted 
proteins
Specificity Sensitivity
CELLO 460 27 X 5.90% 13.00%
LocateP 115 18 15.70% 8.70%
PsortB 156 10 6.40% 4.80%
SecretomeP 426 21 4.90% 10.10%
SignalP 379 24 6.30% 11.60%
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3.2.6. Extracellular protein cost as an indicator of involvement in 
virulence
Extracellular proteins, once released by the cell, cannot usually be recovered and 
as such are a drain on the resources of the cell. Conversely, the constituent amino 
acids of intracellular proteins can be recycled upon protein degradation. It has 
been hypothesised that, because of their permanent loss to the cell, evolution has 
optimised extracellular proteins to reduce their synthetic burden on the cell (Smith 
& Chapman, 2010).
However, BoNT is a large protein that is released, into the extracellular milieu, 
bucking the purported trend for extracellular proteins to be metabolically,cheaper. 
It is also the single most important virulence factor possessed by C. botulinum. 
The hypothesis that extracellular proteins are metabolically more economical to 
produce than non-extracellular proteins was tested in C. botulinum. The 
relationship between cost of extracellular protein and involvement in virulence was 
also examined.
The average cost of synthesis of experimentally identified supernatant proteins 
was calculated (identified at 24 h and/or 96 h) and compared with the average 
synthesis cost of every coding sequence not detected extracellularly in the C. 
botulinum genome. The mean high-energy phosphate bond (HEPB) cost to 
synthesise an extracellular protein was 23.4 HEPBs per amino acid. The average 
cost for coding sequences not identified in the supernatant was 24.6 HEPBs per 
amino acid. The data sets were confirmed as normally distributed and a P-value of 
3.00x10"25 obtained by t-test. This indicates that extracellular proteins are, on
191
average, cheaper than non-extracellular proteins by a small (4.9%) but significant 
margin.
BoNT, NTNH and the HA proteins were in the top 15% of either the total or 
average per amino acid cost. Three of the five toxin complex proteins were within 
the top three of the 207 proteins in terms of either total or average per amino acid 
cost (Table 32 & Table 33). Of the OrfX cluster proteins, OrfX1, OrfX2 and P-47 
were in the top 15% of either the total or average per amino acid cost. OrfX3 was 
in the 25%.
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3.2.7. Identification of toxin complex proteins in clinical strains of C. 
botulinum by LC-MS/MS
The type and range of botulinum toxin complex proteins present in the supernatant
of C. botulinum strains isolated from different clinical types of botulism was 
investigated by initial separation by SDS-PAGE followed by protein detection using 
LC-MS/MS. In order to maximise the number of strains that could be investigated, 
analysis was only undertaken on proteins extracted from targeted regions of the 
SDS-PAGE gel. To enable this approach, as protein products of the 
haemagglutinin and OrfX gene clusters are different in size, the toxin complex type 
of each clinical strain was determined by PCR prior to LC-MS/MS analysis (see 
section 3.3.2). To determine which areas of the gel should be targeted, initial 
experiments were carried out using supernatant protein from ATCC 19397 as an 
example of a haemaglutinin encoding strain and C. botulinum A3 Loch Maree 
(NCTC 2012) as an example of an OrfX encoding strain.
i
Approximately 40 protein bands were identified densitometrically on a 12% Bis- 
Tris SDS-PAGE gel. The gel was divided into 11 sections, taking into account both 
the total section size and the total protein density. These sections were analysed 
by LC-MS/MS and in total, 179 proteins were detected by more than one unique 
peptide. There was a maximum of 28 and a minimum of 9 proteins identified in 
these 11 gel fragments. Seventy of the 179 proteins were identified in the three 
sections between 55 kDa and 36.5 kDa.
All the BoNT complex proteins were identified in ATCC 19397 by LC-MS/MS 
(Figure 54 A) and the unique peptides identified for each protein are shown in 
Table 26. The NTNH protein was identified in gel fragment 1 that contained 
proteins in the 200 kDa to 115 kDa range. This is consistent with the known 138
196
kDa molecular weight of NTNH. Although BoNT is 150 kDa, no peptides from this 
gel fragment matched BoNT. BoNT peptides were identified in the 115 kDa to 66 
kDa section. When the BoNT peptides in this gel section were mapped to the toxin 
sequence they all matched the heavy chain of the toxin which has a molecular 
weight of 100 kDa. BoNT light chain (50 kDa) peptides were identified in the fourth 
gel fragment that included proteins of approximately 55 kDa to 50 kDa. Peptides 
matching HA70, were identified in the fifth gel fragment that included proteins of 
approximately 50 kDa to 42 kDa. All these peptides were localised to 60% of the 
protein on the C-terminus side. Peptides matching the HA33 protein were 
identified in the seventh gel fragment (36.5 kDa to 31 kDa). The ninth gel fragment 
(25 kDa to 20 kDa) contained peptides matching HA70. The peptides from this gel 
fragment mapped to 30% of the HA70 protein on the N-terminus side. HA17 
peptides were identified in the tenth gel fragment that contained proteins from 20 
kDa to 14.4 kDa in size. Based on these results, four SDS-PAGE gel fragments 
were analysed for each of the Haemagglutinin encoding clinical strains: between 
150-95 kDa; 55-40 kDa; 37-30 kDa; 22-14 kDa.
Once the location on the SDS-PAGE gel of BoNT and the neurotoxin associated
proteins from a haemagglutinin encoding C. botulinum strain was established, the
same workflow was carried out for C. botulinum A3 Loch Maree (NCTC 2012)
(Figure 54 B). The toxin gene for this strain is encoded within an OrfX positive
toxin complex. All clinical strains were tested for their toxin complex type by PCR
prior to LC-MS/MS analysis (for details see methods section 1.4.2 and results
section 1.3.1) and the appropriate gel fragments for either the HA proteins or the
OrfX proteins were analysed by LC-MS/MS depending on the results of the PCR.
However, the use of C. botulinum A3 NCTC 2012 as reference for the production
of the OrfX toxin complex proved to be inappropriate. Only NTNH and OrfX2 were
197
identified -  both were in the appropriate gel fragments for their predicted molecular 
weight (Figure 54 B). Therefore, in addition to the NTNH and OrfX2 fragments, gel 
sections corresponding to the predicted molecular weight of BoNT (150 kDa), P-47 
(47 kDa), OrfX1 (16.3 kDa) and OrfX3 (55.1 kDa) were analysed by LC-MS/MS. 
This resulted in three SDS-PAGE gel fragments being analysed for each of the 
OrfX positive clinical strains -  the regions between 150-80 kDa, 60-40 kDa, and 
22-14 kDa.
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1 8 N Y N N N N
2 10 N N N N Y N
3 9 N N N N N N
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Figure 54: Identification of the SDS-PAGE gel fragments that contain the botulinum toxin 
and toxin complex proteins by LC-MS/MS for (A) C. botulinum A1 ATCC 19397 24 h 
supernatant and (B) C. botulinum A3 NCTC 2012 24 h supernatant
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Table 34: The unique peptides identified for each botulinum toxin complex protein in ATCC
19397 supernatant protein at 36 h
Protein
Number of 
unique 
peptides
Unique peptide sequences
NTNH 13
\
EFSIMMPDR
FLQAIITLLK
FSLSSDFVEWSSK
LDEVIISVLDNMEK
LNSLISSTIPFPYAGYR
MNINDNLSINSPVDNK
NIYETEIEGNNAIGNDIK
SLFSSETALLIK
SVLAQETLIK
VAPNIWVAPER
VDGGIYDSNFLSQDSEK
YDEFYIDPAIELIK'
YYGESLSIDEEYK
BoNT He 11 AIINYQYNQYTEEEK
IALTNSVNEALLNPSR
LLSTFTEYIK
NIINTSILNLR
NNINFNIDDLSSK
NQIQLFNLESSK
VLTVQTIDNALSK
VNNTLSTDIPFQLSK
WIFVTITNNR
YFNLFDK
YSQMINISDYINR
BoNT Lc 6 FIDSLQENEFR
MLTEIYTEDNFVK
NFTGLFEFYK
QVPVSYYDSTYLSTDNEK
SIVGTTASLQYMK
VIDTNCINVIQPDGSYR
HA70 - 50 kDa 11 AINYITGFDSPNAK
DAFNVQLFNTSTSLFK
INAQNNLPSLK
IYEAIGSGNR
LLNGAIYILK
LYTSYNQGIGTLFR
SYLWLLNK
TNDKDLIGTLLIEAGSSGSIIQPR
VEVTELNNYNIR
VPQTSSNIENQIQFK
YELIDYQNGSIVNK
H A 70-20kD a 7 AVLYVPSLGYVK
CILNEQFLYK
DFYFLTNDK
NLYMYLQYTYIR
QNQILGGSVISNGSTGIVGDLR
SIEFNPGEK
VINYSDTIDLADGNYWR
HA33 4 DIGNNSFIIASYK
ISPILDLNK
LSTLNNSNYIK
NPNLVLYADTVAR
HA17 3 SIFSGSLYLNPVSK ' 
TFLPNGNYNIK 
WNVEYMAENR
200
Table 35: The unique peptides identified for each botulinum toxin complex protein in NCTC
2012 supernatant protein at 36 h
Number of
Protein unique
peptides
Unique peptide sequences
NTNH 5 GTMDNFYAAYK
INNNFNIDSPVDNK
NSDPFIPVYNITETK
SVLAQESLIK
YYGESLNINEDQK
OrfX2 8 CIIDDGYLDMNFGTSSEK 
ENYSINEIIPK 
IAVEDAGLISDDGTTSIR 
LQGIYLLGGALEK 
NDSGVTDIELQEINR 
NVDSFLKPGK 
QEYELALESK 
SWNLTDEGEGSHPVLK '
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Once the gel fragments that contained BoNT and its associated proteins were 
identified the corresponding gel fragments from clinical isolates of C. botulinum 
were analysed.
Supernatant proteins were precipitated after 36 h growth in liquid culture from 22 
clinical strains of C. botulinum and analysed for the presence of BoNT and 
associated proteins using 1DGE-LC-MS/MS (as described in methods section 
1.3.2-1.3.4). These strains included 15 wound botulism isolates, five infant 
botulism strains and two food botulism strains. There were 14 type A strains, six 
type B strains and two bivalent AB encoding strains. The National Botulinum 
Reference Laboratory at the Health Protection Agency had previously determined 
and documented toxin serotype for these isolates using qPCR and mouse 
neutralisation bioassay (Akbulut et al., 2004). Toxin complex type was determined 
prior to LC-MS/MS according to methods detailed in Materials and Methods 
section 1.4.2. The LC-MS/MS analysis was targeted to the gel fragments where 
the toxin complex proteins had been identified previously (as described above).
The targeted LC-MS/MS approach was used to detect and identify the BoNT 
complex proteins in 22 clinical isolates -  the correct BoNT serotype was detected 
and identified in 20/22 strains (Table 36). At least 2 toxin complex proteins were 
identified in every strain analysed with all the HA toxin complex proteins 
(neurotoxin, NTNH, HA70, HA33 and HA17) being identified in 13/22 strains.
There were 15 wound botulism.strains analysed: 10 type A strains, 4 type B and 1 
type AB. All 15 strains encoded genes for the HA toxin complex type. BoNT, 
NTNH and all the HA toxin complex proteins (HA33, HA17 and HA70) were
identified in 10 of these 15 strains. There were different patterns of protein
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absence in the five strains that lacked at least one member of the toxin complex 
(Table 36). BoNT, NTNH and HA70 were not identified in the supernatant of 
04068341, a type A wound botulism strain. BoNT and NTNH were not identified in 
the supernatant of H091280045, a type B wound botulism strain. HA70 was not 
detected in the supernatant of H065060505, a type A wound botulism strain. HA17 
was not identified in the supernatant of H091140481 or H102120680, type B 
strains which caused wound botulism.
Five infant botulism strains were analysed: three type A strains (H040660361, 
H094460264 and H112480657) and two type B strains (H074400585 and 
H090840606). HA toxin complex genes were detected in three of these isolates 
(two type B and one type A), OrfX genes were identified in one strain (type A) and 
both HA and OrfX genes were identified in one strain (type A) (Table 36). LC- 
MS/MS detected both BoNT and NTNH in the supernatant of all these isolates. All 
three HA toxin complex proteins were identified in the three HA positive infant 
botulism isolates. Only OrfX2 was identified in the supernatant of the OrfX positive 
isolate. In the supernatant of the dual HA and OrfX positive infant botulism isolate, 
OrfX2 and OrfX3 were detected but no HA proteins.
Two strains isolated from clinical food botulism cases were investigated: one type 
A, HA encoding isolate (H114580650) and one bivalent AB isolate, that encoded 
both HA and OrfX genes (H063740588). BoNT/A and NTNH were identified in the 
supernatant of both these strains, BoNT/B was not identified in the supernatant of 
the bivalent strain. In the supernatant of the HA positive isolate, HA70 and HA33 
were detected. In the supernatant of the bivalent strain only HA70 and HA33 were 
detected.
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The type strain C. botulinum A1(B) NCTC 2916 was also examined as part of this 
investigation. In this strain the type A toxin is present in an OrfX toxin complex 
cluster and the type B toxin is present in an HA cluster. Type A toxin protein was 
detected in the culture supernatant of this isolate, while only the HA toxin complex 
proteins (HA70, HA33 and HA17) were detected.
The presence of clostripain, an enzyme putatively involved in nicking the toxin 
resulting in the formation of the active dichain was also investigated. It was 
identified in the supernatant of 20/22 strains, the two strains for which clostripain 
was not identified were associated with foodborne botulism. Both of these 
organisms showed the presence of BoNT in the 50 kDa region of the gel indicating 
that despite the absence of clostripain BoNT was still being cleaved into a dichain.
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3.2.8. Summary of findings of proteomic investigation
• Endopeptidase assay reported decline in active supernatant toxin between 
24 h and 96 h, in contrast to previous reports,
• The C. botulinum supernatant proteome is more complex than previously 
reported, with a larger number of proteins identified.
• The C. botulinum supernatant proteome is stable between 24 h and 96 h, 
although there are signs of protein degradation.
• Significantly more proteins were identified in the supernatant proteome of 
BoNT/A producing ATCC 19397 than BoNT/B producing NCTC 7273.
• All sub-cellular localisation prediction tools have low sensitivities (best was 
15.7%) and specificities (best was 13%) at predicting C. botulinum 
supernatant proteins.
• Novel, potential virulence associated proteins were identified in the C. 
botulinum supernatant.
• C. botulinum extracellular proteins involved in virulence are some of the 
metabolically most expensive proteins identified in the supernatant.
• All 22 clinical strains of C. botulinum produced at least one component of 
the ANTPs, while the majority of strains produced all ANTPs, BoNT and 
NTNH.
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3.3. Genomic diversity and toxin complex type of clinical 
isolates causing botulism in the UK
Botulinum neurotoxin genes are encoded alongside and co-expressed with genes 
encoding the associated non-toxic proteins. There are two known toxin complex 
types, the haemagglutinin (HA) and the OrfX. The HA complex type has been 
more thoroughly characterised; isolates from the majority of cases of botulism 
have been found to encode the HA complex type. Although most strains of C. 
botulinum express a single toxin type, some strains produce more than one type. 
Usually, one type of toxin predominates and this is usually denoted by use of a 
capital letter with the toxin type produced to a lesser extent denoted in lower case. 
Strains that encode two toxin types but only produce one type are denoted A(B), 
where type A is produced and B is not. Some bivalent strains are also bivalent for 
toxin complex type (i.e. encode genes for both HA and Orfx) with the toxin genes 
being associated with different toxin complex types. Toxin types A1, A5, B, C and 
D have been found in ha clusters while A1 (rarely), A2, A3, A4, Bf, E and F type 
toxins have been found in orfX clusters.
The toxin complex type of isolates from cases of botulism in the UK is not routinely 
determined by the National Reference Laboratory. In this study, the relationship 
between toxin complex type, genomic similarity and type of botulism is 
investigated. This involved developing a PCR-based assay to determine toxin 
complex type and applying fluorescent Amplified Fragment Length Polymorphism 
(fAFLP) to provide insight into the genetic diversity of isolates causing botulism in 
the UK. Seven strains from the National Collection of Type Cultures, representing 
a range of toxin and toxin complex types were employed as reference strains.
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3.3.1. Investigating genomic diversity of isolates of causing different 
forms of botulism in the UK
fAFLP was employed to investigate the genomic diversity of 38 isolates of 
proteolytic C. botulinum and neurotoxigenic C. butyricum from clinical cases of 
botulism collected between 2004-2011 and from the National Collection of Type 
Cultures. Three technical replicates of each isolate were processed to ensure 
reproducibility. The average level of similarity of technical replicates was 94.9%, 
with a range of 91.4-96.9%. Isolates with fAFLP profile similarity greater than 90% 
were treated as indistinguishable.
Fragments ranging in size between 60-600 bp were analysed for each strain and a 
dendrogram representing the diversity of fAFLP profiles was generated. The 
strains grouped into five main clusters (Figure 55) that shared more than 60% 
fAFLP profile similarity. With the exception of four strains, all strains examined 
grouped into one of these five clusters. There were also sub-clusters within the 5 
main clusters that showed at least 80% similarity to each other. All four of the non­
clustered isolates were group I C. botulinum and consisted of 3 type strains 
isolated in 1947 (C. botulinum B NCTC 7273), 1976 (C. botulinum Ba4 657) and 
1922 (C. botulinum A3 NCTC 2012) and a BoNT/B producing organism 
(H074400586) which was linked to a case of infant botulism in 2007.
All C. butyricum strains analysed here formed a distinct cluster (Cluster 5) with 
only 22% similarity to the group I C. botulinum strains (clusters 1-4). Within Cluster 
5 there was a sub-cluster of four indistinguishable strains (fAFLP profile >90% 
similar), three of these strains were associated with a single case of infant 
botulism, representing an isolate from the afflicted infant, the infant’s mother
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(asymptomatic carriage) and an environmental isolate (from the family’s terrapin 
tank). The fourth strain was another toxigenic C. butyricum strain isolated from an 
unrelated infant botulism case. The fifth strain in cluster 5, NCTC 7423, is a non- 
toxigenic C. butyricum type strain, which was significantly different (fAFLP profile 
<90% similar) from the other Cluster 5 strains.
The C. botulinum group I isolates analysed clustered into four different groups that 
had more than 60% similarity with the exception of the four strains detailed above 
(three type strains and H074400586) (Figure 55). Cluster 1 contained 12 strains; 9 
type A strains and 3 type B strains. These strains were associated with 11 cases 
of wound botulism (9 type A strains, 2 type B strains) and 1 case of infant botulism 
(a type B strain). There were two sub-clusters (>80% similarity) in Cluster 1, one of 
which contained all nine of the type A encoding strains in Cluster 1. The other sub­
cluster contained two of the three type B strains in Cluster 1. The only infant 
botulism strain in Cluster 1 was a type B encoding strain that was also the only 
, strain not to fall within a sub-cluster.
Cluster 2 consisted of 9 strains; 3 type A, 4 type B and 2 bivalent AB strains. 
There were 5 wound botulism strains (2 type A, 3 type B), 1 infant botulism strain 
(type B) and 2 bivalent AB food borne botulism strains. Three sub-clusters within 
Cluster 2 contained more than one isolate. In addition to grouping by fAFLP profile, 
these sub-clusters were also consistent in their respective toxin types. One sub­
cluster consisted of three type A strains, another consisted of three 
indistinguishable type B strains while the final sub-cluster contained two 
indistinguishable type AB strains. One of the bivalent AB strains was a type strain 
isolated from canned corn in the USA in 1929, while the other was associated with
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food botulism in 2006. One Cluster 2 strain did not share 80% similarity with any 
other isolate this was a type B strain associated with infant botulism in 2011.
Cluster 3 consisted of 4 strains, all type A, that grouped into two pairs of 
indistinguishable (>90% similarity) strains. The first of these pairs consisted of the 
type A encoding National Collection of Type Culture strains NCTC 7272 and 
ATCC 19397, these strains were derived from the same initial culture. The other 
pair of isolates were from a patient and environmental sample from the same food- 
borne outbreak, associated with commercially prepared korma sauce in 2011.
Cluster 4 consisted of 5 strains from different cases, all 5 of which encoded type A 
toxin, all associated with cases of infant botulism between 2007 and 2011. There 
were two sub-clusters with more than one isolate within Cluster 5, with a single 
strain not showing 80% similarity to any other strain.
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3.3.2. Determination of the toxin complex type of clinical strains of C.
botulinum
The toxin complex type (ha or orfX) of the 32 group I clinical strains associated 
with separate incidents of botulism were determined using PCR assays to detect 
ha70, ha33, orfX/2 and orfX/3 (Table 37). Only group I strains were investigated as 
these cause the majority of botulism in the UK and to analyse toxigenic C. 
butyricum strains here would require the use of different primer sets due to the 
variation between their orfX sequences (toxin type E has always been found in 
orfX toxin complex types) and the orfX sequences of group I strains.
Of the 34 clinical C. botulinum strains analysed, 28 were positive for only ha 
encoding genes, 4 were positive for only orfX encoding genes and 2 were positive 
for both ha and orfX genes. Among the 28 ha only strains, 24 were positive for 
both ha70 and ha33 with two testing positive for ha33 but negative for ha70. 
Among the 4 clinical orfX only encoding strains, 3 were positive for both orfX/2 and 
orfX/3 while 1 was negative for orfX/2 and positive for orfX/3. Both the clinical ha 
and orfX positive strains tested positive for ha70, ha33, orfX/2 and orfX/3.
Of the four food botulism isolates from different incidents, three were ha only and 
one was bivalent ha/orfX. Of the eight infant botulism isolates, three were ha only, 
one was bivalent ha/orfX and four were orfX only. All 21 wound botulism strains 
were ha only encoding strains.
Two strains exhibited unusual combinations of genes. H091640054 was bivalent in 
terms of toxin type, encoding both BoNT/A and B, however it was monovalent in 
terms of toxin complex type, encoding only HA. On the other hand H094460264
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encoded only BoNT/A but was positive by PCR for genes from both the HA and 
OrfX complex types.
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Table 37: Clinical strains which were analysed for toxin complex type and 
toxin serotype, type of botulism caused and toxin complex type as 
determined by PCR. Strains marked with + came from the same incident.
Molis Number HA70 HA33 OrfX2 OrfX3 Toxin complex type
Type of 
botulism
Toxin
type
H040660361 + + - - HA WB A ’
H040680341 + + - HA WB A5(B)
H042440055 + + - HA WB A5(B)
H044020065 + + - - HA WB A5(B)
H044640107 + + - - HA WB A5(B)
H052880114 + + - - HA WB A
H062260493 + + - HA WB B
H063740588 + + + + HA/OrfX FB AB
H063960325 + + - - HA WB A
H064620409 + + - - HA WB A
H065060505 - + - - HA WB A
H065260139 + + ' - - HA WB A '
H071040476 + + - - HA WB A
H071400014 + + - - HA WB A
H074240407 - , - + + Orf ,B A
H074400585 + + - HA IB B
H075000578 + + - - HA WB A
H090840606 - + - HA IB B
H091140481. + + - - HA WB B
H091280045 + + - - HA WB B
H091640054 + + - HA WB AB
H092080005 + + - • - HA WB B
H093320637 - - - + OrfX IB A
H093620104 + + - - HA WB B
H094460264 + + + + HA/OrfX IB A
H111860974 - - + + ORF IB A
H112120680 + + - - HA WB B
H112480657 - - + + ORF IB A
H113660204 + + - - HA WB A
H114400598 + + - - HA IB B
H114580650 + + - - HA FB . A
H114580654 + + - HA FB A
H114590007 + + + - - HA FB - env A
H114680633 + + + - - HA FB A
ATCC 19397 + , + - - HA Type strain A1
NCTC 2916 + + + + HA/OrfX Type strain A1(B)
NCTC 2012 - - + + OrfX Type strain - FB A3
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3.3.3. Summary of findings of genomic diversity, toxin complex type 
and form of botulism
• There is considerable diversity among the clinical and type strains 
investigated in the fAFLP experiment.
• There is a relationship between toxin complex type, genomic background 
and type of botulism. Strains that encode OrfX and HA fall into different 
fAFLP clusters. These strains are also associated with different forms of 
disease, with all the OrfX encoding strains being associated with infant 
botulism.
• There are two strains with novel combinations of toxin and toxin complex 
type. H091640054 encodes both BoNT/A and B while only encoding the HA 
toxin complex type. H094460264 encodes both HA and OrfX while 
encoding only BoNT/A.
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3.4. RNA-Seq transcriptome profiling to investigate C. botulinum 
toxin complex expression
RNA-seq was used to investigate transcription of the genes encoding the 
botulinum toxin complex. Initial experiments with C. botulinum A1 ATCC 19397 
were undertaken using reverse transcription quantitative PCR (RT-qPCR) to 
determine the expression profile of bont/A, over a time course, relative to a 
reference housekeeping gene - gluD (encoding glutamate dehydrogenase). Three 
samples from pre-peak, peak and post-peak toxin relative gene expression were 
analysed by RNA-seq. Insight into bont/A regulation and details of transcription 
from both coding and non-coding regions of the genome are reported.
3.4.1. Optimisation of cell lysis and RNA extraction
Preliminary experiments to determine a methodology for consistently providing 
sufficient quantity of high quality RNA for downstream analysis were performed.
Optimisation of lysis and extraction was carried out using C. botulinum A1 ATCC 
19397 cultures grown anaerobically in TPGY at 37°C to mid-log phase. Two 
methods of cell lysis and two methods of RNA-extraction (giving four different 
combinations of lysis and extraction methods) were assessed. For cell lysis, bead 
beating and enzyme lysis were investigated. The RNA extraction methods used 
were phenol:chloroform:isoamyl alcohol treatment and silica column extraction 
(RNeasy, Qiagen). The quantity of RNA was measured using the Quant-iT 
Ribogreen kit (Life Technologies, Paisley, UK) while RNA quality was determined 
by Bioanalyser (Agilent, Wokingham, UK) (Table 38 & Figure 56).
The highest quantity of RNA (373.5 ng/pl) was obtained using bead beating lysis 
and extraction phenol:chloroform:isoamyl alcohol, however this RNA was of a low 
quality, showing significant degradation of the 16S and 23S rRNA (Figure 56 (A)). 
The second highest yield (170.1 ng/pl) was obtained by lysing cells with enzyme 
treatment and extracting RNA by a phenol:chloroform:isoamyl alcohol method. 
However, this RNA also showed signs of degradation. Bead beating lysis followed 
by column extraction gave a very low yield (3.4 ng/pl) of low quality RNA. Enzyme 
lysis followed by column extraction gave an acceptable yield of 104.3 ng/pl and an 
excellent RNA quality (Figure 56). Therefore the combination of enzyme lysis and 
column extraction was employed for further RNA extraction.
The RNeasy columns used for extraction do not capture RNA molecules less than 
200 nucleotides in length. In order to capture these RNAs an additional extraction 
step was carried out in which flow through from the RNeasy columns was 
collected and a phenol:chloroform:isoamyl alcohol RNA extraction performed. This 
RNA was then combined with the RNA captured by the column to provide a high 
quality extract of total cellular RNA (Figure 57).
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Table 38: Quantity of RNA extracted from an 8 h culture of C. botulinum A1 19397 using 
different combinations of lysis and RNA extraction methods.
RNA extraction method
method 
Lysis
Column Phenol:chloroform:isoamyl alcohol
Bead
beating 3.4 pg/|jl 373.5 pg/pl
Enzyme 104.3 pg/pl 170.1 pg/pl
Marker[ F U 3 [FU]
16s rRNA 23s rRNA
Degraded rRNA Marker
5s rRNA 5s rRNA
65 [s][ntj 60200 SCO 5525 1000 20 25 30 35 40 50
Marker
16s rRNA
16s rRNA 23s rRNA
23s rRNAMarker
[ntj 500 100025 200 2000200 500 1000
Figure 56: Assessment of RNA quality by Bioanalyser, high concentration of intact rRNA 
indicates good quality. RNA quality was assessed following extraction by (A) bead beating 
followed by column extraction (B) bead beating and phenokchloroform extraction (C) 
Enzyme lysis followed by column extraction (D) Enzyme lysis followed by 
phenokchloroform extraction. [FU] = arbitrary fluorescence units [nt] = fragment size, 
nucleotides.
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Marker
5s rRNA
i i
45 50 5520 25 65 [sj
[FU]
16s rRNA
23s rRNA
Marker
5s rRNA
65 [s]50 55 6030 35 452520
Figure 57: Total cellular RNA was obtained by combining RNeasy column captured RNA 
with small RNAs captured from the column flow through by phenohchloroform extraction (A) 
RNA extracted from the flow through only(B) Total RNA from flow through and column.
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3.4.2. RT-qPCR investigation of bont/A gene expression relative to the 
reference gene gluD along a time course
Previous work has shown that bont/A expression peaks at late log or early 
stationary phase (Shin et al., 2006). Therefore, a growth curve was carried out to 
determine the time point at which broth cultures of C. botulinum ATCC A1 19397 
reached log and early stationary growth phases. The O D 6oo of an ATCC 19397 
culture was measured at 0, 4, 6, 7, 8, 9, 10, 11, 12 and 13 h. The cultures entered 
logarithmic growth between 4-6 h, undergoing rapid growth until 10-12 h when the 
ODeoo plateaued as the cultures entered stationary phase. The results obtained 
closely mirror those obtained during the proteomic workflow (see section 3.2.1).
The expression of bont/A relative to the expression of the reference gene gluD 
(encodes glutamate dehydrogenase, Gene ID 5395388) was determined by 
quantitative PCR (qPCR) analysis of reverse transcribed RNA (cDNA) taken at 
hourly intervals from 7 h to 13 h and at 24 h from an ATCC 19397 broth culture. 
Before the gene expression of bont/A relative to gluD could be calculated, the 
efficiency of the two reverse transcription qPCRs (RT-qPCR) was determined. 
Five ten-fold dilutions of total RNA were tested in triplicate using the RT-qPCR 
assays for bont/A and gluD and the threshold cycle (Ct) for each dilution 
determined. The Ct and log-RNA concentration were plotted on a graph and the 
slope of the line (Figure 58) used to derive the efficiency of the reaction according 
to (see 2.5.8). The efficiency of the bont/A RT-qPCR was 111.2% and the 
efficiency of the gluDRT-qPCR was 90.9%.
For each cDNA sample the bont/A qPCR and the gluD qPCR Ct values were 
determined. Relative gene expression of bont/A compared with gluD was then
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calculated (Figure 59) for each time point using the method of Pfaffel, 2006, which 
takes the efficiency of the RT-qPCR into account.
The relative expression of bont/A compared to gluD at 7 h is given a base line 
value of 1 and expression at later time-points is normalised to this baseline. The 
relative expression of bont/A in sample A increased 7.6 fold between 7 h and 9 h, 
when it peaked, before gradually decreasing until 24 h when relative expression 
was less than 10% of the 7 h level. In sample B an increase of 6 fold between 7 h 
and 10 h was followed by a rapid decrease of 3.2 fold between 10 h and 11 h, 
stabilising between 11 h and 13 h before decreasing to less than 10% of 7 h 
expression at 24 h.
The reference gene gluD was chosen because of concerns about the most 
commonly used reference gene for relative gene expression experiments in C. 
botulinum, 16S rRNA. These concerns included potential changes in the rate of 
synthesis of rRNA as cell growth slows (Hansen et al., 2001) and the fact that it 
has been proposed to interfere with the calculation of the relative gene expression 
of bont (Lovenklev et al., 2004). Specifically, gluD was chosen because it had 
been previously used in relative gene expression experiments of Clostridium 
difficile (Kirk et al., 2014).
Three time-points from each sample, representing the C. botulinum A1 ATCC 
19397 transcriptome before peak toxin expression, at peak toxin expression and 
after peak toxin expression were selected for analysis using RNA-seq. For sample 
A these were the 7 h, 9 h and 13 h time-points and for sample B the 7 h, 10 h and 
13 h time-points were selected. These samples are hereafter referred to as the
mid-log (7 h), late log (9 h & 10 h) and early stationary phase (13 h) samples. The
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amount of 5S, 16S and 23S rRNA in the samples was reduced by Ribo-Zero rRNA 
reduction kit (CamBio, Cambridge, UK) (Figure 60) and the samples were then 
sent for RNA-seq at an external facility.
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Figure 58: RT-qPCR of Serial dilution of total ATCC 19397 RNA. The slope of the line allows 
the calculation of efficiency.
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Table 39: Calculation of relative gene expression from crossing threshold (Ct) values 
obtained from RT-qPCR experiments.
Replicate
A
ct Ct
Time bont/A gluD
7 21.5 17.7
8 18.8 16.7
9 17.8 16.6
10 18.4 16.9
11 18.5 16.4
12 19.3 16.2
13 19.7 15.9
24 28.6 21.8
Ct - Ct at 
7h
Ct - Ct at 
7h
bont/A gluD
0 0
2.7 0.9
3.6 1.1
3.1 0.7
2.9 1.3
2.2 1.5
1.8 1.8
-7.2 -4.1
Target
efficiency A Ct 
- Ct at 7h
bont/A gluD
1 1
7.3 1.8
15 2
9.8 1.6
8.8 2.3
5.2 2.6
3.8 3.2
0 0.1
RGE
__ 1_
3.9
7.6
6.1
3.8
2
1.2
Replicate
B
Ct Ct
Time bont/A gluD
7 21.1 18
8 19.2 17.3
9 18.4 17.3
10 18.1 17.2
11 19.2 16.7
12 19.4 16.5
13 18.9 16.2
24 27.9 21.8
Ct - Ct at 
7h
Ct - Ct at 
7h
bont/A gluD
0 0
1.9 0.7
2.7 0.6
3 0.7
1.9 1.3
1.7 1.4
2.2 1.8
-6.7 -3.8
Target
efficiency A Ct 
- Ct at 7h
bont/A gluD
1 1
4.2 1.5
7.5 1.5
9.7 1.6
4.2 2.3
3.6 2.3
5.4 3.1
0 0.1
RGE
__ 1_
2.8
___5
6
1.9
1.6
1.7
223
C l 5
«j 3
Time (h)
Figure 59: Relative gene expression of bont/A compared to gluD from 7 to 13 hours in two 
biological replicates A and B. Relative expression peaks at 9 h in sample A and 10 h in 
sample B before decreasing as the cells enter stationary phase. Based on this data three 
time points were selected for analysis from each replicate, from replicate A 7 h, 9 h and 13 h 
were selected and from replicate B 7 h, 10 h and 13 h were selected.
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Figure 60: Presence of rRNA (5S, 16S and 23S) in extracted RNA before (A) and after (B) 
reduction of rRNA using Ribo-Zero rRNA reduction kit (Gram positive bacteria).
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3.4.3. Analysis of gene expression data from the RNA-seq dataset
\ -
In total, 12 samples were analysed by RNA-seq. These samples were multiplexed 
on one flow cell of a SOLiD 4 machine. These 12 samples consisted of two 
technical replicates of two biological replicates of three time points.
’ (
The resulting sequencing reads were then mapped against the published genome 
of C. botulinum A1 19397. The number of RNA sequencing reads mapped to each 
of the 3700 coding sequences annotated in the C. botulinum A1 ATCC 19397 was 
determined. This measure was used to calculate the Reads Per Kilobase of gene 
per Million mapped reads (RPKM), i.e. the number of reads which map to a gene 
normalised for the total number of reads mapped to a sample and the length of the 
gene. This allows comparison of gene expression between samples with different 
sequencing coverages and between genes of different lengths, it can be thought of 
as the concentration of a transcript. The second approach used for ‘read count 
data’ is differential gene expression (DGE) analysis. Most methods for calling 
differentially expressed genes use untransformed data i.e. read counts rather than 
RPKM values. The DGE analysis package used in this work is edgeR, an R 
package (http://www.r-project.org/) that calls differentially expressed genes using a 
negative binomial model to account for biological variation (Oshlack et al., 2010; 
Robinson et al., 2010).
3.4.3.1. C. botulinum A1 ATCC 19397 gene expression
On average, more than 40 million reads were obtained for each of the 12 samples. 
When these reads were mapped to the reference genome an average of 4.5
million or 11.2% (standard deviation = 1.3 million or 3.3%) of the reads mapped
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unambiguously per sample. A significant proportion of reads mapped to rRNA 
encoding regions, with an average 16.1% of mid-log, 20.5% of late log and 30.1% 
of early stationary reads mapping to 5S, 16S and 23S rRNA.
There were 3700 annotated coding sequences (CDS) in the reference genome. 
When technical and biological replicates for each time point were combined there 
were 2684 CDSs at mid-log, 2697 CDSs at late-log and 2326 CDSs at early 
stationary phase with RPKM greater than 10. This threshold was set heuristically 
and is not intended to convey biological meaning but rather to differentiate 
between signal and noise. The CDSs transcribed at each time-point were 
compared. There was a large core transcriptome of 2208 transcripts present at all 
three time-points. There were also 643 transcripts that were only present at one or 
two of the time-points (see Figure 61 for details).
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Figure 61: Venn diagram showing distribution of CDSs with RPKM greater than 10.
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3.4.3.2. Comparison of RNA-seq gene expression data with
microarray data
The RNA-seq results were validated against data from a microarray time-course 
analysis of proteolytic C. botulinum (Artin et al., 2010). The Artin study was 
performed using C. botulinum A1 ATCC 3502 which has nearly identical genome 
synteny with C. botulinum A1 ATCC 19397 (Hill et al., 2009). Orthologous loci 
were identified by an all vs all BLASTp approach and normalised microarray 
expression results compared with normalised RNA-seq results (RPKM) for each 
ortholog. The correlation co-efficent (r2) between microarray and RNA-seq data 
was found to be 0.37 (Figure 62).
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Figure 62: Comparison of gene expression results of microarray study (Artin et al., 2010) 
with RNA-seq data obtained in this study, samples taken at mid-log phase.
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3.4.3.3. Genes which showed differential expression between
timepoints
Differential gene expression analysis was performed on the RNA-seq data using 
the package edgeR implemented in the statistical programming language R. There 
were 252 CDSs (6.8% of total CDSs) that showed significant differential 
expression (FDR < 0.01) between mid-log and late log and 575 CDSs (19.7% of 
total) that showed significant differential expression between late-log and early 
stationary phases (Table 40). There were 93 CDSs that showed differential 
expression at both time points (Figure 63).
Differentially expressed genes were investigated for a potential role in 
pathogenicity in Results section 3.4.3.7.
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Table 40: Number of genes showing significant (false discovery rate, FDR <0.01) positive or 
negative fold change between mid-log and late-log or between late log and early stationary 
phases.
Mid Log vs Late Log Late Log vs Early Stationary
Positive fold change 139 305
Negative fold change 110 270
Total 249 575
LL vs ES 
482
ML vs LL 
156
Figure 63: Venn diagram showing the number of genes which were differentially expressed 
(FDR < 0.01) between mid-log (ML) and late log (LL) and between late log and early 
stationary (ES) phase.
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3.4.3.4. Expression of the botulinum toxin cluster genes
Expression from the genes comprising the bont/A cluster and cioSl (clostripain) 
was examined (Table 41,); botA, ntnH, ha33, ha17 and ha70 were actively 
expressed at mid-log stage (395th to 531st most highly expressed transcripts when 
CDSs ranked by RPKM). Visual inspection indicates transcription of the ntnH-botA 
operon and the ha33-ha17-ha70 operon in contiguous, separate transcripts at all 
three time-points (Figure 65). botR expression was very low, only just above the 
noise threshold (RPKM of 10 or less was deemed noise) and among the genes 
with the lowest expression (2650th of 2684 CDSs with an RPKM of > 10). botR 
expression was 3.6% that of botA. At mid-log cloSl was the 290th most expressed 
gene, showing higher expression than any BoNT complex gene (Table 41 (A) and 
(B)).
Between mid-log and late log botA and ntnH expression increased 5.13 and 5.45 
fold respectively while ha33, ha17 and ha70 increased by 4.22, 4.77 and 6.03 fold 
respectively (all false discovery rate (FDR) <0.01). At late log phase these genes 
were the 78th to 134th most highly expressed genes (Table 41). botR expression 
showed no significant change and remained amongst the least expressed genes, 
at 1.5% of botA expression. cloSl expression decreased 4.37 fold between mid-log 
and late log (FDR = 4.4E-03) becoming the 862nd most expressed gene at late log 
(Table 41 (A) and (B)).
There was a further increase in expression of botA, ntnH, ha33, ha17 and ha70
between late log and early stationary by 1.31, 1.27, 1.60, 1.66 and 1.64 fold
respectively. However, these changes were not deemed to be statistically
significant (FDR <0.01) by edgeR. These genes were the 40th to 94th most
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expressed genes at early stationary phase. botR and cloSl also showed no 
significant change between log and early stationary phases (Table 41 (A) and (B)). 
botR was expressed at 0.6% the level of botA.
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Figure 64: Expression of bont/A cluster genes at mid-log (ML), late log (LL) and early 
stationary (ES) phases.
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Table 41: Expression of bont/A cluster genes at mid-log (ML), late log (LL) and early 
stationary (ES) phases. (A) Shows normalised transcript level,. RPKM, of the toxin gene 
cluster and clostripain and the rank of each gene compared to the expression levels for all 
the genes at that time point (B) shows log fold change and associated confidence scores as 
calculated by edgeR.
(A)
Gene RPKM ML ML ra n k RPKM LL LL ra n k RPKM ES ES ra n k
botA 328.01 531 1681.75 134 2199.01 94
n tn H 378.95 482 2066.12 116 2617.17 79
ha33 486.04 402 2053.29 117 3277.06 65
ha 1 7 397.25 464 1893.12 128 3137.17 69
ha70 497.33 395 2996.57 78 4904.85 40
botR 11.76 2650 25.30 2202 15.26 2,070
c lo S l
(c lo s tr ip a in ) 774.04 290 177.21 862 396.41 327
Gene Fold change ML to LL FDR
Fold change 
LL to ES FDR
botA 5.13 4.40E-04 1.31 7.14E-01
ntnH 5.45 3.40 E-04 1.27 7.12E-01
ha33 4.22 3.49E-03 1.6 4.24E-01
ha17 4.77 8.86E-04 1.66 4.37E-01
ha70 6.03 1.13E-04 1.64 4.31 E-01
botR 2.15 1.54E-01 -1.66 5.37E-01
cloS/ (clostripain) -4.37 4.41E-03 2.24 2.29E-01
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Figure 65: Expression from bont gene cluster at mid-log, late log and early stationary 
phases. Y axis is read depth.
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3.4.3.5. Comparison of bont/A expression as measured by RT- 
qPCR relative to gluD and as measured by RNA-seq
The botA expression values obtained by RNA-seq were compared to those 
obtained from the RT-qPCR results (Figure 66). The expression of botA, 
measured by RT-qPCR relative to gluD, peaked at late log phase before 
decreasing in early stationary phase. This conclusion was not supported by the 
measured expression of the same gene using RNA-seq. The results from the latter 
showed a similar increase between mid-log and late log but then showed a small, 
insignificant increase between late log and early stationary phase. In order to 
resolve this contradiction, expression levels of gluD were examined in the RNA- 
seq data. There was an insignificant (FDR >0.01) increase in expression of 1.3 
fold between mid-log and then a significant increase of 5.8 fold (FDR = 2.8x1 O'12) 
between late log and early stationary. This would result in the relative expression 
of bont/A decreasing at early stationary phase.
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Figure 66: Comparison of RT-qPCR relative gene expression and RNA-seq exression results. 
Expression of botA measured by RT-qPCR relative to gluD, botA expression measured by 
RNA-seq and gluD expression measured by qPCR.
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3.4.3.6. Identifying genes which are suitable reference genes
for relative gene expression experiments
The RNA-seq dataset was examined to determine genes that showed stable 
expression across biological replicates and time points. To this end the coefficient 
of variance was calculated (standard deviation divided by the mean) from the six 
RPKM values for each gene (three time points, two biological replicates). The 
expression details of the 10 genes with the lowest co-efficient of variation are 
given in Table 42 with gluD, used as a reference gene in section 3.4.2, included 
for comparison (only genes with an average RPKM >100 were included). The 
gene with the lowest coefficient of variation was clb_0260, which encodes a 
lipoprotein. Other genes with stable expression across time points and biological 
replicates were spoVG, which encodes a sporulation protein; rpoD that encodes 
an RNA polymerase sigma factor and buk__2 which encodes a butyrate kinase. 
The genes included in the MLST scheme for an organism are often considered as 
candidates for reference genes in relative gene expression results. For C. 
botulinum the 7 MLST genes are mdh, aceK, rpoB, aroE, hsp60, oppB and recA 
(Jacobsen et al., 2008). The expression of the C. botulinum MLST scheme genes 
across the three time points and two biological replicates was also examined 
(Table 44) -  recA was the MLST gene with the lowest coefficient of variation of 
0.22, making it the 28th most stable gene expressed by ATCC 19397. The function 
of the 10 most stably expressed genes is described in Table 43.
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Table 42: Expression levels (RPKM) of the 10 genes with the lowest co-efficient of variance 
across both biological replicates and all timepoints. gluD, used as the reference gene in 
section 3.4.2 is included. T1B1 to T3B2 are RPKM values at time point 1, 2 and 3 for 
biological replicates 1 and 2.
Feature
ID T IB I T1B2 T2B1 T2B2 T3B1 T3B2 Average
Standard
deviation
Coefficient
of
variation
CLB_0260 1,334 995 1,049 1,193 1,125 1,198 1148.9 120.5 0.1
spoVG 4,727 3,916 4,608 5,321 4,499 5,293 4727.3 528.8 0.11
CLB_2031 160 152 160 189 123 176 159.9 22.2 0.14
rpoD 243 213 239 257 169 215 222.7 31.1 0.14
buk_2 200 173 206 221 155 230 197.5 28.8 0.15
CLB_1337 430 292 432 437 355 446 398.7 62.1 0.16
CLB_2907 205 180 260 282 219 254 233.5 38.5 0.16
gcvPA 170 212 136 171 156 216 176.8 31.6 0.18
CLB_3662 179 251 213 242 152 187 204.1 38.3 0.19
CLB_3433 266 227 243 298 161 234 238.2 45.6 0.19
gluD 1167.1 1671.1 1546.1 2313.6 8689.8 13994 4896.9 5279.4 1.08
Table 43: Functional role of the 10 genes with the lowest coefficients of variance.
Gene Main role Sub role Common name
CLB 0260 Cell envelope Other lipoprotein, bmp family
spoVG Cellularprocesses
Sporulation and 
germination stage V sporulation protein G
CLB_2031 Hypotheticalprotein
Hypothetical
protein hypothetical protein
rpoD Transcription Transcriptionfactors RNA polymerase sigma factor RpoD
buk-2 Energymetabolism Fermentation butyrate kinase
CLB_1337 Unknown function Enzymes of unknown specificity
dinitrogenase iron-moiybdenum 
cofactor family protein
CLB 2907 Unknown function General UBA/TS-N domain protein
gcvPA Energymetabolism
Amino acids and 
amines
glycine cleavage system P 
protein, subunit 1
CLB_3662 Unknown function Enzymes of unknown specificity radical SAM domain protein
CLBJ3433 Hypotheticalproteins Conserved conserved hypothetical protein
gluD Energymetabolism
Amino acids and 
amines
glutamate dehydrogenase, NAD- 
specific
241
Table 44: Expression levels (RPKM) of the 6 MLST scheme genes with an RPKM greater 
than 10 for at least one time-point were examined. T1B1 to T3B2 are RPKM values at time 
point 1, 2 and 3 for biological replicates 1 and 2.
Feature
ID T IB I T1B2 T2B1 T2B2 T3B1 T3B2 Average
Standard
deviation
Coefficien
of
variation
recA 510.0 306.2 366.9 417-3 272.5 383.5 376.1 84.1 0.22
CLB_1385
(oppB) 11.9 16.7 5.6 13.0 8.8 8.8 10.8 3.9 0.36
aroE 55.4 46.8 27.8 36.7 18.9 24.6 35.0 14.0 0.40
rpoB 955.8 1139.4 533.3 729.7 129.1 183.7 611.8 408.2 0.67
hsp60 266.1 117.1 104.3 83.7 31.0 26.1 104.7 87.5 0.83
CLB_3479
(aceK) 757.1 1039.8 1625.6 2427.6 7514.9 14521.5 4647.8 5439.3
1.17
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3.4.3.7. Putative pathogenicity associated genes with
increased expression in early stationary phase
Differential gene expression data was analysed to identify putative pathogenicity 
associated genes with significant fold changes. Fold changes with a False 
Discovery Rate (FDR) of less than 0.01 were deemed significant, in total 731 
genes had fold changes supported by FDRs < 0.01.
Six thermolysin metallopeptidase genes (npr-1 to 6) showed significant up- 
regulation between late log and early stationary phase. These six genes are 
encoded in the same operon in the genome of ATCC 19397 (Figure 67) and show 
an average 79% +/- 6% similarity to each other on the nucleotide level, npr-6 and 
npr-5 show the highest level of expression with RPKMs of 349.9 and 238.2, 
increasing 4.4 fold and 4.6 fold between late log and early stationary phase 
respectively, npr-4, npr-3 and npr-2 show the second highest level of expression 
with RPKMs of 85.7, 89.0 and 83.1, increasing 3.4 fold, 3.5 fold and 2.8 fold 
respectively between late log and early stationary phase, npr-1 has the lowest 
level of expression with an RPKM of 8.16, increasing 1.4 fold from late log to early 
stationary phase (Table 45).
C. botulinum encodes a gene, clb_1609, for a hemolysin-lll protein which shows 
significant similarity (BLAST E-value = 1.6x10‘57) to a Bacillus cereus pore forming 
cytotoxin which disrupts hemocytes (Table 46). This protein shows strong up- 
regulation between late log and early stationary phase. The expression level of 
clb_1609 increased 4.2 fold to an RPKM of 10695.2.
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There was significant up-regulation of a bacteriocin/streptolysin-encoding gene, 
clb_0527, between late log and early stationary phase. There was a 1.6 fold 
increase to an RPKM of 3829. Bacteriocins are toxins produced by bacteria to 
inhibit the growth of similar or closely related bacterial strains (Table 46).
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Figure 67: Expression of npr1-6 at mid-log, late log and early stationary phases. The Y-axis 
scale is 200 reads. The average length of the npr genes is 1762 bp.
Table 45: Thermolysin metallopeptidase genes which show increased expression between 
late log and early stationary phase - fold change, False Discovery Rate (FDR) and 
expression level (RPKM)
Gene Fold change - late log to early stat FDR RPKM
npr-1 1.42 9.10x1 O'3 8.16
npr-2 3.51 4.60x1 O'10 83.05
npr-3 2.75 3.61x1 O'8 89.01
npr-4 3.38 6.82x1 O'10 85.7
npr-5 4.58 2.76x1 O'10 238.24
npr-6 4.4 1.21x1 O'9 349.91
Table 46: Putative pathogenesis associated genes which show increased expression 
between late log and early stationary phases - fold change, False Discovery Rate (FDR) and 
expression level (RPKM)
Gene Fold change - late log to early stat FDR RPKM
CLB_1609 (hemolysin) 4.18 9.00x1 O'8 10695.
CLB_0527 (bacteriocin) 1.67 1.50x10‘3 3829.1
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3.4.4. Linking the transcriptome and proteome data
Transcription and translation do not always correlate due to the diverse array of 
post-transcriptional phenomena influencing the rate at which mRNA is translated 
into protein (Maier et al., 2009). The expression of genes encoding proteins that 
were identified in the culture supernatant at 24 h and 96 h was examined. 
However, the complexity of the relationship between mRNA concentration and 
protein concentration necessitates caution when analysing this data.
The protein with the lowest RPKM that was identified in the culture supernatant 
was a putative NADPH-dependent FMN reductase (A7FSA3) involved in electron 
transport. The gene encoding this protein had a maximum RPKM at the timepoints 
measured of just 7. Other proteins with low RPKMs were involved in a 
phosphotransferase system (A7FVJ3, max RPKM = 13.5), a glyoxalase family 
protein (A7FU43, max RPKM = 37) and a MarR family transcriptional regulator 
(A7FSQ9, max RPKM = 75). There were six proteins detected by LC-MS/MS for 
which there was no RNA expression at any time point. These proteins were all 
involved in energy metabolism, with five of the six involved in the utilisation of 
amino acids for energy (A7FPY4, a 2-hydroxyglutaryl-CoA dehydratase; A7FW29 
and A7FW44, D-proline reductases; A7FYN7 and A7FZI3, CoA transferases) and 
one involved in fermentation (A7FZ18, butyrate kinase).
The average expression of genes encoding proteins present at 24 h, 96 h and 
both time-points was calculated for comparison. At mid-log, late log and early 
stationary phases the median gene expression of supernatant proteins present at 
24 h and 96 h was higher than the median gene expression of proteins present at 
only 24 h or 96 h. At early stationary phase, the expression of genes encoding
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proteins present at only 96 h is lower than the expression of genes encoding 
proteins present at only 24 h (Table 47).
The results of the BoNT/A endopeptidase assay (section 3.2.3) were compared 
with the bont/A expression results from the RNA-seq experiment. Between mid-log 
and early stationary phase, the bont/A RPKM increased 6.7 fold. Over the same 
time period BoNT/A, as measured by endopeptidase assay increased only 2.1 fold. 
BoNT/A concentration peaked at 24 h, increasing 4.8 fold between 7 h and 24 h.
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Table 47: Median expression of genes (RPKM) encoding proteins detected at only 24 h, only 
96 h or both at mid-log, late-log and early stationary phase.
Mid-log Late log Early stationary
24 h 663.0 969.3 517.5
96 h 386.0 640.0 96.5
24 h and 96 h 1787.8 1617.3 751.5
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3.4.5. Small RNAs in global gene expression
The different expression patterns of the bont/A transcript and the concentration of 
the BoNT/A protein raises the possibility of the post-transcriptional regulation of 
bont/A. One major mode of post-transcriptional regulation is by the interaction of 
small RNAs (sRNA) with mRNA. Here the sRNA complement of C. botulinum will 
be examined.
Transcription from the non-coding regions of the bont/A gene cluster was 
examined for the presence of possible sRNAs by visual inspection. The 
sequences of any regions of transcription were then compared with the Rfam 
functional RNA database (http://rfam.sanqer.ac.uk/). There was no significant non- 
mRNA transcription in the region of the bont/A gene cluster.
There could be an sRNA encoded elsewhere on the genome which interacts with 
the bont/A mRNA. A thorough characterisation of sRNAs from across the C. 
botulinum ATCC 19397 genome was carried out. All sRNAs identified were 
examined for homology with the bont/A mRNA which could indicate that the sRNA 
played a role in the post-transcriptional regulation of bont/A. No candidates for 
interaction. with the toxin gene were identified but an active transcriptional 
landscape of non-coding sRNAs was uncovered.
There were 17 transcriptionally active T-boxes identified (Table 48). T-boxes are 
sRNAs that are located in the 5’ untranslated region (5’UTR), upstream of mRNA 
encoding amino acid-tRNA ligases. One particularly interesting example is that of 
valS (a valine-tRNA ligase) and CLB_3200 (a GNAT family acetyltransferase) that 
appear to be co-transcribed and jointly regulated by a single T-box (Figure 68).
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There were also 19 transcriptionally active riboswtiches identified in the C. 
botulinum genome (Table 49). Examples of riboswitches identified in C. botulinum 
include magnesium riboswitches, thioamine pyrophosphate riboswitches and 
purines/pyrimindes riboswitches among others.
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Table 48: Genes which had transcriptionally active T-boxes or S-boxes identified in their 
upstream region.
5' UTR 
mechanism
Gene
symbol/locus Gene function
T-box serS-1 Serine-tRNA ligase
T-box CLB 1163 Class V aminotransferase
T-box aspC
Aspartate transaminase (changes aspartate to 
glutamate)
T-box metG Methionine-tRNA ligase
T-box leuS Leucine-tRNA ligase
T-box thrS Threonine-tRNA ligase
T-box valS * Valine-tRNA ligase
T-box CLB 3200* Acetyltransferase, GNAT family
T-box ileS Isoleucine-tRNA ligase
T-box CLB 0276 Sodium:dicarboxylate symporter family protein
T-box serS-2 Serine-tRNA ligase
T-box argS Arginine-tRNA ligase
T-box alaS Alanine-tRNA ligase
T-box tyrS Tyrosine-tRNA ligase
T-box CLB 2881 Putative membrane protein
T-box pheS Phenylalanine-tRNA ligase
T-box CLB 0768
Conserved hypothetical protein, potential 
methyltransferase activity
S-box metK S-adenosylmethionine synthetase
S-box metF Methylenetetrahydrofolate reductase
S-box CLB 3459 Na+/H+ antiporter family protein
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There were also some noteworthy novel features of unknown function. There were 
multiple examples of short areas of sense-antisense transcription (Figure 69). 
Possible toxin-antitoxin systems account for a fraction of the sense-antisense 
transcriptional activity -  any function the other sites may have remains obscure. 
An sRNA which showed strong growth phase regulation was identified, the RPKM 
at mid-log was 551, at late log it was 851 and at late stationary it was 36397. This 
dramatic increase in expression was not mirrored in either of the flanking genes, 
which are both on the positive strand while the sRNA is on the negative strand.
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Figure 68: Transcriptional activity of a T-box region. The va/S-CLB_3200 operon can be seen 
downstream of the T-box. CLB_3200 is the shorter gene which immediately follows the T- 
box and valS, a valine synthesis gene which would be expected gene to be associated with 
the T-box is the larger gene and second in the operon.
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Figure 69: An example of sense-antisense transcription from intergenic region.
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Figure 70: Level of expression in the conserved region to which the sRNA (highlighted in 
purple box) belongs (A) shows expression of the growth phase regulated sRNA at a read 
depth of 200 allowing the visualisation of transcription from other areas within the 
conserved region (B) visualisation of the same conserved region as (A) but the scale is set 
at 20000 read depth showing the extremely high level of transcription of the sRNA at early 
stationary phase compared to early growth phases and to the rest of the conserved region.
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Figure 71: The presence of a growth phase regulated sRNA (dark blue, top centre) in a large 
region (highlighted in red box, 23 kbp) of conservation among proteolytic C. botulinum. 
Conserved genes upstream of the sRNA include an alanine racemase involved in cell wall 
synthesis, 2 methyl accepting chemotaxis proteins, a xanthine/uracil permease family 
protein and a short chain oxidoreductase. Downstream there is a Snf2/Rad54 family 
helicase, formylmethanofuran dehydrogenase E related protein, 3 peptide-opine-nichel 
uptake ABC transporter protein. Only proteins within this region are on the same strand as 
the sRNA (the oxidoreductase and 2 hypothetical proteins).
Table 50: Similarity of nucleotide sequence of growth phase regulated sRNA among 
proteolytic C. botulinum  calculated using BLAST
Genome Query coverage Identity
Clostridium botulinum A2 str. Kyoto 100% 100%
Clostridium botulinum A str. Hall 100% 100%
Clostridium botulinum A str. ATCC 19397 100% 100%
Clostridium botulinum A str. ATCC 3502 100% 100%
Clostridium botulinum H04402065 100% 99%
Clostridium botulinum A3 str. Loch Maree 100% 98%
Clostridium botulinum B1 str. Okra 100% 98%
Clostridium botulinum F str. 230613 100% 97%
Clostridium botulinum F str. Langeland 100% 97%
Clostridium botulinum Ba4 str. 657 99% 97%
Clostridium botulinum A1(B) 2916 N/A N/A
Clostridium botulinum Bf N/A N/A
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3.4.6. Summary of findings of transcriptome investigation of C.
botulinum
• gluD is not a suitable reference gene for relative gene expression 
experiments. Other, more suitable candidates include rpoD that encodes a 
transcription factor.
• The RNA-seq data shows that while expression of the toxin complex genes 
increases, expression of botR shows no significant change.
• There are genes that show up-regulation as the culture enters early 
stationary phase that encode proteins with homology to known virulence 
factors.
• There was an active transcriptional landscape of small RNAs. Some of 
these sRNAs had known functions in regulation cell metabolism or other 
cellular functions. There were also other, uncharacterised sRNAs including 
one that showed massive up-regulation as the culture entered stationary 
phase.
257
4. Discussion
4.1. In silico investigation of the botulinum toxin complex and C. 
botulinum proteome
The sequences of botulinum toxin and the associated non-toxin proteins were 
analysed using BLAST to identify similarity to other proteins and patterns of 
similarity between different types and subtypes of toxin cluster. It was discovered 
that there were multiple heterologous homologues of the OrfX and P-47 proteins in 
numerous species. These homologues were genomically co-localised and in 5 
cases clustered with a putative toxin encoding gene.
4.1.1. In silico investigation of botulinum neurotoxin and non-toxic 
non-haemaglutinin
The amino acid sequences of BoNT and NTNH are much more similar than would 
be expected by chance, although still with 55% identity over 32% of the sequence. 
Interestingly, while the sequences are divergent the crystal structures of the two 
proteins are very similar, with a root mean square deviation of 2.3 Angstroms (Gu 
et al., 2 0 1 2 ) and they are thought to have evolved from a common ancestral zinc 
binding protein via gene duplication (Inui et al., 2012). This shows that there is a 
long evolutionary history of functionally significant rearrangements in the BoNT 
encoding gene cluster.
Comparing the protein sequence dendrograms for BoNT and NTNH suggests that 
homologous recombination has resulted in novel arrangements within the BoNT
encoding gene cluster, as previously suggested (Hill et al., 2009). All the BoNT/A
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subtypes cluster together, with BoNT/B clustering separately. However, their 
corresponding NTNH sequences show a different pattern, with NTNH/A1 and 
NTNH/A5 clustering between between NTNH/A2/A3/A4/F and NTNH/B. This is 
thought to be due to a recombination event occurring approximately 1965 bp into 
the 3594 bp ntnH (Hill et al., 2009). It has been hypothesised that this 
recombination led to the combination of BoNT/A and the HA toxin complex, which 
was previously associated only with BoNT/B (Hill et al., 2009). This combination is 
most frequently associated with human disease. The botR sequences follow the 
same pattern as the NTNH sequences, indicating that BotR and NTNH share an 
evolutionary history, as expected from their genomic co-localisation. The fact that 
Lee et al. (2013) found that NTNH is the major interface between the BoNT-NTNH 
and HA sub-complexes may explain why NTNH is more conserved between 
different types of BoNT than BoNT itself. While the BoNT has undergone changes 
that have altered that neuronal cell binding and cleavage targets, NTNH has to 
conserve binding to the HA sub-complex or else compromise translocation across 
the intestinal epithelium (Lee et al., 2013). It has also been found that the NTNH 
encoded alongside BoNT/A1, B, C, D and G has a conserved motif that is 
responsible for the main interaction between the BoNT-NTNH and the HA sub­
complex. This motif is missing from the NTNHs associated with BoNT/A2, E and F, 
which do not interact with HA (Lee et al., 2013; Lin et al., 2010).
Evidence of further recombination within the BoNT gene cluster is that while 
BoNT/A and BoNT/F are clearly divergent, with BoNT/F showing closer similarity 
to BoNT/E, NTNH/F clusters with the NTNH/A sequences from the OrfX encoding 
strains (e.g. NTNH/A3). This discrepancy indicates that there has been a 
horizontal gene transfer event between the BoNT/F gene cluster and an OrfX
encoding BoNT cluster, resulting in the transfer of NTNH, as has been previously
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noted (Raphael et al., 2010). This analysis extends previous work by showing that 
the OrfX proteins in the BoNT/F toxin gene cluster show greater similarity to the 
OrfX proteins of BoNT/A strains rather than BoNT/E strains.
Recent work has shown that a strain encoding B0 NT/F6  evolved by successive 
disruption of two different ancestral precursors, indicating the role of recombination 
hotspots in the generation of diversity within the toxin gene cluster of type F strains 
(Carter et al., 2013). This extensive recombination may be one of the drivers of the 
considerable diversity within the type F gene cluster (Raphael et al., 2010).
The BoNT and TeNT proteins show similarity in the light chain, which is expected, 
as both are responsible for the enzymatic cleavage of the neuronal cell 
neuroexocytosis apparatus. There is also sequence and structural similarity 
between BoNT and TeNT in the amino terminus of the heavy chain that is 
responsible for the pH dependent translocation out of the endosome (Simpson, 
2004). However, toward the carboxy terminus of the light chain the two proteins 
are highly divergent. It is this region that is responsible for binding to neuronal cells, 
and the divergence in this sequence contributes to their different in vivo targets 
and symptomatic effects. This analysis agrees with previous workers findings 
(Pellizzari et al., 1999).
4.1.2. In silico investigation of the haemaglutinin toxin complex
The amino acid sequence dendrograms for HA70, HA33 and HA17 (Figure 18, 
Figure 20, Figure 22) show the close relationship between the HA proteins found 
in type A and type B strains. This similarity is striking when compared with the low
similarity between the BoNT/A and BoNT/B proteins. This indicates that a
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horizontal gene transfer event has taken place resulting in the HA proteins being 
transferred between the two toxin clusters. It is likely that this transfer was part of 
the same event in which ntnH was transferred (Hill et al., 2009). Due to the fact 
that OrfX proteins have only been found associated with BoNT/A, while BoNT/A is 
found with both OrfX and HA proteins it is hypothesised that prior to this 
recombination, that BoNT/A was associated with OrfX (Hill et al., 2009). The 
identification here of a Ricin B lectin domain in HA33, which is also found in many 
other bacterial and plant toxins, has been previously reported (Arndt et al., 2005) 
thereby confirming the findings presented here.
Interproscan analysis of HA70 explained the significant match between HA70 and 
the C. perfringens enterotoxin; there was a C. perfringens enterotoxin domain in 
HA70. In C. perfringens enterotoxin, this domain is responsible for interaction with 
tight junctions in gut epithelium (Katahira et al., 1997). This is another piece of 
evidence that the HA sub-complex is facilitates interaction with the gut membrane. 
Interproscan analysis of HA17 also showed that it contains the common Ricin B 
lectin domain that is implicated in binding to sugars. This domain is frequently 
found in bacterial AB-toxins, among other proteins.
4.1.3. In silico investigation of the P-47 family toxin complex
There was a conserved domain in OrfX2, OrfX3 and P-47, known as the
Clostridium P-47 protein domain (Pfam id IPR010567). The function of this domain
is unknown. Due to the presence of this common domain in OrfX2, OrfX3 and P-
47, these proteins will be referred to as P-47 family proteins. Whilst these results
confirm and extend previous findings, there is also a novel insight into the P-47
family proteins. OrfX1 had no P-47 family domain, but did have one significant
261
BLAST match to a non-BoNT encoding species; a protein annotated as OrfX1 in 
Paenibacillus dendritiformis. The significance of this result is increased by the 
presence of homologues (>30% amino acid identity) of OrfX2, OrfX3 and P-47 in P. 
dendritiformis.
There were multiple proteins with significant BLAST matches to OrfX2, OrfX3 
and/or P-47 in nine phylogenetically distinct species including Paenibacillus larvae, 
Ricketsiella grylli, Erwinia tasmaniensis, Arsenophonus nasoniae, Pseudomonas 
putida and Nitrobacter winogradskyi. The P-47 family proteins from these species 
show a lower level of similarity to the C. botulinum proteins than those from P. 
dendritiformis, but they all still contain P-47 domains. Depending on the genome 
annotation of their respective strains, these coding sequences are either 
annotated with the name of their closest P-47 family protein or as hypothetical 
proteins. All of these species contained multiple, heterologous P-47 family proteins 
(i.e. within one species there would be at least two proteins showing similarity to 
e.g. OrfX2 and OrfX3 respectively). This raises the possibility that they are 
encoded in clusters, similar to the P-47 family proteins in C. botulinum.
The genomic arrangement of the P-47 family proteins was investigated in nine 
non-BoNT encoding species. In all nine species, the P-47 family proteins were 
clustered together, in a similar fashion to the associated non-toxin protein 
encoding gene cluster in C. botulinum. Furthermore, in 5 of 9 strains, genes 
encoding putative toxin genes were encoded alongside with the P-47 family 
clusters.
262
4.1.4. Analysis of the relationship between P-47 family clusters and 
their co-localised putative toxins
Three different types of putative toxin were identified within the five P-47 family 
gene clusters. These were nematicidal proteins found in Arsenophonus nasoniae, 
Halomonas sp. TD01 and Erwinia tasmaniensis; a Shiga-toxin A-chain component 
homolog found in Ricketsiella grylli and a partially degraded clostridial C2 toxin 
component ll/anthrax protective antigen homolog identified in Paenibacillus larvae.
This finding raises the possibility that P-47 family proteins fulfil a function that is 
important to the activity of different types of toxin. Examining the type of toxins 
encoded alongside the P-47 gene cluster in the non-BoNT encoding strains allows 
the generation of hypotheses of their functional role. Bacterial nematicidal proteins, 
which were identified in P-47 family clusters in three species, are usually toxic via 
ingestion - typically through their action on the midgut epithelium cells (de Maagd 
et al., 2003). The nematode midgut contains digestive enzymes, including 
peptidases, with a role in breaking down food (Terra, 1996). The hypothesis that 
the P-47 family proteins encoded alongside the nematicidal proteins protect the 
toxin from these digestive enzymes -  similar to the role of the associated non-toxic 
proteins during BoNT intoxication, should be investigated. It should be stated that 
the role of the OrfX proteins in toxicity via the oral route in BoNT poisoning is 
unclear. However, the presence of P-47 family proteins in proximity to another oral 
toxin in three other species suggests that its role in toxicity via the oral route is 
worth further investigation. It is also interesting that the nematicidal protein in 
Xenorhabdus nematophilus, to which the A. nasoniae protein shows homology, is 
produced as part of a large protein complex (Sheets et al., 2011). This complex 
shows no similarity to the P-47 family proteins. There is an interesting parallel here
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between BoNT and nematicidal proteins, both are co-localised with two different 
types of toxin complex, one of which consists of P-47 family proteins while the 
other does not.
The function of the P-47 family proteins in the context of the other putative toxin 
genes is less clear. The clostridial G2 toxin homolog is degraded, along with the P- 
47 family cluster, indicating that it is no longer functional in P. larvae. Even if the 
putative toxin gene were intact, the role of the P-47 family gene cluster remains 
unclear, as there is only a homolog of a toxin-binding region, not an activity region. 
However, there is a transposase immediately downstream of the C2 homolog so it 
is possible that component I of the C2 toxin was disrupted by this mobile genetic 
element. Alternatively, the P-47 family proteins may have some toxic activity that is 
complemented by the binding activity of the C2 toxin homolog.
In the case of R. grylll there is a homolog of the shiga-toxin activity subunit 
alongside the P-47 family encoding gene cluster. If this homolog functions in a
similar fashion to the canonical shiga toxin, it would be non-functional without a
/
cogent .binding domain. One hypothesis is that the P-47 family proteins act as the 
binding domain in this scenario.
4.1.5. Analysis of the similarity between P-47 family clusters in 
different species with phylogenetic context
Although it is not feasible to perform detailed phylogenetic analysis on proteins 
that are so distantly related, it is possible to make cautious inferences from the 
similarity of the protein sequences and compare them to phylogenetic information 
derived from 16S rDNA sequence comparison.
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There appears to be two clusters of species that show similarity in at least one P~ 
47 family protein. One of these clusters consists of E. tasmaniensis, A. nasoniae 
and R. grylli, while the other cluster consists of the Paenibacillus species and C.
botulinum. The divergence between the Halomonas, P. putida and N.
. . ' /
winogradskyi P-47 protein sequences and any other P-47 protein sequence 
precludes their detailed analysis.
The phylogenetic and P-47 family sequence similarity relationships between 
Paenibacillus and C. botulinum are coherent, indicating that the P-47 family 
proteins have a similar evolutionary history to the strains that encode them. 
However, while E. tasmaniensis and A. nasoniae are phylogenetically related, R. 
grylli is much more divergent. The stronger similarity of the P-47 family proteins 
between E. tasmaniensis, A. nasoniae and R. grylli compared with the 
phylogenetic relationship indicates that the evolutionary history of the P-47 family 
proteins of these organisms does not match that of the species that encode them. 
It is also noteworth that Paenibacillus species have been shown to have anti­
bacterial properties against C. botulinum, indicating that these two species 
encounter each other in the natural world (Girardin et al., 2002)
There are two other strands of evidence that point to a separate evolutionary 
history for the C. botulinum/Paen\bac\\\us and E. tasmaniensis/A. nasoniae/R. grylli 
P-47 family clusters. Firstly, they are separated by genetic similarity and synteny. 
C. botulinum and the Paenibacillus species encode either OrfX3 or a homologue 
of OrfX3, while E. tasmaniensis, A. nasoniae and R. grylli share the presence of a 
small DNA binding protein in their P-47 family cluster. Secondly, they have distinct
ecological niches; C. botulinum and Paenibacillus species are both soil dwelling,
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anaerobic saprophytes and some species of Paenibacillus show antimicrobial 
activity against C. botulinum. This suggests that these two species may well share 
or have shared the same ecological niche, providing opportunity for horizontal 
gene transfer. R. grylli, A. nasoniae and E. tasmaniensis are all either plant of 
insect associated bacteria -  it is possible that they also share a niche which would 
have enabled horizontal gene transfer of P-47 family proteins between these 
species.
4.1.6. Summary of analysis of the P-47 family clusters
The hypotheses presented here to explain the co-localisation of P-47 and putative 
toxin genes are somewhat speculative due to the lack of functional 
characterisation of P-47 family proteins. However, the fact that this arrangement is
i
identified multiple times with a variety of known and potential toxins, suggests a 
functional relationship. Further characterisation of the P-47 family proteins, their 
associated putative toxin proteins and the relationship between the two will shed 
light on the function of P-47 and it’s relevance in BoNT intoxication. The 
determination of the crystal structure of the P-47 family proteins would allow the 
deduction of the function of these proteins.
It is perhaps surprising that the P-47 family proteins are so poorly characterised, 
considering their wide distribution and association with known and putative toxin 
genes. However, all of the data on the non-BoNT encoding species in which P-47 
family genes were identified comes from massively parallel sequencing 
experiments. These types of study provide a large amount of data, much of which 
will only receive a cursory analysis. These, findings highlight the benefit of putting 
these sequences into searchable databases where it can contribute to other work.
However, one downside of this kind of data (generated using 2nd generation
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sequencing technologies) is that it does not result in finished genomes. The P-47 
family cluster identified in P. dendritiformis was on a small contig with no other 
coding sequences. Therefore it is impossible to definitively say whether or not this 
gene cluster is associated with a putative toxin gene.
The results presented here show for the first time that clusters of P-47 family 
proteins are present in a variety of species and are frequently encoded alongside 
putative toxin encoding genes. This result suggests that the P-47 proteins have a 
functional role in toxicity. The possibility of a relationship between P-47 family 
proteins and toxins that exert their effect via the oral route is also worthy of 
investigation.
4.1.7. Prediction of potential extracellular proteins of C. botulinum
The number of C. botulinum proteins predicted to be extracellular by the software 
described in varied from 460 to 115. This reflects the design of the different tools 
to favour either sensitivity or specificity in their predictions. For example, the 
makers of PSORTb explicitly state that they optimised their algorithm for specificity 
over sensitivity, which is reflected in the fact that PSORTb predicts the second 
lowest number of proteins to be extracellular. The CELLO, SecretomeP and 
SignalP algorithms gave similar results; of the 235 predictions agreed upon by a 
consensus of three tools, 190 were made by these three tools. Conversely, 
LocateP was the tool that made the highest percentage of unique predictions (i.e. 
no other tool predicted that protein as extracellular). Comparison of these 
predictions with the in vitro determined proteins showed that all the tools lacked
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both sensitivity and specificity. However, a full comparison of the predictions with 
the in vitro determined extracellular proteins will take place in section 4.2.5.
4.2. Proteomic investigation of C. botulinum to establish protein 
profiles associated with toxin producing strains
The whole supernatant proteome of C. botulium strains producing type A (ATCC 
19397) and type B (NCTC 7273) toxin were investigated using bottom up 
proteomics coupled with LC-MS/MS. Before this work could be carried out, 
optimisation of protein precipitation methods had to be carried out. This involved 
selecting the precipitant, and subsequently, the concentration of that precipitant 
that gave the best representation of the supernatant proteome. Additionally the 
growth curve of C. botulinum was established to allow sampling from suitable time 
points. The supernatant proteome LC-MS/MS data was analysed for similarities 
between the two strains and for the presence of potential novel virulence factors. 
The relationship between protein cost and virulence was examined for 
extracellular proteins. Additionally, experimentally identified supernatant proteins 
were compared with in silico predictions of extracellular proteins. The generated 
data were used to identify specific gel sections that contained the toxin and 
associated non-toxic proteins (ANTPs). Corresponding gel sections were analysed 
from 22 additional clinical strains of C. botulinum to investigate the production of 
BoNT and the ANTPs in a range of strains.
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4.2.1. C. botulinum and C. sporogenes growth curves
While the OD600 of the cultures decreased dramatically after around 12 h, the cell 
count of the ATCC 19397 culture only decreased marginally. The fact that the cell 
counting method used here does not discriminate between live and dead cells is 
likely to have contributed to this discrepancy. Similar findings were reported in the 
literature suggesting that cell density and optical density are only proportional in 
the positive growth stages (Monod, 1949). The number of viable cells (e.g. 
estimation of number of colony forming units) would be expected to correlate more 
closely with the optical density, although viable counts were not performed.
The decrease in OD and total cell concentration between 12h and 24 h indicates 
that cell lysis and sporulation may have taken place. Botulinum toxin production 
has long been linked to autolysis (Bonventre & Kempe, 1960; Rao et al., 2007), so 
it is expected that peak supernatant toxin concentration would only be reached 
after the culture had entered stationary phase (Bradshaw et al., 2004). However, 
the purported role of autolysis in the release of toxin into the supernatant means 
that the peak toxin and post-peak supernatant toxin concentrations will contain 
significant amounts of intracellular proteins. An attempt to quantiy the impact of 
these proteins on the constitiution of the supernatant proteomeis described in 
section 4.2.5.
4.2.2. Protein precipitation from C. botulinum and C. sporogenes 
culture supernatant
There were two problems with acetone precipitation; the resulting precipitant was 
incompatible with BCA assay quantification and there was a low yield when the
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quantity was assessed densitometrically. The cause of these two problems with 
acetone precipitation is unclear. The acetone precipitation protocol resulted in a 
dark brown precipitant, compared with the off-white pellet of the TCA protocol. 
There was also a translucent, gel-like substance that was difficult to re-suspend. 
Other workers using acetone to precipitate proteins from bacterial culture 
supernatant have observed a similar phenomenon (http://life-sciences- 
forums.com/index.php?topic=12011.0). It is surprising that acetone precipitation 
results in this interference while TCA doesn’t, as both acetone and TCA precipitate 
proteins via the same mechanism i.e. hydrophobic aggregation (Sivaraman et al., 
1997). During acetone precipitation, polypropylene tubes have to be used, this 
was the case during these experiments, but the possibility of a contaminant being 
leached from the tubes would need to be controlled for in a more thorough 
examination of this problem. The impact of further clean up steps on acetone 
precipitation could also be further investigated, however, the excellent yield and 
breadth of proteins obtained by TCA precipitation made this unnecessary in this 
case.
A 5% (v/v) volume of TCA was used to precipitate proteins from the culture 
supernatant as it precipitated significantly more (t-test p-value < 0.05) protein from 
16 h culture than 10% or 20% TCA and significantly more protein from 96 h culture 
than 20% TCA.
There were two problems in the comparison of the concentration of protein in the 
total supernatant with the amount of protein precipitated from the supernatant. 
Firstly, the BCA assay was instantly saturated by the whole supernatant, even with 
serial dilution, meaning that this assay could not be used for the quantification of
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the whole supernatant. Secondly, the Bradford assay overestimated the amount of 
protein in the whole supernatant by a factor of 3-fold.
The BGA assay quantifies polypeptides of more than 3 amino acids in length 
(http://www. piercenet.com/browse.cfm?fldl D=876562B0-5056-8A76-4E0C- 
B764EAB3A339). When the BCA assay is used to quantify total supernatant 
protein, the high level of proteinaceous content in the TPGY (55 mg/ml) 
significantly exceeded the amount of bacterial protein and saturated the assay. 
This saturation does not occur in the TCA precipitated samples as only proteins 
that have a molecular weight greater than 10 kDa are precipitated by TCA 
(personal communication, Thermo Scientific technical support). The majority of 
proteinaceous material in TPGY is below this molecular weight and is therefore not 
precipitated and subsequently quantified when a sample has been TCA 
precipitated. This explains why, when TCA is used to precipitate the protein from 
sterile TPGY, only around 0.5 mg/ml. of protein is obtained despite having 55 
mg/ml of proteinaceous content. This could be empirically confirmed if the proteins 
and polypeptides in TPGY were examined on a 10% Bis-Tris gel with MES running 
buffer, conditions that provide good iresolution at low molecular weights.
When total supernatant protein is quantified using the Bradford assay a 
concentration is obtained, i.e. the assay is not saturated as with the BCA assay. 
This is because the Bradford assay only quantifies proteins that are greater than 3 
kDa (http://www.piercenet.com/browse.cfm7fld I D=876562B0-5056-8A76-4E0C-
B764EAB3A339). The amount of protein in TPGY that is greater than 3 kDa 
results in an overestimation compared with the TCA-precipitated protein sample 
but not in a saturation of the assay.
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These results highlight the high protein content of TPGY, and shows that C. 
sporogenes culture is only metabolising a fraction of the total protein in the , 
medium.
Based on these conclusions it might be expected that when the BCA assay is 
used to quantify a total supernatant sample that has been processed with a 
Molecular Weight Cut-Off filter to reduce the concentration of proteins <3 kDa, a 
similar result to the Bradford assay of the total supernatant would be obtained. 
However, this was not the case and the BCA assay was still saturated by TPGY 
polypeptides. This is likely because if there is a large amount of protein that should 
pass through the MWCO filter, the filter becomes clogged and it’s efficiency is 
reduced. Using multiple MWCO filters per sample may improve this efficiency but 
is not cost-effective.
Due to the technical issues detailed above, it is difficult to draw firm conclusions on 
what proportion of bacterial protein is being precipitated by the addition of TCA. 
Previous workers have reported that it is necessary to precipitate supernatant 
proteins prior to quantification due to the high salt content (Schwarz et al., 2007). 
However, the similarity of the protein profile of the total supernatant and the 
precipitated protein indicates that precipitated proteins are an accurate 
representation of the supernatant proteome. This is unsurprising as the majority of 
bacterial proteins have a molecular weight >10 kDa.
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4.2.3. Determination of toxin concentration in the culture supernatant 
using endopeptidase assay
As the focus of this study is the toxin and toxin complex, an endopeptidase-assay 
that quantifies botulinum neurotoxin activity was employed (Jones et al., 2008) to 
identify the time point at which supernatant toxin concentration was highest. 
Previous tests have shown that proteases formed by ATCC 19397 did not cause a 
false positive reaction in this type A endopeptidase assay (Sharma, 1999).
At 0 h, residual toxin activity was detected in the culture supernatant, this residual 
activity then increased 16 fold to peak at 24 h. The active toxin at 0 h was 
transferred to the culture in the 1 ml inoculum.
The endopeptidase assay showed that supernatant toxin concentration peaked at 
24 h and then decreased steadily until 96 h when the experiment was terminated. 
This is in direct contrast to previous reports by Bradshaw et al. (2004) that have 
shown that, while supernatant toxin concentration varies depending on strain and 
culture conditions, in all tested conditions supernatant toxin concentration and 
activity (as measured by mouse bioassay) was equivalent or higher at 96 h 
compared with 24 h (Bradshaw et al., 2004). One potential explanation for the 
decrease in toxin observed between 24 h and 96 h in this work is that the 
supernatant toxin is being degraded by extracellular proteases. Characterisation of 
the supernatant proteome would help to identify enzymes that could be 
responsible for this. However, there are no reports of C. botulinum  producing a 
protease that can degrade the toxin while it is in the toxin complex. One possibility 
is that the pl-l of these cultures increased to an unusually alkaline level, resulting in 
toxin complex disassociation and subsequent degradation of the toxin complex. A
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definitive answer to this discrepant result is not available from the current data and 
further work to confirm this phenomenon and investigate whether the culture is 
becoming alkaline are required.
4.2.4. Analysis of C. botulinum supernatant proteome
The genome sequence of C. botulinum A  ATCC 19397 was used as a reference in 
the analysis of its proteome. However, the C. botulinum  B strains that had finished 
genomes at the time of this study were not available to us. Therefore, the genome 
of another BoNT/B encoding proteolytic strain, C. botulinum  B Okra was used as 
the reference for the identification of C. botulinum  B NCTC 7273 supernatant 
proteins. This genome was used after intial work showed that it provided more 
matches than any other C. botulinum  genome then available. NCTC 7273 was 
chosen for analysis as it is the UK type strain for C. botulinum  B and is used by the 
Botulinum Reference Lab in the development of new assays.
There were 80 additional proteins identified in the supernatant of C. botulinum  A 
ATCC 19397 than in the supernatant of C. botulinum  B NCTC 7273. This is likely 
because the whole genome sequence of ATCC 19397 was available while another 
C. botulinum B genome, Okra, was used as the reference for the analysis of the 
NCTC 7273 supernatant proteome. When proteomic data is analysed, the 
peptides identified by the mass spectrometer are compared against a database of 
in silico peptides from the reference genome. If there are protein sequence 
differences between the analysed strain and the reference genome then the 
experimentally identified peptides will not match the peptides in the in silico 
database and the protein may not be identified (depending on how divergent the
reference and experimentally identified protein are). The NCTC 7273 proteome
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was also analysed using ATCC 19397 as a reference, this returned fewer protein 
matches than the Okra genome. Previous work has found that the investigation of 
the proteome of un-sequenced bacteria and fungi results in fewer identifications 
than when analysing sequenced strains (Shabbiri et al., 2013; Cobos et al., 2010). 
This emphasises the importance of the availability of appropriate reference 
sequences for bottom up proteomic analysis.
More proteins may have been identified in the NCTC 7273 supernatant if a 
comparison had been performed against a database of proteins from all the 
sequenced C. botulinum  strains. The protein sequences from every available 
genome sequence could have been clustered, e.g. using CD-HIT (Li & Godzik, 
2006) to cluster at 85% similarity, a single representative protein taken from each 
of these clusters, and the NCTC 7273 proteome could be compared against a 
wider range of C. botulinum  proteins, likely resulting in more matches. However, 
this approach requires a level of bioinformatic sophistication that was not available 
at the time of analysis. A simpler database that contains all the proteins from all 
the sequenced strains would contain multiple versions of highly similar proteins. 
This can lead to a decrease in sensitivity as the lack of unique peptides prevents 
unambiguous identification.
The supernatant proteome of C. botulinum  A1 ATCC 19397 was investigated at 24 
h and 96 h while the supernatant proteome of C. botulinum  B NCTC 7273 was 
investigated at 24 h. The supernatant proteome of C. botulinum  A1 ATCC 19397 
was quite stable between 24 h and 96 h with 65% of identified proteins being 
detected at both time points. Of the 72 proteins that were only identified at one
time point, 63 were identified at 24 h only. This is to be expected as there would
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be less protein synthesis between 24 h and 96 h than between 0 h and 24 h. 
Notably, pathogenesis proteins were the largest group in which all members were 
identified at both 24 h and 96 h. There were no functional groups that showed a
strong pattern of presence at only one time point. This indicates that the 96 h
(
proteome is largely similar to the 24 h proteome but with degradation occurring 
across the proteome reducing the number of identifiable proteins at 96 h. Protein 
fate, which includes proteases, was the third largest group at both 24 h and 96 h 
highlighting the highly proteolytic nature of C. botulinum. One of these proteases 
may be responsible for the decrease of BoNT detected by the endopeptidase 
assay.
Previous investigation of the supernatant proteome of C. botulinum  identified 10 
proteins in addition to the botulinum toxin and toxin complex (Cheng et al., 2008). 
The work presented here confirms the presence of some of the previously 
identified proteins (including Clp protease, nlpc/p60 family protein, ornithine 
carbamoyltransferase) and, in addition, builds on them, showing that C. botulinum  
has a much' more complex and diverse supernatant proteome than previously 
thought. While the sophisticated mass spectrometry method used here would 
explain why more proteins were identified from the supernatant in this study than 
in previous work (Cheng et al., 2008) it does not explain why fewer protein bands 
were present by SDS-PAGE. This could be due to the use of a more minimal 
media, Toxin Production Media, resulting in the production of fewer extracellular 
enzymes. It has been hypothesized that cell density is an important factor in BoNT 
production (Zheng et al., 2013; Schantz & Johnson 1992), it could be that 
differences in media composition effect the cell density which effects expression of 
supernatant proteins.
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In addition to the well-characterised botulinum toxin and neurotoxin associated 
proteins, which were previously reported by Cheng et al. (2008), the putative toxin 
activating' enzyme, clostripain, was detected in this study. Proteins exhibiting 
similarity to pathogenicity factors from other organisms were also identified by 
comparison with MvirDB. This database was chosen as it is a comprehensive 
collection that includes proteins from other, more specific databases (e.g. Tox-Prot 
and the Virulence Factor Database). One potential novel virulence factor was 
identified in both C. botulinum A  ATCC 19397 and B NCTC 7273. This was a 
thermolysin metallopeptidase that showed 87% amino acid identity across the 
entire length of its sequence between the ATCC 19397 and NCTC 7273 proteins. 
These proteins showed similarity to the C. perfringens lambda toxin that has been 
shown to activate the C. perfringens epsilon proto-toxin by cleaving 2 kDa from the 
N-terminus (Gibert et al., 2000; Minami et al., 1997). It is only identified in strains 
of C. perfringens that also encode the epsilon toxin, indicating that it is functionally 
related to the epsilon toxin (Matsushita & Okabe, 2001). It is possible that the C. 
botulinum  thermolysin metallopeptidase plays a similar role in activating the 
botulinum neurotoxin by cleaving the light chain and heavy chain. Another C. 
botulinum  A ATCC 19397 extracellular protein with similarity to a previously 
identified virulence protein was the ATP-dependent Clp-protease that showed 
similarity to a Clp-protease from Listeria monocytogenes. The Clp-protease is 
involved in phagosome escape and activation of listeriolysin-0 (Gaillot et al., 2000). 
In C. botulinum  it could be involved in modulating the host response in e.g. wound 
botulism. Host immune system cells recruited to respond to the wound infection 
could be disrupted by bacterial effectors, this type of mechanism is frequently used 
by bacteria and can result in disease or chronic infections (Finlay & McFadden, 
1996). The presence in the C. botulinum  supernatant proteome of an analogue to 
a vital pathogenicity factor from another organism highlights the potential
involvement of hitherto uncharacterised proteins in the virulence of C. botulinum. 
Similarly, a C. botulinum  B NCTC 7273 protein that showed similarity to a 
characterised virulence factor was a collagenase protein. These proteins may play 
an important role in wound botulism due it their ability to destroy tissue integrity in 
an infected host (Harrington, 1996).
There are also a large number of degradative enzymes including proteases and 
lipases. There were 19 proteins involved in protein fate in the core supernatant 
proteome of ATCC 19397 and NCTC 7273, of which 11 were involved in protein 
degradation. The high number of proteases identified in the supernatant reflects 
the large number of protease encoding genes identified in the genome of C. 
botulinum  A Hall strain (Sebaihia et al., 2007). The identification of these proteins 
as expressed, allows a much mpre vivid picture of their role in the ecology of the 
organism, than their presence in the genome alone. The expression of the protein 
fate proteins was highly conserved, with 79% of the protein fate proteins identified 
in the supernatant of either organism being present in the supernatant of both 
organisms. The conserved expression of the protein fate proteins indicates that 
they are important to the metabolism of the organism. Of the three functional 
groups that are more highly conserved than protein fate two are very small and the 
other is pathogenesis. This conservation makes it less likely that one of these 
proteins is responsible for the decrease in BoNT seen in the endopeptidase assay. 
If the toxin was being degraded by a protease with highly conserved expression 
the decrease would have been reported in previous work (Bradshaw et al., 2004). 
In addition, if there were a protease responsible for degradation of BoNT it would 
also have to be capable of degrading the complexed form of the toxin which would 
be present at the pH of a post-exponential C. botulinum  culture. However, it is 
deemed highly unlikely that the organism would produce such an enzyme.
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Cheng et al. (2008) compared the lethal dose of the toxin (in both complexed and 
uncomplexed form) with that of their ‘crude’ extract in an intra-gastric mouse 
model. The crude extract had at least 10 additional proteins (as identified by mass 
spectrometry). They found no significant difference in lethality between the crude 
extract and the toxin complex. The exact protocol for obtaining the ‘crude’ extract 
is unclear from their publication; however, it appears to be an acid precipitation 
from a 96 h culture, with no further purification steps. This is surprising as the 
crude toxin sample they analysed by 1D-GE is much less complex than the one 
analysed in this work, with approximately 17 protein bands identified compared 
with around 40 identified in this work. It could be that the Toxin Production Medium
used in the experiments of Cheng et al. (2008), results in less supernatant proteins
 ^ ' • 
than the TPGY media used here. Toxin Production Medium is less nutritious than
TPGY, with 2% casein hydrolysate and 1% yeast extract compared to 5%
trypticase, 0.5% bacto peptone and 2% yeast extract in TPGY. The effect of
medium composition on toxin production has been widely investigated, with amino
acids and peptides found to be most important for BoNT regulation (Schantz &
Johnson, 1992). However, the effect of medium composition on the diversity of the
broader proteome has not been investigated. In the light of these findings, it would
be interesting to explore the link between medium composition, toxin production
and the diversity of C. botulinum  supernatant proteins. One hypothesis to
investigate is that, in more amino acid limited culture conditions (such as Toxin
Production Medium), C. botulinum  produces more BoNT at expense of the various
degradative enzymes identified here.
There were a large number of proteins in the supernatant of C. botulinum  that
would typically be thought to be intracellular proteins, e.g. proteins involved in
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electron transport, protein synthesis or transcription. This is similar to other studies 
investigating bacterial supernatant proteomes (Kaakoush et al., 2010; Pocsfalvi et 
al., 2008; Walz et al., 2007). These were detected due to cell autolysis during 
growth that results in intracellular proteins being released into the extracellular 
milieu.
4.2.5. Comparison of predicted and experimental supernatant 
proteome
As mentioned above, not all the proteins identified in the culture supernatant are 
expected to be actively secreted by the organism, some will be there as a result of 
cellular autolysis. Therefore, in silico tools were used to predict which supernatant 
proteins had motifs typical of secreted proteins. An analysis of which tool provides 
the best prediction of the supernatant proteome was also carried out. The 5 tools 
used predicted between 10 and 27 of the 207 C. botulinum  A ATCC 19397 
supernatant proteins (4.8-13.0%) to be extracellular. The number of correct 
predictions was positively correlated with the total number of predicted proteins. It 
is difficult to assess how successful individual tools have been due to the following 
uncertainty; are the 87-95% of proteins in the supernatant that are not predicted to 
be extracellular just there as side effect of lysis, or are they secreted but just not 
predicted as such by tools? This dataset is not designed to answer this question, 
but other, previously published datasets can address this question more directly. 
Bumann et al., (2002) investigated the supernatant proteome of H elicobacter pylori 
using methods explicitly designed to minimise autolysis. They identified 26 
secreted proteins using mass spectrometry. When the genome of H . pylori was 
analysed using PSORTb, 241 proteins were predicted to be extracellular. When 
the predicted proteins were compared with the empirically identified extracellular
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proteins, only 3 of the experimentally identified proteins were predicted to be 
extracellular. This means that even in a best-case scenario for reducing 
intracellular contamination, PSORTb predicts only around 10% of supernatant 
proteins to be extracellular.
As a general rule, sensitivity (number of extracellular proteins correctly predicted) 
was only improved with a loss of specificity (number of predictions identified 
experimentally). The specificity was generally low, with between 4.9% and 15.7% 
of predicted proteins being identified and the mean percentage across the 5 tools 
being 7.8%. The sensitivity was also low, with a range of 4.8% to 13.1%, and an 
average of 9.7%. The most sensitive tool was CELLO, which correctly predicted 
13.1% of experimentally identified extracellular proteins. The least sensitive tool 
was PSORTb, which only correctly predicted 4.8% of the experimentally identified 
extracellular proteins.
The most specific tool was LocateP, which runs each protein sequence through a 
series of Hidden Markov Models each of which predicts whether the protein has a 
different sub-cellular location. This approach is not significantly different to the 
other sub-cellular location prediction tools, which generally employ a machine- 
learning algorithm (such as Hidden Markov Models or Support Vector Machines) 
trained on a dataset of proteins of known sub-cellular location. However, the 
predictions of LocateP were notably better than any other tool, with 15.7% of it’s 
predictions being identified in the culture supernatant while the next best accuracy 
was 6.4% (PSORTb). While LocateP had the highest specificity, it had the second 
worst sensitivity, with only 8.7% of extracellular proteins correctly predicted. 
CELLO had the highest sensitivity (13%), but any advantage this might provide is
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lessened by its having the second worst specificity, with only 5.9% of it’s 
predictions being found extracellularly.
In future work, if an in silico tool was sought to predict supernatant proteins an 
assessment of whether sensitivity or specificity was more desirable would need to 
be carried out. Even then, the low success rate of even the best of these tools 
would need to be taken into consideration when interpreting the results of such an 
analysis.
The CELLO, SecretomeP and SignalP algorithms gave similar results; of the 235 
predictions agreed upon by a consensus of three tools, 190 were made by these
three tools. Conversely, LocateP was the tool that made the highest percentage of
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unique predictions (i.e. no other tool predicted that protein as extracellular). Of the 
18 proteins that LocateP correctly predicted as being extracellular, 5 were not 
predicted as extracellular by any other tool. Two of these proteins were transport 
proteins, two were cell envelope proteins and one was hypothetical. The two 
transport proteins could be expected to be extracellular as substrate binding 
proteins are often released into the extracellular milieu in order to scavenge 
resources. Cell envelope proteins are obviously required to pass through the 
plasma membrane in order to fulfil their role on the outer surface of the bacterium, 
and so it is expected that they would have motifs typical of extracellular proteins 
that are responsible for their trans-membrane transport (Van Wely et al., 2001).
Although LocateP had the highest accuracy generally, it was the only tool not to 
successfully predict that BoNT and NTNH would be extracellular. CELLO was the 
only tool to successfully predict HA33, HA17 and HA70 as supernatant proteins.
Of the 11 proteins predicted as extracellular by all 5 tools, 6 of them were
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thermolysin metallopeptidases. These proteases are well characterised as being 
extracellular and would be in the training set of all these tools.
In order to investigate whether the poor performance of extracellular prediction
tools was specific to C. botulinum, a meta-analysis of previous work characterising
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bacterial supernatant proteomes was carried out. PSORTb was then used to 
predict the supernatant proteome of organisms with experimentally characterised 
supernatant proteomes and the prediction results compared to the experimental 
evidence. PSORTb was employed as it is a widely used tool that accepts protein 
sequences in FASTA format while other tools such as LocateP only work for pre­
computed genomes. Four studies were identified; looking at the supernatant 
proteomes of Listeria monocytogenes (Dumas et al., 2009), Cam pylobacter 
concisus (Kaakoush et al., 2011), methicillin resistant Staphylococcus aureus  
(Burlack et al., 2007) and Helicobacter pylori (Bumann et al., 2002). The L. 
monocytogenes and MRSA studies were performed using a 2DGE-MALDI 
approach while the Cam pylobacter and  Helicobacter studies were performed using 
a 1DGE-LC-MS/MS approach. When the experimental results were compared with 
the predictions, 16.3% of the L. monocytogenes, 0.5% of the C. concisus, 14.9% 
of the MRSA and 1.2% of the H. pylori predictions were experimentally identified. 
When this is compared with the 6.4% specificity of, C. botulinum  PSORTb 
predictions the C. botulinum  specificity is the median value of these five 
comparisons while the other results are bimodally distributed. While there is no 
relationship between higher specificity and technique used, the organisms with 
higher prediction accuracy are Gram-positive. PSORTb performs different 
analyses based on Gram-stain predictions, from this small sample, it appears that 
the Gram-positive algorithms perform significantly better. The approach taken to 
develop the Gram-positive and Gram-negative PSORTb algorithms was identical,
with the only difference being the datasets used to train the Support Vector 
Machines. The results presented here indicate that the training dataset for the 
Gram positive organisms was better than that for the Gram negative bacteria. This 
highlights one of the key limitations of machine learning approaches for sub- 
cellular localisation; the algorithm can only be as good as the data used to train it. 
The fact that experimentally identified extracellular proteins in the literature were 
not identified as extracellular by PSORTb indicates that these proteins were not in 
it’s training dataset (PSORTb v3 has 97.3% specificity and 92% sensitivity at 
predicting the subcellular location of proteins in it’s training dataset). Expansion of 
the training dataset used to develop these algorithms is likely to improve the 
results obtained here.
It is difficult to accurately predict the sub-cellular location of bacterial proteins due 
to the varied nature of bacterial protein export systems (Holland, 2010). While 
some systems, such as the Sec pathway, are well understood (Chatzi et al., 2013) 
our understanding of most of these systems is still in a state of flux. It is difficult to 
implement in silico methods to predict the targets of poorly understood systems. 
Therefore the majority of tools rely on a machine learning approach that can only 
be as good as the training data set used in it’s development. Until more 
experimental evidence is accrued, both through bottom up proteomic approaches 
like those evidenced here and targeted investigation of secretion mechanisms, 
secreted protein prediction is unlikely to significantly improve.
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4.2.6. Relationship between extracellular protein cost and association 
with virulence
This section addresses the hypothesis that extracellular proteins are metabolically 
cheaper than non-extracellular proteins and whether extracellular protein cost is 
an indicator of importance to ecological niche/pathogenesis.
Previous work has presented evidence that there is an evolutionary pressure on 
bacteria to reduce the metabolic cost of extracellular proteins (Smith & Chapman, 
2010). However, this work was performed using sub-cellular locations predicted by 
PSORTb, which, as the previous section showed, is not an accurate method for 
predicting extracellular proteins. Here, the average metabolic cost of 
experimentally confirmed supernatant proteins was compared against the average 
metabolic cost of non-extracellular proteins. A small but significant difference was 
identified between the extracellular and non-extracellular proteins. This difference 
is the first experimental evidence that suggests extracellular proteins are 
metabolically less expensive than intracellular proteins. The difference in cost 
between the extracellular and non-extracellular proteins is smaller than was found 
by Smith and Chapman, 1.2 HEPBs (High Energy Phosphate Bonds) per amino 
acid compared with 2.7 HEPBs. However, there were only 16 predicted 
extracellular proteins in the E. coli K-12 genome they used in their work and the 
small sample increases the chance of skewed results (Tversky & Kahneman, 
1971).
A major caveat to this analysis is that the proteins that are identified here as 
extracellular may be present in the culture supernatant as a result of autolysis 
rather than deliberate secretion.
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Despite being generally cheaper, some extracellular proteins were large and 
metabolically expensive. These include BoNT that is the second most expensive 
protein in the culture supernatant in terms of total cost and the 14th most 
expensive protein in terms of average amino acid cost. All the other BoNT 
complex proteins and clostripain are within the top 15% of either the total or 
average amino acid cost. These are the six C. botulinum  supernatant proteins that 
are annotated as having a role in pathogenesis.
This pattern of virulence proteins being among the most expensive proteins in the
supernatant was continued in other organisms for which data was available. In two
<
studies on Staphylococcus aureus, 8 of 8 and 7 of 11 extracellular pathogenicity 
proteins were in the top 25% most expensive extracellular proteins (Burlack et al., 
2007; Pocsfalvi et al., 2008). These proteins included extracellular enterotoxin L, 
entertoxin H, enterotoxin B and various hemolysins. Analysis of data from studies 
on Listeria monocytogenes and Cam pylobacter concisus found that 3 of 4 and 3 of 
6 extracellular pathogenicity proteins were in the top 25% expensive proteins 
respectively (Dumas et al., 2009; Kaakoush et al., 2010). This suggests that 
extracellular virulence proteins, including toxins, are more expensive than the 
average extracellular protein for various bacterial pathogens.
Smith and Chapman hypothesised that it was evolutionary pressure on the 
organism that resulted in extracellular proteins being metabolically cheaper. The 
fact that these expensive proteins (BoNT and the ANTPs) are vital to the 
ecological niche of the organism could support this hypothesis because there is an 
opposing evolutionary pressure on the organism to conserve these proteins. This
conservation of amino acid sequence will prevent the reduction in cost of these
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important extracellular proteins while proteins that play a less pivotal role for the 
organism become cheaper under the evolutionary pressure postulated by Smith 
and Chapman. One example of cheaper extracellular proteins in C. botulinum  is a 
copper chaperone (A7FTI3) that is in the bottom 25% of extracellular proteins in 
terms of total and average per amino acid cost.
It is also interesting that the 3 of the 4 OrfX proteins are in the top 15% of proteins 
in terms of total or average per amino acid cost. There has been limited 
phenotypic characterisation of these proteins, but their expense relative to the 
other C. botulinum  supernatant proteins indicates that they are being conserved.
Protein cost could be used as a guide for investigating the supernatant proteome 
of uncharacterised pathogens and other organisms. Proteins that are important to 
the ecological niche of the organism are likely to be more conserved as there is a 
strong pressure on the organism to maintain the function of the important protein. 
This conservation will counteract the evolutionary pressure to reduce protein cost 
resulting in more important proteins tending to be more metabolically expensive.
It would be preferable to be able to compare the cost of the supernatant proteins 
with the cost of the proteins identified in whole cell proteomic work rather than the 
non-extracellular proteins used here. However, this dataset was unavailable in this ; 
work.
287
4.2.7. Identification of toxin complex proteins in clinical strains of C.
botulinum by LC-MS/MS
The expression of BoNT and ANTPs was investigated in clinical strains of C. 
botulinum. The vast majority of proteomic work investigating C. botulinum  has 
focused on a small number of type strains. Here, we utilise the unique clinical 
strain collection of Public Health England to improve understanding of the role of 
the botulinum toxin complex in clinical strains associated with food, wound and 
infant botulism.
When the supernatant proteome of ATCC 19397 was analysed by 1D-GE/LC- 
MS/MS, no BoNT peptides were identified in the 115-200 kDa gel section, while 
peptides matching the BoNT heavy chain were identified in the 97-115 kDa gel 
section and peptides matching the light chain were identified in the 50-55 kDa gel 
section. This shows that all the BoNT in these culture supernatants was in the 
‘nicked’ form, with the light chain and heavy chain only joined by a disulphide bond 
that would be broken by the reducing conditions present in the buffer. The fact that 
all the toxin was present in the nicked form indicates highly active toxin activating 
enzymes in the culture supernatant, of which clostripain has been previously 
implicated as one (Dekleva & Dasgupta, 1990). HA70 also showed post- 
translational cleavage, as has been previously characterised (Inoue et al., 1996), 
into two subunits of 50 kDa and 20 kDa. This post-translational nicking of HA70 
has recently been implicated in the formation of the hetero-dodecameric HA sub­
subcomplex (Lee et al., 2013). This nicking suggests that the toxin complex 
present in the supernatant of ATCC 19397 is of the form suggested by Lee et al 
(2013). NTNH, HA33 and HA17 appeared un-cleaved. This result contrasts with 
previous reports that NTNH/A is nicked to give fragments of 13 kDa and 106 kDa
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indicating that the previously reported cleavage is not a universal phenomenon 
(Fujita et al., 1995)
When the supernatant proteome of NCTC 2012 was analysed, BoNT, P-47, OrfX1 
and OrfX3 were not identified. NCTC 2012 was isolated from the first reported 
outbreak of botulism in the UK (food botulism associated with duck paste in Loch 
Maree in 1922) and has been shown to produce 100-1000 fold less toxin than 
BoNT/A1 producing strains (Tepp et al., 2012). The reason for this reduction in 
toxin production is unclear, although yield has been shown to be increased 10-100 
fold by culturing in modified Mueller-Miller medium (Tepp et al., 2012). The fact 
that OrfX2 and NTNH were identified in the culture supernatant indicates that it is 
unlikely that NCTC 2012 lost the plasmid that encodes the toxin gene cluster. Two 
component systems are thought to be involved in regulation of the BoNT/A1 gene 
(Connan et al., 2012). Variation between A1 and A3 producing strains in the two 
component systems involved in toxin regulation could explain the difference in 
production. It is noteworthy that changes in the media composition, which would 
be detected by two component systems (Connan et al., 2012), result in higher 
levels of toxin expression in A3. This indirectly supports the hypothesis that two 
component systems are involved in toxin regulation. A more detailed picture of the 
transcriptional activity of NCTC 2012 under various growth conditions, along with 
characterisation of the two component systems involved in BoNT/A3 gene 
regulation would assist in understanding the lower toxin production in this strain. 
As BoNT/A3, P-47, OrfX1 and OrfX3 were not identified in the supernatant of the 
type strain NCTC 2012, gel fragments corresponding to their predicted molecular 
weights were analysed in clinical strains encoding OrfX.
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This work is the first to examine the production of the botulinum toxin and 
associated proteins in a variety of clinical isolates. The method used identified 
toxin in 20 of 22 clinical isolates. In all 20 of these isolates, the type of toxin 
identified matched the type of toxin identified by PCR. No unique peptides 
matching the toxin were identified in one type A strain from 2004 and one type B 
strain from 2009, both strains were associated with wound botulism. Interestingly, 
these were also the only two strains for which NTNH was not detected. The 
presence of the toxin genes in these strains had been confirmed prior to these 
experiments so it is unlikely the toxin gene has been lost. Also, the presence in the 
culture supernatant of other neurotoxin-associated proteins indicates that at least 
part of the toxin gene cluster is operational. As BoNT and NTNH are encoded as 
part of the same operon, one potential hypothesis is that either the RNA 
polymerase binding site on the DNA, or the ribosome-binding site on the mRNA is 
disrupted in these strains. This would disrupt the bont-ntnH  operon while leaving 
the ha operon functional. It is also possible that these strains showed a different 
dynamic of toxin production through the time-course than the reference strain, with 
toxin being present at a detectable concentration at times other than the 24 h point 
sampled here. The proteomic analysis of the toxin complex components produced 
by a BoNT/G producing organism identified BoNT, NTNH, HA17 and HA70 (Terilli 
et al., 2011). This indicates that expression of only some parts of the toxin 
complex could be a biological phenomenon. In the case of BoNT/G, the lack of 
HA33, hypothesised to be essential in transport of the toxin across the gut 
epithelium (Sugawara et al., 2010; Lee et al., 2013) could explain why this toxin 
type is not associated with food borne botulism. In contrast, the HA33 protein was 
ever-present in the clinical C. botulinum  strains investigated here. The work of Lee 
et al. (2013) also raises the question of whether strains that don’t produce all the 
HA components of the toxin complex would form a functional HA sub-complex.
However, further technical validation of this result in the C. botulinum  strains 
investigated here would be the first step to investigating these exceptions. Three 
bivalent strains that encoded toxin types A and B were also investigated but only a 
single toxin type was identified in each strain. This follows the usual pattern for 
bivalent strains where either all or the majority of toxin produced is of one type 
(Peck, 2009).
As mentioned above, prior to proteomic analysis, PCR amplification a fragment 
from two genes for each toxin complex was used to determine whether a strains 
encoded HA or OrfX proteins; 19 of the clinical isolates investigated only encoded 
the HA complex with the other 3 clinical isolates encoding both HA and OrfX 
encoding genes. \  '
Of the 19 HA only encoding clinical isolates, all three HA proteins were identified in 
13 strains, with HA70 missing from two and HA17 missing from four isolates. 
Before investigating alternative hypotheses for the absence of these proteins 
further technical validation of these results should be carried out. Despite these 
exceptions, production of the HA toxin complex was highly conserved among 
clinical strains of C. botulinum  associated with food, wound and infant botulism. 
Lee et al. (2013) found that the entire HA sub-complex is required to facilitate 
absorption of the toxin through the gut epithelium. Therefore, it is deemed likely 
that the absence of HA70 and HA17 from two and four isolates respectively is a 
technical issue rather than a biological one. This is because; according to the 
model of Lee et al. (2013) the absence of these proteins would render the toxin 
incapable of passing through the gut epithelium and two of the strains that lacked 
HA17 were associated with food-borne botulism.
291
Three bivalent HA/OrfX strains were investigated, none of which were found to 
produce proteins from both toxin complex types with two strains producing HA 
proteins and one strain producing OrfX proteins. One strain that only encoded 
OrfX genes was also investigated. Of the two isolates that produced OrfX proteins, 
both were associated with infant botulism. Of the four OrfX cluster proteins (P-47, 
OrfX1, 2 and 3), OrfX2 was identified in the culture supernatant of both strains 
while OrfX3 was only identified in one. Neither OrfX1 nor P-47 was identified in 
either culture supernatant. This contrasts with previous work that has shown that 
in a C. botulinum  A2 (i.e. OrfX) encoding strain, OrfX2, OrfX3 and P-47 were 
identified while OrfX1 was not (Lin et al., 2010). Although only a small number of 
OrfX producing strains were analysed here, these results indicate that OrfX 
proteins are produced by clinical strains of C. botulinum. However, not all the OrfX 
cluster proteins were produced to levels detectable by the methodology used here. 
It should also be mentioned that there could be cleavage of the OrfX cluster 
proteins that would result in their being a different molecular weight and thus not 
migrating to the section of the SDS-PAGE gel selected for investigation. Further 
work to resolve this would involve a full supernatant proteome characterisation of 
these OrfX encoding strains.
\
Another interesting facet of the results presented here is the insight into the toxin 
production of strains that encode two toxin types. There were three strains 
investigated that encode two complete bont genes (A5(B) strains encode an 
incomplete bont/B). NCTC 2916 is known to only produce BoNT/A (Bradshaw et 
al., 2004) and the results presented show that it produces the HA toxin complex 
proteins. This result is particularly interesting because in NCTC 2916 the bont/A1
is encoded as part of an OrfX gene cluster and the HA proteins are encoded as
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part of the same cluster as the silent bont/B gene (Rodriguez Jovita et al., 1998). 
This indicates that there is coordinated expression from two genomically separate 
toxin complex clusters, one that produces BoNT/A and NTNH while the other 
produces the HA proteins. The mechanism by which this expression is regulated 
would be very interesting to probe. There are two other strains that were shown to 
encode two toxin genes by PCR, a food-botulism strain (H063740588) and a 
wound botulism strain (H091640054) that both encoded toxin types A and B. 
However, proteomic analysis of the supernatant of these strains showed that only 
one toxin type was produced to detectable levels, BoNT/A in both strains. The fact 
that they seem to only produce one toxin type, rather than producing a biologically 
inactive secondary toxin type agrees with and extends previous findings (Singh et 
al., 2013; Rodriguez Jovita et al., 1998; Hutson et al., 1996).
In summary, toxin complex proteins are expressed in all clinical isolates of C. 
botulinum investigated here. In the majority of strains, all toxin complex proteins 
were detected. Expression of OrfX proteins appear to be not as well maintained as 
that of HA proteins, although the small number of OrfX encoding strains analysed 
here prevents firm conclusions from being drawn.
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4.3. Genomic diversity and toxin complex type of clinical
isolates causing botulism in the UK
fAFLP was employed to investigate the genomic diversity of 38 isolates of 
proteolytic C. botulinum  and neurotoxigenc C. butyricum  from clinical cases of 
botulism in the UK.
The resulting clusters, representing the genetic diversity of BoNT producing 
organisms, were compared with the toxin, complex type (i.e. HA and/or OrfX) of 
each strain and the type of botulism (i.e. food, wound or infant) that each strain 
was associated with.
The AFLP results obtained here are consistent with results from earlier work 
differentiating C. botulinum strains from different countries using AFLP, MLVA and 
MLST (Hill et al., 2007; Macdonald et al., 2008; Jacobsen et al., 2008; Hill & Smith, 
2013). Similarly to previous work, they show the genomic diversity present in C. 
botulinum  (Carter et al., 2009). Specific similarities include distinct clustering of 
bivalent, AB strains; the distant relationship between Ba4 657/NCTC 2012 strains 
and the other proteolytic C. botulinum  and the very distant relationship between 
the proteolytic C. botulinum  and the toxigenic C. butyricum.
There was concordance between genomic similarity and toxin complex profile. Of 
the 25 strains in clusters 1, 2, and 3 there were 23 that encoded HA only, while 
two were bivalent, encoding both HA and OrfX gene clusters. The two bivalent 
strains were closely related to each other and distantly related to the other cluster 
2 strains. Cluster 4 consisted of 5 strains, of which 4 encoded OrfX only while 1 
was bivalent, with both HA and OrfX encoding genes. This separation of strains
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encoding HA and OrfX strains is seen in previous work, although toxin subtype 
has to stand in as surrogate for toxin complex type (i.e. A2, A3, A4 are OrfX 
encoding; A1 and B are HA encoding) (Hill et al., 2007; Fillo et al., 2011; Luquez et 
al., 2012).
There is also correlation between the type of botulism caused and genomic 
similarity. Of the 20 clinical strains in clusters 1 and 2 there were 18 wound 
botulism strains and 2 infant botulism strains. The infant botulism strains in 
clusters 1 and 2 were distantly related to the other strains in their respective 
clusters. There was only 1 clinical strain in cluster 3, an isolate associated with a 
case of food botulism. All 5 strains in cluster 4 were infant botulism associated.
Cluster 5 consisted of 5 C. butyricum  strains, 4 of which were toxigenic. The non- 
toxigenic C. butyricum  was distantly related to the toxigenic strains that were 
indistinguishable from each other. Three of the toxigenic strains were from a single 
incident of infant botulism, while the fourth toxigenic strain was linked to a 
separate case of infant botulism.
Four hypotheses could explain these results.
4.3.1. Hypothesis 1 -  toxin complex type directly contributes to 
disease type
One hypothesis is that there is a functional relationship between toxin complex 
type and type of botulism caused. The data presented here show that HA 
encoding strains can cause wound, food or infant botulism while strains that 
encode only OrfX are, with one exception, associated with infant botulism. The
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one exceptional OrfX only encoding strain linked with food botulism was C. 
botulinum  A3 NCTC 2012 which caused 8 deaths at Loch Maree in 1922. It is also 
interesting that while this strain (and toxin type) is known to produce low amounts 
of toxin (Tepp et al., 2012), it resulted in more deaths than any other incident of 
food borne botulism in the UK. However, this is likely due to lack of knowledge of 
the disease and the unavailability of the anti-toxin (McLaughlin et al., 2006). It is 
noteworthy that this pattern extends to the expression of toxin complex by strains 
that encode two toxin complex types. There was one clinical bivalent HA/OrfX 
strain that was associated with food-borne botulism that proteomic work showed 
only produces proteins from the HA cluster. There is also one bivalent HA/OrfX 
strain that was associated with infant botulism and proteomic analysis showed this 
strain to produce only OrfX proteins.
One key question in addressing this hypothesis is whether the OrfX proteins 
actually provide an advantage during infant botulism toxico-infection, or whether 
OrfX strains are just less able to cause wound and food botulism. The fact that, of 
the 10 infant botulism associated strains investigated here 8 encoded OrfX, is 
suggestive that the OrfX cluster may provide an advantage in infant botulism. One 
hypothesis to explain this is that the infant gut epithelium has histological 
characteristics that make it susceptible to disruption by a P-47 family protein 
complex. This kind of age-dependent susceptibility of the gut to a pathogen has 
been seen in rotavirus, which affects infants less than 6 years, while adults do not 
develop symptomatic disease (Pott et al., 2012). The changing susceptibility was 
due to the increased expression of the innate immune receptor for viral dsRNA in 
older mice (Pott et al., 2012). When looking for OrfX targets, cell receptors that are 
over-expressed in infants are worthy of close investigation. There is also a link
between infant botulism and weaning, the infant gut epithelium shows accelerated
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epithelial growth during weaning, with increases in the number of vilous and crypt 
cells (Cummins & Thompson, 2002). It is possible that this accelerated epithelial 
growth is an important host factor in allowing BoNT intoxication by P-47 family 
encoding strains.
An association between OrfX strains and infant botulism can also be seen in other 
samples for which the necessary data is available (Fillo et al., 2011). It should be 
noted that while Fillo et al. did not experimentally determine the toxin complex type, 
for the purposes of this analysis it was inferred from the toxin type. This inference 
should be accompanied by the caveat that rare exceptions from the general 
pattern have been noted (e.g. BoNT/A1 associated with OrfX gene cluster). In their 
study, there were 9 clinical strains which encoded toxin types typically associated 
with OrfX gene clusters, 6 of these strains were associated with infant botulism. 
The other 3 strains were associated with food botulism. One of these strains was 
bivalent, encoding A2 (OrfX associated) and B1 (HA associated) leaving two 
clinical strains that are likely to encode only OrfX associated with food-borne 
botulism, compared with 6 probable OrfX strains associated with infant botulism. In 
comparison to the 6 infant botulism cases caused by toxin types associated with 
OrfX encoding strains there were 18 infant botulism cases caused by toxin types 
associated with HA clusters. Despite the majority of probable OrfX strains 
investigated by Fillo et al. being associated with infant botulism, it should be noted 
that B0NT/A2 (OrfX associated) has been linked with outbreaks of food botulism in 
Italy, so it could be more prevelant in the environment, and hence more likely to 
cause both food and infant botulism in Italy (Bigliardi & Sansebastianio, 2007). 
Further characterisation and epidemiological studies are required. Fillo et al. are 
unique in literature for providing toxin subtype along with tyoe disease caused. 
The lack of BoNT/A subtyping information and/or information on type of disease
hampers the wider investigation of the hypotheses presented here. For example, 
of 366 cases of infant botulism diagnosed in Argentina, 100% were BoNT/A, 
however subtype information is not given (Koepke et al., 2007). Similarly, it is 
known that at least 39 C. botulinum  strains encoding BoNT/A subtypes associated 
with OrfX have been isolated in Argentina but the type of botulism associated with 
these strains is unknown (Luquez et al., 2012). Between 2001-2010, 52% of infant 
botulism cases in the United States were due to serotype A producing strains, 
however, th e . subtype is not available
(http://www.cdc.qov/nationalsurveillance/botulism surveillance.html). Similarly, 
while it is known that 50% of food botulism cases in the USA between 1990-2000 
were associated with BoNT/A, the proportion caused by different subtypes is not 
known (Sobel et al., 2004).
While the work of Fillo et al. provides more evidence that OrfX encoding strains 
are more likely to be associated with infant botulism, it sheds no light on whether 
this is because the OrfX toxin complex provides an advantage in infant botulism or 
whether encoding the OrfX toxin complex is a disadvantage to the organism 
compared to encoding the HA toxin complex in causing food or wound botulism. 
Due to the lack of functional characterisation of the OrfX proteins we cannot 
usefully speculate on their role in infant botulism. In the case of food botulism, the 
possible disadvantage of OrfX compared with HA is that there is evidence that the 
binding of OrfX to BoNT/A-NTNH is weaker than that of HA to BoNT/NTNH (Lin et 
al., 2010), however spontaneous association between BoNT/E and OrfX proteins 
has been reported (Kukreja & Singh, 2007). As larger toxin complexes provide 
more protection from acids and proteases in the gut (Sakaguchi, 1982) and the HA 
complex plays a key role in BoNT crossing the gut epithelium (Sugawara et al.,
2010; Lee et al., 2012), if OrfX doesn’t form a complex with BoNT/NTNH then less
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BoNT may enter the circulation. This disadvantage would lessen in the milder 
conditions of the infant gut, resulting in more OrfX encoding strains causing infant 
botulism. It is not expected that toxin complex type would have any significant 
impact on wound botulism toxico-infection as the toxin complex dissociates at 
physiological pH (Simpson, 2004).
While the presence of OrfX in the toxigenic C. butyricum  investigated in this work 
was not experimentally confirmed, BoNT/E is typically associated with OrfX (Hill & 
Smith, 2013). There were two incidents of botulism associated with the toxigenic C. 
butyricum  investigated here, both were cases of infant botulism.
Although the epidemiological evidence suggests that OrfX encoding strains are 
associated with infant botulism, the lack of a functional explanation that explains 
this association weakens this hypothesis. Further work on the functional 
significance of the OrfX proteins in a model of infant botulism would address this 
hypothesis more fully. Characterisation of the toxin complex type associated with 
all types of botulism would provide epidemiological evidence that would also 
address this hypothesis.
4.3.2. Hypothesis 2 -  ability to cause different disease is caused by 
factors present in the accessory genome
An alternative hypothesis to explain the results seen here is that, there is variation 
between the accessory genomes of the different clusters that is important in 
determining the type of botulism caused. For example, the genomes of strains in 
clusters 1 and 2 could contain a virulence factor that enables them to cause 
wound botulism at a higher rate than other clusters. In other species of bacteria,
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virulence factors suggested to enable wound infections include hemolysins in 
Aeromonas hydrophila (Gold & Salit, 1993) and quorum sensing in Pseudomonas 
aeruginosa (Rumbaugh et al., 1999). Likewise, the genomes of strains in cluster 4 
could encode a virulence factor that results in them being well suited to cause 
infant botulism such as pili or other attachment factors, which are known to have 
been acquired by Gram positive pathogens via horizontal gene transfer (Telford et 
al., 2006).
In this scenario, differences in disease type are independent of toxin complex type, 
with the correlation between the two being secondary to the genomic background. 
This hypothesis of uncharacterised virulence factors resulting in ‘specialisation’ of 
different clusters of C. botulinum at causing different types of botulism could be 
investigated using a Genome Wide Association Study (Falush & Bowden, 2006). 
This approach required the whole genome sequences of a large number of wound, 
food and infant botulism strains.
4.3.3. Hypothesis 3 -  the correlation between disease type and toxin 
complex type/genomic similarity is due to common exposure
Another hypothesis that could explain the results presented here is that the toxin 
complex type has no influence on disease type. Alternatively, the correlation 
between genomic similarity/toxin complex type and disease type could reflect a 
common geographic source of C. botulinum associated with different forms of 
botulism. It is known that certain toxin types predominate in different regions; a 
study on C. botulinum in British soil identified only BoNT/B producing organisms 
(Smith & Young, 1980), in the western USA most strains are type A, while east of
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the Mississippi River is mostly type B strains (Smith, 1978) and in Argentina the 
majority of strains are type A (Luquez et al., 2005).
This hypothesis states that, if exposure were the main factor in occurrence of 
botulism (rather than organism specific factors, as hypothesised above), then 
clinical cases of C. botulinum would follow a similar distribution to those in 
environment from which they originated, both in terms of toxin type and genomic 
similarity (i.e. fAFLP clustering). For example, strains associated with wound 
botulism originate from the country of origin of the heroin. If toxin type and 
genomic similarity information was available for environmental isolates from these 
regions, the hypothesis that strains cluster 1 and 2 originate from the same 
country as the heroin the drug users were taking could be tested. The fact that 
cluster 1 and cluster 2 are different, and yet both contain wound botulism strains 
could be explained by different countries of origin for the heroin associated with 
these two clusters e.g. Afghanistan and Morocco. This theory, of spores in a 
sample, reflecting the origin of the sample, underpins forensic palynology (the use 
of pollen and spores in solving legal issues), which has been successfully 
employed for over 50 years (Mildenhall et al., 2006). It is expected that infant 
botulism strains would be derived from either the local environment or the origin of 
an implicated foodstuff such as honey or chamomile tea (Luquez et al., 2012) or 
other source of spores such as pet terrapins. In order for this hypothesis to be 
accurate, the cluster 4 infant botulism cases would have to be caused by strains 
from the same region. This region could be the region of exposure, i.e. the UK or 
the region of origin of a common risk factor i.e. honey. However, the cases in 
cluster 4 do not share a common risk factor. Food botulism associated strains 
would, depending on the time of contamination, originate from the place the 
foodstuff was grown, processed or consumed.
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A global phylogeography of C. botulinum would allow us at whether 
phylogeographic source attribution is possible e.g. an infant botulism strain from a 
major honey producing nation could be linked to honey consumption. Having the 
whole genome sequence of these strains and a comprehensive global collection of 
C. botulinum would allow these phylogeographic relationships to be explored and 
directly address this hypothesis.
4.3.4. Hypothesis 4 -  differences between toxin types are responsible 
for disease type specificity
The final hypothesis that should be addressed is that it is differences between the 
toxin subtypes, rather than the toxin complex, that is responsible for Cluster 4 
being associated with infant botulism. This hypothesis assumes that, as is the 
case for all previously characterised strains, that OrfX strains encoding BoNT/A 
encode subtypes A2, A3 or A4.
There have been few biological differences identified between the BoNT/A 
subtypes; BoNT/A2 has been shown to enter neuronal cells faster than BoNT/A1 
(Pier et al., 2011) while BoNT/A3 showed intoxication signs significantly different 
from those seen with BoNT/A1 when injected intravenously into mice (Tepp et al.,
2012). Recent work by Whitemarsh et al. (2013) showed that BoNT/A1-A5 have 
distinct characteristics. Particularly relevant for this work is the fact that when mice 
were treated intravenously with BoNT/A1-A5, the BoNT/A1 and A5 symptoms 
closely resembled each other (classic ruffled fur, flaccid paralysis, laboured 
breathing), while the B0NT/A2 and A3 symptoms resembled each other (paralysis 
of front legs, hind legs and then whole body). This suggests that, perhaps, 
BoNT/A1 and A5 have distinct somatic targets or activities compared with
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BoNT/A2 and A3. The potential impact of these differences on type of botulism is 
unclear, but is worthy of consideration in any future work.
4.3.5. Novel toxin and toxin complex combinations
There were two strains identified that had interesting combinations of toxin and 
toxin complex; H091640054 encoded BoNT/A and B but only the HA complex type 
and H094460264 which encoded both HA and OrfX toxin complex types, but only 
BoNT/A.
Three possible toxin and toxin complex arrangements to explain the results seen 
in H091640054 can be seen in Figure 72. Previous work on characterisation of 
bivalent A(B) strains has not identified arrangement (A) (Hill et al., 2009; Smith et 
al., 2007), while arrangement (B) is similar to that observed in the A5(B) strains 
(Carter et al., 2010), however it could not be an identical arrangement as the 
boni/B gene identified by Carter et al was not detected by the qPCR used here for 
toxin identification due to a gene truncation, while the same qPCR assay identified 
the bont/B gene here. Arrangement (C) has also not been previously reported in 
the literature on bivalent A(B) strains (Hill et al., 2009; Smith et al., 2007). Any of 
these arrangements are feasible explanations for the results obtained in this study. 
Additionally, the bont/A gene could be present in an OrfX complex if there is 
sequence variation between the PCR primers and the OrfX target sequences that 
lead to no OrfX product. It would be enlightening to know the toxin sub-type, 
especially of the bont/A.
The second interesting strain, H094460264 was an infant botulism associated
strain that encoded genes from two toxin complex types (HA and OrfX) but only
303
one toxin type, bont/A. Possible arrangements that explain this result can be seen 
in Figure 73. The explanation that fits with our current understanding of the 
relationship between toxin complex and toxin complex type, is that there are two 
bont/A complex clusters, one of which encodes OrfX while the other encodes HA 
(Figure 73A). However, there is no evidence presented here that requires both the 
toxin complexes to be complete and one of them could be missing the bont/A gene 
(Figure 7$B & C). Similarly to H091640054, there could also be sequence 
variation or gene truncation in e.g. bont/B that would provide an alternate 
explanation to the ones listed here.
In both strains detailed above, there is likely to be a novel arrangement of the 
genes encoding BoNT and the toxin complex. It would be enlightening to obtain 
the subtype of the bont genes encoded by these strains, however, a definitive 
answer could be obtained from the whole genome sequence of these strains.
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HA - A1/A5 — V - HA B
(B)
HA - A1/A5 ------------- ----------  B
(C)
A2-4 — ^ — HA B
Figure 72: Schematic representation of two possible toxin and toxin complex arrangements 
that explain the results seen in H091640054. Toxin genes in red/pink, complex in green.
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Figure 73: Schematic representation of two possible toxin and toxin complex arrangements 
that explain the results seen in H094460264
A1/A5 — ^ — OrfX -  A2-
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OrfX
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305
4.4. RNA-Seq transcriptome profiling to investigate C. botulinum 
toxin complex expression
RNA-sequencing (RNA-seq) is the application of second generation sequencing 
technologies to the whole transcriptome of an organism. RNA is isolated from an 
organism, genomic DNA is enzymatically removed and reverse transcription used 
to create a cDNA library. This cDNA library is then sequenced using the same 
chemistry as for genomic DNA. Once sequencing results are obtained, the 
resulting ‘reads’ are mapped to the genome of the organism from which they were 
obtained and used to investigate numerous transcriptional phenomena.
4.4.1. Analysis of gene expression data from the RNA-seq dataset
An average of only 11.2% of reads from each sample were mapped to the 
reference genome. Even considering that with RNA-seq experiments it is only 
expected to be able to map 40-50% of reads (Blow, 2009) this is low. One possible 
explanation for this is that a high proportion of reads mapped ambiguously (i.e. to 
more than one place). In the analysis carried out here, reads that mapped to more 
than one place were discarded from the analysis. These ambiguous reads include 
the 16-30% of reads that mapped to 5S, 16S and 23S rRNA. Transcription from 
other repetitive regions of the genome, such as tRNAs, would also be ambiguously 
mapped. Another possibility to explain the high proportion of unmapped reads is 
that the RNA sent for sequencing was contaminated. One way of investigating this 
would be to use e.g. MEGAN, a metagenome analysis tool, to analyse whether the 
reads that didn’t map to the C. botulinum genome were from other organisms. 
However, this tool requires a level of bioinformatic sophistication that was not 
available at the time of analysis. Additionally, although ~90% of reads had to be
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discarded, the high throughput of the SOLiD system means that an average 
coverage of the genome of >50x was still achieved with the 11% of reads that 
mapped. In an analysis by Haas et al. (2012), it was found that reduction in 
coverage from 25 million to 3.2 million reads had a, negligible impact, on the 
proportion of CDSs from which expression was detected. Coverage was more 
important for the determination of differentially expressed genes, with a 10 fold 
reduction in number of reads (from 25 million to 2.5 million) resulting in 5-40% 
fewer differentially expressed genes, depending on the magnitude of the 
differential expression (genes with higher differential expression were more robust 
to decreases in coverage) (Haas et al., 2012). This shows that the low proportion 
of reads mapping to the reference genome in the data presented here may have 
some negative impact on the number of differentially expressed genes that could 
be identified.
4.4.2. Quality of RNA-seq data
When validating results obtained from a new methodology it is important to 
compare with previous gold-standard techniques. In the case of C. botulinum 
transcriptomics, the current gold standard is the microarray. Artin et al., 2010 
analysed the transcriptome of C. botulinum A ATCC 3502 that is closely related to 
the ATCC 19397 strains used here. When the normalised expression detected in 
the Artin et al. microarray experiments was compared with the normalised RNA- 
seq expression from this work, a correlation similar to previous comparisons of 
RNA-seq and microarray work was found (Porcelli et al., 2013). The transcriptome 
of C. botulinum is highly active, with 86% of CDSs showing transcription of >10 
RPKM.
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There were more genes that showed significant differential gene expression (i.e. 
EdgeR False Discovery Rate of < 0.01) between late-log and early stationary 
phase than between mid-log and late-log. A higher number of genes being 
differentially expressed as a bacterial culture enters stationary phase has been 
observed in Helicobacter pylori (Thompson et al., 2003), Escherichia coli (Chang
et al., 2002) and Pseudomonas aeruginosa (Wagner et al., 2003). This is due to
/
widespread physiological responses of the cell to slowing growth rate (Wagner et 
al., 2003).
4.4.3. RNA-seq analysis of expression from botA gene cluster
RNA-seq analysis shows that transcription from the bont cluster occurs in two 
operons; the bont-ntnH and ha33-ha17-ha70, confirming in ATCC 19397 what had 
previously been found in strain NCTC 2916 (Henderson et al., 1996; Raffestin et 
al., 2005).
The concentration of transcripts (i.e. RPKM) from the genes in the two operons 
(bont-ntnH and ha33-ha17-ha70) showed a comparable level of similarity to that 
observed for operons from other Clostridia for which RNA-seq experiments have 
been carried out (Wang et al., 2012). It is notable however, that between mid-log 
and late log botA, ntnH, ha17 and ha33 increase an average of 4.9 fold while ha70 
increases 6 fold. One hypothesis to explain this is that there is a secondary 
transcriptional start site within the ha operon that results in more ha70 transcription. 
Secondary transcriptional start sites have been observed for a number of bacteria, 
including Salmonella Typhimurium and H. pylori (Kroger et al., 2012; Porcelli et al.,
2013). However, studies that identify secondary transcriptional start sites use an
enzyme treatment with terminator exonuclease that degrades non-primary mRNA
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(Sharma et al., 2010). This process enriches for the 5’ end of mRNA fragments, 
allowing the single nucleotide identification of transcriptional start sites. 
Alternatively, for a single transcript, a method such as 5’ RACE (rapid 
amplification of cDNA ends) could be used to obtain the full length sequence of the 
mRNA (Schramm et al., 2000). It is also clear from the RNA-seq data that 
clostripain is not co-regulated with the bont gene cluster.
A recent paper has determined the crystal structure of the BoNT complex and 
found the stoichiometry of the different components to be 1:1:3:3:6 
(BoNT:NTNH:HA70:HA17:HA33) (Lee et al., 2013). The relatively even 
transcription from across the BoNT complex cluster indicates that this 
stoichiometry is determined on a translational level, as has been identified for 
other toxins such as cholera toxin (Hirst, 1995).
When the expression of the bont complex genes is examined it is obvious that 
botR is expressed at much lower levels than botA, ntnH, ha33, ha17 and ha70 (i.e. 
the ANTP genes). BotR is an alternative sigma factor involved in the regulation of 
the botulinum locus, encoded by the botR gene. It is interesting that botR is not 
present in most botE encoding strains and is missing it’s sigma factor binding site 
in the bont/A5 gene cluster without effect (Carter et al., 2010). BotR binds to 
promoter sequences upstream of bont and ha33 when it is part of a complex with 
RNA-polymerase (Raffestin et al., 2005). When BotR is overexpressed, there is an 
increase in production of the BoNT and the ANTPs and their respective mRNAs 
(Marvaud et al., 1998). Previous work has found that botR is expressed at 
approximately 1% of the level of botA (Couesnon et al., 2006). The data in our 
study finds that botR is expressed at 0.6-4% of the level of botA and that there is
no significant change in the expression of botR through the time-course. When this
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is' compared with the significant upregulation of botA and the ANTP encoding 
genes, the precise role of botR in the regulation of the bont cluster is unclear. The 
fact that C. botulinum E strains produce toxin and cause disease with no botR 
makes it clear that there are multiple factors involved in the regulation of bont. It 
also seems possible that these other factors play a significant role in the regulation 
of botA in the strain investigated here, due to the lack of any significant change in 
expression of the botR even while botA expression increased significantly. In other 
toxigenic bacteria, small RNAs (sRNAs) are involved in the regulation of virulence 
factors (Toledo-Arana et al., 2007). These include C. perfringens, where an sRNA 
controls the synthesis of collagenase A and alpha toxin at the transcriptional level 
(Shimizu et al., 2002).
4.4.4. Problems with using gluD as reference gene in RT-qPCR
There is disagreement in the measurement of botA expression between the RT-
qPCR relative gene expression experiment and the RNA-seq expression analysis.,
The reason for this discrepancy is apparent if the expression of gluD, the
reference gene in the RT-qPCR experiment, is examined. Expression of gluD
increased 5.8 fold between late log and early stationary phase. This increase in
expression of the reference gene decreased the relative gene expression of botA,
indicating that the expression of botA has decreased (under the assumption that
gluD expression is stable). This resulted in the sampling of RNA too early i.e. still
during high toxin expression rather than post-peak toxin expression.
Transcriptome analysis at the time point of post-peak toxin expression was
expected to yield interesting information on the expression of the agr loci, putative
quorum sensing proteins with a potential role in control of sporulation and toxin
production (Cooksley et al., 2010) or the expression of sigma factor K which is
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purported to be involved in early stage sporulation (Kirk et al., 2012). Unfortunately, 
due to the upregulation of the reference gene in the relative gene expression 
experiment, this was not possible.
In order to prevent future relative gene expression experiments from being 
compromised by poor choice of reference gene, the RNA-seq data was mined for 
genes that showed stable expression between mid-log, late-log and early 
stationary growth phases. The genes with the lowest co-efficient of variation 
(standard deviation divided by mean) across biological replicates are suggested as 
candidate reference genes for future relative gene expression analyses in C. 
botulinum. These genes include a cell envelope lipoprotein (clb_0260), a 
sporulation protein (spoVG), hypothetical proteins and an RNA polymerase sigma 
factor (rpoD). It is expected that transcription of spoVG would increase later in the 
time course as the culture starts to form spores, while it is difficult to predict what 
changes might occur in the transcription of a hypothetical protein. Therefore if 
future relative gene experiments were being planned, mRNA from clb_0260' 
(lipoprotein) or rpoD would be considered as reference genes. Additionally, in this 
work the TaqMan quantitative PCR system was used which provides excellent 
specificity, reproducibility and quantification. However, the custom fluorescent 
oligonucleotide probes necessary for TaqMan assays are expensive, prohibiting 
the testing of multiple reference genes for stability of expression. In future work, 
SYBR Green dsDNA-binding dye would be considered, as it is non-specific, 
allowing the testing of multiple candidate reference genes. The most commonly 
used reference in relative gene experiments is the rrn 16S rRNA locus. This was 
not used here as changes in the rate of synthesis of rRNA as growth slows have 
been observed (Hansen et al., 2001) and proposed to interfere with the calculation
of the relative gene expression of bont (Lovenklev et al., 2004). Housekeeping 
genes selected for MLST schemes are often proposed as reference genes for 
relative gene expression experiments, none of the C. botulinum MLST scheme 
genes were among the 10 genes with the lowest coefficient of variation.
4.4.5. Identification of up-regulated potential pathogenicity genes
The RNA-seq data was mined to identify potential virulence factors with a similar 
expression profile to G. botulinum. There were 6 thermolysin metallopeptidase 
genes (npr-1 to 6) that showed significant upregulation between late log and early
stationary phase. The protein product of npr-6 was identified in the whole
' *
supernatant proteome analysis at both 24 h and 96 h and was found to be similar 
to the C. perfringens lambda toxin that activates C.‘ perfringens epsilon toxin. 
Expression of these genes may be under-estimated because the RNA-seq reads 
were only allowed to map unambiguously and these sequences are around 79% 
similar to each other. Two other genes that were significantly upregulated in early 
stationary phase with similarity to previously characterised virulence factors were 
clb_1609 and clb_0527 that encode a hemolysin and a bacteriocin respectively. In 
Bacillus cereus, an enteric pathogen, hemolysin is an exotoxin that effects 
endothelial integrity (Beecher et al., 1995). Pore forming toxins, such as 
hemolysins, are also implicated in the disruption of epithelial gap junctions and the 
necrosis of intestinal epithelium (Los et al., 2013). Hemolysins are typically 
upregulated in the absence of iron as the organism attempts to scavenge iron from 
the heme of lysed hemocytes (Griffiths & McClain, 1988). This indicates that as 
the C. botulinum culture is entering stationary phase, nutrients such as iron are 
becoming limited. It is possible that C. botulinum hemolysin plays a role in
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disrupting host gut epithelium in food botulism or ensuring an adequate supply of 
iron for the organism in a wound botulism infection.
4.4.6. Analysis of small RNAs
Second-generation sequencing technologies have led to an explosion in the 
identification and understanding of regulatory roles for small, non-coding RNAs 
(sRNAs). In bacteria, sRNAs have been found to control stress response and to 
regulate expression of virulence factors (Toledo-Arana et al., 2007; Sharma & 
Heidrich, 2012). Here, we find the transcriptome of C. botulinum to be highly active 
in terms of both characterised sRNAs and uncharacterised sRNAs.
As the focus of this project is the production of the toxin, the transcriptome of C. 
botulinum was examined for potential small RNAs that influence botA expression. 
One common way for sRNAs to influence the expression of a gene is on a post- 
transcriptional level. The homology-mediated binding of an sRNA to the 5’ 
Untranslated Region (5’ UTR) of an mRNA can occlude the ribosome binding site 
of the mRNA, dramatically slowing it’s rate of translation (Papenfort & Vogel, 2010). 
One piece of evidence that sRNAs could be involved in regulation of bont is the 
intriguing finding that in one bivalent strain that produces BoNT/B and BoNT/F, the 
relative amounts of toxin produced were temperature dependent (Barash & Arnon, 
2004). RNA mechanisms are known to be responsible for temperature dependent 
regulation of pathogenicity factors, with the canonical example being prfA in 
Listeria monocytogenes (Johansson et al., 2002). Additionally growth temperature 
also effects the patterns of relative expression from the toxin gene cluster in C. 
botulinum producing BoNT/E, with growth at 30°C resulting in more botE
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transcription compared with growth at 10°C (Chen et al., 2008). All sRNAs 
identified were examined for homology with the 5’ end of the botA mRNA and the 
ha33 mRNA. No candidates were identified but an active transcriptional landscape 
of non-coding sRNAs was uncovered.
The database Rfam (Burge et al., 2012) is a collection of non-coding RNA families, 
many of which have putative functions assigned. When the sRNAs in C. botulinum 
were compared against Rfam using Infernal (Nawrocki et al., 2009) there were 17 
transcriptionally active T-boxes. These are found in the 5’ UTR of of mRNAs 
encoding amino-acid tRNA ligases, they upregulate tRNA ligase expression in the 
presence of a cogent uncharged tRNA, resulting in more enzymes to link amino 
acids with the appropriate tRNA (Gutierrez-Preciado et al., 2009). Additionally, 
there were 19 transcriptionally active riboswitches which are 5’ UTR elements that 
sense the presence of small metabolites such as magnesium and purines and 
altering the regulation of transporters of those metabolites (Bastet et al., 2011). 
While these sRNAs have been previously characterised, this is first time that they 
have been experimentally identified in C. botulinum and they provide an insight 
into the amount of sRNA mediated regulation that is taking place in this organism.
Perhaps the most interesting sRNAs are the uncharacterised ones. There was an
sRNA, approximately 500 bp long, that showed strong growth phase regulation.
The RPKM .at mid-log was 551, at late log it was 851 and at late stationary it was
36397. This dramatic increase in expression was not mirrored in either of the
flanking genes, which are both on the positive strand while the sRNA is on the
negative strand. The genomic region encoding the sRNA is highly conserved
(100%) in other sequenced proteolytic C. botulinum but shows no significant
homology in any other species. The sRNA is part of an approximately 23 kbp long,
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highly conserved region of the genome. The function of this sRNA is a mystery, 
however, it’s level of expression is more analogous with structural sRNAs such as 
4.5S RNA which is involved in trafficking proteins with signal peptides (Waters & 
Storz, 2009) rather than the expression levels of regulatory sRNAs. There were 
also high levels of expression of a large sRNA, the Ornate Large Extremophilic 
RNA that has been previously identified in extremophilic bacteria (Puerta- 
Fernandez et al., 2006). It has been posited that this sRNA has a role in protecting 
Bacillus halodurans from alcohol toxicity (Wallace et al., 2012). It’s role in C. 
botulinum, where it is expressed at high levels at all time points but with an in 
intensity that increases through the growth curve is unclear, although perhaps it is 
a response of the cell to the production of volatile secondary metabolites and by 
products of fermentation. Finally, there were at least 9 occurrences through the 
genome of short areas of sense-antisense transcription. Some of these share 
some characteristics of toxin-antitoxin systems -  i.e. one strand encodes short 
open reading frame, with Shine-Delgarno sites, typical of type I toxin-antitoxin 
systems. However, the primary and secondary structure of the peptides is not 
typical of type I toxin-antitoxin system which typically have high hydrophobicity and 
alpha-helices (Fozo et al., 2008). Characterisation of these active transcriptional 
regions requires further work.
4.5. Final discussion and future work
The botulinum toxin complex in its entirity is important for the toxicity of the 
botulinum neurotoxin. All bont genes characterised to date are co-localised with 
one of two toxin complex types. The fact that this co-localisation is ever-present, 
despite evidence of there being extensive recombination in this locus (Hill et al.,
2009) suggests that strains where the bont is separate from the complex are not
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successful. There are two toxin complex arrangements that are associated with 
disease, the HA and the OrfX, with the majority of disease associated with HA 
encoding strains (Hill & Smith, 2013).
This work provides further evidence for the importance of the toxin complex 
proteins through a combination of in silico, proteomic and genomic experiments 
that were directed to achieve the aims laid out in section 1.6. These aims were to 
use in silico techniques to analyse the toxin complex protein sequences, a 
proteomic investigation of the C. botulinum whole supernatant proteome, to 
chracterise the toxin complex components produced by clinical strains associated 
with botulism, to explore the association between toxin complex type, genomic 
similarity and disease type and to analyse the C. botulinum transcriptome for 
insight into the regulation of bont.
Prior to this work, the only evidence that P-47 family proteins played a role in
toxicity was their proximity to the BoNT encoding gene: there is no evidence that
they form a complex with BoNT/A-NTNH (Lin et al., 2010) although a spontaneous
association between BoNT/E and the P-47 family proteins has been reported
(Kukreja & Singh, 2007). The findings presented in this work on clusters of P-47
family sequences encoded alongside putative toxin sequences provides further
evidence that these proteins are likely to contribute to toxicity in various species by
having a functional role. Additionally, there are other similarities between some of
the putative toxins in P-47 family clusters and BoNT. An example of this is the
nematicidal proteins. In addition to being encoded alongside P-47 clusters, these
toxins share two other characteristics with BoNT; they are often active via the oral
route and they are also expressed as part of large, non-P-47 family protein
complexes known as Xpt toxin complexes (Sheets et al., 2011). Thus, nematicidal
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proteins like BoNT are associated with two types of toxin complex; P-47 family 
clusters and distinct non-P-47 family complexes (Xpt and HA complex 
respectively). It is intriguing that these two oral toxins, BoNT and the nematicidal 
proteins, are both found as part of P-47 gene clusters and alternative toxin 
complexes. Our understanding of complex aggregations of toxin associated 
proteins and their contribution to in vivo pathogenicity is constantly developing. 
This is very well illustrated by two things; the recent discovery that typhoid toxin 
has a novel A2B5 stoichiometry (Song et al., 2013) and the modularity of the 
BoNT-NTNH and HA toxin sub-complexes (Lee et al., 2013). Firstly, the novel 
stoichiometry of the typhoid toxin consists of a typical AB5 toxin where the activity 
subunit is closely bound to the binding pentamer with an additional activity subunit 
joined by a single disulphide bond to the other activity subunit (Song et al., 2013). 
It has been proposed that this structure constitutes a ‘missing link’ in toxin 
evolution, and that in millions of years a better-integrated multicomponent toxin will 
have replaced the A2B5 toxin (Stebbins, 2013). The finding of Lee et al. (2013), 
that the BoNT-NTNH and HA proteins form structurally and functionally separate 
sub-complexes also has implications for our model of the role of the ANTPs. In this 
light it is tempting to hypothesise that the P-47 family cluster is an evolutionary 
pre-cursor to the HA sub-complex in the case of BoNT and the Xpt complex for 
nematicidal proteins.
The fact that, in the limited literature on the subject (Lin et al., 2010), there is no
direct interaction between BoNT/A-NTNH and the P-47 family proteins indicates
that if the P-47 family proteins play a role in BoNT intoxication, it is via a different
model to the HA proteins. However, the fact that there has been spontaneous
association reported between BoNT/E and P-47 family proteins (Kukreja & Singh,
2007) highlights the lack of understanding of the interaction between these
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proteins. There may be an interesting parallel with the bi-modular structure 
identified by Lee et al. (2013). One potential model is that in the P-47 family 
encoding strains, the BoNT-NTNH forms the tightly bound complex that has been 
previously identified (Gu et al., 2012) while the P-47 family proteins form a 
separate complex that fulfils a similar role to the HA sub-complex i.e. the 
disruption of the gut epithelium (Sugawara et al., 2010; Lee et al., 2013). The 
interface between the HA sub-complex and the BoNT-NTNH sub-complex is small, 
and their structures and functions are quite separate. Perhaps in the P-47 family 
encoding strains there is no link between the BoNT-NTNH sub-complex and the P- 
47 family complex, but the P-47 family protein complex is still responsible for 
disruption of the gut epithelium. This hypothetical arrangement of separate sub­
complexes could be less efficient at translocating BoNT across the gut epithelium 
than the HA sub-complex. This could be because, either the P-47 family complex 
is not as efficacious at epithelium disruption as the HA complex or the gut 
epithelium disrupted by the P-47 family complex and the BoNT-NTNH are not co­
localised. In this scenario, the linked BoNT-NTNH-HA sub-complex arrangement
i
would have an evolutionary advantage, being more efficient at intoxication, 
resulting in the BoNT-NTNH-HA complex arising and causing more disease.
Previous work looking at the expression of the toxin complex proteins has always
focused on a small number of type strains (Bradshaw et al., 2004; Cheng et al.,
2008; Tepp et al., 2012; Jacobson et al., 2011; Lin et al., 2010). This is the first
study to look at the expression of the toxin in a larger number of clinical strains.
This kind of broad investigation is required to get a fuller picture of the importance
of the toxin complex to the virulence of the organism. The expression of at least
one toxin complex protein in every strain and the production of all toxin complex
proteins by the majority of strains indicates the importance of the toxin complex in
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the pathogenicity of the organism. There were only three P-47 family protein- 
producing strains analysed here. None of them produced all the components of 
the toxin complex and OrfX1 and P-47 were not identified in any of the strains. It 
should be noted that two of the OrfX producing strains only had targeted bands of 
the SDS-PAGE gel analysed by LC-MS/MS and that an analysis of the full 
supernatant proteome would be informative. Previous work has also identified only 
some of the P-47 family proteins in C. botulinum A2 (Lin et al., 2010). Without the 
functional characterisation of P-47 family proteins it is not possible to speculate on 
implications of partial expression. For example, if there were a large amount of 
functional, overlap between the different proteins, expression from one loci could 
confer the same phenotypic effect as expression of all loci. Probing the details and 
the regulation of expression of BoNT/A and the HA proteins from NCTC 2916, 
when the .HA proteins are in one toxin gene cluster and BoNT is expressed from 
another gene cluster would provide insight into the control of expression o f the 
toxin and toxin complex genes. RT-qPCR experiments could be used to assess 
whether this regulation occurs on a transcriptional or translational level i.e. are 
bont/B and the orfX genes transcribed into mRNA or not? Is expression of the 
bont/A and ha genes coordinated to the same degree as strains where these 
genes are encoded in the same toxin gene cluster? This would be a significant 
improvement on previous work on this subject that has been done using northern 
blots (Bradshaw et al., 2004).
The expression of the toxin complex proteins, which are among the most 
metabolically expensive proteins in the C. botulinum supernatant, indicates that 
they are important to the ecological niche of the organism. There appears to be a 
relationship between extracellular protein cost and virulence in other organisms,
including S. aureus and L. monocytogenes (Burfack et al., 2007; Pocsfalvi et al.,
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2008; Dumas et al., 2009). This novel way of identifying potential virulence factors 
builds on previous work by Smith & Chapman, (2010) and the solid evolutionary 
framework they describe. The poor correlation between predicted supernatant 
proteins and empirically identified supernatant proteins suggests that these tools 
are of limited utility.
The large number of supernatant proteins identified in this work indicates that the 
C. botulinum supernatant proteome is more complex than previously thought 
(Cheng et al., 2008). The impact of this complexity on virulence is uncertain, 
although the identification of potential virulence factors in the supernatant 
proteome suggests that this warrants further investigation. Ideally, the intra-gastric 
lethality tests of Cheng et al., (2008) would be repeated with the culture 
supernatant from this work in order to determine whether any of the potential novel 
virulence factors identified here have an impact on pathogenesis compared with 
the purified toxin. The post-translational nicking of HA70 identified in this study has 
been proposed to allow the formation of the HA70 trimer that mediates the binding 
of the HA sub-complex, with the BoNT-NTNH sub-complex (Lee et al., 2013). This 
indicates that the BoNT complex identified in this study is in the form suggested by 
Lee et al. (2013). Also, the results presented here suggest that the cost of 
extracellular proteins associated with virulence is higher than is typical for 
extracellular proteins. This finding was replicated in a range of other bacterial 
pathogens for which the extracellular proteome had been characterized (Burlack et 
al., 2007; Pocsfalvi et al., 2008; Dumas et al., 2009; Kaakoush et al., 2010).
There were four hypotheses generated to explain the results from the comparison
of fAFLP, toxin complex type and type of disease caused. Reflecting on the results
320
presented in the fAFLP section, the hypothesis that P-47 family proteins provide a 
functional advantage in the causation of infant botulism requires significant further 
work. Understanding of the nature of this putative advantage could also be 
increased by investigating the histological differences between the infant and adult 
gut epithelium, perhaps with a particular focus on the epithelium of the weaning 
infant. Previously, mouse models have been useful in the identification of age- 
dependent host factors that influence susceptibility to infectious disease (Pott et al.,
2012). If the association between toxin type and disease type is valid then this is 
very strong evidence of the importance of the toxin complex. The hypothesis that 
suggests that uncharacterised virulence factors in fAFLP cluster 4 are responsible 
for the association with infant botulism is the weakest presented here. Hoping to 
find ‘virulence factors’ that explain differences between strains is rather 
speculative although it would still be useful to address this hypothesis. One piece 
of evidence in favour of this hypothesis is the close genomic relationship of 
BoNT/A2 and A3 strains as assessed by MLST and PFGE (Luquez et al., 2012), 
indicating that they share a common evolutionary history and could have a 
common set of pathogenicity factors. The fourth hypothesis; that functional 
differences in activity between different subtypes of BoNT/A could lead to 
differences in type of disease caused, arises largely due to the intriguing resits of 
Whitemarsh et al., (2013). When they compared the in vivo symptoms of 
BoNT/A1-A5, they found that BoNT/A1 and A5 had shared characteristics while 
B0NT/A2 and A3 had distinct shared characteristics. This is relevant as the former 
are associated with HA toxin complex and the later with P-47 family cluster and so 
cluster 4 could contain BoNT/A2 and A3 strains. Therefore, cluster 4 could be 
associated with infant botulism due to a shared functional characteristic such as 
the one identified by Whitemarsh et al. (2013). However, the relevance of their 
findings to food, infant and wound botulism is uncertain as they intoxicated their
mice with large doses of toxin delivered intravenously. It would help to address this 
hypothesis if the toxin subtype were determined for the BoNT/A strains as if the 
cluster 4 strains encoded BoNT/A4 then support for this hypothesis would diminish.
The current understanding of infant botulism fits with the hypothesis that exposure 
to spores is a key determinant in the development of C. botulinum. This 
understanding is that infant botulism is a disease caused by a combination of a 
susceptible host (due to a disrupted gastrointestinal flora) and environmental 
exposure, with not much consideration given to the role of pathogen factors 
(Koepke et al., 2007; Fenicia & Anniballi, 2009). However, given the small amount 
of global context for the isolates investigated here, it is premature to dismiss the 
alternative hypotheses. Of course, the relationship between OrfX and infant 
botulism identified here could be insignificant, further epidemiological studies are 
required to confirm or refute this relationship, although studies not designed with 
this aim in mind provide additional support (Fillo et al., 2011). As infant botulism is 
thought to be associated with a disrupted gut microbiota, an interesting experiment 
would be to compare the gut flora of infants diagnosed with infant botulism 
compared with those that have not developed botulism. This could be done using 
faecal samples sent to the Botulinum Reference Laboratory, as long as the 
samples were taken prior to antibiotic treatment. Either shotgun metagenomics or 
bacterial community profiling (i.e. using 16S rDNA) could be used to profile the 
level of diversity in the gut flora of infants with and without botulism to determine if 
there is an association between complexity of gut flora and susceptibility to infant 
botulism. Additionally, an in vitro model of the infant gut could be used and 
seeded with different levels of bacterial diversity (Nicholson et al., 2012). The 
ability of C. botulinum spores to colonise this environment could then be assessed.
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It is difficult to compare the strains investigated here to previously investigated 
strains due to differences in the enzymes used for fragmentation of the DNA in the 
fAFLP analysis. The use of a sequence based method, such as whole genome 
sequencing, would create a portable resource that could also inform future studies 
of diversity. The evidence presented here, that of the 5 OrfX encoding strains, all 5 
were associated with infant botulism warrants further investigation. It would be 
very informative to know the number of cases of infant botulism caused by OrfX 
encoding strains, compared with the number of cases of all forms of botulism 
caused by OrfX encoding strains. However, the information currently in the 
literature only allows a piecemeal analysis. If the relationship between OrfX and 
infant botulism is borne out, it is likely to be the result of a combination of factors. 
The evidence presented here suggests that one factor worthy of investigation is 
the role of the P-47 family proteins.
Another question that should be addressed is whether the Botulinum Reference 
Laboratory should routinely determine toxin complex type. While it would not effect 
clinical management of the cases in the way that knowledge of the toxin type does 
(appropriate anti-toxin can be given). It would help confirm or deny epidemiological 
questions about the association between infant botulism and OrfX encoding 
strains. This epidemiological support would help justify functional studies that 
could lead to an increased understanding of the route of infection.
There vyere two strains with interesting, potentially novel combinations of toxin and 
toxin complex genes. Obtaining the whole genome sequence of these isolates 
would provide a definitive answer as to the toxin gene arrangement in these 
strains. Increasing our understanding of the diversity of toxin gene arrangements,
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especially in bivalent strains, may provide insight into the co-evolution of the toxin 
and toxin complex.
Due to flaws in the experimental design (i.e. inappropriate choice of reference 
gene) the RNA-seq work presented here has not been particularly useful to 
directly address the importance of the toxin complex to the development of 
botulism. However, the RNA-seq work has found that the expression of botR 
undergoes no significant detectable change between mid-log and early stationary 
phase, despite the significant increase in bont expression. Furthermore, the RNA- 
seq data has raised questions as to the role of small RNAs in the regulatory and 
functional landscape of C. botulinum that it would be very interesting to probe 
further as the number of sRNAs involved in expression of bacterial pathogenicity 
factors continues to increase (Loh et al., 2013).
This work fits well into the existing C. botulinum and BoNT literature. It builds on 
the increasing amount of literature that supports the view that the botulinum toxin 
complex is important for disease (Lee et al., 2013; Sugawara et al., 2010) but from 
an ‘omic’ point of view, compared with previous functional studies. These two 
approaches to science are complementary, and a significant portion of the future 
work to test the hypotheses presented here is more functional in nature i.e. the 
impact of knock-outs on BoNT production and toxicity. There has not been a lot of 
omic work performed on C. botulinum and where there has, this study has aimed 
to build on that work and use the latest technologies to provide new insight. For 
example, Artin et al. (2010) performed enlightening transcriptomic work on 
proteolytic C. botulinum using microarrays and the work performed here with RNA- 
seq provides a different perscpective to that work, allowing characterisation of 
novel features .such as sRNAs.
324
A full characterisation of the transcriptional activity and expression of proteins from 
the P-47 family cluster in C. botulinum would be a suitable first step. Investigating 
the interaction between the P-47 family proteins and gut epithelial cells would be 
an interesting additional experiment to probe their possible function. Establishing 
the crystal structure of these proteins would enable more specific hypotheses to 
be generated as to their function. As part of these experiments it would also be 
useful to establish the crystal structure of the NTNH associated with the P-47 
family cluster. This is because the OrfX associated NTNH lacks a motif that 
mediates the interaction between NTNH and the HA sub-complex (Lee et al.,
2013). The crystal structure of the OrfX NTNH would allow the investigation of the 
hypothesis that there is an alternative motif that mediates interaction with P-47 
family proteins. Additionally, knocking-out the P-47 family encoding genes using 
e.g. ClosTron (Heap et al., 2007) and examining the effect on toxicity in an animal 
model would help address the question of P-47 family protein function.
Obtaining the whole genome sequence of a representative selection of C. 
botulinum isolates associated with different diseases and different geographical 
regions would help to address the hypotheses proposed by the fAFLP work. It 
would also help address questions about the evolution of the toxin, the toxin 
complex and the organism. For example, is OrfX the ancestral toxin complex? 
Finally, functional studies looking at the phenotype of strains that had the growth 
phase dependent sRNA knocked out would elucidate whether there was any 
involvement between this and toxin production or sporulation.
Originally the role of the HA proteins was thought to be relatively minor, only
providing protection against degradation in the gut. However, recent work has
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shown that the HA forms a sub-complex that is vital for the toxin to translocate the 
gut epithelium (Sugawara et al., 2010; Lee et al., 2013). Although the role of the P- 
47 family proteins is currently obscure, the results presented here provide 
encouragement that further work may result in the uncovering of interesting, novel 
and widely used mechanisms by which a toxin complex can enable toxin activity.
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5. Abbreviations
AB toxin = Activity Binding toxin
AFLP = Amplified Fragment Length Polymorphism
ANTPs “  Associated Non-Toxic Proteins
BIG-IV = Botulism Immune Globulin Intravenous
BoNT = Botulinum Neurotoxin
BoNT Hc/Lc = BoNT heavy chain/light chain
bp = base pair
CBI = C. botulinum isolating medium 
CDS = coding sequence 
DTT = dithiothretiol
ELISA = Enzyme Linked Immunosorbent Assay 
EF = Anthrax toxin edema factor
fAFLP = fluorescent Amplified Fragment Length Polymorphism
FB = food botulism
gDNA = genomic DNA
IB = infant botulisum
IDUs = injecting Drug Users
kDa = kilodalton
LF = Anthrax toxin lethal factor
MBA = Mouse Bioassay
mRNA = messenger RNA
ORF = Open Reading Frame
PA = Anthrax toxin protective antigen
\
PFGE = Pulse Field Gel Electrophoresis
PTX = Pertussis toxin
qPCR = Quantitative PCR
rDNA -ribosomal DNA
RME = Receptor mediated endocytosis
rRNA = ribosomal RNA
RT = room temperature
RT-qPCR = reverse transcripton quantitative PCR
SDW = sterile distilled water
SIDS = Sudden Infant Death Syndrome
SNARE = Soluble NSF (N-ethylmaleimide sensitive fustion protein) Attachment 
Protein Receptor 
SV = Synaptic Vesicle
SV2 = Synaptic Vesicle protein 2 aka synaptotagmin
TeNT -Tetanus Neurotoxin
TER = trans-epithelial electrical resistance
VAMP = vesicle associated membrane protein aka synaptobrevin
WB = wound botulism
Xpt = Xenorhabdus protein toxin
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1.1. Appendix  
Appendix Table 
1: HMMer 
matches for P-47 
family proteins 
from non-C. 
botulinum 
organisms. 
Ricketsiella grylli
Query Match uniprot Match protein name . H Match score
>Annotation was 
generated
automatically without 
man -717439: 
719067 MW: 
59884.02
A8PMG2 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0717)
Rickettsiella grylli 0.00E+00
D2TXI8 9EN 
TR
Toxin complex component 
ORF-X2 (gene:
ARN 08100)
Arsenophonus
nasoniae 5.10E-201
B2VCQ8 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30270)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
3.80E-169
E9N6Q5 CL 
OBO OrfX2 (gene: orfX2)
Clostridium
botulinum 3.70E-32
H3SNG8 9B 
ACL
Toxin complex component 
ORF-X2 (gene: 
PDENDC454_25591)
Paenibacillus
dendritiformis
C454
2.40E-31
F7SP90 9G 
AMM
Putative uncharacterized 
protein (gene: 
GME_11572)
Halomonas sp. 
TD01 3.20E-18
Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
2.30E-15
B1QQF2 CL 
OBO
Toxin complex component 
ORF-X3 (gene:
CBB A0177) '
Clostridium 
botulinum Bf 1.80E-08
H3SNG7 9B 
ACL
Toxin complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus
dendritiformis
C454
7.00E-08
G5C996 HE 
TGA
Obscurin (gene: 
GW7 06474)
Heterocephalus
glaber 3.40E-05
F7CQP1 MA 
CMU
Uncharacterized protein 
(gene: OBSCN) Macaca mulatta 3.80E-05
F7C4M0 CA 
LJA
Uncharacterized protein 
(gene: OBSCN) Callithrix jacchus 5.60E-05
F1LVE2_RAT Uncharacterized protein (Fragment)
Rattus
norvegicus 6.30E-05
H2N3G8_PO
NAB
Uncharacterized protein 
(gene: OBSCN) Pongoabelii 6.60E-05
>Annotation was 
generated
automatically without 
man -719085: 
720371 MW: 
47997.836
A8PMG3 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0718)
Rickettsiella grylli 7.90E-292
D2TXI9 9EN 
TR
Putative uncharacterized 
protein (gene: 
ARN_081010)
Arsenophonus
nasoniae 4.80E-154
B2VCQ7 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETAJ30260)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
4.00E-95
H3SNG6 9B 
ACL
P-47 protein (Fragment) 
(gene:
PDENDC454_25581)
Paenibacillus
dendritiformis
C454
1.50E-31
Q3SU91 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391) .
1.50E-20
Q6RI05 CLO 
BO P-47 (gene: p47)
Clostridium
botulinum , 2.30E-17
H3SNG7 9B 
ACL
Toxin complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus
dendritiformis
C454
2.00E-10
i
A7GBF7 CL 
OBL
Toxin complex component 
ORF-X3 (gene:
CLI_0845)
Clostridium 
botulinum (strain 
Langeland / 
NCTC 10281 / 
Type F)
8.50E-10
D2TXI8 9EN 
TR
Toxin complex component 
ORF-X2 (gene: 
ARN_08100)
Arsenophonus
nasoniae 1.10E-07
F7SWZ6 AL 
CXX
Putative uncharacterized 
protein (gene: 
AXXA_06258)
Achromobacter
xylosoxidans
AXX-A
1.30E-07
H3SNG8 9B 
ACL
Toxin complex component 
ORF-X2 (gene: ‘ 
PDENDC454_25591)
Paenibacillus
dendritiformis
C454
9.50E-06
>Annotation was 
generated
automatically without 
man -720419: 
720865 MW: 
17117.98
A8PMG4 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0719)
Rickettsiella grylli 6.40E-94
D2TXJ1 9EN 
TR
Putative uncharacterized 
protein (gene: 
ARN_08130)
Arsenophonus
nasoniae 1.30E-30
B2VCQ5 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30250)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
8.00E-12
E5B9Q2 ER 
WAM
Putative uncharacterized 
protein (gene: 
EAIL5_3309)
Erwinia
amylovora ATCC 
BAA-2158
3.20E-11
>Annotation was 
generated
automatically without 
man - 844573: 
845499 MW: 
34598.996
A8PMG6 9C 
OXI
Shiga toxin A-chain 
(RRNA N-glycosidase) 
(gene: RICGR_0720)
Rickettsiella grylli 1.90E-200
Q2HWU1 E 
COLX
Shiga toxin 2 variant f A- 
subunit (gene: stx2fA)
Escherichia coli 
063:HNM 4.50E-60
1 B3GK88 EC 
OLX
Shiga toxin 1 subunit A 
(gene: stxA1) Escherichia coli 3.70E-58
- Q2L9B4 AC I 
HA
Shiga toxin II subunit A 
(gene: stx2A)
Acinetobacter
haemolyticus 3.50E-56
D5WND3 B 
URSC
Ribosome-inactivating 
protein (Precursor) (gene: 
BC1002_7046)
Burkholderia sp.
(strain
CCGE1002)
6.00E-32
D6MWK5 Rl 
CCO
rRNA N-glycosidase 
(Fragment)
Ricinus
communis 9.30E-06
>Annotation was 
generated
automatically without 
man -844116: 
844526 MW: 
15174.371
A8PMG7 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0721)
Rickettsiella grylli 2.60E-89
C4SAT8 YE 
RMO
Putative uncharacterized 
protein (gene: 
ymoll0001_30930)
Yersinia mollaretii 
ATCC 43969 6.90E-08
B6SD00 9VI 
RU
Putative uncharacterized 
protein P10 (gene: P10)
Bacteriophage
APSE-4 1.50E-05
B6SD14 9VI 
RU
Putative uncharacterized 
protein X (gene: X)
Bacteriophage
APSE-7 1.80E-05
P. larvae
Query Match uniprot Match protein name . K Match scoreJ ;  ________   species
>PlarlB 02010002289 
8 -60616:61908 
MW: 48777.277
H3SNG8 9B 
ACL
Toxin complex component 
ORF-X2 (gene:
P D E N DC454_25591)
Paenibacillus
dendritiformis
C454
7.60E-147
E9N6Q5 CL 
OBO OrfX2 (gene: orfX2)
Clostridium
botulinum 1.50E-76
D2TXI8 9EN 
TR
Toxin complex component 
ORF-X2 (gene:
ARN 08100)
Arsenophonus
nasoniae 1.00E-18
A8PMG2 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0717)
Rickettsiella grylli 8.90E-16
F7SWZ6 AL 
CXX
Putative uncharacterized 
protein (gene: 
AXXA_06258)
Achromobacter
xylosoxidans
AXX-A
3.90E-14
F7SP90 9G 
AMM
Putative uncharacterized 
protein (gene: 
GME_11572)
Halomonas sp. 
TD01 2.90E-13
B2VCQ8 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30270)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
9.10E-11
Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
1.20E-07
Q3SU91 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
2.70E-06
H3SNG7 9B 
ACL
Toxin complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus
dendritiformis
C454
1.40E-05
C3KS19 CL 
OB6
Toxin complex component 
ORF-X3 (gene:
CLJ_0010)
Clostridium 
botulinum (strain 
657 / Type Ba4)
3.40E-03
misc_feature
complement(5378..67
75)
H3SNG7 9B 
ACL ,
Toxin complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus
dendritiformis
C454
5.10E-279
/note="p 
otential frameshift: 
common BLAST hit:
E9N6Q4 CL 
OBO OrfX3 (gene: orfX3)
Clostridium
botulinum 3.00E-122
gi| 15393 
92711 ref | YP_0013901 
17.11 toxin complex 
component
F7SP91 9G 
AMM
Putative uncharacterized 
protein (gene: 
GME_11577)
Halomonas sp. 
TD01 4.00E-62
ORF-X3" Q3SU91 NIT WN
Putative uncharacterized 
protein (gene: Nwi__0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
3.40E-42
Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
6.80E-37
F7SWZ7 AL 
CXX
Toxin complex component 
ORF-X3 (gene: 
AXXA_06263)
Achromobacter
xylosoxidans
AXX-A
2.00E-20
B2V3V1 CL 
OBA
Toxin complex component 
ORF-X2 (gene: 
CLH_1114)
Clostridium 
botulinum (strain 
Alaska E43 / 
Type E3)
1.50E-15
H3SNG6 9B 
ACL
P-47 protein (Fragment) 
(gene:
PDENDC454_25581)
Paenibacillus
dendritiformis
C454
5.10E-11
'misc_feature
complement(3984..52
74)
H3SNG6 9B 
ACL
P-47 protein (Fragment) 
(gene:
PDENDC454_25581)
Paenibacillus
dendritiformis
C454
9.00E-201
/note="p 
otential frameshift: 
common BLAST hit:
B1L2G3 CL 
OBM P-47 protein (gene: p47)
Clostridium 
botulinum (straim 
Loch Maree / 
Type A3)
3.40E-52
gi|22694 
8034|ref|YP 0028031 
25.1| P-47 protein"
Q3SU90 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0887)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
1.90E-28
D2TXI9 9EN 
TR
Putative uncharacterized 
protein (gene: 
ARN_081010)
Arsenophonus
nasoniae 1.40E-18
A8PMG3 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0718)
Rickettsiella grylli 1.20E-14
Q88LC8 PS 
EPK
P-47-related protein 
(gene: PP_2007)
Pseudomonas 
putida (strain 
KT2440)
3.00E-14
Q3SU91 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
1.70E-11
F7SP89 9G 
AMM
P-47 protein (gene: 
GMEJ1567)
Halomonas sp. 
TD01 1.70E-07
E9N6Q4 CL 
OBO OrfX3 (gene: orfX3)
Clostridium
botulinum 3.60E-05
>PlarlB 02010002287 
3 -64828:65511 
MW: 25735.86
H3SHP6 9B 
ACL
Protective antigen (gene: 
PDENDC454_15317)
Paenibacillus
dendritiformis
C454
O.OOE+OO
and F7J0A3 CLO PE
lota toxin component lb 
(gene: ibp)
Clostridium
perfringens 1.10E-80
misc_feature
complement(1378..32
97)
006498 9FI 
RM
Sb component (gene: 
sbs)
Clostridium
spiroforme 1.30E-78
/note="p 
otential frameshift: 
common BLAST hit:
C6DXY3 CL 
OBO
C2 toxin, component II 
(gene: CLG_0130)
Clostridium 
botulinum D str. 
1873
6.80E-71
gi|26068 
7838|ref|YP 0032189 
72.11ADP- 
ribosyltransferase
B3ZYH5 BA 
CCE
lota toxin component lb 
(gene:
BC03BB108_C0181)
Bacillus cereus 
03BB108 1.70E-62
binding
protein"
C3FB27 BA 
CTU
lota toxin component lb 
(gene: bthur0007_55280)
Bacillus ^
thuringiensis
serovar
monterrey BGSC 
4AJ1
9.60E-61
F7TW88 BR 
ELA
Protective antigen (gene: 
pagA2)
Brevibacillus 
laterosporus 
LMG 15441
1.50E-58
’ C3LLD4 BA CAC
Protective antigen (gene: 
pagA)
Bacillus anthracis 
(strain CDC 684 / 
NRRL3495)
1.50E-49
G9XXH2 SPI 
ME
Protective antigen (gene: 
SPM_01175)
Spiroplasma 
melliferum KC3 2.20E-45
Erwinia
tasmaniensis
Query Match uniprot Match protein name . Match score
>silverDB:etchr03014 
- 503464: 505140 
MW: 60636.168
B2VCQ8 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30270)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
0.00E+00
D2TXI8 9EN 
TR '
Toxin complex component 
ORF-X2 (gene: 
ARN_08100)
Arsenophonus
nasoniae 1.20E-169
A8PMG2 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0717)
Rickettsiella grylli 8.90E-169
E9N6Q5 CL 
OBO OrfX2 (gene: orfX2)
Clostridium
botulinum 5.40E-30
H3SNG8 9B 
ACL
Toxin complex component 
ORF-X2 (gene: 
PDENDC454_25591)
Paenibacillus
dendritiformis
C454
5.70E-28
B0FNR1 CL 
OBO OrfX3 (Fragment)
Clostridium
botulinum 5.60E-15
C5UY10 CL 
OBO
Toxin complex component 
ORF-X3 (gene: 
CLO_2647)
Clostridium 
botulinum E1 str. 
'BoNT E Beluga’
7.40E-07
F7SWZ6 AL 
CXX
Putative uncharacterized 
protein (gene: 
AXXA_06258)
Achromobacter 
xylosoxidans 
AXX-A t
4.60E-06
>silverDB:etchr03013 
-505151: 506356 
MW: 44426.043
B2VCQ7 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30260)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
2.20E-274
D2TXI9 9EN 
TR
Putative uncharacterized 
protein (gene: 
ARN_081010)
Arsenophonus
nasoniae 2.80E-119
A8PMG3 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0718)
Rickettsiella grylli 2.50E-97
H3SNG6 9B 
ACL
P-47 protein (Fragment) 
(gene:
PDENDC454 25581)
Paenibacillus
dendritiformis
C454
5.40E-20
Q6RI05 CLO 
BO P-47 (gene: p47)
Clostridium
botulinum 3.40E-15
Q3SU91 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
2.50E-13
H3SNG7 9B 
ACL
Toxin complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus
dendritiformis
C454
4.10E-10
C9WWY1 C 
LOBO ORFX3 (Fragment)
Clostridium
botulinum 1.70E-09
>silverDB:etchr03012 
-506359: 506814 
MW: 17165.527
B2VCQ5 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30250)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
6.20E-94
A8PMG4 9C 
OXI
Putative uncharacterized 
protein (gene: ■ 
RICGR_0719)
Rickettsiella grylli 1.10E-11
D2TXJ1 9EN 
TR
Putative uncharacterized 
protein (gene: 
ARN_08130)
Arsenophonus
nasoniae 9.60E-06
'
>silverDB:etchr03011 
- 506899: 508029 
MW: 42732.51
B2VCQ4 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30240)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
1.30E-259
B6SD26 9VI 
RU
Putative uncharacterized 
protein Y (gene: Y)
Bacteriophage
APSE-3 5.00E-67
B8NDI1 ASP 
FN
Putative uncharacterized 
protein (gene: 
AFLA_059200)
Aspergillus flavus 
(strain ATCC 
200026 / FGSC 
A1120 / NRRL 
3357/JCM 
12722/SRRC 
167)
6.70E-10
A9ZJ22 CO 
XBE
Putative uncharacterized 
protein (gene: 
COXBURSA334_A0135)
Coxiella burnetii 
RSA 334 3.70E-04
>silverDB:etchr03010 
-508094: 513058 
MW: 181298.03
B2VCQ3 ER 
WT9
Nematicidal protein (gene: 
rhsA)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
0.00E+00
B6SD27 9VI 
RU
Putative YD-repeat toxin 
(gene: Z)
Bacteriophage
APSE-3 0.00E+00
C4T5C2 YE 
RIN
Rhs family protein (gene: 
yinte0001_39190)
Yersinia
intermedia ATCC 
29909
0.00E+00
H1ZAP4 9FL 
AO
RHS repeat-associated 
core domain-containing 
protein (gene: 
Myrod_3544)
Myroides 
odoratus DSM 
2801
1.90E-284
H3RHE1 ER 
WST
Putative uncharacterized 
protein (gene: CKS_5332)
Pantoea stewartii 
subsp. stewartii 
DC283
5.20E-260
Q9EVR7 XE 
NBV
Nematicidal protein 2 
(gene: xnp2)
Xenorhabdus
bovienii 1.90E-252
B2Q268 PR 
OST
Putative uncharacterized 
protein (gene: 
PROSTU_02624)
Providencia 
stuartii ATCC 
25827
1.50E-246
G7XWY4 AS 
PKW
RHS repeat protein (gene: 
AKAW_09557)
Aspergillus 
kawachii (strain 
NBRC 4308)
4.60E-188
G3JUS5 CO 
RMM
RHS Repeat protein 
(gene: CCM_09498)
Cordyceps 
militaris (strain 
CM01)
2.30E-175
F3DCZ3 9P 
SED
YD repeat-containing 
protein (gene: 
PSYAE_09539)
Pseudomonas 
syringae'pv. 
aesculi str. 
0893 23
3.00E-146
Q7N4A7 PH 
OLL
Putative uncharacterized 
protein piu2442 (gene: 
plu2442)
Photorhabdus 
luminescens 
subsp. laumondii 
(strain TT01)
5.10E-120
052883 CO 
XBE
Putative uncharacterized 
protein orf 526 (gene: orf 
526)
Coxiella burnetii 1.90E-93
A7MZ70 VIB 
HB
Putative uncharacterized 
protein (gene: 
VIBHAR_01748)
Vibrio harveyi 
(strain ATCC 
BAA-1116/ 
BB120)
4.90E-86
C7HJS3 CL 
OTM
YD repeat protein 
(Precursor) (gene: 
ClothDRAFT_2932)
Clostridium 
thermocellum 
DSM 2360
6.70E-12
Arsenophonus
nasoniae
Query Match uniprot Match protein name Match protein Match score
>ARN_08100 -4071: 
5693 MW: 59243.086
D2TXI8 9EN 
TR
Toxin complex component 
ORF-X2 (gene: 
ARN_08100)
Arsenophonus
nasoniae 0.00E+00
A8PMG2 9C 
OXI
Putative uncharacterized 
protein (gene:
RICGR 0717)
Rickettsiella grylli 1.20E-200
B2VCQ8 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30270)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
1.20E-169
C5UY11 CL 
OBO
Toxin complex component 
ORF-X2 (gene: 
CLO_2648)
Clostridium 
botulinum E1 str. 
'BoNT E Beluga'
1.80E-30
H3SNG8 9B 
ACL
Toxin complex component 
ORF-X2 (gene: 
PDENDC454_25591)
Paenibacillus
dendritiformis
C454
4.00E-29
C9WWY1 C 
LOBO ORFX3 (Fragment)
Clostridium
botulinum 8.00E-16
Q3SU91 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
3.40E-17
>ARN 081010 - 
5721:6992 MW: 
47093.24
D2TXI9 9EN 
TR
Putative uncharacterized 
protein (gene: 
ARN_081010)
Arsenophonus
nasoniae 1.40E-285
A8PMG3 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR0718)
Rickettsiella grylli 2.40E-154
B2VCQ7 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30260)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
2.10E-117
P71115 CLO 
BO P-47 protein (gene: P-47)
Clostridium
botulinum 2.00E-13
Q3SU91_NIT
WN
Putative uncharacterized 
protein (gene: Nwi_0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
2.20E-12
B0FNR1 CL 
OBO OrfX3 (Fragment)
Clostridium
botulinum 3.50E-10
Q88LC8 PS 
EPK
P-47-related protein 
(gene: PP_2007)
Pseudomonas 
putida (strain 
KT2440)
3.80E-07
C4IHL6 CLO 
BU
Toxin complex component 
ORF-X2 (gene: 
CLP_2747)
Clostridium 
butyricum E4 str. 
BoNT E BL5262
3.20E-04
D2TXI8 9EN 
TR
Toxin complex component 
ORF-X2 (gene: 
ARN_08100)
Arsenophonus
nasoniae 3.90E-03
>ARN 08120 -7022: 
8646 MW: 59423.383
exact match 
isnt in uniprot
E3DHB7 ER 
WSE .
Putative toxin-like protein 
(gene: EJP617_07250)
Erwinia sp. 
(strain Ejp617) 4.70E-62
D2TXI8 9EN 
TR
Toxin complex component 
ORF-X2 (gene:
ARN 08100)
Arsenophonus
nasoniae 1.80E-60
A8PMG2 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0717)
Rickettsiella grylli 4.60E-58
B2V3V1 CL 
OBA
Toxin complex component 
ORF-X2 (gene:
CLH_1114)
Clostridium 
botulinum (strain 
Alaska E43 / 
Type E3)
3.4bE-26
.*
C4IHL5 CLO 
BU
Toxin complex component 
ORF-X3 (gene: 
CLP_2746)
Clostridium 
butyricum E4 str. 
BoNT E BL5262
1.40E-09
P71113 CLO 
BO P-47 protein (gene: P-47)
Clostridium
botulinum 5.70E-03
>ARN 08130 -8728: 
9174 MW: 16951.338
D2TXJ1 9EN 
TR
Putative uncharacterized 
protein (gene: 
ARN_08130)
Arsenophonus
nasoniae 4.30E-90
A8PMG4 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0719)
Rickettsiella grylli 4.50E-31
B2VCQ5 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30250)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
2.70E-06
>ARN 08140 -9255: 
12254 MW:
114877.19
D2TXJ2 9EN 
TR
Nematicidal protein (gene: 
ARN_08140)
Arsenophonus
nasoniae 0.00E+00
Q7N4A7 PH 
OLL
Putative uncharacterized 
protein plu2442 (gene: 
plu2442)
Photorhabdus 
luminescens 
subsp. laumondii 
(strain TT01)
5.40E-173
H3RHE1 ER 
WST
Putative uncharacterized 
protein (gene: CKS_5332)
Pantoea stewartii 
subsp. stewartii 
DC283
7.40E-136
B2VJI1 ERW 
T9
Similar to Nematicidal 
protein 2 (gene: xnp2)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
4.80E-121
G4KI80 YER 
EN
Rhs family protein (gene: 
IOK_17811)
Yersinia 
enterocolitica 
subsp. 
palearctica 
PhRBD Ye1
1.80E-113
Q9EVR7 XE 
NBV
Nematicidal protein 2 
(gene: xnp2)
Xenorhabdus
bovienii 1.20E-104
>ARN 08150 - 
12390: 14057 MW: 
61276.785
exact match 
isnt.in uniprot
Q7N4A7 PH 
OLL
Putative uncharacterized 
protein plu2442 (gene:. 
plu2442)
Photorhabdus 
luminescens 
subsp. laumondii 
(strain TT01)
4.10E-98
C4T5C2 YE 
RIN
Rhs family protein (gene: 
yinte0001_39190)
Yersinia
intermedia ATCC 
29909
4.60E-82
Q9S6J1 CO 
XBE
Putative uncharacterized 
protein Coxiella burnetii 9.20E-79
B2VJI1 ERW 
T9
Similar to Nematicidal 
protein 2 (gene: xnp2)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
4.00E-76
Similar to the nematicidal Photorhabdus
Q7MB38 PH protein 2. Probable luminescens 1.90E-65OLL membrane protein (gene: 
plu2222)
subsp. laumondii 
(strain TT01)
Halomonas
Query Match uniprot Match protein name rotein Match score
>GME 11567 - 
5384: 6736 MW: 
48127.82
F7SP89 9G 
AMM
P-47 protein (gene: 
GME_11567)
Halonrionas sp. 
TD01 3.30E-302
H3SNG6 9B 
ACL
P-47 protein (Fragment) 
(gene:
PDENDC454_25581)
Paenibacillus
dendritiformis
C454
2.30E-13
Q88LC8 PS 
EPK
P-47-related protein 
(gene: PP_2007)
Pseudomonas 
putida (strain 
KT2440)
2.90E-10
P71115 CLO 
BO P-47 protein (gene: P-47)
Clostridium
botulinum 7.60E-09
A8PMG3 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0718)
Rickettsiella grylli 9.00E-09
A3WXE0 9B 
RAD
Putative uncharacterized 
protein (gene:
NB311A_13581)
Nitrobacter sp. 
Nb-311A 1.70E-08
>GME 11572 - 
6805: 8967 MW: 
78051.65
F7SP90 9G 
AMM
Putative uncharacterized 
protein (gene: 
GME^11572)
Halomonas sp. 
TD01 0.00E+00
Q3SU91 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
2.20E-28
F7SP91 9G 
AMM
Putative uncharacterized 
protein (gene:
GME 11577)
Halomonas sp. 
TD01 2.70E-24
.
Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
9.60E-21
C9WWY1 C 
LOBO ORFX3 (Fragment)
Clostridium
botulinum 3.80E-20
D2TXI8 9EN 
TR
Toxin complex component 
ORF-X2 (gene:
ARN 08100)
Arsenophonus
nasoniae 3.40E-18
B2VCQ8 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30270)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
5.30E-18
A8PMG2 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0717)
Rickettsiella grylli 2.00E-17
C9WWY2 C 
LOBO ORFX2
Clostridium
botulinum 2.20E-12
>GME 11577 - 
8991: 10388 MW: 
49702.94
F7SP91 9G 
AMM
Putative uncharacterized 
protein (gene: 
GMEJ1577)
Halomonas sp. 
TD01 1.30E-306
H3SNG7 9B 
ACL
Toxin complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus
dendritiformis
C454
4.40E-70
Q3SU91 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
1.20E-68
C5UY10 CL 
OBO
Toxin complex component 
ORF-X3 (gene: 
CLO_2647)
Clostridium 
botulinum E1 str. 
'BoNT E Beluga'
4.10E-65
C3KS19 CL 
OB6
Toxin complex component 
ORF-X3 (gene:
CLJ_0010)
Clostridium 
botulinum (strain 
657 / Type Ba4)
5.90E-62
F7SWZ7 AL 
CXX
Toxin complex component 
ORF-X3 (gene:
AXXA 06263)
Achromobacter
xylosoxidans
AXX-A
4.60E-36
Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
5.80E-34
Q88LC8 PS 
EPK
P-47-related protein 
(gene: PP_2007)
Pseudomonas 
putida (strain 
KT2440)
1.70E-12
Q45890 CL 
OBO P-47 protein (gene: P-47)
Clostridium
botulinum 3.40E-09
C3KS18 CL 
OB6
Toxin complex component 
ORF-X2 (gene:
CLJ_0009)
Clostridium 
botulinum (strain 
657/Type Ba4)
2.10E-07
D2T7Z2 ER 
WP6
Putative uncharacterized 
protein (gene: 
EPYR_03487)
Erwinia pyrifoliae 
(strain DSM 
12163/CIP 
106111/ 
Ep16/96)
3!10E-07
>GME 11582 - 
10418: 10933 MW: 
19189.484
F7SP92 9G 
AMM
Putative uncharacterized 
protein (gene:
GME 11582)
Halomonas sp. 
TD01 8.80E-113
F7SP93 9G 
AMM
Putative uncharacterized 
protein (gene: 
GME_11587)
Halomonas sp. 
TD01 3.20E-50
D2AVY8 ST 
RRD
Putative uncharacterized 
protein (gene: Sros_0049)
Streptosporangiu 
m roseum (strain 
ATCC 12428/ 
DSM 43021 / 
JCM 3005 / Nl 
9100)
1.20E-48
D8NKW8 RA 
LSL AidA (gene: aidA)
Ralstonia
solanacearum
CFBP2957
8.00E-47
G2ZPF3 9R 
ALS
Conserved hypothetical 
protein (gene:
BDB_110385)
blood disease 
bacterium R229 3.80E-45
B4EQ59 BU 
RCJ
Nematocidal protein AidA 
(gene: aidA)
Burkholderia 
cepacia (strain 
J2315/LMG 
16656)
3.50E-35
Q1I3W7 PS 
EE4
Putative uncharacterized 
protein (gene: 
PSEEN5035)
Pseudomonas 
entomophila 
(strain L48)
4.40E-33
D9X2B6 ST 
RVR
Nematocidal protein AidA 
(gene: SSQG_04103)
Streptomyces 
viridochromogen 
es DSM 40736
3.60E-31
D3VHG3 XE 
NNA
Putative uncharacterized 
protein (gene: 
XNC1_2550)
Xenorhabdus 
nematophila 
(strain ATCC 
19061 /DSM 
3370/LMG 1036 
/ NCIB 9965 / 
AN6)
2.60E-19
>GME_11587 - 
10993: 11508 MW: 
18868.629
F7SP93 9G 
AMM
Putative uncharacterized 
protein (gene:
GME 11587)
Halomonas sp. 
TD01 1.60E-111
F7SP92 9G 
AMM
Putative uncharacterized 
protein (gene: 
GME_11582)
Halomonas sp. 
TD01 3.10E-50
'
D2AVY8 ST 
RRD
Putative uncharacterized 
protein (gene: Sros_0049)
Streptosporangiu 
m roseum (strain 
ATCC 12428/ 
DSM 43021 / 
JCM 3005 / Nl 
9100)
1.70E-34
B4EQ59 BU 
RCJ
Nematocidal protein AidA 
(gene: aidA)
Burkholderia 
cepacia (strain 
J2315/LMG 
16656)
3.00E-33
D8NKW8 RA 
LSL AidA (gene: aidA)
Ralstonia
solanacearum
CFBP2957
2.60E-32
D9X2B6 ST 
RVR
Nematocidal protein AidA 
(gene: SSQG_04103)
Streptomyces 
viridochromogen 
es DSM 40736
8.90E-27
Q4KD92 PS 
EF5
Putative uncharacterized 
protein (gene: PFL_2684)
Pseudomonas . 
fluorescens 
(strain Pf-5 / 
ATCC BAA-477)
6.00E-19
D3VHG3 XE 
NNA
Putative uncharacterized 
protein (gene: 
XNC1_2550)
Xenorhabdus 
nematophila 
(strain ATCC 
19061 / DSM 
3370/LMG 1036 
/ NCIB 9965 / 
AN6)
6.20E-12
B6VM50 PH 
OAA
Similar to aida protein of 
ralstonia solanacearum 
(gene: aidA)
Photorhabdus
asymbiotica
subsp.
asymbiotica
(strain ATCC
43949/3105-77)
3.20E-10
>GME 11592 - 
11533: 11889 MW: 
13480.565
F7SP94 9G 
AMM
Putative uncharacterized 
protein (gene:
GME 11592)
Halomonas sp. 
TD01 1.60E-73
Paenibacillus
dendritiformis
Query ..  . . , , . , . Match protein Match umprot Match protein name spsciss Match score
>PDENDC454 25596 
-342:761 MW: 
16418.139
H3SNG9 9B 
ACL
Toxin complex component 
ORF-X1 (gene: 
PDENDC454_25596)
Paenibacillus
dendritiformis
C454
1.20E-87
Q6RI07 CLO 
BO ORF-X1 (gene: orfxl)
Clostridium
botulinum 4.30E-13
>PDENDC454 25591 
-784:3051 MW: 
85771.44
H3SNG8 9B 
ACL
Toxin complex component 
ORF-X2 (gene: 
PDENDC454_25591)
Paenibacillus
dendritiformis
C454
0.00E+00
B0FNQ5 CL 
OBO OrfX2
Clostridium
botulinum 9.20E-139
A8PMG2 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR__0717)
Rickettsiella grylli 3.10E-27
D2TXI8 9EN 
TR
Toxin complex component 
ORF-X2 (gene: 
ARN_08100) ‘
Arsenophonus
nasoniae 1.00E-26
B2VCQ8 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30270)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
2.00E-26
Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
1.60E-19
Q3SU91 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
3.70E-17
C4IHL5 CLO 
BU
Toxin complex component 
ORF-X3 (gene: 
CLP_2746)
Clostridium 
butyricum E4 str. 
BoNT E BL5262
3.90E-13
C9WWY1 C 
LOBO ORFX3 (Fragment)
Clostridium
botulinum 6.30E-13
H3SNG7 9B 
ACL
Toxin complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus 
dendritiformis ' 
C454
7.10E-11
>COG0054 Riboflavin 
synthase beta-chain ■ 
3162: 4643 MW: 
55331.68'
H3SNG7 9B 
ACL
Toxin complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus
dendritiformis
C454
0.00E+00
E9N6Q4 CL 
OBO OrfX3 (gene: orfX3)
Clostridium
botulinum 3.30E-135
Q3SU91 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
3.10E-50
Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
3:40E-35
F7SWZ7 AL
cxx
Toxin complex component 
ORF-X3 (gene: 
AXXA_06263)
Achromobacter
xylosoxidans
AXX-A
1.40E-20
C4IHL6 CLO 
BU
Toxin complex component 
ORF-X2 (gene: 
CLP_2747)
Clostridium 
butyricum E4 str. 
BoNT E BL5262
1.60E-16
A3WXD6 9B 
RAD
Putative uncharacterized 
protein (gene: 
NB31.1A_13596)
Nitrobacter sp. 
Nb-311A 2.60E-15
F7SP90 9G 
AMM
Putative uncharacterized 
protein (gene:
GME 11572)
Halomonas sp. 
TD01 9.80E-15
H3SNG8 9B 
ACL
Toxin complex component 
ORF-X2 (gene: 
PDENDC454_25591)
Paenibacillus
dendritiformis
C454
8.20E-11
A8PMG3 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0718)
Rickettsiella grylli 2.20E-10
H3SNG6 9B 
ACL
P-47 protein (Fragment) 
(gene:
PDENDC454_25581)
Paenibacillus
dendritiformis
C454
3.20E-08
P71115 CLO 
BO P-47 protein (gene: P-47)
Clostridium
botulinum 8.80E-06
>PDENDC454 25581 
-4667:6072 MW: 
52571.297
H3SNG6 9B 
ACL
P-47 protein (Fragment) 
(gene:
PDENDC454_25581)
Paenibacillus
dendritiformis
C454
0.00E+00
P71113 CLO 
BO P-47 protein (gene: P-47)
Clostridium
botulinum 3.00E-81
Q3SU90 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0887)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
9.00E-38
D2TXI9 9EN
TR
Putative uncharacterized 
protein (gene: 
ARN_081010)
Arsenophonus
nasoniae 3.60E-36
A8PMG3 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0718)
Rickettsiella grylli 7.50E-32
* B2VCQ7 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30260)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
5.70E-18
F7SWZ7 AL 
CXX
Toxin complex component 
ORF-X3 (gene: 
AXXA_06263)
Achromobacter
xylosoxidans
AXX-A
2.30E-08
H3SNG7 9B 
ACL
Toxjn complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus
dendritiformis
C454
3.40E-08
Nitrobacter
winogradskyi
Query Match uniprot Match protein name Match protein Match score
>Nwi 0887 - 
2435137: 2436387 
MW: 44933.914
Q3SU90 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0887)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
4.40E-278
A3WXE0 9B 
RAD
Putative uncharacterized 
protein (gene: 
NB311A_13581)
Nitrobacter sp. • 
Nb-311A 3.00E-249
Q88LC8 PS 
EPK
P-47-related protein 
(gene: PP_2007)
Pseudomonas 
putida (strain 
KT2440)
2.00E-38
H3SNG6 9B 
ACL
P-47 protein (Fragment) 
(gene:
PDENDC454_ 25581)
Paenibacillus
dendritiformis
C454
8.40E-38
C3KS15 CL 
OB6 P-47 protein (gene: p47)
Clostridium 
botulinum (strain 
657 /Type Ba4)
4.10E-25
B0FNR1 CL 
OBO OrfX3 (Fragment)
Clostridium
botulinum 6.50E-12
B2VCQ7 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30260)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
1.50E-11
H3SNG7 9B 
ACL
Toxin complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus
dendritiformis
C454
4.60E-11
F7SWZ7 AL 
CXX
Toxin complex component 
ORF-X3 (gene: 
AXXA_06263)
Achromobacter
xylosoxidans
AXX-A
7.00E-11
>Nwi 0886 - 
2436442: 2438055 
MW: 56572.258
Q3SU91 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
0.00E+00
A3WXE1 9B 
RAD
Putative uncharacterized 
protein (gene:
NB311A_13586)
Nitrobacter sp. 
Nb-311A 0.00E+00
Q3SU92 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0885)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
7.90E-107
F7SP91 9G 
AMM
Putative uncharacterized 
protein (gene: 
GME_11577)
Halomonas sp. 
TD01 7.10E-69
Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
1.10E-68
H3SNG7 9B 
ACL
Toxin complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus
dendritiformis
C454
1.60E-50
E9N6Q4 CL 
OBO OrfX3 (gene: orfX3)
Clostridium
botulinum 3.50E-46
F7SWZ7 AL 
CXX
Toxin complex component 
ORF-X3 (gene: 
AXXA_06263)
Achromobacter
xylosoxidans
AXX-A
1.60E-27
Q6RI02 CLO 
BO ORF-X2 (gene: orfx2)
Clostridium
botulinum 3.10E-21
Q88LC8 PS 
EPK
P-47-related protein 
(gene: PP_2007) ’
Pseudomonas 
putida (strain 
KT2440)
4.30E-21
A8PMG3 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0718)
Rickettsiella grylli 2.00E-20
P71115 CLO 
BO P-47 protein (gene: P-47)
Clostridium
botulinum 7.90E-13
>Nwi 0885 - 
2438058: 2439650 
MW: 56652.863
Q3SU92 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0885)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
0.00E+00
A3WXD5 9B 
RAD
Putative uncharacterized 
protein (gene: 
NB311A_13591)
Nitrobacter sp. 
Nb-311A 0.00E+00
Q3SU91 NIT 
WN '
Putative uncharacterized 
protein (gene: Nwi_0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
1.70E-106
F7SP91 9G 
AMM
Putative uncharacterized 
protein (gene: 
GME_11577)
Halomonas sp. 
TD01 4.30E-59
- Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
6.70E-57
H3SNG7 9B 
ACL
Toxin complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus
dendritiformis
C454
1.10E-43
Q6RI09 CLO 
BO ORF-X3 (gene: orfx3)
Clostridium
botulinum 6.80E-33
F7SP90 9G 
AMM
Putative uncharacterized 
protein (gene: 
GME_11572)
Halomonas sp. 
TD01 1.30E-24
F7SWZ7 AL 
CXX
Toxin complex component 
ORF-X3 (gene:
AXXA 06263)
Achromobacter
xylosoxidans
AXX-A
3.00E-23
B2VCQ8 ER 
WT9
Putative uncharacterized 
protein (gene: 
ETA_30270)
Erwinia 
tasmaniensis 
(strain DSM 
17950 / Et1/99)
3.10E-16
D2TXI8 9EN 
TR
Toxin complex component 
ORF-X2 (gene: 
ARN_08100)
Arsenophonus
nasoniae 2.90E-15
P71115 CLO 
BO P-47 protein (gene: P-47)
Clostridium
botulinum 3.80E-07
>Nwi 0884 - 
2439745:2441265 
MW: 52274.707
Q3SU93 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0884)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
0.00E+00
A3WXD6 9B 
RAD
Putative uncharacterized 
protein (gene: 
NB311A_13596)
Nitrobacter sp. 
Nb-311A 5.30E-300
A3WXD5 9B 
RAD
Putative uncharacterized 
protein (gene:
NB311A 13591)
Nitrobacter sp. 
Nb-311A 1.80E-44
Q3SU92 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0885)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
2.30E-43
F7SP91 9G 
AMM
Putative uncharacterized 
protein (gene: 
GME_11577)
Halomonas sp. 
TD01 1.80E-23
Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
1.30E-17
H3SNG7 9B 
ACL
Toxin complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus
dendritiformis
C454
4.80E-12
C4IHL5 CLO 
BU
Toxin complex component 
ORF-X3 (gene: 
CLP_2746)
Clostridium 
butyricum E4 str. 
BoNT E BL5262
9.20E-07
C5UY10 CL 
OBO
Toxin complex component 
ORF-X3 (gene: 
CLO_2647)
Clostridium 
botulinum E1 str. 
'BoNT E Beluga'
9.20E-07
B0FNR1 CL 
OBO OrfX3 (Fragment)
Clostridium
botulinum 3.30E-06
F7SWZ7 AL 
CXX
Toxin complex component 
ORF-X3 (gene: 
AXXA_06263)
Achromobacter
xylosoxidans
AXX-A
3.50E-06
E9N6Q4 CL 
OBO OrfX3 (gene: orfX3)
Clostridium
botulinum 5.60E-06
Q88LC8 PS 
EPK
P-47-related protein 
(gene: PP_2007)
Pseudomonas 
putida (strain 
KT2440)
1.10E-05
F7SP90 9G 
AMM
Putative uncharacterized 
protein (gene: 
GME_11572)
Halomonas sp. 
TD01 1.70E-05
Streptomyces
scabei
Query Match uniprot Match protein name Match protein Match score
>with SCAB58511 - 
3636359: 3638053 
MW: 59991.6
Q3SU92 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0885)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
2.00E-47
Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
2.70E-39
Q6RI03 CLO 
BO ORF-X3 (gene: orfx3)
Clostridium
botulinum 3.90E-3D
H3SNG7 9B 
ACL
Toxin complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus
dendritiformis
C454
1.40E-28
F7SP90 9G 
AMM
Putative uncharacterized 
protein (gene: 
GME_11572)
Halomonas sp. 
TD01 2.20E-17
F7SWZ7 AL 
CXX
Toxin complex component 
ORF-X3 (gene:
AXXA 06263)
Achromobacter
xylosoxidans
AXX-A
4.60E-15
H3SNG8 9B 
ACL
Toxin complex component 
ORF-X2 (gene: 
PDENDC454_25591)
Paenibacillus
dendritiformis
C454
2.10E-12
H3SNG6 9B 
ACL
P-47 protein (Fragment) 
(gene:
PDENDC454_25581)
Paenibacillus
dendritiformis
C454
8.70E-07
D2TXI8 9EN 
TR
Toxin complex component 
ORF-X2 (gene: 
ARN_08100)
Arsenophonus
nasoniae 7.20E-05
>with SCAB58531 - 
3638202: 3639821 
MW: 57924.875
Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
5.00E-34
Q3SU92 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0885)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
2.10E-30
B0FNR1 CL 
OBO OrfX3 (Fragment)
Clostridium
botulinum 2.10E-21
C3KS18 CL 
0B6
Toxin complex component 
ORF-X2 (gene:
CLJ_0009)
Clostridium 
botulinum (strain 
657/Type Ba4)
1.10E-09
C3KS15 CL 
OB6 P-47 protein (gene: p47)
Clostridium 
botulinum (strain 
657 / Type Ba4)
2.80E-05
Achromobacter 
xylosoxidans AXX-A
Query Match uniprot Match protein name ^e^cies'r°*0in Match score
>AXXA 06258 - 
163885: 165699 MW: 
64139.195
F7SWZ6 AL 
CXX
Putative uncharacterized 
protein (gene: 
AXXA_06258)
Achromobacter
xylosoxidans
AXX-A
0.00E+00
A3WXE1 9B 
RAD
Putative uncharacterized 
protein (gene: 
NB311A_13586)
Nitrobacter sp. 
Nb-311A 1.20E-25
E9N6Q4 CL 
OBO OrfX3 (gene: orfX3)
Clostridium
botulinum 1.80E-15
H3SNG8 9B 
ACL
Toxin complex component 
ORF-X2 (gene: 
PDENDC454_25591)
Paenibacillus
dendritiformis
C454
1.30E-14
F7SWZ7 AL 
CXX
Toxin complex component 
ORF-X3 (gene: 
AXXA_06263)
Achromobacter
xylosoxidans
AXX-A
7.10E-14
Q88LC8 PS 
EPK
P-47-related protein 
(gene: PP_2007)
Pseudomonas 
putida (strain 
KT2440)
5.40E-13
H3SNG6 9B 
ACL
P-47 protein (Fragment) 
(gene:
PDENDC454_25581)
Paenibacillus
dendritiformis
C454
4.20E-07
P71115 CLO 
BO P-47 protein (gene: P-47)
Clostridium
botulinum 5.00E-04
>AXXA 06253 - 
161108: 163804 MW: 
96362.31
F7SWZ5 AL 
CXX
Putative uncharacterized 
protein (gene: 
AXXA_06253)
Achromobacter
xylosoxidans
AXX-A
0.00E+00
F7SWZ6 AL 
CXX
Putative uncharacterized 
protein (gene: 
AXXA_06258)
Achromobacter
xylosoxidans
AXX-A
9.10E-04
>AXXA 06263 - 
165738: 167090 MW: 
48627.824
F7SWZ7 AL 
CXX
Toxin complex component 
ORF-X3 (gene: 
AXXA_06263)
Achromobacter
xylosoxidans
AXX-A
2.90E-301
F7SP91 9G 
AMM
Putative uncharacterized 
protein (gene: 
GME_11577)
Halomonas sp. 
TD01 9.90E-37
Q3SU91 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
9.70E-27
Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
1.60E-25
A7GBF7 CL 
OBL
Toxin complex component 
ORF-X3 (gene:
CLI_0845)
Clostridium 
botulinum (strain 
Langeland / 
NCTC 10281 / 
Type F)
2.00E-24
Q88LC8 PS 
EPK
P-47-related protein 
(gene: PP_2007)
Pseudomonas 
putida (strain 
KT2440)
3.30E-13
Q45843 CL 
OBO
P-47 protein (Fragment) 
(gene: p-47)
Clostridium
botulinum 2.10E-06
E9N6Q5 CL 
OBO OrfX2 (gene: orfX2)
Clostridium
botulinum 7.70E-04
>AXXA 06268 - 
167087: 168436 MW: 
47213.496
F7SWZ8 AL 
CXX
Putative uncharacterized 
protein (gene:
AXXA 06268)
Achromobacter
xylosoxidans
AXX-A
2.30E-297
Q88LC8 PS 
EPK
P-47-related protein 
(gene: PP_2007)
Pseudomonas 
putida (strain 
KT2440)
1.70E-04
A3WXD5 9B 
RAD
Putative uncharacterized 
protein (gene:
NB311A 13591)
Nitrobacter sp. 
Nb-311A 2.90E-04
Q3MB33 AN 
AVT
Peptidase C14, caspase 
catalytic subunit p20 
(gene: Ava_2183)
Anabaena 
variabilis (strain 
ATCC 29413 / 
PCC 7937)
1.00E-03
Q3SU92 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0885)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
7.40E-03
Pseudomonas
putida ■
Query Match uniprot Match protein name ro e^'n Match score
>similar to 
GB:D14445, 
SP:Q07411, and 
PID:286035; i - 
3903288: 3904520 
MW: 44707.453
Q88LC8 PS 
EPK
P-47-related protein 
(gene: PP_2007)
Pseudomonas 
putida (strain 
KT2440)
2.70E-282
Q3SU90 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0887)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
2.10E-39
H3SNG6 9B 
ACL
P-47 protein (Fragment) 
(gene:
PDENDC454_25581)
Paenibacillus
dendritiformis
C454
7.80E-27
Q6RI05 CLO 
BO P-47 (gene: p47)
Clostridium
botulinum 1.10E-21
Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
5.70E-20
F7SWZ7 AL 
CXX
Toxin complex component 
ORF-X3 (gene: 
AXXA_06263)
Achromobacter
xylosoxidans
AXX-A
1.60E-13
F7SP91 9G 
AMM
Putative uncharacterized 
protein (gene: 
GME_11577)
Halomonas sp. 
TD01 1.60E-13
A8PMG3 9C 
OXI
Putative uncharacterized 
protein (gene: 
RICGR_0718)
Rickettsiella grylli 1.90E-11
D2TXI9 9EN 
TR
Putative uncharacterized 
protein (gene: 
ARN_081010)
Arsenophonus
nasoniae 1.60E-07
>PP 2006 - 
3904411: 3906189 • 
MW: 63712.24
Q88LC9 PS 
EPK
Putative uncharacterized 
protein (gene: PP_2006)
Pseudomonas 
putida (strain 
KT2440)
0.00E+00
Q3SU91 NIT 
WN
Putative uncharacterized 
protein (gene: Nwi_0886)
Nitrobacter 
winogradskyi 
(strain Nb-255 / 
ATCC 25391)
4.90E-68
E9N6Q4 CL 
OBO OrfX3 (gene: orfX3)
Clostridium
botulinum 8.40E-36
H3SNG7 9B 
ACL
Toxin complex component 
ORF-X3 (gene: 
PDENDC454_25586)
Paenibacillus ■
dendritiformis
C454
1.80E-35
F7SP91 9G 
AMM
Putative uncharacterized 
protein (gene:
GME 11577)
Halomonas sp. 
TD01 5.60E-34
F7SWZ7 AL 
CXX
Toxin complex component 
ORF-X3 (gene: 
AXXA_06263)
Achromobacter
xylosoxidans
AXX-A
3.60E-25
' E5B9Q4 ER 
WAM
Putative uncharacterized 
protein (gene: 
EAIL5_3311)
Erwinia
amylovora ATCC 
BAA-2158
5.80E-19
Q6RI02 CLO 
BO ORF-X2 (gene: prfx2)
Clostridium
botulinum 3.80E-17
H3SNG6 9B 
ACL
P-47 protein (Fragment) 
(gene:
PDENDC454_25581)
Paenibacillus
dendritiformis
C454
5.50E-15
>similar to 
GP:9949202; 
identified by sequence 
simi - 3906378: 
3907496 MW: 
41070.066
E4RBH0 PS 
EPB
Nitrilase/cyanide 
hydratase and 
apolipoprotein N- 
acyltransferase (gene: 
PPUBIRD1J3665)
Pseudomonas 
putida (strain 
BIRD-1)
4.90E-250
identified by match
to PFAM protein Q88LD1 PS 
EPK
Transcriptional regulator, Pseudomonas
family HMM PFO - AraC family (gene: putida (strain 4.90E-228
3907501: 3908541 PP_2004) KT2440)
MW: 38701.61
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